RESULT_COUNT: 1545,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
GSK,GSK:US,BBG000BLB481,FDA approves better vaccine against painful shingles virus,2017-10-20 23:51:55 +0000,http://finance.yahoo.com/r/94402ac7-5c3e-38ca-8d42-590cc25e90bd/fda-approves-better-vaccine-against-painful-shingles-virus-230351910--finance.html?.tsrc=rss,"U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus."
GSK,GSK:US,BBG000BLB481,FDA approves better vaccine against painful shingles virus,2017-10-20 23:51:55 +0000,https://finance.yahoo.com/news/fda-approves-better-vaccine-against-painful-shingles-virus-230351910--finance.html?.tsrc=rss,"U.S. regulators have approved a new, more effective vaccine to prevent painful shingles, which is caused by the chickenpox virus. Drugmaker GlaxoSmithKline said the Food and Drug Administration approved ..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline adult shingles vaccine wins U.S. approval,2017-10-20 23:18:40 +0000,https://finance.yahoo.com/news/glaxosmithkline-adult-shingles-vaccine-wins-231840357.html?.tsrc=rss,"Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N).  The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data.  Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday."
GSK,GSK:US,BBG000BLB481,Shingrix approved in the US for prevention of shingles in adults aged 50 and over,2017-10-20 23:16:00 +0000,https://finance.yahoo.com/news/shingrix-approved-us-prevention-shingles-231600127.html?.tsrc=rss,"Pooled clinical trial results showed > 90 percent efficacy across all age groups LONDON , Oct. 20, 2017 /PRNewswire/ -- GlaxoSmithKline plc  today announced that the US Food and Drug ..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline adult shingles vaccine wins U.S. approval,2017-10-20 22:54:00 +0000,https://finance.yahoo.com/news/glaxosmithkline-adult-shingles-vaccine-wins-225400907.html?.tsrc=rss,"Shingrix is seen as an improvement over Zostavax, the only currently marketed shingles prevention vaccine, sold by Merck & Co (MRK.N).  The vaccine is considered one of the more important products in Glaxo's pipeline, with annual sales forecast to reach $1 billion by 2023, according to Thomson Reuters data.  Glaxo said the U.S. Centers for Disease Control and Prevention's advisory committee on immunization practices is expected to vote on a recommendation for the use of Shingrix at its meeting on Wednesday."
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?,2017-10-20 14:55:02 +0000,https://finance.yahoo.com/news/glaxo-gsk-q3-earnings-deliver-145502766.html?.tsrc=rss,"The performance of GlaxoSmithKline plc&apos;s (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair ."
GSK,GSK:US,BBG000BLB481,3 High-Yield Pharmaceutical Stocks,2017-10-20 14:00:00 +0000,https://finance.yahoo.com/news/3-high-yield-pharmaceutical-stocks-140000362.html?.tsrc=rss,"High-yield pharma stocks are rare, but these three offer comparatively fat payouts."
GSK,GSK:US,BBG000BLB481,Comeback Thursday,2017-10-20 13:53:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZFtjKMIBEy4/comeback-thursday-cm862376,SPECIAL NOTE Eric Dutram is moving on from Zacks to pursue other career opportunities so today was his last time as the head of ETF Investor The new editor will be Neena Mishra who takes over next week The financial media was all abuzz on Thursday about the 30th anniversary of
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 20, 2017 :  GE, GSK, ERIC, BAC, PYPL, SFR, TVIX, CLF, CELG, SKX, MU, TLT",2017-10-20 12:53:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dpqm12US3SE/pre-market-most-active-for-oct-20-2017-ge-gsk-eric-bac-pypl-sfr-tvix-clf-celg-skx-mu-tlt-cm862441,The NASDAQ 100 Pre Market Indicator is up 11 32 to 6 103 94 The total Pre Market volume is currently 4 950 834 shares traded The following are the most active stocks for the pre market session General Electric Company GE is 1 61 at 21 97 with 8 757 989 shares
GSK,GSK:US,BBG000BLB481,China Biotech Promise Struggles to Keep Foreign Innovators,2017-10-19 21:00:01 +0000,http://finance.yahoo.com/r/ce149f4c-17cc-3252-86a1-69dd10196b1f/china-s-biotech-promise-is-struggling-to-keep-foreign-innovators?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"As money rushes into China’s fledgling biotechnology sector, Eli Lilly & Co. and other foreign drugmakers are scaling back."
GSK,GSK:US,BBG000BLB481,Novartis Reports Positive Results on Thrombocytopenia Drug,2017-10-19 13:00:01 +0000,https://finance.yahoo.com/news/novartis-reports-positive-results-thrombocytopenia-130001643.html?.tsrc=rss,Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 19, 2017 :  ERIC, TVIX, GSK, QQQ, EBAY, AAPL, BAC, XIV, VZ, VNTV, KB, NOK",2017-10-19 12:53:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2cv2M_xZbbs/pre-market-most-active-for-oct-19-2017-eric-tvix-gsk-qqq-ebay-aapl-bac-xiv-vz-vntv-kb-nok-cm861808,The NASDAQ 100 Pre Market Indicator is down 35 04 to 6 079 31 The total Pre Market volume is currently 6 813 147 shares traded The following are the most active stocks for the pre market session Ericsson ERIC is 0 04 at 5 94 with 1 921 405 shares traded ERIC
GSK,GSK:US,BBG000BLB481,What to Expect from Big Pharmas After J&J&apos;s Solid Q3 Results?,2017-10-18 20:21:08 +0000,https://finance.yahoo.com/news/expect-big-pharmas-j-j-202108992.html?.tsrc=rss,"Large-cap pharmas are expected to report encouraging third-quarter results, following J&J&apos;s earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter."
GSK,GSK:US,BBG000BLB481,What GlaxoSmithKline’s 3Q17 Performance Tells Us,2017-10-18 11:42:55 +0000,http://finance.yahoo.com/r/87dc5a2b-89dc-34bc-9161-7dd744e5c996/what-glaxosmithklines-3q17-performance-tells-us?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GSK stock fell ~4.7% in 3Q17 but has risen ~6.0% YTD (year-to-date) as of October 16.
GSK,GSK:US,BBG000BLB481,FDA Grants Priority Review for Exelixis' RCC Drug Cabomteyx,2017-10-17 14:55:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZZXqkk2SHBQ/fda-grants-priority-review-for-exelixis-rcc-drug-cabomteyx-cm860718,Exelixis Inc EXEL announced that the FDA has granted priority review to its supplemental New Drug Application sNDA for Cabomteyx The sNDA seeks approval of Cabometyx for patients with previously untreated advanced renal cell carcinoma RCC The FDA determined the sNDA to be
GSK,GSK:US,BBG000BLB481,Glaxo's Shingles Vaccine Shingrix Gets Approval in Canada,2017-10-17 13:54:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-1s7lmZvA2E/glaxos-shingles-vaccine-shingrix-gets-approval-in-canada-cm860573,GlaxoSmithKline plc GSK announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles herpes zoster in older patients aged 50 years or older This is the first regulatory approval for this key pipeline product of Glaxo which has blockbuster potential So
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 17, 2017 :  GSK, IPXL, NFLX, MU, MS, FCX, SNCR, BAC, QQQ, CS, TEVA, NEWS",2017-10-17 12:55:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cxPqGZA7VwA/pre-market-most-active-for-oct-17-2017-gsk-ipxl-nflx-mu-ms-fcx-sncr-bac-qqq-cs-teva-news-cm860471,The NASDAQ 100 Pre Market Indicator is down 06 to 6 114 47 The total Pre Market volume is currently 4 917 773 shares traded The following are the most active stocks for the pre market session GlaxoSmithKline PLC GSK is 0 0376 at 40 82 with 792 000 shares
GSK,GSK:US,BBG000BLB481,Glaxo&apos;s Shingles Vaccine Shingrix Gets Approval in Canada,2017-10-16 22:07:10 +0000,https://finance.yahoo.com/news/glaxo-apos-shingles-vaccine-shingrix-220710696.html?.tsrc=rss,GlaxoSmithKline plc (GSK) announced that its vaccine Shingrix has been approved in Canada for the prevention of shingles (herpes zoster) in people aged between 50 years or more.
GSK,GSK:US,BBG000BLB481,GSK January 2020 Options Begin Trading,2017-10-16 15:17:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e90uoCSHnR4/gsk-january-2020-options-begin-trading-cm860120,Investors in GlaxoSmithKline plc Symbol GSK saw new options become available today for the January 2020 expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 823 days until expiration the newly available contracts represent
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 16, 2017 :  F, EXEL, GSK, VALE, NVO, BAC, JD, MNKD, TEVA, AAPL, MU, XT",2017-10-16 12:55:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fQcGC3YCL_0/pre-market-most-active-for-oct-16-2017-f-exel-gsk-vale-nvo-bac-jd-mnkd-teva-aapl-mu-xt-cm859997,The NASDAQ 100 Pre Market Indicator is up 12 88 to 6 105 33 The total Pre Market volume is currently 6 077 323 shares traded The following are the most active stocks for the pre market session Ford Motor Company F is 0 08 at 11 97 with 1 260 112 shares traded F
GSK,GSK:US,BBG000BLB481,5 Large-Cap Drug Stocks Well Poised to Beat on Q3 Earnings,2017-10-13 20:14:08 +0000,https://finance.yahoo.com/news/5-large-cap-drug-stocks-201408113.html?.tsrc=rss,The pharma/biotech sector has a number of things going in its favor.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's shingles vaccine gets approval in Canada,2017-10-13 19:00:00 +0000,https://finance.yahoo.com/news/glaxosmithklines-shingles-vaccine-gets-approval-190000243.html?.tsrc=rss,"(Reuters) - Canadian health regulators have approved GlaxoSmithKline's (GSK.L) key shingles vaccine, the company said on Friday. Shingrix, the British pharma company's shingles vaccine for people aged ..."
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 13, 2017 :  BAC, MON, ITEK, WFC, GSK, GE, T, MSFT, AAPL, CSCO, INTC, CMCSA",2017-10-13 12:51:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aJ7Kf4muDd8/pre-market-most-active-for-oct-13-2017-bac-mon-itek-wfc-gsk-ge-t-msft-aapl-csco-intc-cmcsa-cm859245,The NASDAQ 100 Pre Market Indicator is up 15 04 to 6 085 03 The total Pre Market volume is currently 21 610 996 shares traded The following are the most active stocks for the pre market session Bank of America Corporation BAC is unchanged at 25 45 with 2 402 762
GSK,GSK:US,BBG000BLB481,Pharma companies are starting to recruit top talent from tech giants like Google and LinkedIn,2017-10-12 22:32:31 +0000,http://finance.yahoo.com/r/de6ef495-5c04-3801-bbcd-d21da52cc6ac/104769782?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104769782&yptr=yahoo&.tsrc=rss,Pharma companies are recruiting technologists to help speed up their drug discovery and development processes.
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 12, 2017 :  MU, AZN, ACRX, ARDX, INFI, JILL, BAC, C, GSK, SNAP, MNKD, TVIX",2017-10-12 13:00:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rFgMTX5T4fA/pre-market-most-active-for-oct-12-2017-mu-azn-acrx-ardx-infi-jill-bac-c-gsk-snap-mnkd-tvix-cm858607,The NASDAQ 100 Pre Market Indicator is down 7 6 to 6 073 65 The total Pre Market volume is currently 7 505 857 shares traded The following are the most active stocks for the pre market session Micron Technology Inc MU is 0 56 at 41 05 with 2 408 485 shares
GSK,GSK:US,BBG000BLB481,Validea Joel Greenblatt Strategy Daily Upgrade Report - 10/12/2017,2017-10-12 09:11:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QjTSQc9dSG0/validea-joel-greenblatt-strategy-daily-upgrade-report-10122017-cm858552,The following are today s upgrades for Validea s Earnings Yield Investor model based on the published strategy of Joel Greenblatt This value model looks for companies with high return on capital and earnings yields The following are today s upgrades for Validea s Earnings Yield Investor
GSK,GSK:US,BBG000BLB481,[$$] Ebola Vaccines Show Promise in New Study,2017-10-11 21:31:06 +0000,http://finance.yahoo.com/r/8a109240-3c4f-3661-98b2-112c8835cbd8/ebola-vaccines-show-promise-in-new-study-1507755629?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ..."
GSK,GSK:US,BBG000BLB481,Pfizer Considering Sale/Spin-Off of Consumer Healthcare Unit,2017-10-11 16:14:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mQoBBF_KP3c/pfizer-considering-salespin-off-of-consumer-healthcare-unit-cm858185,Pfizer Inc PFE said it is exploring strategic alternatives for its Consumer Healthcare segment including a partial or a full separation through a spin off sale or other transaction A decision regarding the same is expected to be made next year and it may ultimately opt to retain the
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 11, 2017 :  MU, MNKD, GSK, GE, QQQ, TVIX, ROKU, SNAP, NOK, HIMX, SNN, BABA",2017-10-11 13:00:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xJrxSEYMCS0/pre-market-most-active-for-oct-11-2017-mu-mnkd-gsk-ge-qqq-tvix-roku-snap-nok-himx-snn-baba-cm857959,The NASDAQ 100 Pre Market Indicator is to 6 063 52 The total Pre Market volume is currently 2 609 972 shares traded The following are the most active stocks for the pre market session Micron Technology Inc MU is 1 23 at 40 75 with 1 647 579 shares traded
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 10, 2017 :  MNKD, NVDA, GSK, BABA, BAC, WMT, NVO, MU, CHL, TVIX, ERIC, ANAB",2017-10-10 13:00:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gF9CgL3oft8/pre-market-most-active-for-oct-10-2017-mnkd-nvda-gsk-baba-bac-wmt-nvo-mu-chl-tvix-eric-anab-cm857369,The NASDAQ 100 Pre Market Indicator is up 14 04 to 6 072 57 The total Pre Market volume is currently 5 343 333 shares traded The following are the most active stocks for the pre market session MannKind Corporation MNKD is 0 72 at 6 05 with 619 408 shares
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 9, 2017 :  CHL, LYG, GSK, GE, ERIC, MNKD, SWCH, NVO, FLXN, AMKR, QQQ, TVIX",2017-10-09 13:00:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oLdVpcmL-To/pre-market-most-active-for-oct-9-2017-chl-lyg-gsk-ge-eric-mnkd-swch-nvo-flxn-amkr-qqq-tvix-cm856838,The NASDAQ 100 Pre Market Indicator is up 7 01 to 6 071 58 The total Pre Market volume is currently 2 892 965 shares traded The following are the most active stocks for the pre market session China Mobile Hong Kong Ltd CHL is 0 22 at 50 35 with 525 542
GSK,GSK:US,BBG000BLB481,New Drugs Approved In September,2017-10-09 05:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AMA7U9Q5EXE/new-drugs-approved-in-september-20171009-00181,New Drugs Approved In September
GSK,GSK:US,BBG000BLB481,May to consult business leaders on Brexit,2017-10-08 23:27:38 +0000,https://finance.yahoo.com/news/may-consult-business-leaders-brexit-231033264.html?.tsrc=rss,"Prime Minister Theresa May will meet GlaxoSmithKline, Vodafone and HSBC and other major companies on Monday to hear what they want from talks on Britain's relationship with the EU after Brexit.  Businesses have become increasingly alarmed by the slow progress of negotiations and the prospect that the country could crash out of the trading bloc without a deal in 2019."
GSK,GSK:US,BBG000BLB481,3 High-Yield Healthcare Stocks,2017-10-08 13:00:00 +0000,http://finance.yahoo.com/r/f8834e3a-dc19-39fb-a3f6-e7cec19bb6a5/3-high-yield-healthcare-stocks.aspx?yptr=yahoo&.tsrc=rss,"If you&apos;re on the hunt for above-average yields, these three healthcare stocks should be on your radar."
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal",2017-10-06 14:44:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7icxbt800Go/pharma-stock-roundup-mylan-up-teva-down-on-copaxone-news-lawmakers-question-allergan-deal-cm856152,This week companies like Allergan AGN Teva TEVA and Mylan MYL were in the limelight While Mylan and Teva were in the news related to the FDA approval of Mylan s generic versions of Teva s top selling branded drug Copaxone Allergan is under fire for its agreement with the Saint Regis
GSK,GSK:US,BBG000BLB481,[$$] Consumer drugs do not always work for big pharma ,2017-10-06 05:36:22 +0000,"http://finance.yahoo.com/r/df25027a-623b-3391-9f46-ced6a0ecade3/2ffe076c-a485-11e7-b797-b61809486fe2,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss",There is a big difference between a cold and the flu - and it is a distinction on which drugmakers have long relied when selling throat lozenges and fortified lemon drinks over the counter for one condition ...
GSK,GSK:US,BBG000BLB481,Changes in GlaxoSmithKline’s Valuation,2017-10-05 14:38:09 +0000,http://finance.yahoo.com/r/30acc338-c42a-3243-bd25-150cdfddf12a/changes-in-glaxosmithklines-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x."
GSK,GSK:US,BBG000BLB481,Performance of GlaxoSmithKline’s Consumer Healthcare Segment,2017-10-05 13:08:22 +0000,http://finance.yahoo.com/r/26fc499d-69a8-3af3-8788-dde68dcb9cad/performance-of-glaxosmithklines-consumer-healthcare-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s (GSK) Consumer Healthcare segment has improved its supply chain over the last few years while adding new products to the portfolio.
GSK,GSK:US,BBG000BLB481,Quarterly Performance of GlaxoSmithKline’s Vaccines Segment,2017-10-05 11:39:44 +0000,http://finance.yahoo.com/r/23e228d1-2a10-35bf-a041-a2b53f15d31d/quarterly-performance-of-glaxosmithklines-vaccines-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The Vaccines segment reported a 16.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16.
GSK,GSK:US,BBG000BLB481,Emergent Completes Acquisition of Anthrax Drug Raxibacumab,2017-10-04 16:11:04 +0000,https://finance.yahoo.com/news/emergent-completes-acquisition-anthrax-drug-161104515.html?.tsrc=rss,"Emergent BioSolutions Inc. (EBS) completes the acquisition of anthrax monoclonal antibody, raxibacumab, from GlaxoSmithkline."
GSK,GSK:US,BBG000BLB481,Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg,2017-10-04 15:35:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H6Rl-TaeMDA/mylan-myl-gets-fda-approval-for-generic-copaxone-40mg-cm855170,Mylan N V MYL announced that the FDA has approved Abbreviated New Drug Applications ANDAs for the generic version of Teva Pharmaceutical Industries Limited s TEVA multiple sclerosis MS drug Copaxone glatiramer acetate 40 mg mL thrice weekly Notably this is the first generic
GSK,GSK:US,BBG000BLB481,Quarterly Performance of GlaxoSmithKline’s Global Pharmaceuticals,2017-10-04 14:39:27 +0000,http://finance.yahoo.com/r/f907652d-5073-3b37-85c1-c2c27387d866/quarterly-performance-of-glaxosmithklines-global-pharmaceuticals?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline's (GSK) immuno-inflammation franchise, which includes Benlysta, reported a rise of 9.0% in revenues at constant exchange rates to 93.0 million pounds in 2Q17 compared to 2Q16."
GSK,GSK:US,BBG000BLB481,Quarterly Performance for GlaxoSmithKline’s HIV Business,2017-10-04 13:10:24 +0000,http://finance.yahoo.com/r/c443d860-ba80-3bba-98bf-7fd2883ae927/quarterly-performance-for-glaxosmithklines-hiv-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"HIV products reported a 29.0% rise in revenues to 1.1 billion pounds in 2Q17 compared to 2Q16, driven by the strong performances of Tivicay and Triumeq."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Pharmaceuticals Segment in 2Q17,2017-10-04 11:43:30 +0000,http://finance.yahoo.com/r/f60e6fe1-1a3f-38f7-9efe-e8b47ab4a1c9/glaxosmithklines-pharmaceuticals-segment-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s (GSK) Pharmaceuticals segment reported a 3.0% rise in revenues at constant exchange rates and a 9.0% positive impact of foreign exchange in 2Q17.
GSK,GSK:US,BBG000BLB481,Quarterly Performance of GlaxoSmithKline’s Segments,2017-10-03 20:36:42 +0000,http://finance.yahoo.com/r/ea23dda0-2130-326f-9740-fc893804aed6/quarterly-performance-of-glaxosmithklines-segments?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, the company reported a 2.0% rise in revenues at constant exchange rates to 7.3 billion pounds, driven by increased sales across all three segments."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Quarterly Revenues,2017-10-03 19:06:58 +0000,http://finance.yahoo.com/r/267fe28e-0984-3073-9dea-72369e7d3676/glaxosmithklines-quarterly-revenues?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline (GSK) reported a 12.0% rise in revenues to 7.3 billion pounds in 2Q17 compared to 6.5 billion pounds in 2Q16.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Recent 3Q17 Developments,2017-10-03 17:17:07 +0000,http://finance.yahoo.com/r/5ba481c9-4598-3c61-8247-c91586ca299e/glaxosmithklines-recent-3q17-developments?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On September 27, 2017, the Japanese Ministry of Health, Labour and Welfare approved Benlysta for the treatment of systemic lupus erythematosus in patients not cured with existing therapies."
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Oct 3, 2017 :  ECYT, BRCD, ERIC, RIGL, GSK, TTS, ZGNX, BAC, GM, TEVA, BABA, MFGP",2017-10-03 12:55:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l_kLMMC7Cbg/pre-market-most-active-for-oct-3-2017-ecyt-brcd-eric-rigl-gsk-tts-zgnx-bac-gm-teva-baba-mfgp-cm854375,The NASDAQ 100 Pre Market Indicator is up 1 59 to 5 983 51 The total Pre Market volume is currently 2 054 180 shares traded The following are the most active stocks for the pre market session Endocyte Inc ECYT is 2 27 at 5 90 with 4 111 676 shares traded
GSK,GSK:US,BBG000BLB481,"Emergent BioSolutions Completes Acquisition of Raxibacumab, an FDA-Approved Anthrax Monoclonal Antibody, From GSK",2017-10-03 11:00:00 +0000,https://finance.yahoo.com/news/emergent-biosolutions-completes-acquisition-raxibacumab-110000302.html?.tsrc=rss,"Transaction anticipated to be additive by approximately $9 million to revenue and neutral to GAAP net income for full year 2017. GAITHERSBURG, Md., Oct. 03, 2017-- Emergent BioSolutions Inc. announced ..."
GSK,GSK:US,BBG000BLB481,U.S. judge dismisses ex-sleuths' lawsuit against GlaxoSmithKline,2017-10-02 20:27:47 +0000,https://finance.yahoo.com/news/u-judge-dismisses-ex-sleuths-202747237.html?.tsrc=rss,"U.S. District Judge Nitza Quinones Alejandro in Philadelphia on Friday threw out the case by British investigator Peter Humphrey and his American wife, Yu Yingzeng, who were arrested in 2013 in China after GSK hired them to look into a former employee.  The judge said a U.S. Supreme Court ruling barred lawsuits filed under the federal Racketeer Influenced and Corrupt Organizations Act (RICO) over injuries that occur entirely outside the United States such as this one involving incidents in China."
GSK,GSK:US,BBG000BLB481,Advanced Accelerator (AAAP) Cancer Therapy Approved in EU,2017-10-02 15:51:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/89cH5qtr4XE/advanced-accelerator-aaap-cancer-therapy-approved-in-eu-cm853937,Advanced Accelerator Applications S A AAAP announced that the European Commission has authorized the marketing of its drug Lutathera lutetium oxodotreotide for the treatment of gastroenteropancreatic neuroendocrine tumors GEP NET in adult patients The approval allows the company to
GSK,GSK:US,BBG000BLB481,Biotech Stocks Facing FDA Decision In October,2017-09-29 07:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nmihicMyCXk/biotech-stocks-facing-fda-decision-in-october-20170929-00332,Biotech Stocks Facing FDA Decision In October
GSK,GSK:US,BBG000BLB481,"Attention Biotech Investors, Here's Your PDUFA Primer For October",2017-09-28 14:51:16 +0000,https://finance.yahoo.com/news/attention-biotech-investors-heres-pdufa-145116345.html?.tsrc=rss,"The biotech space can be an investor's delight, fetching staggering returns, while at the same time taking them through the throes of despair if bets go wrong — all courtesy of make-or-break events. In ..."
GSK,GSK:US,BBG000BLB481,Agenus (AGEN) Remains Focused on Drug Development Programs,2017-09-28 14:46:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ifJ_UwRI0J8/agenus-agen-remains-focused-on-drug-development-programs-cm852562,We issued an updated research report on Agenus Inc AGEN on Sep 26 2017 Notably Agenus is an immuno oncology company focused on the discovery and development of checkpoint modulators vaccines and adjuvants for the treatment of cancer In fact the company has collaboration agreements with
GSK,GSK:US,BBG000BLB481,Agenus (AGEN) Remains Focused on Drug Development Programs,2017-09-28 13:20:01 +0000,https://finance.yahoo.com/news/agenus-agen-remains-focused-drug-132001495.html?.tsrc=rss,Agenus&apos; (AGEN) collaboration agreements provide a steady source of funds to boost pipeline development.
GSK,GSK:US,BBG000BLB481,"PPH, AZN, MRK, GSK: ETF Outflow Alert",2017-09-27 16:54:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WF4uqRbsNpI/pph-azn-mrk-gsk-etf-outflow-alert-cm851963,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 28 7 million dollar outflow that s a 10 6 decrease week over week from 4 738 138
GSK,GSK:US,BBG000BLB481,AstraZeneca's Bevespi Improves Lung Function in Phase III Study,2017-09-27 14:58:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c9HEZap6WeI/astrazenecas-bevespi-improves-lung-function-in-phase-iii-study-cm851768,AstraZeneca plc AZN announced top line data from a late stage study which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with moderate to very severe chronic obstructive pulmonary disease COPD The phase III PINNACLE 4
GSK,GSK:US,BBG000BLB481,AstraZeneca&apos;s Bevespi Improves Lung Function in Phase III Study,2017-09-27 13:05:01 +0000,https://finance.yahoo.com/news/astrazeneca-apos-bevespi-improves-lung-130501205.html?.tsrc=rss,"AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD."
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Sep 27, 2017 :  MU, BAC, TLT, ERIC, AAPL, CASC, GSK, CTLT, SNY, QQQ, NKE, TOT",2017-09-27 12:51:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4apUWj8LlOQ/pre-market-most-active-for-sep-27-2017-mu-bac-tlt-eric-aapl-casc-gsk-ctlt-sny-qqq-nke-tot-cm851535,The NASDAQ 100 Pre Market Indicator is up 21 38 to 5 902 72 The total Pre Market volume is currently 5 410 334 shares traded The following are the most active stocks for the pre market session Micron Technology Inc MU is 1 87 at 36 05 with 1 929 147 shares
GSK,GSK:US,BBG000BLB481,What Happened to Allergan’s Valuation after 2Q17?,2017-09-27 11:37:12 +0000,http://finance.yahoo.com/r/08cec61f-6888-3ef7-a419-b673d64a59e6/what-happened-to-allergans-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Of the 21 analysts tracking Allergan stock, 14 recommend a “buy,” and seven analysts recommend a “hold.” None recommends a “sell.”"
GSK,GSK:US,BBG000BLB481,Axovant Sciences' Alzheimer's Disease Trial Comes Up Empty -- What Now?,2017-09-26 23:52:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IQEzQ1sTb28/axovant-sciences-alzheimers-disease-trial-comes-up-empty-what-now-cm851431,Historically 99 of Alzheimer s disease drugs to enter clinical trials have failed yet Axovant Sciences NASDAQ AXON believed it could design a phase 3 trial for its Alzheimer s disease drug intepirdine that could overcome those stiff odds Sadly 160 Axovant Sciences
GSK,GSK:US,BBG000BLB481,Biotech's Boy Wonder Calls Alzheimer's Drug His 'Single Greatest Failure',2017-09-26 19:00:00 +0000,http://finance.yahoo.com/r/235cb22c-b347-3e79-8ab0-e4937f4b00d0/biotechs-boy-wonder-calls-alzheimers-drug-his-single-greatest-failure?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Vivek Ramaswamy's would-be Alzheimer's drug failed terribly in its clinical trial. ""It stings me personally."""
GSK,GSK:US,BBG000BLB481,J&J's Arthritis Candidate Sirukumab Denied FDA Approval,2017-09-26 13:57:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E_YDM-Zy_KQ/jjs-arthritis-candidate-sirukumab-denied-fda-approval-cm850880,Johnson amp Johnson JNJ announced that the FDA has denied approval to its investigational rheumatoid arthritis RA treatment sirukumab an IL 6 inhibitor for want of additional safety data The FDA issued a complete response letter CRL for J amp J s Biologics License Application BLA
GSK,GSK:US,BBG000BLB481,Caveat Emptor When Buying High-Yield Drug Stocks,2017-09-26 13:54:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L2o7W8NSZUI/caveat-emptor-when-buying-high-yield-drug-stocks-cm850892,Income investors seemingly have hundreds of stocks to choose from that currently pay a dividend The telecom and utility sectors often generate some of the most robust payouts for investors with FactSet Research data from the third quarter of 2016 showing that sector aggregate yield
GSK,GSK:US,BBG000BLB481,3 High-Yield Stocks for Conservative Investors,2017-09-26 13:52:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vw8ajnZMBOg/3-high-yield-stocks-for-conservative-investors-cm850935,High yield stocks are generally off limits for risk averse investors because they tend to be fundamentally unsound types of equities bringing with them high debt loads falling top lines and so on However there are a few rare gems that may be attractive to conservative
GSK,GSK:US,BBG000BLB481,3 High-Yield Stocks for Conservative Investors,2017-09-26 13:00:00 +0000,http://finance.yahoo.com/r/1f62d87d-55ff-317a-91f3-4aacdf42d6c9/3-high-yield-for-conservative-investors.aspx?yptr=yahoo&.tsrc=rss,These three high-yield dividend stocks won&apos;t keep you awake at night.
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Sep 26, 2017 :  AXON, ERIC, NOK, CHL, SBRA, AZN, NVDA, QQQ, AAPL, CHK, BABA, GSK",2017-09-26 12:56:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E98nVpogYuM/pre-market-most-active-for-sep-26-2017-axon-eric-nok-chl-sbra-azn-nvda-qqq-aapl-chk-baba-gsk-cm850845,The NASDAQ 100 Pre Market Indicator is up 19 53 to 5 886 88 The total Pre Market volume is currently 6 039 936 shares traded The following are the most active stocks for the pre market session Axovant Sciences Ltd AXON is 18 3 at 5 95 with 4 882 387 shares traded
GSK,GSK:US,BBG000BLB481,Axovant Alzheimer's Drug Fails To Help Patients,2017-09-26 11:14:00 +0000,http://finance.yahoo.com/r/b613727b-414b-3c0b-94bb-6d8b2217aa71/axovant-raised-hundreds-of-millions-around-its-alzheimers-drug-it-just-failed?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Investors poured hundreds of millions of dollars into Axovant and its experimental Alzheimer’s drug, intepirdine. But in the end, the medicine was no different from 99% of medicines tested against the brain-wasting disease since 2002 -- it failed."
GSK,GSK:US,BBG000BLB481,UPDATE 2-FDA declines to approve J&J arthritis drug sirukumab,2017-09-25 14:25:56 +0000,https://finance.yahoo.com/news/2-fda-declines-approve-j-142556877.html?.tsrc=rss,"The U.S. Food and Drug Administration  has declined to approve Johnson & Johnson's rheumatoid  arthritis drug sirukumab, saying additional clinical data is  needed to further evaluate its safety, the company said on  Friday.  The FDA's decision is in keeping with an advisory panel's  recommendation in August that the FDA reject the drug.  ""We are disappointed by this development as we feel the data  accumulated to date support the efficacy and safety of  sirukumab,""  He added that the company is seeking to ""gain a  full understanding of FDA requirements for U.S. approval"" and  plans to have a follow-up discussion with the agency."
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Sep 25, 2017 :  AAPL, GSK, ICPT, VSAR, MT, TLT, RIG, AZN, QQQ, MU, GM, CHK",2017-09-25 12:56:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8HMvLEkbVkI/pre-market-most-active-for-sep-25-2017-aapl-gsk-icpt-vsar-mt-tlt-rig-azn-qqq-mu-gm-chk-cm850257,The NASDAQ 100 Pre Market Indicator is down 16 95 to 5 915 37 The total Pre Market volume is currently 3 554 858 shares traded The following are the most active stocks for the pre market session Apple Inc AAPL is 1 69 at 150 20 with 353 243 shares traded
GSK,GSK:US,BBG000BLB481,12 Flu Season Facts You Need to Know,2017-09-24 16:47:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yd46zRxlgeo/12-flu-season-facts-you-need-to-know-cm850159,Fall is officially here and that usually means three things pumpkin spiced everything is back in style our lush trees are about to become leafless sticks and that sniffle and cough could be your warning that flu season is upon us While you ve been busy enjoying the summer and
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update",2017-09-22 14:40:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aD0-fF1ZJ_8/pharma-stock-roundup-pfizer-files-suit-against-jj-supernus-hit-by-study-update-cm849533,Key highlights this week include a lawsuit filed by Pfizer PFE accusing Johnson amp Johnson JNJ of adopting exclusionary contracts and other anticompetitive practices to prevent biosimilar uptake Meanwhile companies like GlaxoSmithKline GSK and Supernus Pharmaceuticals SUPN were in the
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update",2017-09-22 12:42:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-pfizer-files-124212253.html?.tsrc=rss,Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
GSK,GSK:US,BBG000BLB481,Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III,2017-09-21 15:40:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kU0-Nz28pZQ/glaxo-innovivas-triple-combo-inhaler-positive-in-phase-iii-cm848989,GlaxoSmithKline plc GSK and partner Innoviva Inc INVA announced that its once daily single inhaler triple therapy Trelegy Ellipta FF UMEC VI fluticasone furoate umeclidinium vilanterol met primary endpoint in a phase III IMPACT study showing reduction in exacerbations in patients
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry,2017-09-21 14:42:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hongiZpuMmE/how-glaxosmithkline-gsk-stock-stands-out-in-a-strong-industry-cm848955,One stock that might be an intriguing choice for investors right now is GlaxoSmithKline plc GSK This is because this security in the Large Cap Pharmaceuticals space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective This
GSK,GSK:US,BBG000BLB481,Glaxo-Innoviva&apos;s Triple Combo Inhaler Positive in Phase III,2017-09-21 13:44:01 +0000,https://finance.yahoo.com/news/glaxo-innoviva-apos-triple-combo-134401325.html?.tsrc=rss,"GlaxoSmithKline plc (GSK) along with partner Innoviva reports positive results from a phase III study, evaluating a single inhaler triple therapy in patients with COPD."
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Sep 21, 2017 :  CCC, VEON, MTU, GSK, NOK, BCRX, NVDA, ERIC, VAC, IOVA, BBL, MU",2017-09-21 12:55:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wkIJpeBvb3Y/pre-market-most-active-for-sep-21-2017-ccc-veon-mtu-gsk-nok-bcrx-nvda-eric-vac-iova-bbl-mu-cm848888,The NASDAQ 100 Pre Market Indicator is down 4 21 to 5 969 39 The total Pre Market volume is currently 9 639 647 shares traded The following are the most active stocks for the pre market session Calgon Carbon Corporation CCC is 8 16 at 21 36 with 3 241 191
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline (GSK) Stock Stands Out in a Strong Industry,2017-09-21 12:33:12 +0000,https://finance.yahoo.com/news/glaxosmithkline-gsk-stock-stands-strong-123312863.html?.tsrc=rss,"GlaxoSmithKline (GSK) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective."
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?,2017-09-20 15:43:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NP3FdnRFWgE/is-glaxosmithkline-plc-gsk-a-suitable-value-stock-cm848370,Value investing is easily one of the most popular ways to find great stocks in any market environment After all who wouldn t want to find stocks that are either flying under the radar and are compelling buys or offer up tantalizing discounts when compared to fair value One way to find
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline plc (GSK) a Suitable Value Stock?,2017-09-20 13:40:01 +0000,https://finance.yahoo.com/news/glaxosmithkline-plc-gsk-suitable-value-134001628.html?.tsrc=rss,"GlaxoSmithKline is an inspired choice for value investors, as it is hard to beat its incredible lineup of statistics on this front."
GSK,GSK:US,BBG000BLB481,GSK's new triple lung drug beats other modern inhalers in study,2017-09-20 07:17:22 +0000,https://finance.yahoo.com/news/gsks-triple-lung-drug-beats-071722139.html?.tsrc=rss,"GlaxoSmithKline produced  clinical data on Wednesday showing its newly approved  three-in-one inhaler reduced life-threatening attacks in chronic  obstructive pulmonary disease (COPD) patients more than other  modern treatments.  Britain's biggest drugmaker believes the results confirm the  potential of the once-daily single inhaler, Trelegy Ellipta, a  product it hopes will offset the impact of generic competition  to the older lung drug Advair.  Trelegy won approval based on clinical tests showing it  improved lung function and exacerbations more than AstraZeneca's  long-established two-drug inhaler Symbicort, which works  in a similar way to Advair."
GSK,GSK:US,BBG000BLB481,GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations,2017-09-20 06:00:00 +0000,https://finance.yahoo.com/news/gsk-innoviva-report-positive-headline-060000397.html?.tsrc=rss,"GlaxoSmithKline plc and Innoviva, Inc. today announced positive headline results from the landmark phase III IMPACT study of Trelegy Ellipta, the first and only FDA approved once-daily single inhaler triple therapy comprising an inhaled corticosteroid , long-acting muscarinic antagonist and long-acting beta agonist ."
GSK,GSK:US,BBG000BLB481,Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD,2017-09-19 21:38:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yfbq-he4Rvw/glaxoinnovivas-triple-combo-therapy-gets-fda-nod-for-copd-cm848042,GlaxoSmithKline plc GSK and partner Innoviva Inc INVA announced that the FDA has approved a once daily single inhaler triple combination therapy FF UMEC VI fluticasone furoate umeclidinium vilanterol as maintenance treatment for patients with chronic obstructive pulmonary
GSK,GSK:US,BBG000BLB481,"FDA OKs Glaxo's inhaler, first one to combine 3 medicines",2017-09-19 20:40:59 +0000,http://finance.yahoo.com/r/b6b814c3-f409-3657-a948-3fb67c8d961a/fda-oks-glaxos-inhaler-first-155337662.html?.tsrc=rss,"TRENTON, N.J. (AP) — The Food and Drug Administration has approved the first inhaler combining three medicines to ease breathing in patients with emphysema or chronic bronchitis."
GSK,GSK:US,BBG000BLB481,Glaxo/Innoviva&apos;s Triple Combo Therapy Gets FDA Nod for COPD,2017-09-19 19:05:07 +0000,https://finance.yahoo.com/news/glaxo-innoviva-apos-triple-combo-190507628.html?.tsrc=rss,"The FDA approves GlaxoSmithKline (GSK) and Innoviva&apos;s triple combination therapy, FF/UMEC/VI, for COPD. The drug will be accessed as Trelegy Ellipta in the U.S. market."
GSK,GSK:US,BBG000BLB481,[$$] Andrew Witty jumps into biotech venture capital,2017-09-19 17:26:41 +0000,"http://finance.yahoo.com/r/3214106b-9a42-3ab0-9c10-57971ce0d224/adfadcdc-9d49-11e7-8cd4-932067fbf946,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Sir Andrew Witty, the former long-serving chief executive of UK drugmaker GlaxoSmithKline, has jumped into the biotech venture-capital sector and been hired by a former industry mentor to join Hatteras ..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline breathes easier as U.S. approves triple lung drug,2017-09-19 08:02:57 +0000,https://finance.yahoo.com/news/glaxosmithkline-breathes-easier-u-approves-080257505.html?.tsrc=rss,"U.S. regulators have approved  GlaxoSmithKline's three-in-one inhaler for chronic lung  disease, a key new product for the group as it strives to keep  its lead in respiratory medicine despite falling sales of the  older drug Advair.  Trelegy Ellipta is the first once-daily triple medicine for  chronic obstructive pulmonary disease (COPD), putting Britain's  biggest drugmaker ahead of rivals such as AstraZeneca  and Novartis."
GSK,GSK:US,BBG000BLB481,Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US,2017-09-19 00:30:00 +0000,https://finance.yahoo.com/news/trelegy-ellipta-approved-first-once-003000965.html?.tsrc=rss,"LONDON , Sept. 18, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single ..."
GSK,GSK:US,BBG000BLB481,U.S. FDA approves GSK's three-in-one drug inhaler for COPD,2017-09-18 23:18:03 +0000,https://finance.yahoo.com/news/u-fda-approves-gsks-three-231803803.html?.tsrc=rss,GlaxoSmithKline Plc and Innoviva Inc said on Monday the U.S. Food and Drug Administration has approved their triple drug inhaler for treatment of chronic obstructive pulmonary disease . GSK's once-daily ...
GSK,GSK:US,BBG000BLB481,Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US,2017-09-18 22:29:00 +0000,https://finance.yahoo.com/news/trelegy-ellipta-approved-first-once-222900703.html?.tsrc=rss,"GlaxoSmithKline plc and Innoviva, Inc. today announced that the US Food and Drug Administration has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol , under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease , including chronic bronchitis and/or emphysema, who are on ..."
GSK,GSK:US,BBG000BLB481,FDA Okays GSK's Three-in-one Drug Inhaler For COPD,2017-09-18 21:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G3zkdRcRMEQ/fda-okays-gsks-threeinone-drug-inhaler-for-copd-20170918-01306,FDA Okays GSK's Three-in-one Drug Inhaler For COPD
GSK,GSK:US,BBG000BLB481,What Analysts Recommend for Novartis in September 2017,2017-09-18 18:19:40 +0000,http://finance.yahoo.com/r/b2abd793-25e1-39d4-b8dc-faf8e4a167ef/what-analysts-recommend-for-novartis-in-september-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”"
GSK,GSK:US,BBG000BLB481,Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU,2017-09-18 16:40:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qv95kHKxPGg/glaxos-triple-therapy-copd-inhaler-gets-chmp-nod-in-the-eu-cm847176,GlaxoSmithKline plc GSK and partner Innoviva Inc INVA announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has granted a positive opinion recommending approval of its once daily single inhaler triple therapy in the EU So far this
GSK,GSK:US,BBG000BLB481,3 High-Yield Healthcare Stocks,2017-09-18 15:40:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/soqTbR9SJd0/3-high-yield-healthcare-stocks-cm847092,One downside to a long lasting bull market is that the market s dividend yield declines That s a big problem for retirees who rely on their portfolio to meet their income needs Even in today s pricey market there are a few high yield stocks still worth buying Want proof We asked
GSK,GSK:US,BBG000BLB481,Interesting GSK Put And Call Options For May 2018,2017-09-18 15:36:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aXu4sgGrXrI/interesting-gsk-put-and-call-options-for-may-2018-cm847138,Investors in GlaxoSmithKline plc Symbol GSK saw new options become available today for the May 2018 expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 242 days until expiration the newly available contracts represent
GSK,GSK:US,BBG000BLB481,3 High-Yield Healthcare Stocks,2017-09-18 14:30:00 +0000,http://finance.yahoo.com/r/6861f713-422b-35b4-9667-ce166b10aab5/3-high-yield-healthcare-stocks.aspx?yptr=yahoo&.tsrc=rss,"GlaxoSmithKline, HCP, and Pfizer all offer their shareholders fat payouts. Here&apos;s why income investors can safely buy each of these stocks today."
GSK,GSK:US,BBG000BLB481,Glaxo&apos;s Triple Therapy COPD Inhaler Gets CHMP Nod in the EU,2017-09-18 14:23:02 +0000,https://finance.yahoo.com/news/glaxo-apos-triple-therapy-copd-142302010.html?.tsrc=rss,Glaxo&apos;s (GSK) single inhaler triple therapy for the treatment of COPD in patients who are already being treated with a ICS/LAMA combination received a positive opinion from the CHMP in the EU.
GSK,GSK:US,BBG000BLB481,"FDA Nod For NEOS, One Step Closer To EU Approval Are GSK, TSRO, On Watch Is MTFB",2017-09-17 23:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sj0CBpkf7lQ/fda-nod-for-neos-one-step-closer-to-eu-approval-are-gsk-tsro-on-watch-is-mtfb-20170917-00103,"FDA Nod For NEOS, One Step Closer To EU Approval Are GSK, TSRO, On Watch Is MTFB"
GSK,GSK:US,BBG000BLB481,France's Neovacs takes on GSK and AstraZeneca in battle to treat lupus,2017-09-15 14:24:55 +0000,https://finance.yahoo.com/news/frances-neovacs-takes-gsk-astrazeneca-142455921.html?.tsrc=rss,"French biotech company Neovacs  is confident that its experimental drug to treat  lupus could grab significant market share from standard  treatments of the auto-immune disease, its chief executive said.  About 5 million people globally suffer from some form of  lupus, the Lupus foundation of America says, affecting multiple  organs and leading to a range of symptoms that can include skin  rashes, swollen joints and fevers.  Until now, treatments from the likes of GlaxoSmithKline  (GSK) and AstraZeneca's MedImmune have focused on  the use of monoclonal antibodies, but Neovacs is working on  therapeutic vaccines covered by five patent families it calls  kinoids, with patent protection until 2032."
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO",2017-09-15 12:38:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nEtZLBtU3oM/pharma-stock-roundup-achillion-slumps-on-end-of-hcv-deal-teva-gets-a-new-ceo-cm846148,Several important developments were reported this week with key highlights including the termination of a hepatitis C virus deal the approval of the first cancer biosimilar in the United States and the presentation of data by companies like Pfizer PFE and Bristol Myers Squibb BMY among
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO",2017-09-15 10:52:10 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-achillion-slumps-105210457.html?.tsrc=rss,Key highlights this week include Teva&apos;s (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.
GSK,GSK:US,BBG000BLB481,GSK's three-in-one inhaler gets positive opinion from EU agency,2017-09-15 07:23:16 +0000,https://finance.yahoo.com/news/gsks-three-one-inhaler-gets-072316479.html?.tsrc=rss,"GlaxoSmithKline said on Friday  that a European Medicines Agency (EMA) panel has recommended the  company's three-in-one inhaled lung drug.  GSK's once-daily triple inhaler combines the drugs  fluticasone furoate, umeclidinium and vilanterol.  The idea is to  use three different mechanisms to help open airways of patients  with severe chronic obstructive pulmonary disease (COPD)."
GSK,GSK:US,BBG000BLB481,GSK's three-in-one inhaler gets positive opinion from EU agency,2017-09-15 06:44:58 +0000,https://finance.yahoo.com/news/gsks-three-one-inhaler-gets-064458249.html?.tsrc=rss,"GlaxoSmithKline said on Friday  that a European Medicines Agency (EMA) panel has recommended the  company's three-in-one inhaled lung drug.  GSK's once-daily triple inhaler combines the drugs  fluticasone furoate, umeclidinium and vilanterol.  The idea is to  use three different mechanisms to help open airways of patients  with severe chronic obstructive pulmonary disease (COPD)."
GSK,GSK:US,BBG000BLB481,Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD,2017-09-15 06:00:00 +0000,https://finance.yahoo.com/news/trelegy-ellipta-once-daily-single-060000469.html?.tsrc=rss,"GlaxoSmithKline plc and Innoviva, Inc. today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive opinion recommending marketing authorisation for fluticasone furoate/ umeclidinium/vilanterol as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease who are not adequately treated by a combination ..."
GSK,GSK:US,BBG000BLB481,"GSK, Innoviva: Trelegy Ellipta Gets CHMP Positive Opinion In Europe For COPD",2017-09-15 02:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RuJUVjE2Vvg/gsk-innoviva-trelegy-ellipta-gets-chmp-positive-opinion-in-europe-for-copd-20170915-00066,"GSK, Innoviva: Trelegy Ellipta Gets CHMP Positive Opinion In Europe For COPD"
GSK,GSK:US,BBG000BLB481,Glaxo's Shingles Candidate Gets Positive FDA Committee Vote,2017-09-14 17:38:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PTYsiVXTvO8/glaxos-shingles-candidate-gets-positive-fda-committee-vote-cm845841,GlaxoSmithKline plc GSK recently announced that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate Shingrix in older patients Glaxo said the FDA s Vaccines and Related Biological Products Advisory Committee were impressed by
GSK,GSK:US,BBG000BLB481,Glaxo&apos;s Shingles Candidate Gets Positive FDA Committee Vote,2017-09-14 15:25:03 +0000,https://finance.yahoo.com/news/glaxo-apos-shingles-candidate-gets-152503006.html?.tsrc=rss,"Glaxo (GSK) declared that an FDA advisory panel has unanimously voted recommending approval for its shingles vaccine candidate, Shingrix, in older patients."
GSK,GSK:US,BBG000BLB481,Another 'Picks And Shovels' Nasdaq Stock With Massive Potential,2017-09-14 13:42:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LmRQuuAgTOs/another-picks-and-shovels-nasdaq-stock-with-massive-potential-cm845629,"Shutterstock photo    A couple of years ago, I wrote  an article  that pointed out something that I believe to be important about investing in biotech. Small cap stocks in the sector can have massive potential but enormous risk, and whether or not you play in that area depends largely on your ability to deal with"
GSK,GSK:US,BBG000BLB481,Corporate News Blog - GlaxoSmithKline Declares Publication of Phase-III Results Of Mepolizumab in Patients with Eosinophilic COPD at Risk of Exacerbations,2017-09-14 11:40:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-glaxosmithkline-declares-114000305.html?.tsrc=rss,"Research Desk Line-up: China Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 14, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ..."
GSK,GSK:US,BBG000BLB481,"FDA Panel Nod For GSK's Shingles Vaccine, FOLD Beyond Essence, FENC Is Red Hot",2017-09-14 03:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/09APhjRftng/fda-panel-nod-for-gsks-shingles-vaccine-fold-beyond-essence-fenc-is-red-hot-20170914-00117,"FDA Panel Nod For GSK's Shingles Vaccine, FOLD Beyond Essence, FENC Is Red Hot"
GSK,GSK:US,BBG000BLB481,GSK Announces Unanimous FDA Approval For Shingrix In Over 50s - Quick Facts,2017-09-14 02:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-Z4teVjVDeU/gsk-announces-unanimous-fda-approval-for-shingrix-in-over-50s--quick-facts-20170914-00088,GSK Announces Unanimous FDA Approval For Shingrix In Over 50s - Quick Facts
GSK,GSK:US,BBG000BLB481,'Impressed' FDA panel unanimously recommends GSK shingles vaccine,2017-09-13 19:49:22 +0000,https://finance.yahoo.com/news/fda-panel-unanimously-votes-recommend-184604571.html?.tsrc=rss,"A U.S. Food and Drug Administration  advisory panel on Wednesday voted 11-0 that the safety and  efficacy of GlaxoSmithKline's Shingrix shingles vaccine  warrants approval for its use in adults aged 50 and over.  Panel members said they were ""very impressed"" by efficacy  data from Shingrix clinical trials, and that it represents an  improvement over Zostavax, the only marketed shingles prevention  vaccine from Merck & Co.  While the FDA is not required to follow recommendations of  its advisory panels, the enthusiasm expressed would seem to  indicate that approval is a virtual certainty in coming weeks."
GSK,GSK:US,BBG000BLB481,FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over,2017-09-13 19:49:00 +0000,https://finance.yahoo.com/news/fda-advisory-committee-votes-unanimously-194900883.html?.tsrc=rss,"LONDON , Sept. 13, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration ..."
GSK,GSK:US,BBG000BLB481,Regeneron's Dupixent Takes Another Step Toward Blockbuster Status,2017-09-13 12:36:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-Fn8nLbfBIk/regenerons-dupixent-takes-another-step-toward-blockbuster-status-cm844767,Regeneron Pharmaceuticals NASDAQ REGN unveiled phase 3 study data for its autoimmune disease drug Dupixent earlier this week that show it is effective in treating asthma The success has management planning to file for Dupixent s approval in asthma patients soon and that
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : August 11th, 2017 (record date) : By the numbers : September 12, 2017",2017-09-12 21:23:37 +0000,http://finance.yahoo.com/r/cf376999-7ac6-3a8f-a1d5-e80f5209a142/glaxosmithkline-plc-gsk-us-dividend-analysis-august-11th-2017-record-date-by-the-numbers-september-12-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing GlaxoSmithKline Plc with the following peers – Astrazeneca PLC Sponsored ADR, Merck & Co., Inc., Pfizer Inc., Novartis AG Sponsored ADR, Sanofi Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Shire PLC Sponsored ADR, Dynavax Technologies Corporation and Innoviva, Inc. (AZN-US, MRK-US, PFE-US, NVS-US, SNY-US, ... Read more
<b>(Read more...)</b>"
GSK,GSK:US,BBG000BLB481,"‘Invest Like a Guru’ to Be Out in Four Languages: English, Chinese, Japanese and Korean",2017-09-12 18:35:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3zAUYKztWwk/invest-like-a-guru-to-be-out-in-four-languages-english-chinese-japanese-and-korean-cm844530,Over the past three months three publishers from China Japan and Korea have acquired the publishing rights to translate Dr Charlie Tian s book Invest Like a Guru into Chinese Japanese and Korean respectively by the end of 2018 Over the past three months three publishers from China
GSK,GSK:US,BBG000BLB481,"Causeway International Value Buys BP PLC, Barclays PLC, Komatsu, Sells Sanofi SA, Akzo Nobel ...",2017-09-12 18:34:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BIpxC2a4MgA/causeway-international-value-buys-bp-plc-barclays-plc-komatsu-sells-sanofi-sa-akzo-nobel-cm844525,Causeway International Value New Purchases BP BLT ALBK Added Positions BARC 6301 ECA GSK MFC 9433 COB LIN BAS RDSB Reduced Positions SAN AKZA AZN AV ZURN CABK ENGI LLOY BNP 6501 Sold Out FP 2502 UBSG New Purchases
GSK,GSK:US,BBG000BLB481,When Should You Buy GlaxoSmithKline plc (LSE:GSK)?,2017-09-12 07:55:09 +0000,https://finance.yahoo.com/news/buy-glaxosmithkline-plc-lse-gsk-075509724.html?.tsrc=rss,"GlaxoSmithKline plc (LSE:GSK) trades with a trailing P/E of 37.8x, which is lower than the industry average of 34.8x. While GSK might seem like an attractive stock to buy, itRead More..."
GSK,GSK:US,BBG000BLB481,GSK Publishes Results Of Phase III Studies For Mepolizumab In COPD,2017-09-12 05:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hRtYUfwvOF8/gsk-publishes-results-of-phase-iii-studies-for-mepolizumab-in-copd-20170912-00178,GSK Publishes Results Of Phase III Studies For Mepolizumab In COPD
GSK,GSK:US,BBG000BLB481,How Merck’s Gardasil and Other Human Vaccines Performed in 2Q17,2017-09-11 14:36:52 +0000,http://finance.yahoo.com/r/b369cde1-2ef8-3b70-8417-464e04da2e7d/how-mercks-gardasil-and-other-human-vaccines-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Merck's (MRK) Gardasil franchise includes vaccines for the prevention of certain strains of HPV infections that are sexually transmitted.
GSK,GSK:US,BBG000BLB481,"Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress",2017-09-11 07:01:00 +0000,https://finance.yahoo.com/news/positive-results-pioneering-salford-lung-070100709.html?.tsrc=rss,"GlaxoSmithKline plc and Innoviva, Inc. today announced positive results from the Salford Lung Study in asthma have been simultaneously published in The Lancet journal and presented at the European Respiratory Society International Congress in Milan."
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018",2017-09-08 13:54:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gWEYvBsFK_k/pharma-stock-roundup-lilly-to-cut-jobs-streamline-operations-nvs-ceo-to-step-down-in-2018-cm842878,There were quite a few important developments this week with Eli Lilly and Company LLY announcing that it is streamlining its operations and cutting down its workforce as it focuses on developing new medicines and improving its cost structure Meanwhile Novartis NVS announced that its CEO
GSK,GSK:US,BBG000BLB481,Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc,2017-09-08 12:51:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F33aKsLTJys/better-buy-abbvie-inc-vs-glaxosmithkline-plc-cm842748,Big drugmaker High dividend yield Promising new products All three apply to AbbVie Inc NYSE ABBV They also all apply to GlaxoSmithKline plc NYSE GSK But while AbbVie stock has achieved solid gains so far in 2017 GlaxoSmithKline s share price isn t very far
GSK,GSK:US,BBG000BLB481,Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc,2017-09-08 11:18:00 +0000,http://finance.yahoo.com/r/c014a61b-ab22-3557-b841-56ed3c3d572e/better-buy-abbvie-inc-vs-glaxosmithkline-plc.aspx?yptr=yahoo&.tsrc=rss,Which big pharma stock wins in a head-to-head match-up between AbbVie and GlaxoSmithKline?
GSK,GSK:US,BBG000BLB481,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted",2017-09-07 22:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5UtajTIgaUI/nlnk-rallies-on-indoximod-data-vrna-breathes-easy-alny-jolted-20170907-01658,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted"
GSK,GSK:US,BBG000BLB481,Amgen/AstraZeneca Asthma Candidate Tezepelumab Shows Promise,2017-09-07 16:51:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tpAgI1yDMH0/amgenastrazeneca-asthma-candidate-tezepelumab-shows-promise-cm842337,Amgen Inc 160 AMGN and AstraZeneca plc AZN announced that their pipeline candidate tezepelumab reduced annual asthma exacerbation rate AAER a measure of deterioration of asthma in PATHWAY study in patients with severe uncontrolled asthma Tezepelumab an anti thymic
GSK,GSK:US,BBG000BLB481,5 Things Gilead Sciences' Management Just Said That You'll Want to Know,2017-09-07 11:59:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NVtGDnyiJQw/5-things-gilead-sciences-management-just-said-that-youll-want-to-know-cm842060,Last week Gilead Sciences NASDAQ GILD generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma NASDAQ KITE On Wednesday several of the company s top executives sat down at the Citi biotech conference to field questions
GSK,GSK:US,BBG000BLB481,GSK Exercises Option over SPEAR T-cell Therapy Program Targeting NY-ESO,2017-09-07 11:30:00 +0000,https://finance.yahoo.com/news/gsk-exercises-option-over-spear-113000257.html?.tsrc=rss,"PHILADELPHIA and OXFORD, United Kingdom, Sept. 07, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc has exercised its option under ..."
GSK,GSK:US,BBG000BLB481,5 Things Gilead Sciences&apos; Management Just Said That You&apos;ll Want to Know,2017-09-07 10:04:00 +0000,http://finance.yahoo.com/r/ea53f393-01e3-3bd5-9678-398d10317f91/5-things-gilead-sciences-management-just-said-that.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences executives answer the big questions on investors&apos; minds -- from the Kite Pharma deal to competition for its HIV and HCV products.
GSK,GSK:US,BBG000BLB481,Adaptimmune: GSK Exercises Option Over NY-ESO SPEAR T-Cell Therapy Program,2017-09-07 07:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jkjM_eT6whk/adaptimmune-gsk-exercises-option-over-nyeso-spear-tcell-therapy-program-20170907-00457,Adaptimmune: GSK Exercises Option Over NY-ESO SPEAR T-Cell Therapy Program
GSK,GSK:US,BBG000BLB481,Germany’s Merck Puts Consumer Drugs Business on the Block,2017-09-06 04:19:16 +0000,http://finance.yahoo.com/r/e08ac17e-62ac-3726-b0e2-40b6c103664b/germanys-merck-puts-consumer-drugs-business-on-the-block-1504616461?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Merck KGaA Chief Executive Stefan Oschmann put the Germany company’s consumer-health unit on the block in a move that will focus its health-care activities on the riskier business of developing prescription ...
GSK,GSK:US,BBG000BLB481,Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018,2017-09-05 22:49:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ol9pgMfBBQM/narasimhan-to-replace-jimenez-as-novartis-nvs-ceo-in-2018-cm841279,Novartis AG NVS announced that its Chief Executive Officer CEO Joseph Jimenez will step down from his position in 2018 Vasant Narasimhan M D Global Head of Drug Development and Chief Medical Officer will replace him effective Feb 1 2018 Narasimhan is a member of the Executive
GSK,GSK:US,BBG000BLB481,Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018,2017-09-05 20:37:08 +0000,https://finance.yahoo.com/news/narasimhan-replace-jimenez-novartis-nvs-203708630.html?.tsrc=rss,"Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018."
GSK,GSK:US,BBG000BLB481,Performance of AstraZeneca’s Respiratory Segment in 2Q17,2017-09-05 14:36:52 +0000,http://finance.yahoo.com/r/9213e175-9eab-324d-b021-1e4127963d4c/performance-of-astrazenecas-respiratory-segment-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Pulmicort, a drug for the prevention of asthma attacks, reported revenues of $226 million during 2Q17, a 3% decline at constant exchange rates compared to 2Q16."
GSK,GSK:US,BBG000BLB481,Key FDA Regulatory Events to Watch Out for in Sep 2017,2017-09-04 13:50:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ytCH56SlVIQ/key-fda-regulatory-events-to-watch-out-for-in-sep-2017-cm840710,The FDA which approved 22 novel drugs last year has given its approval to 31 drugs so far in 2017 including five in August Key approvals this year include Gilead s Vosevi hepatitis C virus Puma s Nerlynx to reduce the risk of breast cancer returning J amp J s Tremfya moderate to
GSK,GSK:US,BBG000BLB481,Key FDA Regulatory Events to Watch Out for in Sep 2017,2017-09-04 12:05:12 +0000,https://finance.yahoo.com/news/key-fda-regulatory-events-watch-120512052.html?.tsrc=rss,Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan&apos;s biosimilars?
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Consumer Healthcare Business Improved,2017-09-04 11:36:39 +0000,http://finance.yahoo.com/r/d93b01c0-2971-3478-988e-4b2ccec8c349/glaxosmithklines-consumer-healthcare-business-improved?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline (GSK) added new products and improved the supply chain for consumer healthcare products in the last few years.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Vaccines Business in 2Q17,2017-09-01 14:37:13 +0000,http://finance.yahoo.com/r/f2cfc48f-919e-38df-9fef-c23b9f6ae0e7/glaxosmithklines-vaccines-business-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline's (GSK) vaccine business includes meningitis vaccines, influenza vaccines, and the established vaccines in its portfolio."
GSK,GSK:US,BBG000BLB481,Analyzing GlaxoSmithKline’s Global Pharmaceuticals Business,2017-09-01 13:07:55 +0000,http://finance.yahoo.com/r/edd8b062-211b-3ceb-b611-ca3ebd13b065/analyzing-glaxosmithklines-global-pharmaceuticals-business-2?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s (GSK) global pharmaceuticals business is a part of the pharmaceuticals segment. It reported revenues of 3.24 billion pounds during 2Q17.
GSK,GSK:US,BBG000BLB481,Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017,2017-09-01 13:06:33 +0000,http://finance.yahoo.com/r/2d1c81c2-feae-3ecf-8367-1cfe99d160ea/promacta-continues-major-growth-driver-ligand-pharmaceuticals-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Is Wasting Money Paying a Dividend,2017-09-01 11:50:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fIWaWEK5Y8g/glaxosmithkline-is-wasting-money-paying-a-dividend-cm840088,As a general rule I love companies that pay big dividends and British pharmaceutical giant GlaxoSmithKline NYSE GSK pays some of the best dividends on the planet That said there s one very good reason why GlaxoSmithKline should not be paying a dividend and that reason
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s HIV Business in 2Q17,2017-09-01 11:38:12 +0000,http://finance.yahoo.com/r/b3d9eebd-8bd0-38b9-9e43-4e293cb2e1bf/glaxosmithklines-hiv-business-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,ViiV Healthcare is a global specialist company in HIV medicines. It focuses on developing and delivering advanced treatments for patients with HIV.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Is Wasting Money Paying a Dividend,2017-09-01 10:02:00 +0000,http://finance.yahoo.com/r/9f54a00f-14da-3014-bad1-423e8ac4a3ad/glaxosmithkline-is-wasting-money-paying-a-dividend.aspx?yptr=yahoo&.tsrc=rss,It&apos;s rarely a good idea to spend money you don&apos;t have.
GSK,GSK:US,BBG000BLB481,Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 9/1/2017,2017-09-01 08:48:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZXYWnen3PiU/validea-james-p-oshaughnessy-strategy-daily-upgrade-report-912017-cm840064,The following are today s upgrades for Validea s Growth Value Investor model based on the published strategy of James P O Shaughnessy This two strategy approach offers a large cap value model and a growth approach that looks for persistent earnings growth and strong relative strength
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's 5% Yield Carries Considerable Risk,2017-08-31 23:01:54 +0000,https://finance.yahoo.com/news/glaxosmithklines-5-yield-carries-considerable-174121735.html?.tsrc=rss,What risk lies behind the attractive yield?
GSK,GSK:US,BBG000BLB481,Why GlaxoSmithKline’s Pharmaceuticals Business Grew,2017-08-31 19:35:59 +0000,http://finance.yahoo.com/r/d09d5563-584e-372d-a1d7-bce8e416e7d8/glaxosmithklines-pharmaceuticals-business-grew?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline is a major shareholder of ViiV Healthcare. Its HIV products reported revenue of 1.12 billion pounds during 2Q17.
GSK,GSK:US,BBG000BLB481,How Did GlaxoSmithKline’s Segments Perform in 2Q17?,2017-08-31 18:06:12 +0000,http://finance.yahoo.com/r/f7c316fb-b35b-339e-b439-e5934d54677f/glaxosmithklines-segments-perform-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline's Pharmaceuticals segment reported revenues of 4.36 billion pounds during 2Q17—12% growth compared to 2Q16.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Reported Revenue Growth in 2Q17,2017-08-31 16:34:15 +0000,http://finance.yahoo.com/r/406462be-1d7d-3293-9844-b9061392eb72/glaxosmithkline-reported-revenue-growth-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline (GSK) reported revenues of 7.32 billion pounds in 2Q17—12% growth compared to revenues of 6.53 billion pounds in 2Q16.
GSK,GSK:US,BBG000BLB481,Changes in GlaxoSmithKline’s Valuation after 2Q17,2017-08-31 16:34:10 +0000,http://finance.yahoo.com/r/1f7978bc-3038-361b-94f4-d8fc6d93e4f0/changes-glaxosmithklines-valuation-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x."
GSK,GSK:US,BBG000BLB481,Behind Novartis’s Valuation after 2Q17,2017-08-30 18:54:23 +0000,http://finance.yahoo.com/r/630f9090-ad8c-3473-80f0-ab573d9c6f41/behind-novartiss-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis missed the analysts’ estimate for 2Q17 revenues, reporting $12.24 billion and falling short of $12.27 billion, but surpassed the estimate for EPS."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy,2017-08-30 13:55:38 +0000,https://finance.yahoo.com/news/glaxosmithkline-recent-pullback-delivers-healthy-135538171.html?.tsrc=rss,Argus said in a note on Wednesday that the recent weakness in GlaxoSmithKline plc (ADR) (NYSE: GSK ) shares offers a buying opportunity. The firm noted that as against the 1 percent gain by the broader ...
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Aug 29, 2017 :  TVIX, BBY, FINL, QQQ, ACOR, XIV, ABCO, BAC, MYCC, SAP, BABA, GSK",2017-08-29 12:58:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/318qRMHg71I/pre-market-most-active-for-aug-29-2017-tvix-bby-finl-qqq-acor-xiv-abco-bac-mycc-sap-baba-gsk-cm838329,The NASDAQ 100 Pre Market Indicator is down 32 66 to 5 805 42 The total Pre Market volume is currently 4 944 442 shares traded The following are the most active stocks for the pre market session VelocityShares Daily 2x VIX Short Term ETN TVIX is 1 93 at 18 59
GSK,GSK:US,BBG000BLB481,Biotech Stocks Facing FDA Decision In September,2017-08-29 08:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eLoYmPQkXWM/biotech-stocks-facing-fda-decision-in-september-20170829-00502,Biotech Stocks Facing FDA Decision In September
GSK,GSK:US,BBG000BLB481,3 High-Yield Dividend Aristocrat Stocks,2017-08-28 20:49:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pi8oIvMfTho/3-high-yield-dividend-aristocrat-stocks-cm838159,High yield dividend stocks can produce exceptional returns on capital At the same time these stocks can also present unacceptable levels of risk for average investors One way to lower your exposure to the inherent risks associated with high yielders however is to comb
GSK,GSK:US,BBG000BLB481,"A Serious Reaction After Vaccination Rarely Occurs Again With Later Immunization, Study Finds",2017-08-28 10:01:00 +0000,http://finance.yahoo.com/r/d3fbbba9-c4ae-3e1d-92ee-8d47be929c92/a-serious-reaction-after-vaccination-rarely-occurs-again-with-later-immunization?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Very few serious adverse events after a vaccination occur with another vaccination, a new study finds."
GSK,GSK:US,BBG000BLB481,Mylan and Otsuka Ink Agreement to Commercialize Deltyba,2017-08-25 17:40:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DsK3Ay1t5rc/mylan-and-otsuka-ink-agreement-to-commercialize-deltyba-cm837283,Mylan N V MYL and Japan based Otsuka Pharmaceutical signed a license agreementto commercialize Deltyba delamanid in low and middle income countries including South Africa and India The drug is approved for treatment of pulmonary multidrug resistant tuberculosis MDR TB in adults
GSK,GSK:US,BBG000BLB481,Analysts Predict 16% Upside For PPH,2017-08-25 14:40:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ARXzL21CQU8/analysts-predict-16-upside-for-pph-cm837049,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
GSK,GSK:US,BBG000BLB481,Novartis picks retail expert for new role of digital chief,2017-08-24 06:56:15 +0000,https://finance.yahoo.com/news/novartis-picks-retail-expert-role-065615970.html?.tsrc=rss,"Novartis has appointed a  senior retail expert to the new post of chief digital officer,  following a similar move by GlaxoSmithKline last month,  underscoring how drugmakers are grappling with the impact of new  technology.  Pharmaceutical companies face a range of challenges from the  digital world as mobile apps offer patients new ways to monitor  their health and online communications with prescribers and  consumers become routine.  Bertrand Bodson, currently chief digital and marketing  officer for Sainsbury's Argos chain, will start in his  new role on Jan. 1, 2018, and report directly to CEO Joe  Jimenez, the Swiss drugmaker said on Thursday."
GSK,GSK:US,BBG000BLB481,Propeller Health Expands Its Collaboration With GSK - Quick Facts,2017-08-24 06:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGDOEoAP69U/propeller-health-expands-its-collaboration-with-gsk--quick-facts-20170824-00232,Propeller Health Expands Its Collaboration With GSK - Quick Facts
GSK,GSK:US,BBG000BLB481,Why Have Mylan's (MYL) Shares Lost 19.4% So Far This Year?,2017-08-23 23:37:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N6YXe7oyKZw/why-have-mylans-myl-shares-lost-194-so-far-this-year-cm836257,Shares of Mylan N V MYL have lost almost 19 4 in the year so far thereby underperforming the 4 5 increase registered by the industry during this period Here we analyze the factors that led to the underperformance Mylan a global pharmaceutical company has a well
GSK,GSK:US,BBG000BLB481,Are Glaxo's Successful New Drugs Enough to Drive Growth?,2017-08-23 15:41:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aJUWCw-mbFc/are-glaxos-successful-new-drugs-enough-to-drive-growth-cm835959,GlaxoSmithKline plc GSK enjoys a diversified base and presence in different geographical areas GlaxoSmithKline reshaped its business following the Mar 2015 completion of the three part inter conditional transaction with Novartis AG NVS Under the deal Glaxo sold its oncology assets
GSK,GSK:US,BBG000BLB481,Are Glaxo&apos;s Successful New Drugs Enough to Drive Growth?,2017-08-23 13:47:01 +0000,https://finance.yahoo.com/news/glaxo-apos-successful-drugs-enough-134701634.html?.tsrc=rss,"Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked."
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins",2017-08-23 13:42:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8GxZmTpRSuk/the-zacks-analyst-blog-highlights-allergan-ecolab-exelon-glaxosmithkline-and-rockwell-collins-cm835892,For Immediate Release Chicago IL August 23 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins",2017-08-23 12:31:12 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-allergan-123112454.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Allergan, Ecolab, Exelon, GlaxoSmithKline and Rockwell Collins"
GSK,GSK:US,BBG000BLB481,"Top Analyst Reports for Allergan, Ecolab & Exelon",2017-08-22 23:38:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cdP9f42tYMY/top-analyst-reports-for-allergan-ecolab-exelon-cm835713,Tuesday August 22 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Allergan AGN Ecolab ECL and Exelon EXC These research reports have been hand picked from the
GSK,GSK:US,BBG000BLB481,Perrigo's (PRGO) OTC Version of Nexium Secures FDA Approval,2017-08-22 23:37:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PufzgZGKR7c/perrigos-prgo-otc-version-of-nexium-secures-fda-approval-cm835683,Perrigo Company plc PRGO announced that the FDA has granted a final approval to the over the counter OTC version of AstraZeneca s AZN Nexium 24HR esomeprazole magnesium capsules for treating patients with frequent heartburn Perrigo s shares have significantly underperformed the
GSK,GSK:US,BBG000BLB481,Perrigo&apos;s (PRGO) OTC Version of Nexium Secures FDA Approval,2017-08-22 22:05:10 +0000,https://finance.yahoo.com/news/perrigo-apos-prgo-otc-version-220510984.html?.tsrc=rss,Perrigo (PRGO) gains an FDA consent for the OTC version of AstraZeneca&apos;s Nexium post the ongoing patent lawsuit settlement through an agreement.
GSK,GSK:US,BBG000BLB481,"Top Analyst Reports for Allergan, Ecolab & Exelon",2017-08-22 21:15:09 +0000,https://finance.yahoo.com/news/top-analyst-reports-allergan-ecolab-211509289.html?.tsrc=rss,"Top Analyst Reports for Allergan, Ecolab & Exelon"
GSK,GSK:US,BBG000BLB481,3 High-Yield Pharmaceutical Stocks,2017-08-22 11:38:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rr6cT10nRYo/3-high-yield-pharmaceutical-stocks-cm835100,The pharmaceutical industry is a natural hunting ground for reliable income stocks since people buy drugs in good times and in bad But which high yield dividend stocks are actually worthy of your investment dollars We posed that question to a team of Motley Fool
GSK,GSK:US,BBG000BLB481,3 High-Yield Pharmaceutical Stocks,2017-08-22 10:30:00 +0000,http://finance.yahoo.com/r/ca0e67d1-9e3e-3335-94d4-33cad7830214/3-high-yield-pharmaceutical-stocks.aspx?yptr=yahoo&.tsrc=rss,"Pfizer, GlaxoSmithKline, and Novo Nordisk all offer up temptingly high yields. Here&apos;s why they&apos;re worth putting on your radar."
GSK,GSK:US,BBG000BLB481,3 High-Yield Stocks to Own in a Market Crash,2017-08-21 21:38:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/II_cEy3FyA4/3-high-yield-stocks-to-own-in-a-market-crash-cm834982,Although the broader markets are currently trading at historic highs and investor sentiment remains strong there is always the possibility of an unforeseen correction that sends valuations tumbling downward So it might be a smart move to consider buying a handful of so called
GSK,GSK:US,BBG000BLB481,3 High-Yield Stocks to Own in a Market Crash,2017-08-21 20:00:00 +0000,http://finance.yahoo.com/r/62683898-7d1a-3308-8719-0731e68e7782/3-high-yield-stocks-to-own-in-a-market-crash.aspx?yptr=yahoo&.tsrc=rss,"If you&apos;re concerned about a forthcoming market correction, GlaxoSmithKline, AT&T, and Procter & Gamble may be worth buying right now."
GSK,GSK:US,BBG000BLB481,[$$] The questionable strategy of a pharmaceuticals CEO,2017-08-21 09:36:46 +0000,"http://finance.yahoo.com/r/c4dfb141-d440-33ee-9608-6763c6964b21/16ffe91c-81c9-11e7-a4ce-15b2513cb3ff,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Sir, Joining in the discussion about GlaxoSmithKline's new plans, I find chief executive Emma Walmsley's strategic thinking on research and development questionable. I suggest it shows the terrible consequences ..."
GSK,GSK:US,BBG000BLB481,3 Top Biotech Stocks Under $5,2017-08-19 20:37:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zq3eM_Nae6E/3-top-biotech-stocks-under-5-cm834351,The biotech field is littered with stocks under 5 160 that probably won t walk away from the crash landings that made them look so cheap You ll be glad to know that sifting through the wreckage to find hidden gems is one daunting task that you don t need to slog through I
GSK,GSK:US,BBG000BLB481,Mylan Finalizes Settlement Agreement with DOJ for $465M,2017-08-18 22:37:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2liiKTmyS3A/mylan-finalizes-settlement-agreement-with-doj-for-465m-cm834212,Mylan N V MYL recently announced that its subsidiaries Mylan Inc and Mylan Specialty L P have signed an agreement with the U S Department of Justice DOJ and two other relators The agreement finalizes the Medicaid drug rebate settlement worth 465 million announced in
GSK,GSK:US,BBG000BLB481,Mylan Finalizes Settlement Agreement with DOJ for $465M,2017-08-18 20:18:08 +0000,https://finance.yahoo.com/news/mylan-finalizes-settlement-agreement-doj-201808510.html?.tsrc=rss,"Mylan N.V. (MYL) signed an agreement with the U.S. Department of Justice (DOJ) and two other relators to finalize the Medicaid drug rebate settlement worth $465 million, announced in Oct 2017."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Becomes Oversold (GSK),2017-08-18 18:38:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0viv3QJE2eE/glaxosmithkline-becomes-oversold-gsk-cm834103,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo",2017-08-18 13:42:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QJF6KhgQNco/pharma-stock-roundup-multiple-sclerosis-drug-prices-in-focus-mixed-data-on-bmys-opdivo-cm833799,Pharmaceutical stocks were in the limelight this week with Merck s MRK CEO Ken Frazier resigning from President Donald Trump s manufacturing council The sector was also in the news with an investigation being launched into the rising prices of multiple sclerosis MS drugs Recap of
GSK,GSK:US,BBG000BLB481,Shire Gains as it Seeks European Approval For Dry Eye Treatment,2017-08-15 08:55:00 +0000,http://finance.yahoo.com/r/1b5139a0-34e0-33da-8c3e-dae49eb80cd1/shire-gains-as-it-seeks-european-approval-for-dry-eye-treatment.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The drug would be the first such treatment in Europe.
GSK,GSK:US,BBG000BLB481,[$$] The key to innovation is balancing risk and rigour,2017-08-14 17:39:40 +0000,"http://finance.yahoo.com/r/9b9effec-1bee-31d7-b294-87b4703aadec/09fc6a36-7dd4-11e7-ab01-a13271d1ee9c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Barely four months into her tenure as chief executive of GlaxoSmithKline, Emma Walmsley is showing her determination to focus the pharmaceutical company's research and development efforts. Having said ..."
GSK,GSK:US,BBG000BLB481,3 Beaten-Up Biotech Stocks: Are They Bargains?,2017-08-14 15:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m1-ab5q1E8k/3-beaten-up-biotech-stocks-are-they-bargains-cm831691,The iShares Nasdaq Biotechnology Index has tacked on a healthy gain of around 15 so far this year without any help from Celldex Therapeutics Inc NASDAQ CLDX Agenus Inc NASDAQ AGEN or Progenics Pharmaceuticals Inc NASDAQ PGNX All three of these
GSK,GSK:US,BBG000BLB481,What Happened In Biotech Last Week?,2017-08-14 14:14:00 +0000,http://finance.yahoo.com/r/8c45635b-82f7-30fd-a656-faa4236eae9f/what-happened-in-biotech-last-week-1502720099?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The Nasdaq Biotechnology Index (NBI) was down 2.8% last week, trailing the Nasdaq and S&P 500 again, as those two broader indexes fell just 1.5% and 1.4%, respectively. Nomura Instinet's Christopher Marai ..."
GSK,GSK:US,BBG000BLB481,"Ionis Pharmaceuticals Retains Rights to Inotersen, Stock Up",2017-08-14 12:32:12 +0000,https://finance.yahoo.com/news/ionis-pharmaceuticals-retains-rights-inotersen-123212147.html?.tsrc=rss,Ionis Pharmaceuticals (IONS) will independently develop Inotersen and IONIS-FB-L Rx as GlaxoSmithKline declines its option on both drugs.
GSK,GSK:US,BBG000BLB481,Stocks That Fell to 3-Year Lows in the Week of August 11,2017-08-13 16:49:20 +0000,https://finance.yahoo.com/news/stocks-fell-3-lows-week-164920337.html?.tsrc=rss,"GlaxoSmithKline PLC (GSK), Simon Property Group Inc (SPG), GGP Inc (GGP), and CenturyLink Inc (CTL) have declined to their respective three-year lows."
GSK,GSK:US,BBG000BLB481,Where Does Zika Virus Vaccine Research Stand Now?,2017-08-12 18:51:49 +0000,https://finance.yahoo.com/news/where-does-zika-virus-vaccine-185149694.html?.tsrc=rss,"After a lull, the Zika virus was back in headlines early last week, as the Florida Department of Health confirmed the first sexually transmitted Zika case of 2017 in Pinellas County. The release from the ..."
GSK,GSK:US,BBG000BLB481,"ETFs with exposure to GlaxoSmithKline Plc : August 11, 2017",2017-08-11 21:36:15 +0000,http://finance.yahoo.com/r/5a2aa0dd-25b9-3361-b78a-3081be1ca334/etfs-with-exposure-to-glaxosmithkline-plc-august-11-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GlaxoSmithKline Plc Here are 5 ETFs with the largest exposure to GSK-US. Comparing the performance and risk of GlaxoSmithKline Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
GSK,GSK:US,BBG000BLB481,"Ionis Pharmaceuticals Inc: Growing Royalties, an Advancing Pipeline, and Getting Back Rights to Some Drugs",2017-08-11 20:07:00 +0000,http://finance.yahoo.com/r/b38182a2-d547-3c08-9cb1-25d62313a97b/ionis-pharmaceuticals-inc-growing-royalties-advanc.aspx?yptr=yahoo&.tsrc=rss,"A solid second quarter from the biotech, with growing royalties on Spinraza and two more drugs to be reviewed by regulators, and it regained full rights to two drugs after its partner declined to license them."
GSK,GSK:US,BBG000BLB481,Biotech movers: Ionis Drops After GSK Bows Out of Partnership,2017-08-11 14:01:00 +0000,http://finance.yahoo.com/r/0fa763b6-f49d-3ebe-80b3-9e11ebab3640/biotech-movers-ionis-drops-after-gsk-bows-out-of-partnership.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Ionis retained all rights to inotersen and IONIS-FB-LRx as part of reprioritizing its pipeline and a strategic review of its Rare Diseases business.
GSK,GSK:US,BBG000BLB481,"Ionis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options",2017-08-11 07:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vXde4xQRWk8/ionis-retains-all-rights-to-inotersen-ionisfbl-rx-gsk-declines-its-options-20170811-00282,"Ionis Retains All Rights To Inotersen, IONIS-FB-L Rx; GSK Declines Its Options"
GSK,GSK:US,BBG000BLB481,Former GSK exec resigns from Intellia board due to 'conflict',2017-08-10 17:39:49 +0000,http://finance.yahoo.com/r/11800f42-9bdb-3ae2-a749-20f7611505b6/former-glaxosmithkline-exec-resigns-from-intellia.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"The former head of GlaxoSmithKline’s vaccines division has resigned suddenly from the board of Cambridge gene editing biotech Intellia Therapeutics after just two weeks in that role due to an unexplained conflict of interest, according to a federal filing on Tuesday.  Intellia (NTLA) issued a press release on July 24 announcing the appointment of Moncef Slaoui, who retired from GSK (GSK) in June after nearly 30 years at the pharma giant.  In the new filing , however, Intellia said that Slaoui had informed the board of his resignation on Monday."
GSK,GSK:US,BBG000BLB481,"UK fraud office expects decision on GSK, Rolls-Royce cases next year",2017-08-10 16:30:01 +0000,https://finance.yahoo.com/news/uk-fraud-office-expects-decision-163001427.html?.tsrc=rss,The UK Serious Fraud Office (SFO) said on Thursday it expects to decide next year whether it will file criminal charges in bribery investigations related to drugs giant GlaxoSmithKline (GSK.L) and aero engine company Rolls-Royce (RR.L).  The SFO launched an investigation into GSK and its subsidiaries in 2014.
GSK,GSK:US,BBG000BLB481,"UK fraud office expects decision on GSK, Rolls-Royce cases next year",2017-08-10 16:16:26 +0000,https://finance.yahoo.com/news/uk-fraud-office-expects-decision-161626178.html?.tsrc=rss,The UK Serious Fraud Office (SFO)  said on Thursday it expects to decide next year whether it will  file criminal charges in bribery investigations related to drugs  giant GlaxoSmithKline and aero engine company  Rolls-Royce.  The SFO launched an investigation into GSK and its  subsidiaries in 2014.  Britain's biggest drugmaker has already  been fined a record 3 billion yuan ($452 million) by Chinese  authorities for paying bribes to doctors to use its drugs.
GSK,GSK:US,BBG000BLB481,3 High-Yield Healthcare Stocks,2017-08-10 14:37:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Wbd_HysZ_5Y/3-high-yield-healthcare-stocks-cm830108,The healthcare sector is a natural hunting ground for income investors since consumers demand access to high quality healthcare products in good times and bad That fact helps keep many healthcare companies profits and dividend payments flowing even during periods of economic
GSK,GSK:US,BBG000BLB481,3 High-Yield Healthcare Stocks,2017-08-10 13:15:00 +0000,http://finance.yahoo.com/r/bcb95228-1cde-3fe7-993e-5f77d582c51b/3-high-yield-healthcare-stocks.aspx?yptr=yahoo&.tsrc=rss,"Looking for income from the healthcare sector? Here&apos;s why you should check out GlaxoSmithKline, Pfizer, and CVS Health. "
GSK,GSK:US,BBG000BLB481,European Stocks Set for Mixed Open as Global Markets Stabilize,2017-08-10 05:54:00 +0000,http://finance.yahoo.com/r/2a47a354-b671-3f34-b450-710ff3361c0a/european-stocks-set-for-mixed-open-as-global-markets-stabilize-despite-north-korea-concerns.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,FTSE 100 could see ex-dividend impact at the opening bell.
GSK,GSK:US,BBG000BLB481,"[$$] Blockbuster drugs depend on marketing, not design",2017-08-09 23:03:35 +0000,"http://finance.yahoo.com/r/8fd481b2-3d47-3dc4-87bb-88fdff7cf766/e374bdac-7c64-11e7-ab01-a13271d1ee9c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Sir, I read the interview with Emma Walmsley (August 7), the new chief executive of GlaxoSmithKline pharmaceuticals, with a certain sense of sadness. Coming from cosmetic-maker L'Oréal, she has not a clue ..."
GSK,GSK:US,BBG000BLB481,"Mylan (MYL) Misses on Q2 Earnings & Sales, Lowers View",2017-08-09 20:36:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IrnYDL3A2lw/mylan-myl-misses-on-q2-earnings-sales-lowers-view-cm829781,Mylan N V MYL reported disappointing second quarter 2017 results wherein both earnings and sales missed estimates The company also lowered its guidance Shares are trading down due to dismal results Mylan s stock fell 16 7 year to date compared with the industry s decline of 14
GSK,GSK:US,BBG000BLB481,Mexico watchdog finds big pharma faces no competition on some drugs,2017-08-09 20:11:39 +0000,https://finance.yahoo.com/news/mexico-watchdog-finds-big-pharma-165951996.html?.tsrc=rss,"Major drugmakers including  GlaxoSmithKline Plc and Pfizer Inc face no  competition in Mexico from generics that are readily available  elsewhere, partly because of regulatory failings, Mexico's  antitrust body said on Wednesday.  The companies have done nothing illegal, Juan Manuel Espino,  Cofece's director of economic studies, said at a presentation of  the body's probe into the Mexican drugs market, which found a  lack of promotion for generics led to limited competition.  The report, released by Cofece on Wednesday, also said some  of the companies used unspecified legal strategies to extend  drug exclusivity after patents expire."
GSK,GSK:US,BBG000BLB481,"VEU, TOT, RY, GSK: Large Inflows Detected at ETF",2017-08-09 16:34:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vOtYWu7fw_s/veu-tot-ry-gsk-large-inflows-detected-at-etf-cm829512,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 467 4 million dollar inflow that s a 2 4 increase week over week
GSK,GSK:US,BBG000BLB481,Drugmakers' hopes for gene therapy rise despite tiny sales in Europe,2017-08-08 10:17:48 +0000,https://finance.yahoo.com/news/drugmakers-hopes-gene-therapy-rise-101748104.html?.tsrc=rss,"The science of gene therapy is  finally delivering on its potential, and drugmakers are now  hoping to produce commercially viable medicines after tiny sales  for the first two such treatments in Europe.  After decades of frustrations, firms believe there are now  major opportunities for gene therapy in treating inherited  conditions such as haemophilia."
GSK,GSK:US,BBG000BLB481,Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2,2017-08-07 22:37:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5uduDicn0Lc/epizyme-epzm-incurs-narrower-than-expected-loss-in-q2-cm828400,Epizyme Inc EPZM witnessed a loss of 48 cents per share in the second quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 56 cents and 160 a penny narrower than the year ago loss of 49 cents Notably the company s stock has stock gained 17 so far this year
GSK,GSK:US,BBG000BLB481,Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2,2017-08-07 20:09:08 +0000,https://finance.yahoo.com/news/epizyme-epzm-incurs-narrower-expected-200908128.html?.tsrc=rss,"Epizyme, Inc. (EPZM) posted narrower-than-expected loss in Q2 as the company focuses on the development of tazemetostat."
GSK,GSK:US,BBG000BLB481,[$$] GSK chief vows to stop 'drifting off in hobbyland' with R&D,2017-08-06 14:23:54 +0000,"http://finance.yahoo.com/r/916cc1e9-65e0-3e64-885b-ee5ba98e0aea/93055876-76cf-11e7-90c0-90a9d1bc9691,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The chief executive of GlaxoSmithKline has said the UK drugmaker will stop ""drifting off in hobbyland"" by producing medicines with little prospect of billion-dollar sales, as she seeks to reverse ..."
GSK,GSK:US,BBG000BLB481,[$$] GSK chief says her lack of 'baggage' in pharma is an advantage,2017-08-06 14:15:21 +0000,"http://finance.yahoo.com/r/f63fabde-aa08-3198-ba2f-d64d3cf6486b/deec0e46-76bc-11e7-90c0-90a9d1bc9691,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","When Emma Walmsley addressed investors after delivering GlaxoSmithKline's second-quarter results last month, she was clear about her overriding priority for the UK company: it must become more adept at ..."
GSK,GSK:US,BBG000BLB481,United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk,2017-08-05 01:59:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eWqxlUIjv4E/united-therapeutics-corporation-uthr-shares-soar-on-takeover-talk-cm827644,InvestorPlace Stock Market News Stock Advice amp Trading Tips United Therapeutics Corporation NASDAQ UTHR stock surged on Friday as rumors of a takeover surged The company is reportedly being considered as an acquisition by a
GSK,GSK:US,BBG000BLB481,Analysts say a United Therapeutics sale is premature,2017-08-04 22:04:40 +0000,http://finance.yahoo.com/r/090b1829-e942-3f19-b2d2-9b8c474545dd/united-therapeutics-stock-up-9-percent-on-gsk.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Silver Spring-based United Therapeutics Corp.'s stock jumped Friday following a report that GlaxoSmithKline PLC or other drug giants may be looking to acquire it.  According to a report from the Evening Standard in London on Friday , GSK may be eyeing United Therapeutics in a deal worth nearly $9 billion, or $200 a share.  United Therapeutics' share price jumped more than 9 percent on the report from a previous close of $126.96 to open at $138.90."
GSK,GSK:US,BBG000BLB481,"Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y",2017-08-04 22:00:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mwPXMn5C3c0/emergent-ebs-q2-earnings-miss-estimates-revenues-rise-yy-cm827552,Emergent BioSolutions Inc EBS reported earnings of 13 cents per share in the second quarter of 2017 which missed the Zacks Consensus Estimate of 26 cents Earnings however increased from the year ago loss of 1 cent Emergent s shares underperformed the industry so far this year The company
GSK,GSK:US,BBG000BLB481,United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk,2017-08-04 21:08:43 +0000,https://finance.yahoo.com/news/united-therapeutics-corporation-uthr-shares-210843508.html?.tsrc=rss,"United Therapeutics Corporation (NASDAQ:UTHR) stock surged on Friday as rumors of a takeover surged.  The company is reportedly being considered as an acquisition by a major pharmaceutical giant, including Gilead Sciences Inc (NASDAQ:GILD), GlaxoSmithKline PLC (NYSE:GSK) and Novartis AG (NYSE:NVS).  GlaxoSmithKline and United Therapeutics both declined to comment on the matter."
GSK,GSK:US,BBG000BLB481,"Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Rise Y/Y",2017-08-04 20:19:08 +0000,https://finance.yahoo.com/news/emergent-ebs-q2-earnings-miss-201908354.html?.tsrc=rss,"Emergent&apos;s (EBS) earnings and revenues miss estimates in Q2. However, revenue increased year-over-year due to product sales and increase in contract manufacturing revenues."
GSK,GSK:US,BBG000BLB481,Gilead Could Be Making An Acquisition — But It&apos;s Not What You Think,2017-08-04 16:15:05 +0000,http://finance.yahoo.com/r/85b1f35d-463e-30a6-9503-52af91e9b1de/gilead-could-be-making-an-acquisition-but-its-not-what-you-think?src=A00220&yptr=yahoo&.tsrc=rss,"United Therapeutics surged to an 18-week high Friday on reports Gilead, Glaxo and Novartis could be considering takeover bids on it."
GSK,GSK:US,BBG000BLB481,"Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag",2017-08-04 16:04:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iT4OHxU526c/agenus-agen-q2-loss-narrower-than-expected-revenues-lag-cm827244,Agenus Inc AGEN incurred second quarter 2017 loss of 32 cents per share narrower than the Zacks Consensus Estimate of a loss of 36 cents and the year ago loss of 33 cents Revenues were 4 2 million and missed the Zacks Consensus Estimate of 6 million Also the top line was down from 6
GSK,GSK:US,BBG000BLB481,"Agenus (AGEN) Q2 Loss Narrower Than Expected, Revenues Lag",2017-08-04 14:12:02 +0000,https://finance.yahoo.com/news/agenus-agen-q2-loss-narrower-141202491.html?.tsrc=rss,"Agenus Inc. (AGEN) witnesses narrower-than-expected loss and also misses revenue estimates. However, the company is progressing well with the candidates in its pipeline in Q2."
GSK,GSK:US,BBG000BLB481,United Therapeutics Corp. stock surges 9% on report of possible bids for company,2017-08-04 12:47:13 +0000,http://finance.yahoo.com/r/add22b3c-b97f-32c7-af18-aedfee93fb1b/Story.aspx?guid=C83EE73F-FFCA-431E-94B4-AF25D246805A&siteid=yhoof2&yptr=yahoo&.tsrc=rss,United Therapeutics Corp. shares surged 8.7% premarket on Friday after a news report suggested that major pharmaceutical companies were weighing a bid for it. The Evening Standard report said that Gilead ...
GSK,GSK:US,BBG000BLB481,Company Spotlight: Dynavax,2017-08-04 00:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7iYwCASWTiE/company-spotlight-dynavax-20170804-00004,Company Spotlight: Dynavax
GSK,GSK:US,BBG000BLB481,Company Spotlight: Dynavax,2017-08-03 23:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XW-2rUmFY2A/company-spotlight-dynavax-20170803-00657,Company Spotlight: Dynavax
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Valuations after Its 2Q17 Earnings,2017-08-03 11:36:19 +0000,http://finance.yahoo.com/r/3a0852ad-3af6-31b6-8718-d08e095147c5/glaxosmithklines-valuations-after-its-2q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On July 28, 2017, GlaxoSmithKline (GSK) traded at a forward PE multiple of 13.4x, which is slightly lower than the industry average of 15.2x."
GSK,GSK:US,BBG000BLB481,Validea Joel Greenblatt Strategy Daily Upgrade Report - 8/3/2017,2017-08-03 08:54:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VgRvZzQtWkA/validea-joel-greenblatt-strategy-daily-upgrade-report-832017-cm826205,The following are today s upgrades for Validea s Earnings Yield Investor model based on the published strategy of Joel Greenblatt This value model looks for companies with high return on capital and earnings yields The following are today s upgrades for Validea s Earnings Yield Investor
GSK,GSK:US,BBG000BLB481,"FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps",2017-08-03 00:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KOyym_iFjbQ/fda-panel-snubs-jnj-chmp-seeks-more-data-from-pbyi-tbph-on-watch-agrx-slumps-20170803-00017,"FDA Panel Snubs JNJ, CHMP Seeks More Data From PBYI, TBPH On Watch, AGRX Slumps"
GSK,GSK:US,BBG000BLB481,U.S. FDA panel votes against approval of J&J arthritis drug,2017-08-02 20:28:59 +0000,https://finance.yahoo.com/news/u-fda-panel-votes-against-202859540.html?.tsrc=rss,"The benefits of Johnson & Johnson's  experimental rheumatoid arthritis drug sirukumab do not  outweigh the risks, an advisory panel to the U.S. Food and Drug  Administration concluded on Wednesday.  The most common causes of death were major heart  problems, infection and malignancies.  ""The safety is not there,"" said Dr. Beth Jonas, interim head  of the division of rheumatology at the University of North  Carolina School of Medicine."
GSK,GSK:US,BBG000BLB481,GSK’s 2Q17 Earnings: Consumer Healthcare,2017-08-02 14:37:15 +0000,http://finance.yahoo.com/r/5420ccbf-0a19-3b94-8572-1d0566e91a5e/gsks-2q17-earnings-consumer-healthcare?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline (GSK) reported flat international revenues at constant exchange rates to 843.0 million pounds during 2Q17.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 2Q17 Earnings: Vaccines Business,2017-08-02 13:07:50 +0000,http://finance.yahoo.com/r/1b936996-5900-3396-8f31-a5a5bd685134/glaxosmithklines-2q17-earnings-vaccines-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GSK's Vaccines business reported 16.0% growth to ~1.1 billion pounds in 2Q17, including 5.0% growth at constant exchange rates and 11.0% positive impact of foreign exchange."
GSK,GSK:US,BBG000BLB481,GSK’s 2Q17 Earnings: Global Pharmaceuticals,2017-08-02 11:37:06 +0000,http://finance.yahoo.com/r/b2b961b0-7ec1-34de-b6c1-1101566ea265/gsks-2q17-earnings-global-pharmaceuticals?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The Global Pharmaceuticals franchise reported revenues of ~3.2 billion pounds in 2Q17.
GSK,GSK:US,BBG000BLB481,3 Diverse Dividend Stocks With 6%-Plus Payouts,2017-08-01 23:53:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tOtpyikr5CM/3-diverse-dividend-stocks-with-6-plus-payouts-cm825380,InvestorPlace Stock Market News Stock Advice amp Trading Tips The hunt for yield continues in a persistently low interest rate environment Source Shutterstock High yield dividend stocks sometimes exists because of a deterioration in the fundamentals of a company that puts
GSK,GSK:US,BBG000BLB481,"Innoviva, Inc. -- Moody's assigns B3 CFR to Innoviva; stable outlook",2017-08-01 17:58:22 +0000,http://finance.yahoo.com/r/709300bb-f4ec-3469-a188-069e520eab81/viewresearchdoc.aspx?docid=PR_370550&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX0NWX1JhdGluZ19OZXdzX0FsbF9Fbmc=~20170801_PR_370550&yptr=yahoo&.tsrc=rss,"Rating Action: Moody's assigns B3 CFR to Innoviva; stable outlook. Global Credit Research- 01 Aug 2017. New York, August 01, 2017-- Moody's Investors Service assigned a B3 Corporate Family Rating to Innoviva, ..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 2Q17 Earnings: HIV Business,2017-08-01 14:39:44 +0000,http://finance.yahoo.com/r/ecf190da-f13e-33dc-acd6-8c0af8d224ef/glaxosmithklines-2q17-earnings-hiv-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GSK's HIV Products franchise reported growth of 29.0% to ~1.1 billion pounds in 2Q17 compared to 2Q16.
GSK,GSK:US,BBG000BLB481,August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty,2017-08-01 13:20:31 +0000,https://finance.yahoo.com/news/august-pdufa-dates-biotech-investors-132031505.html?.tsrc=rss,"The biotech sector's performance moderated in July, although the month had its fair share of action on the FDA front , as well as boasting conferences and trial result announcements aplenty. The NYSE ARCA ..."
GSK,GSK:US,BBG000BLB481,How Gilead Sciences Performed in 2Q17,2017-08-01 13:13:03 +0000,http://finance.yahoo.com/r/57f9ce4f-75e1-342c-b690-fa652f0706d3/how-gilead-sciences-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2Q17, Gilead Sciences (GILD) generated revenues of ~$7.1 billion, which reflected an ~8% decline on a year-over-year basis."
GSK,GSK:US,BBG000BLB481,GSK’s 2Q17 Earnings: Pharmaceuticals Segment,2017-08-01 13:10:51 +0000,http://finance.yahoo.com/r/677e991d-ddfa-34f2-8a62-0cbf8e3ccd63/gsks-2q17-earnings-pharmaceuticals-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GSK's Pharmaceuticals segment’s contribution to the company's total revenues was 59.5% in 2Q17.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 2Q17 Earnings: Business Segments,2017-08-01 11:41:47 +0000,http://finance.yahoo.com/r/4d3ea23d-f0e1-3031-a7da-856e65ebcc48/glaxosmithklines-2q17-earnings-business-segments?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GSK reported operational growth of 3% in its revenues to ~7.3 billion pounds for 2Q17.
GSK,GSK:US,BBG000BLB481,"Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings",2017-07-31 23:54:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UF5LaVkZ2Fg/foreign-stock-roundup-gsk-shell-astrazeneca-beat-on-earnings-cm824602,Investors across the globe focused on earning numbers and the outcome of the Fed s policy meeting this week Regulatory pressures on tobacco and auto stocks weighed on Europe s stocks Meanwhile key earnings results guided markets across Asia Brazil s markets gained direction from shifts
GSK,GSK:US,BBG000BLB481,5 Things Gilead Sciences' Q2 Earnings Numbers Didn't Tell You,2017-07-31 21:55:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fhM_lUlZKX8/5-things-gilead-sciences-q2-earnings-numbers-didnt-tell-you-cm824564,The numbers didn t lie Gilead Sciences NASDAQ GILD posted pretty good second quarter results While revenue and earnings fell compared to the prior year period the big biotech still managed to beat expectations thanks to strong HIV drug sales and a better than
GSK,GSK:US,BBG000BLB481,"Foreign Stock Roundup: GSK, Shell, AstraZeneca Beat on Earnings",2017-07-31 21:21:09 +0000,https://finance.yahoo.com/news/foreign-stock-roundup-gsk-shell-212109134.html?.tsrc=rss,Investors across the globe focused on earning numbers and the outcome of the Fed&apos;s policy meeting this week.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 2Q17 Earnings Reveal Growth,2017-07-31 20:32:07 +0000,http://finance.yahoo.com/r/7b4a2cca-a730-381d-bfcd-f689d48f1682/glaxosmithklines-2q17-earnings-reveal-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In its earnings release on July 26, GlaxoSmithKline (GSK) reported 12% growth to ~7.3 billion pounds in its 2Q17 revenues. GSK surpassed analysts’ estimates for revenues and earnings per share."
GSK,GSK:US,BBG000BLB481,Up 81.6%: Is Dynavax Technologies Corporation Stock Still a Buy?,2017-07-31 13:56:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_rGQK1zsbck/up-816-is-dynavax-technologies-corporation-stock-still-a-buy-cm824058,What happened Dynavax Technologies Corporation NASDAQ DVAX stock jumped a whopping 81 6 in after hours trading Friday because of a favorable 12 to 1 advisory committee vote for its experimental hepatitis B vaccine Heplisav B 160 This panel of independent experts was
GSK,GSK:US,BBG000BLB481,J&J arthritis drug sirukumab raises safety concerns -FDA staff,2017-07-31 13:56:21 +0000,https://finance.yahoo.com/news/j-j-arthritis-drug-sirukumab-125605503.html?.tsrc=rss,"There were more deaths in patients  taking Johnson & Johnson's experimental rheumatoid  arthritis drug sirukumab than among those taking a placebo,  staff reviewers for the U.S. Food and Drug Administration said  in a report published Monday.  The FDA is not obliged to follow the advice  of its advisers but typically does so.  The most common causes of death were major heart problems,  infection and malignancies."
GSK,GSK:US,BBG000BLB481,8 Of The Biggest Whistles Ever Blown On Wall Street,2017-07-31 13:46:19 +0000,https://finance.yahoo.com/news/8-biggest-whistles-ever-blown-134619837.html?.tsrc=rss,"Chelsea Manning, Edward Snowden, Julian Assange, Deep Throat. You know the names. Whether you consider them informants, patriots or glorified tattle-tales, whistleblowers have significantly impacted United ..."
GSK,GSK:US,BBG000BLB481,Former Walmart CIO Named Chief Digital And Technology Officer Of GlaxoSmithKline,2017-07-31 12:33:00 +0000,http://finance.yahoo.com/r/afe003dc-cb23-3448-9263-a6bdd85af601/former-walmart-cio-named-chief-digital-and-technology-officer-of-glaxosmithkline?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Former Walmart CIO Karenann Terrell has joined GlaxoSmithKline as the Chief Digital and Technology Officer, a new role for the company. She will start on September 4."
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More",2017-07-31 12:06:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-q2-earnings-120612184.html?.tsrc=rss,Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.
GSK,GSK:US,BBG000BLB481,Biotech Stocks Facing FDA Decision In August,2017-07-31 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T6SiGP_nfTo/biotech-stocks-facing-fda-decision-in-august-20170731-00044,Biotech Stocks Facing FDA Decision In August
GSK,GSK:US,BBG000BLB481,Data supports safety of Dynavax hepatitis B vaccine -U.S. FDA panel,2017-07-28 21:21:35 +0000,https://finance.yahoo.com/news/data-supports-safety-dynavax-hepatitis-212135492.html?.tsrc=rss,"Available data supports the safety of  Dynavax Technologies Corp's experimental hepatitis B  vaccine when administered to adults, a panel of expert advisers  to the U.S. Food and Drug Administration said on Friday.  Much of the panel discussion focused on the need for Dynavax  to carefully track patient outcomes due to concerns about safety  of the vaccine, which has been rejected twice before by the  regulatory agency.  A prior  panel voted 13 to 1 that clinical trial data supports the  vaccine's effectiveness, Dynavax said."
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q2, 2017 By the Numbers : July 28, 2017",2017-07-28 16:36:24 +0000,http://finance.yahoo.com/r/114ed6cc-de9f-3616-9861-e1f3d250740a/glaxosmithkline-plc-gsk-us-earnings-analysis-q2-2017-by-the-numbers-july-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis GlaxoSmithKline Plc reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of GlaxoSmithKline Plc – Novartis AG Sponsored ADR and Innoviva, Inc. (NVS-US and INVA-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 9,476.11 million, Net ... Read more
<b>(Read more...)</b>"
GSK,GSK:US,BBG000BLB481,Interesting GSK Put And Call Options For June 2018,2017-07-28 15:00:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gp7wbKKrGGg/interesting-gsk-put-and-call-options-for-june-2018-cm823281,Investors in GlaxoSmithKline plc Symbol GSK saw new options begin trading today for the June 2018 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 322 days until expiration the newly trading contracts represent
GSK,GSK:US,BBG000BLB481,Gilead's HCV and HIV Drugs Support Wide Moat,2017-07-28 11:00:00 +0000,http://finance.yahoo.com/r/c8a2ff27-c4f6-3237-97b4-8975f8b18dae/article.aspx?id=817933&SR=Yahoo&yptr=yahoo&.tsrc=rss,We don't think the current price accounts for the company's pipeline.
GSK,GSK:US,BBG000BLB481,"Dividends a worry at drugmakers Astra, GSK after dramatic week",2017-07-28 10:36:34 +0000,https://finance.yahoo.com/news/dividends-worry-drugmakers-astra-gsk-103634116.html?.tsrc=rss,"Britain's two big drugmakers face very different challenges but they share a common problem: how to convince investors that their dividends are safe.  With both stocks offering a dividend yield of more than 5 percent, AstraZeneca and GlaxoSmithKline provide islands of decent income in a sea of low returns.  The chief executives of both companies faced a barrage of questions from analysts about future payouts and were forced to defend their dividend strategies at post-results meetings this week."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Capital Inc. -- Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings,2017-07-27 20:27:10 +0000,http://finance.yahoo.com/r/cf54cb1e-880d-3082-820c-cf2bb6a39df4/viewresearchdoc.aspx?docid=PR_370520&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX0NWX1JhdGluZ19OZXdzX0FsbF9Fbmc=~20170727_PR_370520&yptr=yahoo&.tsrc=rss,"Rating Action: Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings. Global Credit Research- 27 Jul 2017. London, 27 July 2017-- Moody's Investors Service has today changed ..."
GSK,GSK:US,BBG000BLB481,Overhaul Drug R&D? Easier Said Than Done,2017-07-27 18:00:10 +0000,http://finance.yahoo.com/r/a667e4a1-8b4e-3ec0-97d9-a56c7b155f17/eli-lilly-glaxosmithkline-earnings-r-d-overhauls-good-luck?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Both in-house and M&A solutions will be risky and take time to bear fruit.
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance",2017-07-27 17:59:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0RgtXB7cTqQ/glaxosmithkline-gsk-beats-on-q2-earnings-lowers-guidance-cm822714,GlaxoSmithKline plc s GSK reported core earnings of 70 cents per American depositary share in the second quarter of 2017 which beat the Zacks Consensus Estimate of 68 cents by almost 3 Earnings were however down 2 year over year at constant exchange rates CER driven by a negative
GSK,GSK:US,BBG000BLB481,"Pharma Stocks to Watch for Earnings on Jul 28: ABBV, MRK",2017-07-27 17:04:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r5d88A5Qm7A/pharma-stocks-to-watch-for-earnings-on-jul-28-abbv-mrk-cm822646,The second quarter reporting cycle is in full swing The quarter undoubtedly is off to a strong start As of Jul 26 2017 171 S amp P 500 members accounting for 44 1 of the index s total market capitalization reported results according to Earnings Preview Total earnings for these
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance",2017-07-27 15:27:03 +0000,https://finance.yahoo.com/news/glaxosmithkline-gsk-beats-q2-earnings-152703657.html?.tsrc=rss,"Glaxo&apos;s (GSK) second-quarter earnings beat estimates, while revenues miss the same. The company cuts its core 2017 earnings growth at CER, with no Advair generics launched this year."
GSK,GSK:US,BBG000BLB481,[$$] Glaxo Slashes R&D Projects to Focus on Top Prospects,2017-07-27 05:09:50 +0000,http://finance.yahoo.com/r/ddad1f08-c66d-3274-9b1c-3b167ae98bb6/glaxo-ditches-raft-of-r-d-projects-to-focus-on-best-prospects-1501074855?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline axed more than 30 drug-research projects to focus on four key disease areas, in a push by new Chief Executive Emma Walmsley to sharpen the company’s research-and-development operations...."
GSK,GSK:US,BBG000BLB481,Glaxo reports 2Q loss,2017-07-27 01:58:11 +0000,https://finance.yahoo.com/news/glaxo-reports-2q-loss-125903660.html?.tsrc=rss,"The Brentford Middlesex, Britain-based company said it had a loss of 9 cents per share. Earnings, adjusted for non-recurring costs and restructuring costs, were 70 cents per share. The results exceeded ..."
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline's new boss streamlines R&D, axes slew of drugs",2017-07-26 20:38:26 +0000,https://finance.yahoo.com/news/glaxosmithklines-boss-streamlines-drug-research-104129013.html?.tsrc=rss,"GlaxoSmithKline's new  chief executive announced plans on Wednesday to narrow the focus  of the group's drug research by ditching more than 30 drug  projects to improve returns in its core pharmaceuticals  business.  Emma Walmsley, who took over in April, said GSK would in  future allocate 80 percent of its R&D budget to respiratory and  HIV/infectious diseases, along with two other potential areas of  oncology and immuno-inflammation."
GSK,GSK:US,BBG000BLB481,Why Dynavax Technologies Corporation Stock Is Slumping Today,2017-07-26 18:00:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QgcEoQy62pY/why-dynavax-technologies-corporation-stock-is-slumping-today-cm821878,What happened Dynavax Technologies Corporation s NASDAQ DVAX stock is slumping this morning after the FDA released the briefing documents for the company s experimental hepatitis B vaccine known as Heplisav B The vaccine is scheduled to be reviewed by a panel of
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline is Now Oversold (GSK),2017-07-26 17:58:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LVcuJH0hKAU/glaxosmithkline-is-now-oversold-gsk-cm821870,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
GSK,GSK:US,BBG000BLB481,GSK gives up on rare diseases as gene therapy gets two customers,2017-07-26 16:59:54 +0000,https://finance.yahoo.com/news/gsk-gives-rare-diseases-gene-165954748.html?.tsrc=rss,"GlaxoSmithKline is  swimming against the tide by getting out of treatments for rare  diseases at a time when rivals like Sanofi and Shire  see the field as a rich seam for profits.  Successful medicines for rare conditions are potentially  very lucrative, since prices frequently run into hundreds of  thousands of dollars, but patient numbers can be extremely low.  New GSK Chief Executive Emma Walmsley announced the  strategic review and potential divestment of rare diseases on  Wednesday as part of a wide-ranging drive to streamline  pharmaceutical operations."
GSK,GSK:US,BBG000BLB481,[$$] Love Island adds to attraction of ITV ad hopes,2017-07-26 16:49:47 +0000,"http://finance.yahoo.com/r/4cfac50c-3ee7-3bd0-a057-02455a2d5e31/e4175ecc-71f1-11e7-aca6-c6bd07df1a3c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss",ITV made a rare appearance at the top of the FTSE 100 leaderboard as hit shows such as Love Island and signs of easing advertising pressures rekindled some investor affection for the broadcaster. Unease ...
GSK,GSK:US,BBG000BLB481,[$$] Glaxo Slashes R&D Projects to Focus on Top Prospects,2017-07-26 15:22:24 +0000,http://finance.yahoo.com/r/ddad1f08-c66d-3274-9b1c-3b167ae98bb6/glaxo-ditches-raft-of-r-d-projects-to-focus-on-best-prospects-1501074855?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline axed more than 30 drug-research projects to focus on four key disease areas, in a push by new Chief Executive Emma Walmsley to sharpen the company’s research-and-development operations...."
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q2 Earnings, Misses Sales",2017-07-26 13:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JpcKi6aCaE4/glaxo-gsk-beats-q2-earnings-misses-sales-cm821557,GlaxoSmithKline plc 160 GSK one of the largest health care companies reshaped its business following the Mar 2015 completion of the three part inter conditional transaction with Novartis related to its Consumer Healthcare Vaccines and Oncology businesses Under the deal Glaxo sold
GSK,GSK:US,BBG000BLB481,Glaxo Looks Beyond the Lab,2017-07-26 13:46:09 +0000,http://finance.yahoo.com/r/09d4192b-4eb0-3609-b062-2f6d444e2712/glaxo-s-ceo-pivots-from-scientists-to-shareholders?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,She shouldn't forget profit is a byproduct of success in the lab.
GSK,GSK:US,BBG000BLB481,Glaxo CFO Says Prioritizing R&D for Product Growth,2017-07-26 13:27:56 +0000,https://finance.yahoo.com/video/glaxo-cfo-says-prioritizing-r-132756483.html?.tsrc=rss,"Jul.26 -- Simon Dingemans, chief financial officer at GlaxoSmithKline PLC, discusses second-quarter results and expanding R&D to develop more products. He speaks on &quot;Bloomberg Daybreak: Americas.&quot;"
GSK,GSK:US,BBG000BLB481,Drugmaker GSK calls for at least two years' Brexit transition,2017-07-26 13:12:10 +0000,https://finance.yahoo.com/news/drugmaker-gsk-calls-least-two-131210484.html?.tsrc=rss,"Britain's pharmaceutical  industry needs at least two years' transition to cope with the  impact of the country leaving the European Union, the chief  executive of GlaxoSmithKline said on Wednesday.  Emma Walmsley, who leads Britain's largest drugmaker and  employs 17,000 UK staff, said she was ""encouraged by the more  pragmatic approach"" from ministers, but warned the industry  needed time to adjust to the coming disruption.  ""Our main focus is to make sure that we are given a  sufficiently long transition period, that is really the thing  that matters in our sector,"" she told reporters after quarterly  results."
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q2 Earnings, Misses Sales",2017-07-26 13:10:01 +0000,https://finance.yahoo.com/news/glaxo-gsk-beats-q2-earnings-131001708.html?.tsrc=rss,"Glaxo&apos;s (GSK) Q2 earnings beat estimate, with revenue missing the same. Glaxo lowered its core 2017 earnings growth in the quarter, with no Advair generics are launched this year."
GSK,GSK:US,BBG000BLB481,Drugmaker GSK reviewing its R&D programs under new CEO,2017-07-26 11:58:50 +0000,http://finance.yahoo.com/r/14f6dd31-98d8-38c0-bbd0-b8b94ba77d37/drugmaker-gsk-reviewing-r-d-programs-under-ceo-115852837--finance.html?.tsrc=rss,LONDON (AP) — Drugmaker GlaxoSmithKline says it will halt some 30 clinical and pre-clinical programs as it reviews its research and development pipeline and focuses on improving efficiency.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline on the Street: Analyst Recommendations after 2Q17,2017-07-26 11:44:25 +0000,http://finance.yahoo.com/r/b3e784ad-6365-302c-8b4f-e866c1d21b6a/glaxosmithkline-on-the-street-analyst-recommendations-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Wall Street analysts estimate that GSK's top line will rise 11.4% to ~7.3 billion British pounds for 2Q17. Its EPS is expected come in at 0.26 pounds.
GSK,GSK:US,BBG000BLB481,GSK Stock Falls on Reduced Guidance,2017-07-26 11:10:00 +0000,http://finance.yahoo.com/r/56962a8f-8fd8-3ee5-830e-36a833bab3b8/gsk-stock-falls-on-reduced-guidance.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Higher investment in HIV led GSK to cut earnings guidance
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's new boss streamlines drug research,2017-07-26 10:13:09 +0000,https://finance.yahoo.com/news/glaxosmithklines-boss-streamlines-drug-research-101309875.html?.tsrc=rss,"GlaxoSmithKline's new  Chief Executive Emma Walmsley announced plans on Wednesday to  streamline drug research in a bid to improve returns in the  group's core pharmaceuticals business.  Walmsley, who took over in April, said GSK would allocate  capital to priority areas including respiratory and HIV and  infectious diseases, and two potential areas of oncology and  immuno-inflammation."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Q2 Loss Narrows; Reiterates Outlook To 2020 - Quick Facts,2017-07-26 06:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nGKZqy3ZD2M/glaxosmithkline-q2-loss-narrows-reiterates-outlook-to-2020--quick-facts-20170726-00359,GlaxoSmithKline Q2 Loss Narrows; Reiterates Outlook To 2020 - Quick Facts
GSK,GSK:US,BBG000BLB481,Unpacking GlaxoSmithKline’s 2Q17 Revenue Expectations,2017-07-25 22:06:06 +0000,http://finance.yahoo.com/r/de8d0f66-bd03-3613-932f-5961e9b2480c/unpacking-glaxosmithklines-2q17-revenue-expectations?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Analysts expect to see a growth of ~11.4% in GlaxoSmithKline’s (GSK) 2Q17 revenues, which are expected to total nearly 7.3 billion British pounds."
GSK,GSK:US,BBG000BLB481,Inside GlaxoSmithKline’s 2Q17 Earnings Estimates,2017-07-25 20:25:42 +0000,http://finance.yahoo.com/r/8166368f-3acb-3258-858b-e0b141780dcc/inside-glaxosmithklines-2q17-earnings-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, analysts estimate that GSK's revenues will rise ~11.4% to ~7.3 billion pounds, as compared to ~6.5 billion pounds for 2Q16."
GSK,GSK:US,BBG000BLB481,"Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK",2017-07-25 18:03:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LVJd7sECmpI/drug-stocks-q2-earnings-releases-on-jul-26-gild-vrtx-gsk-cm820959,We are entering the peak period of the second quarter reporting cycle this week The quarter undoubtedly is off to a strong start As of Jul 21 2017 97 S amp P 500 members accounting for 28 1 of the index s total market capitalization reported results according to 160 Earnings
GSK,GSK:US,BBG000BLB481,"Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK",2017-07-25 15:18:03 +0000,https://finance.yahoo.com/news/drug-stocks-q2-earnings-releases-151803505.html?.tsrc=rss,We have three pharma giants that are set to report second-quarter results on Jul 26. Let&apos;s see how things are shaping up for this quarter.
GSK,GSK:US,BBG000BLB481,ViiV Healthcare Announces Superior Efficacy of Dolutegravir Versus Lopinavir/Ritonavir in Second-line HIV Treatment in Resource-limited Settings,2017-07-25 13:34:00 +0000,https://finance.yahoo.com/news/viiv-healthcare-announces-superior-efficacy-133400054.html?.tsrc=rss,"ViiV Healthcare, the global specialist HIV company, majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive interim results from DAWNING.  This is a non-inferiority study conducted to compare second-line treatment of the protease inhibitor-sparing regimen of dolutegravir and 2 nucleoside reverse transcriptase inhibitors (NRTIs), with a current WHO-recommended regimen of lopinavir/ritonavir and 2 NRTIs in HIV-1-infected adults.  The study's Independent Data Monitoring Committee (IDMC) noted significant and clinically-relevant differences between treatment arms in favour of dolutegravir and recommended that the boosted lopinavir treatment arm be discontinued."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Names Former Walmart Exec as New CTO,2017-07-25 13:02:00 +0000,http://finance.yahoo.com/r/0dc09838-3474-3f93-a266-5ddc43b9b3fa/glaxosmithkline-names-former-walmart-exec-as-new-cto.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,GSK is looking to expand its digital platforms.
GSK,GSK:US,BBG000BLB481,GSK hires ex-Wal-Mart executive to transform tech operations,2017-07-25 12:08:54 +0000,https://finance.yahoo.com/news/gsk-hires-ex-wal-mart-120854628.html?.tsrc=rss,"GlaxoSmithKline has  appointed former Wal-Mart Stores executive Karenann  Terrell to the new senior position of chief digital and  technology officer as the drugmaker looks to harness smart tech  systems across the group.  The move reflects a desire by Chief Executive Emma Walmsley,  who took over in April, to apply digital platforms in everything  from clinical trials to customer interactions."
GSK,GSK:US,BBG000BLB481,Corporate News Blog - GlaxoSmithKline and Innoviva Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma,2017-07-25 11:40:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-glaxosmithkline-innoviva-114000307.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / July 25, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for GlaxoSmithKline PLC (NYSE: GSK ), following which we have published ..."
GSK,GSK:US,BBG000BLB481,Analysts’ Recommendations for Merck in July 2017,2017-07-25 11:35:43 +0000,http://finance.yahoo.com/r/ec1db567-6e18-392a-8c2e-5dbfe58cf724/analysts-recommendations-merck-july-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Twenty-two analysts covered Merck in July 2017. Four analysts recommended a “strong buy” while ten analysts recommended a “buy.”
GSK,GSK:US,BBG000BLB481,GSK hires ex-Wal-Mart executive to transform tech operations,2017-07-25 11:25:15 +0000,https://finance.yahoo.com/news/gsk-hires-ex-wal-mart-112515123.html?.tsrc=rss,GlaxoSmithKline said on Tuesday it had appointed former Wal-Mart Stores executive Karenann Terrell to the new senior position of chief digital and technology officer. The move comes a day before the drugmaker's ...
GSK,GSK:US,BBG000BLB481,ViiV Healthcare Reports Positive Interim Results From DAWNING - Quick Facts,2017-07-25 08:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CE4xw8RLK14/viiv-healthcare-reports-positive-interim-results-from-dawning--quick-facts-20170725-00794,ViiV Healthcare Reports Positive Interim Results From DAWNING - Quick Facts
GSK,GSK:US,BBG000BLB481,GSK : ViiV Healthcare Announces Results From NEAT 022 Study,2017-07-25 08:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6YcQLamzMIU/gsk--viiv-healthcare-announces-results-from-neat-022-study-20170725-00791,GSK : ViiV Healthcare Announces Results From NEAT 022 Study
GSK,GSK:US,BBG000BLB481,GSK-backed ViiV Healthcare pushing forward in HIV treatments,2017-07-24 22:05:11 +0000,http://finance.yahoo.com/r/d4cddf80-1e15-373d-b113-d256fd2a0189/gsk-backed-viiv-healthcare-pushing-forward-in-hiv.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline-backed ViiV Healthcare – which is based in the U.K. and has its U.S. headquarters in Research Triangle Park – continues to push forward in HIV treatments.  ViiV announced Monday positive results of its LATTE-2 Phase IIb study, evaluating long-acting, injectable cabotegravir (from ViiV Healthcare) and rilpivirine (from Janssen Sciences Ireland) as a two-drug treatment for HIV.  “These study results are important because we now have data showing the durability and tolerability of long-acting viral suppression for a two-drug regimen out to 96 weeks,” John C. Pottage Jr., chief scientific and medical officer of ViiV Healthcare, said in prepared remarks."
GSK,GSK:US,BBG000BLB481,Gilead&apos;s HIV Drug Matches Glaxo Rival In Late-Stage Trials,2017-07-24 20:45:18 +0000,http://finance.yahoo.com/r/0e579ab8-37be-39e6-ba0c-0638b066e849/gileads-hiv-drug-matches-glaxo-rival-in-late-stage-trials?src=A00220&yptr=yahoo&.tsrc=rss,Glaxo shares dipped near a two-week low after Gilead&apos;s HIV drug combination proved to be non-inferior in a late-stage trial.
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX",2017-07-24 15:09:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2Su-BAlIepU/the-zacks-analyst-blog-highlights-alphabet-glaxosmithkline-t-mobile-northrop-grumman-and-csx-cm820047,For Immediate Release Chicago IL July 24 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX",2017-07-24 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-alphabet-133001966.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Alphabet, GlaxoSmithKline, T-Mobile, Northrop Grumman and CSX"
GSK,GSK:US,BBG000BLB481,"HIV fight advances with new drug cocktails, fresh vaccine hopes",2017-07-24 08:00:00 +0000,https://finance.yahoo.com/news/hiv-fight-advances-drug-cocktails-080000118.html?.tsrc=rss,"Three decades after approval of  the first-ever AIDS treatment, HIV medicine is seeing a new wave  of innovation with scientists reporting positive data on Monday  for improved drug cocktails and a novel experimental vaccine.  The Achilles heel for us is drug  resistance because the virus is incredibly quick to mutate,""  Linda-Gail Bekker, deputy director of the Desmond Tutu HIV  Centre in South Africa, said.  The race for better and more convenient medicines has made  HIV a rich battleground for drug companies such as Gilead  Sciences and GlaxoSmithKline, which generate  billions of dollars from modern therapies."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline: ViiV Healthcare Presents 96-week Data From LATTE-2 Study,2017-07-24 04:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pDY9mC17vUk/glaxosmithkline-viiv-healthcare-presents-96week-data-from-latte2-study-20170724-00138,GlaxoSmithKline: ViiV Healthcare Presents 96-week Data From LATTE-2 Study
GSK,GSK:US,BBG000BLB481,"Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile",2017-07-21 23:03:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GVnx-WhxxTE/top-stock-reports-for-alphabet-glaxosmithkline-t-mobile-cm819660,Friday July 21 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Alphabet GOOGL GlaxoSmithKline GSK and T Mobile TMUS These research reports have been hand picked
GSK,GSK:US,BBG000BLB481,"Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile",2017-07-21 21:01:09 +0000,https://finance.yahoo.com/news/top-stock-reports-alphabet-glaxosmithkline-210109637.html?.tsrc=rss,"Top Stock Reports for Alphabet, GlaxoSmithKline & T-Mobile"
GSK,GSK:US,BBG000BLB481,GSK Submits EU Filing for Extended Use of Relvar Ellipta in Patients with Controlled Asthma on an ICS/LABA Combination,2017-07-21 13:00:00 +0000,https://finance.yahoo.com/news/gsk-submits-eu-filing-extended-130000924.html?.tsrc=rss,"GlaxoSmithKline plc and Innoviva, Inc. today announced a submission to the European Medicines Agency for the extended use of once-daily Relvar Ellipta , an inhaled corticosteroid / long-acting β2-agonist combination, in patients already adequately controlled on an ICS/LABA combination."
GSK,GSK:US,BBG000BLB481,GSK Submits EU Filing For Extended Use Of Relvar Ellipta,2017-07-21 09:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5sPmsdQoiWI/gsk-submits-eu-filing-for-extended-use-of-relvar-ellipta-20170721-00530,GSK Submits EU Filing For Extended Use Of Relvar Ellipta
GSK,GSK:US,BBG000BLB481,Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab,2017-07-21 00:02:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6iD91ML5Hug/emergent-inks-agreement-to-acquire-anthrax-drug-raxibacumab-cm819007,Emergent BioSolutions Inc s EBS shares increased more than 2 after the company announced that it has inked an agreement with GlaxoSmithKline plc GSK to acquire its anthrax monoclonal antibody raxibacumab Note that raxibacumab was approved of by the FDA in Dec 2012 for the treatment
GSK,GSK:US,BBG000BLB481,Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab,2017-07-20 22:19:10 +0000,https://finance.yahoo.com/news/emergent-inks-agreement-acquire-anthrax-221910214.html?.tsrc=rss,Emergent&apos;s shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter&apos;s anthrax monoclonal antibody raxibacumab.
GSK,GSK:US,BBG000BLB481,These Non-Tech Firms Are Making Big Bets On Artificial Intelligence,2017-07-20 20:12:46 +0000,http://finance.yahoo.com/r/7082e324-3f9e-3e3d-ac1f-cce2703a3823/17-non-tech-firms-making-big-bets-on-artificial-intelligence?src=A00220&yptr=yahoo&.tsrc=rss,Loup Ventures has compiled a portfolio of 17 publicly traded non-tech companies that are making investments in artificial intelligence to improve their businesses.
GSK,GSK:US,BBG000BLB481,Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million,2017-07-20 19:10:13 +0000,http://finance.yahoo.com/r/ea989fe9-4fed-38c4-bfc4-b70f4e874fdf/emergent-biosolutions-acquires-glaxosmithkline.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately.  On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million.  The deal came less than a week after Emergent (EBS) announced it would buy French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million."
GSK,GSK:US,BBG000BLB481,What Lies in Store for Glaxo (GSK) this Earnings Season?,2017-07-20 17:04:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rr47N5wiCfs/what-lies-in-store-for-glaxo-gsk-this-earnings-season-cm818776,GlaxoSmithKline plc GSK is scheduled to report second quarter 2017 results on Jul 26 before market opens Last quarter the company delivered in line earnings Glaxo s shares are up 10 1 this year so far underperforming the 11 9 increase witnessed by the Zacks classified Large Cap
GSK,GSK:US,BBG000BLB481,What Lies in Store for Glaxo (GSK) this Earnings Season?,2017-07-20 15:12:03 +0000,https://finance.yahoo.com/news/lies-store-glaxo-gsk-earnings-151203709.html?.tsrc=rss,"The performance of GlaxoSmithKline plc&apos;s (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair."
GSK,GSK:US,BBG000BLB481,[$$] GlaxoSmithKline to Sell Its U.K. Horlicks Brand,2017-07-19 16:18:14 +0000,http://finance.yahoo.com/r/f1349635-b1ba-32bc-a583-ac9d524cef06/glaxosmithkline-to-sell-its-u-k-horlicks-brand-1500481062?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Drug and healthcare products giant GlaxoSmithKline said it plans to sell its Horlicks drinks brand in the U.K. and cut around 320 jobs in the country.
GSK,GSK:US,BBG000BLB481,GSK puts old antibiotics and UK Horlicks business on the block,2017-07-19 13:27:13 +0000,https://finance.yahoo.com/news/gsk-puts-old-antibiotics-uk-132713195.html?.tsrc=rss,"GlaxoSmithKline said it  was considering the sale of its cephalosporins antibiotics  business and intended to divest its small Horlicks business in  Britain, while retaining the much bigger malted drink operation  in India.  The antibiotics business under strategic review covers the  brands Zinnat/Ceftin, Zinacef and Fortum and has worldwide  annual sales estimated at around 200 million pounds ($260  million), but it faces growing competition from cheap generics."
GSK,GSK:US,BBG000BLB481,"[$$] Novartis, Glaxo and Lilly Bigly Back New Biotech",2017-07-19 13:21:00 +0000,http://finance.yahoo.com/r/25ac3e8d-d93e-3285-9d3e-8e3027a7f8db/novartis-glaxo-and-lilly-bigly-back-new-biotech-1500458556?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Aileron Therapeutics’ initial public offering was priced at $15 a share on June 28.  You can be forgiven if you hadn’t heard of the cancer biotech’s IPO.  Apart from a low media profile, the low-end IPO pricing was also a disappointment."
GSK,GSK:US,BBG000BLB481,Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval,2017-07-19 00:02:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xaMjkjRGb40/pumas-pbyi-breast-cancer-drug-neratinib-gets-fda-approval-cm817798,Puma Biotechnology Inc PBYI shares rose more than 7 in after hours trading on Monday after the company announced that the FDA has approved of its lead breast cancer candidate neratinib Puma Biotech expects to make the drug commercially available in September under the brand name
GSK,GSK:US,BBG000BLB481,3 Value Stocks for Conservative Investors,2017-07-18 02:45:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/icAH6xSI2wA/3-value-stocks-for-conservative-investors-cm817227,You say you ve found yourself a cheap stock and congratulations for that But doesn t it seem like it s a bit too cheap Every value investor may eventually encounter the suspicion that a cheap stock may be a value trap instead one that s cheap for a reason and may never rise
GSK,GSK:US,BBG000BLB481,3 Value Stocks for Conservative Investors,2017-07-18 01:33:00 +0000,http://finance.yahoo.com/r/a6f343d1-c9ff-3090-b780-76aa5d8f6834/3-value-stocks-for-conservative-investors.aspx?yptr=yahoo&.tsrc=rss,We&apos;re looking for cheap stocks -- not value traps.
GSK,GSK:US,BBG000BLB481,3 Small Biotech Stocks Being Run by Proven Winners,2017-07-17 12:49:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZbNbDPfQ970/3-small-biotech-stocks-being-run-by-proven-winners-cm816698,Great leaders are important in any industry but perhaps they re even more valuable in biotech where any number of clinical stage and regulatory obstacles can derail drug research and send share prices reeling For that reason investing in biotech stocks such as Aurinia
GSK,GSK:US,BBG000BLB481,Gilead (GILD) Application for HIV Drug Validated in EU,2017-07-15 09:44:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NMuJ3Lj4etw/gilead-gild-application-for-hiv-drug-validated-in-eu-cm816467,Gilead Sciences Inc GILD announced that the company s Marketing Authorization Application MAA for a once daily single tablet regimen containing bictegravir 50 mg BIC and emtricitabine tenofovir alafenamide 200 25mg FTC TAF for the treatment of HIV 1 infection in adults has been
GSK,GSK:US,BBG000BLB481,Gilead (GILD) Application for HIV Drug Validated in EU,2017-07-15 08:00:08 +0000,https://finance.yahoo.com/news/gilead-gild-application-hiv-drug-080008832.html?.tsrc=rss,"Gilead Sciences, Inc. (GILD) announced that the company&apos;s Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency."
GSK,GSK:US,BBG000BLB481,Gilead (GILD) Application for HIV Drug Validated in EU,2017-07-14 18:35:06 +0000,https://finance.yahoo.com/news/gilead-gild-application-hiv-drug-183506815.html?.tsrc=rss,"Gilead Sciences, Inc. (GILD) announced that the company&apos;s Marketing Authorization Application for once-daily single tablet for the treatment of HIV-1 infection in adults has been fully validated by the European Medicines Agency."
GSK,GSK:US,BBG000BLB481,GSK September 1st Options Begin Trading,2017-07-13 14:51:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/brmf79m1m8w/gsk-september-1st-options-begin-trading-cm815613,Investors in GlaxoSmithKline plc Symbol GSK saw new options become available today for the September 1st expiration At Stock Options Channel our YieldBoost formula has looked up and down the GSK options chain for the new September 1st contracts and identified one put and one call
GSK,GSK:US,BBG000BLB481,"Gainers & Losers Of July 12: CALA, TRVN, GEMP, ALDR, INSY...",2017-07-12 22:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J0mW0CsSDfQ/gainers--losers-of-july-12-cala-trvn-gemp-aldr-insy-20170712-01296,"Gainers & Losers Of July 12: CALA, TRVN, GEMP, ALDR, INSY..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Performance in 2Q17,2017-07-07 20:07:28 +0000,http://finance.yahoo.com/r/b916d02e-f484-3250-b462-9cd9f7fc992b/glaxosmithklines-performance-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in Brentford, Middlesex, GlaxoSmithKline (GSK) is a British multinational pharmaceutical company. The company has segregated its business into three business segments: Pharmaceuticals, Vaccines, ..."
GSK,GSK:US,BBG000BLB481,Puma (PBYI) Ends Patient Enrollment in Phase III Cancer Trial,2017-07-07 15:51:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yx3osU0wkT4/puma-pbyi-ends-patient-enrollment-in-phase-iii-cancer-trial-cm813044,Puma Biotechnology Inc PBYI announced that it has completed enrollment of patients in a phase III study to evaluate its lead pipeline candidate PB272 neratinib in combination with Roche Holding AG s RHHBY Xeloda capecitabine for treatment of third line HER2 positive metastatic
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook",2017-07-07 13:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2RgckUoZQQ8/pharma-stock-roundup-mrks-keytruda-mm-combo-studies-on-clinical-hold-bayer-to-revise-outlook-cm812971,Merck s MRK Keytruda has hit a stumbling block with the FDA placing three combination studies on clinical hold Meanwhile Bayer BAYRY said that it will be revising its outlook when it reports second quarter results later this month to reflect inventory issues associated with the Crop
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: MRK&apos;s Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook",2017-07-07 12:25:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-mrk-apos-122512550.html?.tsrc=rss,3 studies on Merck&apos;s (MRK) Keytruda have been put on clinical hold while Bayer said that it expects to revise its 2017 outlook when it reports Q2 results.
GSK,GSK:US,BBG000BLB481,Tesla&apos;s Stock Is Only Worth This Much: Goldman,2017-07-05 20:14:57 +0000,http://finance.yahoo.com/r/e4b5dc5c-db27-3403-839d-5a3932986031/tesla-worth-half-its-current-stock-price-goldman-says-oracle-cloud-cheered-novartis-cut?src=A00220&yptr=yahoo&.tsrc=rss,Tesla&apos;s price target was cut while Oracle was upgraded on cloud offerings. Novartis was downgraded.
GSK,GSK:US,BBG000BLB481,"Healthcare Repeal Bad For GlaxoSmithKline, Other HIV Treatment Stocks",2017-07-05 16:17:27 +0000,https://finance.yahoo.com/news/healthcare-repeal-bad-glaxosmithkline-other-161727067.html?.tsrc=rss,The Congressional Budget Office has said that the Senate version of the Republicans’ Affordable Care Act replacement bill could result in 22 million fewer Americans with health insurance. That dramatic ...
GSK,GSK:US,BBG000BLB481,Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days,2017-07-05 15:01:46 +0000,https://finance.yahoo.com/news/attention-biotech-investors-keep-date-150146969.html?.tsrc=rss,"June was event-filled as far as the PDUFA calendar was concerned. The month ushered in good tidings for the biotech sector, as most applications for approval pending before the FDA were favorably viewed. ..."
GSK,GSK:US,BBG000BLB481,"Bank on Gilead Sciences, Inc. (GILD) Stock Getting Its Mojo Back",2017-07-05 14:20:24 +0000,https://finance.yahoo.com/news/bank-gilead-sciences-inc-gild-142024734.html?.tsrc=rss,"For the past 12 months Gilead Sciences, Inc. (NASDAQ:GILD) could have served as the poster-child for a falling knife to avoid.  Finally, GILD stock was able to participate in the biotech sector bounce that happened in June."
GSK,GSK:US,BBG000BLB481,3 Top High-Yield Pharmaceutical Stocks to Buy Now,2017-07-03 19:43:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6oRA351SpMo/3-top-high-yield-pharmaceutical-stocks-to-buy-now-cm811338,Stocks that sport unusually high dividend yields compared to their peers often do so because an underlying problem with their business has cut into their value Still high yielders can on occasion represent fantastic bargains for risk tolerant investors Big pharma
GSK,GSK:US,BBG000BLB481,3 Top High-Yield Pharmaceutical Stocks to Buy Now,2017-07-03 19:11:00 +0000,http://finance.yahoo.com/r/a9365adc-2b41-3ac8-9fb3-24dbef45c6b8/3-top-high-yield-pharmaceutical-stocks-to-buy-now.aspx?yptr=yahoo&.tsrc=rss,"AstraZeneca, GlaxoSmithKline, and Teva Pharmaceutical Industries sport some of the highest dividend yields among drugmakers today. Here&apos;s why their rewards could outweigh their risks."
GSK,GSK:US,BBG000BLB481,"Early movers: TSLA, GSK, LVS, WYNN, CAT, GS, BMY & more",2017-07-03 12:08:08 +0000,http://finance.yahoo.com/r/6e4efc03-e6fb-3e0f-81c0-9a60371be417/104565061?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104565061&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves before the bell.
GSK,GSK:US,BBG000BLB481,"Big pharma turns to AI to speed drug discovery, GSK signs deal",2017-07-03 06:00:00 +0000,https://finance.yahoo.com/news/big-pharma-turns-ai-speed-060000902.html?.tsrc=rss,"The world's leading drug  companies are turning to artificial intelligence to improve the  hit-and-miss business of finding new medicines, with  GlaxoSmithKline unveiling a new $43 million deal in the  field on Sunday.  Other pharmaceutical giants including Merck & Co,  Johnson & Johnson and Sanofi are also  exploring the potential of artificial intelligence (AI) to help  streamline the drug discovery process.  The aim is to harness modern supercomputers and machine  learning systems to predict how molecules will behave and how  likely they are to make a useful drug, thereby saving time and  money on unnecessary tests."
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb,2017-07-02 15:36:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AbfLFJAhdZg/better-buy-glaxosmithkline-plc-vs-bristol-myers-squibb-cm810952,Big pharma stocks are arguably set to shine now that the threat of hard caps 160 on drug prices is off the table Global prescription drug sales after all are forecast to grow at a healthy 6 5 per year for the next five years running according to EvaluatePharma Keeping
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. Bristol-Myers Squibb,2017-07-02 13:47:00 +0000,http://finance.yahoo.com/r/a4f91118-090e-35e4-859e-0e0ccd2435c6/better-buy-glaxosmithkline-plc-vs-bristol-myers-sq.aspx?yptr=yahoo&.tsrc=rss,Is GlaxoSmithKline or Bristol-Myers Squibb the better big pharma stock to buy right now?
GSK,GSK:US,BBG000BLB481,"Big pharma turns to AI to speed drug discovery, GSK signs deal",2017-07-02 00:43:09 +0000,https://finance.yahoo.com/news/big-pharma-turns-ai-speed-000955210.html?.tsrc=rss,"The world's leading drug companies are turning to artificial intelligence to improve the hit-and-miss business of finding new medicines, with GlaxoSmithKline unveiling a new $43 million deal in the field on Sunday.  Other pharmaceutical giants including Merck & Co, Johnson & Johnson and Sanofi are also exploring the potential of artificial intelligence (AI) to help streamline the drug discovery process.  The aim is to harness modern supercomputers and machine learning systems to predict how molecules will behave and how likely they are to make a useful drug, thereby saving time and money on unnecessary tests."
GSK,GSK:US,BBG000BLB481,Exscientia Enters Strategic Drug Discovery Collaboration With GSK,2017-07-01 23:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XPhdmYhQDjA/exscientia-enters-strategic-drug-discovery-collaboration-with-gsk-20170701-00011,Exscientia Enters Strategic Drug Discovery Collaboration With GSK
GSK,GSK:US,BBG000BLB481,Amgen's Colorectal Cancer Drug Gets FDA Nod to Expand Label,2017-06-30 16:44:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qVIxLY-NyRI/amgens-colorectal-cancer-drug-gets-fda-nod-to-expand-label-cm810618,Amgen Inc AMGN announced that the FDA has approved a label expansion of its colorectal cancer drug Vectibix Vectibix is now approved for use as first line treatment of wild type RAS metastatic colorectal cancer mCRC patients in combination with Folfox and as monotherapy following
GSK,GSK:US,BBG000BLB481,"Dova Pharmaceuticals Targets a 9-Figure Opportunity, but Should You Buy Its IPO?",2017-06-30 12:04:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/90fgFfSATiE/dova-pharmaceuticals-targets-a-9-figure-opportunity-but-should-you-buy-its-ipo-cm810317,Patients with thrombocytopenia already receive treatment with drugs that work the same way Dova Pharmaceuticals NASDAQ DOVA 160 lead drug candidate does but that isn t stopping the freshly minted company from planning a Food and Drug Administration filing this year Can
GSK,GSK:US,BBG000BLB481,3 Pivotal Drug Trials to Watch for Explosive Potential,2017-06-30 07:03:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uuxEsWGSVlY/3-pivotal-drug-trials-to-watch-for-explosive-potential-cm810308,InvestorPlace Stock Market News Stock Advice amp Trading Tips We re midway through the year and the U S Food and Drug Administration FDA has already approved just shy of 50 new drugs The second half of the year however promises to be just as interesting as the first
GSK,GSK:US,BBG000BLB481,Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion,2017-06-29 16:08:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eyIsO9lupAs/novartis-gets-ec-nod-for-lung-cancer-drugs-label-expansion-cm809991,Novartis AG NVS announced that the European Commission has approved a label expansion of oncology drug Zykadia The drug is now approved for the first line treatment of patients with advanced non small cell lung cancer NSCLC whose tumors are anaplastic lymphoma kinase ALK positive
GSK,GSK:US,BBG000BLB481,5 Biotech Stocks With Major Catalysts in July,2017-06-28 20:22:00 +0000,http://finance.yahoo.com/r/66aab481-87c1-3787-a38f-26ad86dee364/5-biotech-stocks-with-major-catalysts-in-july.aspx?yptr=yahoo&.tsrc=rss,"Big news is on the way soon for AcelRx, Alnylam, Amgen, Dynavax, and Merck."
GSK,GSK:US,BBG000BLB481,"Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe",2017-06-28 15:08:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_7D9qBHjVOA/novartis-erelzi-biosimilar-of-enbrel-approved-in-europe-cm809364,Novartis AG NVS announced that the European Commission EC has approved Erelzi the biosimilar version of Amgen s AMGN Enbrel Erelzi is approved for use in all indications of the branded drug like rheumatoid arthritis axial spondyloarthritis ankylosing spondylitis and non
GSK,GSK:US,BBG000BLB481,Is This the Next Home-Run Biotech Stock?,2017-06-28 15:07:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4Eko_I18-4o/is-this-the-next-home-run-biotech-stock-cm809218,Alzheimer s disease is incredibly tough to treat and 99 of Alzheimer s disease drugs to enter clinical trials have failed But Axovant Sciences NYSE AXON thinks it s designed a trial that can pan out and given that its management includes been there and done that leaders it
GSK,GSK:US,BBG000BLB481,"Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike",2017-06-27 20:50:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dQ24C-ACv3I/top-analyst-reports-for-alphabet-berkshire-hathaway-nike-cm809076,Tuesday June 27 2017 The Zacks Research Daily presents the best research output of our analyst team Today s Research Daily features new research reports on 16 major stocks including Alphabet Inc GOOGL Berkshire Hathaway Inc BRK B and Nike Inc NKE These research reports have
GSK,GSK:US,BBG000BLB481,"Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike",2017-06-27 17:53:05 +0000,https://finance.yahoo.com/news/top-analyst-reports-alphabet-berkshire-175305236.html?.tsrc=rss,"Top Analyst Reports for Alphabet, Berkshire Hathaway & Nike"
GSK,GSK:US,BBG000BLB481,The Forgotten $35 Billion U.S. Healthcare Problem,2017-06-27 12:38:00 +0000,http://finance.yahoo.com/r/07d39e54-4eb1-3e02-ba4f-43b125958718/the-forgotten-35-billion-u-s-health-care-problem?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Each year, more than 23,000 people die in the U.S. as a result of bacterial infections that are resistant to antibiotics – the equivalent of a Boeing 747 crashing each week. Worse, there are at least 2 million people each year who acquire serious infections by bacteria resistant to antibiotics."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Begins Mepolizumab Phase III Study - Quick Facts,2017-06-27 05:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k8Rh_laOT-w/glaxosmithkline-begins-mepolizumab-phase-iii-study--quick-facts-20170627-00154,GlaxoSmithKline Begins Mepolizumab Phase III Study - Quick Facts
GSK,GSK:US,BBG000BLB481,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",2017-06-26 14:55:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1pXkDJkLVzE/novartis-cardiovascular-drug-positive-nsclc-drug-approved-cm808013,Shares of Novartis AG NVS were up after the company announced positive top line results from the global phase III study CANTOS The study evaluated the efficacy safety and tolerability of ACZ885 canakinumab in combination with standard of care in patients with a prior heart attack
GSK,GSK:US,BBG000BLB481,GSK's new CEO aims to divest sports nutrition brand: sources,2017-06-22 21:17:21 +0000,https://finance.yahoo.com/news/gsks-ceo-aims-divest-sports-211552645.html?.tsrc=rss,"GlaxoSmithKline Plc's new Chief Executive Officer Emma Walmsley is shaking up the British drugmaker's portfolio of smaller products with plans to divest its MaxiNutrition sports nutrition brand, two people familiar with the matter said on Thursday.  GSK bought the business, which makes protein bars, drinks and powders, for 162 million pounds ($205 million) in 2010 under previous CEO Andrew Witty.  The original acquisition was seen as complementing GSK's Lucozade sports drinks."
GSK,GSK:US,BBG000BLB481,Glaxo's (GSK) Shingles Candidate Phase III Data Positive,2017-06-22 16:24:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FDaAJrW7Wn4/glaxos-gsk-shingles-candidate-phase-iii-data-positive-cm806943,GlaxoSmithKline plc GSK announced positive top line results from a phase III revaccination study on its shingles vaccine candidate Shingrix in older patients The Zoster 048 study administered Shingrix in patients aged 50 years or older who have been vaccinated against shingles with
GSK,GSK:US,BBG000BLB481,Novartis Announces Positive Results for Cardiovascular Drug,2017-06-22 15:24:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PF5L0sm4-us/novartis-announces-positive-results-for-cardiovascular-drug-cm806791,Novartis AG NVS announced positive top line results from the global phase III study CANTOS The study evaluated the efficacy safety and tolerability of ACZ885 canakinumab in combination with standard of care in patients with a prior heart attack and inflammatory atherosclerosis CANTOS is
GSK,GSK:US,BBG000BLB481,Glaxo&apos;s (GSK) Shingles Candidate Phase III Data Positive,2017-06-22 14:06:02 +0000,https://finance.yahoo.com/news/glaxo-apos-gsk-shingles-candidate-140602662.html?.tsrc=rss,"GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients."
GSK,GSK:US,BBG000BLB481,"Early movers: ORCL, HAIN, ACN, SCS, ATUS, NVS, GSK & more",2017-06-22 12:08:39 +0000,http://finance.yahoo.com/r/68417481-00cd-342b-83a3-e69428c061df/104545028?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104545028&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves before the bell.
GSK,GSK:US,BBG000BLB481,GSK wins $235 million from Teva in Coreg patent trial,2017-06-21 22:41:52 +0000,https://finance.yahoo.com/news/gsk-wins-235-million-teva-224152421.html?.tsrc=rss,"A U.S. jury has ordered Teva  Pharmaceutical Industries Ltd to pay GlaxoSmithKline  Plc more than $235 million for infringing a patent  covering its blood pressure drug Coreg, court documents showed.  A federal jury in Wilmington, Delaware on Tuesday found that  Teva willfully infringed the patent in connection with its sales  of a generic version of the drug with a label indicating it  could be used for treating chronic heart failure.  The jury rejected Teva's contention that the patent was  invalid."
GSK,GSK:US,BBG000BLB481,Amgen An Undervalued Industry Leader,2017-06-21 19:00:00 +0000,http://finance.yahoo.com/r/32350ffa-bf78-341a-9966-7802574a289f/amgen-an-undervalued-industry-leader?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Given the company’s industry leading position, solid fundamentals and attractive stock valuation, we view it as a preferable alternative to traditional competitors in its industry."
GSK,GSK:US,BBG000BLB481,GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting,2017-06-21 15:19:00 +0000,https://finance.yahoo.com/news/gsk-presents-positive-results-phase-151900891.html?.tsrc=rss,"Study conducted in individuals who had previously received current standard of care LONDON , June 21, 2017 /PRNewswire/ -- GSK (LSE/NYSE: GSK) today will be presenting new results from a clinical study ..."
GSK,GSK:US,BBG000BLB481,Dupixent May Prove Effective in Multiple Diseases,2017-06-20 18:06:09 +0000,http://finance.yahoo.com/r/54a23092-8e5b-3fbf-9847-c11a49caed5c/dupixent-may-prove-effective-multiple-diseases-caused-overactivity-il-4-il-13-pathway?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Regeneron plans to discuss Dupixent’s innovative mechanism-based treatment approach with regulatory authorities.
GSK,GSK:US,BBG000BLB481,Label Expansion May Boost Regeneron’s Dupixent in the Future,2017-06-20 16:20:50 +0000,http://finance.yahoo.com/r/8ab8524c-dda7-36c1-ab70-31624ea9bef1/label-expansion-may-boost-dupixents-sales-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Regeneron (REGN) and Sanofi (SNY) are exploring the use of Dupixent in other indications such as asthma, pediatric AD, nasal polyps, and eosinophilic esophagitis."
GSK,GSK:US,BBG000BLB481,Novartis (NVS) Biosimilar of MabThera Approved in the EU,2017-06-19 23:20:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/utLNnKRjv5g/novartis-nvs-biosimilar-of-mabthera-approved-in-the-eu-cm805387,Novartis AG NVS announced that its generic arm Sandoz has received European Commission EC approval for Rixathon a biosimilar version of Roche s RHHBY MabThera in Europe The biosimilar version has been approved for all the indications of the branded drug Rixathon is approved
GSK,GSK:US,BBG000BLB481,"GSK Confirms Start Date For Luke Miels As President, Global Pharma",2017-06-19 21:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v_3ipRl2g2U/gsk-confirms-start-date-for-luke-miels-as-president-global-pharma-20170619-01247,"GSK Confirms Start Date For Luke Miels As President, Global Pharma"
GSK,GSK:US,BBG000BLB481,Novartis (NVS) Biosimilar of MabThera Approved in the EU,2017-06-19 20:56:08 +0000,https://finance.yahoo.com/news/novartis-nvs-biosimilar-mabthera-approved-205608212.html?.tsrc=rss,"Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon."
GSK,GSK:US,BBG000BLB481,GSK's new pharma head to join in September after AstraZeneca tussle,2017-06-19 16:26:37 +0000,https://finance.yahoo.com/news/gsk-pharma-head-sept-astrazeneca-154611350.html?.tsrc=rss,"GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.  Britain's biggest drugmaker poached Miels in January in the first major appointment by incoming GSK Chief Executive Emma Walmsley.  GSK said on Monday it had now struck an agreement with AstraZeneca for Miels to start on Sept. 4, avoiding the need for a court case over his contract."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's Benlysta Positive in Continuation Trial,2017-06-19 16:21:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gUyxoqQcGcw/glaxosmithklines-benlysta-positive-in-continuation-trial-cm805103,GlaxoSmithKline plc GSK announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug Benlysta belimumab in combination with standard of care for treatment of patients with systemic lupus erythematosus SLE The study was presented at
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline&apos;s Benlysta Positive in Continuation Trial,2017-06-19 14:21:02 +0000,https://finance.yahoo.com/news/glaxosmithkline-apos-benlysta-positive-continuation-142102670.html?.tsrc=rss,"GlaxoSmithKline plc (GSK) announced positive results from a phase II continuation study evaluating the efficacy and safety of its marketed drug, Benlysta, in combination with standard of care for treatment systemic lupus erythematosus (SLE)."
GSK,GSK:US,BBG000BLB481,Could Legalized Marijuana Be Making Big Pharma Nervous?,2017-06-18 19:19:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hJp4i0ldJpI/could-legalized-marijuana-be-making-big-pharma-nervous-cm804826,An effort in Arizona to legalize recreational marijuana failed last year Insys Therapeutics NASDAQ INSY helped make it happen The drugmaker donated 500 000 to an organization that opposed a marijuana legalization proposition It makes sense that Insys would be
GSK,GSK:US,BBG000BLB481,5 Answers to Questions Gilead Sciences' Investors Probably Have,2017-06-18 17:19:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8dAXvPkMCYQ/5-answers-to-questions-gilead-sciences-investors-probably-have-cm804819,If you re a Gilead Sciences NASDAQ GILD shareholder or you re thinking about buying the stock you probably have a lot of questions And if you don t you should have It hasn t been a pretty picture for the biotech for quite a while now Gilead s hepatitis C virus
GSK,GSK:US,BBG000BLB481,5 Answers to Questions Gilead Sciences&apos; Investors Probably Have,2017-06-18 15:42:00 +0000,http://finance.yahoo.com/r/6fb1f917-368f-300c-b3a3-8c990896643f/5-answers-to-questions-gilead-sciences-investors-p.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences executives provide some answers at the Goldman Sachs healthcare conference.
GSK,GSK:US,BBG000BLB481,Should Value Investors Pick GlaxoSmithKline (GSK) Stock Now?,2017-06-16 13:45:01 +0000,https://finance.yahoo.com/news/value-investors-pick-glaxosmithkline-gsk-134501755.html?.tsrc=rss,Let&apos;s put GlaxoSmithKline PLC (GSK) stock into this equation and find out if it is a good choice for value-oriented investors right now.
GSK,GSK:US,BBG000BLB481,"Health Care Sector Update for 06/16/2017: JNJ, PFE, ABT, MRK, AMGN, GSK, PFE, LLY",2017-06-16 13:07:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/swpIP_zoMS0/health-care-sector-update-for-06162017-jnj-pfe-abt-mrk-amgn-gsk-pfe-lly-cm804231,Top Health Care stocks Top Health Care stocks JNJ flatJNJ flat PFE flatPFE flat ABT flatABT flat MRK flatMRK flat AMGN flatAMGN flat Health care shares were inactive in pre market trade Friday Health care shares were inactive in pre market trade Friday In health care stocks
GSK,GSK:US,BBG000BLB481,Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval,2017-06-15 23:07:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7lrUXK2K9A/puma-pbyi-stock-surges-as-neratinib-nears-fda-approval-cm804131,Puma Biotechnology Inc PBYI is a Los Angeles CA based biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care Puma s stock has significantly outperformed the Zacks classified Medical Biomed Genetics industry in
GSK,GSK:US,BBG000BLB481,Gilead (GILD) Submits NDA for HIV Combination Therapy Regimen,2017-06-13 23:27:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_muM12cmcXw/gilead-gild-submits-nda-for-hiv-combination-therapy-regimen-cm803005,Gilead Sciences Inc GILD announced that it has submitted a New Drug Application NDA to the FDA for an investigational once daily single tablet regimen containing bictegravir 50 mg BIC and emtricitabine tenofovir alafenamide 200 25 mg FTC TAF The regimen is novel
GSK,GSK:US,BBG000BLB481,Novartis Presents Positive Data on CAR-T Cell Therapy Drug,2017-06-12 23:27:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gzatca_SWnI/novartis-presents-positive-data-on-car-t-cell-therapy-drug-cm802378,Novartis AG NVS announced data from an interim analysis from its multi center global phase II study JULTIET NCT02445248 The study examined pipeline candidate CTL019 among adult patients suffering from relapsed or refractory r r diffuse large B cell lymphoma DLBCL The study showed
GSK,GSK:US,BBG000BLB481,Why GlaxoSmithKline Stock Had a Breakout May,2017-06-09 23:27:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RprppeJCZzU/why-glaxosmithkline-stock-had-a-breakout-may-cm801532,What happened The British pharmaceutical giant GlaxoSmithKline NYSE GSK seemingly defied gravity last month by gaining a noteworthy 8 33 160 according to data from S amp P Global Market Intelligence By contrast the iShares Nasdaq Biotechnology ETF NASDAQ IBB
GSK,GSK:US,BBG000BLB481,Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma,2017-06-09 22:28:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mUbsbBzgLjw/get-paid-while-you-wait-3-top-dividend-stocks-in-big-pharma-cm801509,It s a fact Dividend stocks are often the foundation of most retirement portfolios But not all dividend stocks are created equally Income investors are usually on the lookout for stocks with as high a dividend yield as possible but also a yield that ll be sustainable over
GSK,GSK:US,BBG000BLB481,Why GlaxoSmithKline Stock Had a Breakout May,2017-06-09 22:22:00 +0000,http://finance.yahoo.com/r/503b5d35-9f6f-3629-8649-1528d9cec2e4/why-glaxosmithkline-stock-had-a-breakout-may.aspx?yptr=yahoo&.tsrc=rss,A pair of catalysts lifted the British pharmaceutical giant&apos;s shares last month.
GSK,GSK:US,BBG000BLB481,Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma,2017-06-09 20:45:00 +0000,http://finance.yahoo.com/r/2ee72777-339d-3ef7-8524-04abd0a8e13c/get-paid-while-you-wait-3-top-dividend-stocks-in-b.aspx?yptr=yahoo&.tsrc=rss,Good things come to those income investors who wait.
GSK,GSK:US,BBG000BLB481,"Inovio's HPV Immunotherapy Moves to Phase III, Stock Rises",2017-06-09 14:31:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/md2pPWdk7Nw/inovios-hpv-immunotherapy-moves-to-phase-iii-stock-rises-cm801079,Inovio Pharmaceuticals Inc s INO shares rose over 10 after the company initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy VGX 3100 to treat cervical dysplasia caused by human papillomavirus HPV This phase III study initiation was
GSK,GSK:US,BBG000BLB481,"Inovio&apos;s HPV Immunotherapy Moves to Phase III, Stock Rises",2017-06-09 12:46:12 +0000,https://finance.yahoo.com/news/inovio-apos-hpv-immunotherapy-moves-124612852.html?.tsrc=rss,"Inovio Pharmaceuticals, Inc (INO) initiated a pivotal phase III REVEAL study to evaluate the safety and efficacy of immunotherapy, VGX-3100 to treat cervical dysplasia caused by human papillomavirus."
GSK,GSK:US,BBG000BLB481,[$$] Four innovators help to improve healthcare access for the poor,2017-06-07 23:02:08 +0000,"http://finance.yahoo.com/r/5329a049-2bb7-30c2-b001-21e6ff54b12b/b30e83ce-3645-11e7-99bd-13beb0903fa3,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","From the high costs of medical care and drugs, to the lack of safe equipment and advice, there are many problems restricting access to healthcare in Africa and Asia. The FT has identified a series of innovative ..."
GSK,GSK:US,BBG000BLB481,Novartis' (NVS) Tasigna Receives Label Update Nod in EU,2017-06-07 15:28:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4L41Nd5hfqc/novartis-nvs-tasigna-receives-label-update-nod-in-eu-cm800064,Novartis AG NVS announced that the European Commission EC has approved the inclusion of Treatment free Remission TFR data in the oncology drug Tasigna s Summary of Product Characteristics SmPC We note that Tasigna is approved for the treatment of chronic phase and accelerated
GSK,GSK:US,BBG000BLB481,2 High-Yield Dividend Stocks That Might Be Incredible Bargains Right Now,2017-06-07 14:19:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wkMoy2e61oA/2-high-yield-dividend-stocks-that-might-be-incredible-bargains-right-now-cm799916,High yield dividend stocks on the balance tend to be more trouble than they re worth Those high dividends are often the Having said that there are arguably a handful of rare exceptions such as the 160 big pharma 160 stocks AstraZeneca NYSE AZN 160
GSK,GSK:US,BBG000BLB481,2 High-Yield Dividend Stocks That Might Be Incredible Bargains Right Now,2017-06-07 12:38:00 +0000,http://finance.yahoo.com/r/f160286e-7842-39de-b8ad-0aca86a36999/3-dividend-stocks-that-could-double-your-money.aspx?yptr=yahoo&.tsrc=rss,These two high-yield dividend stocks should turn out to be outstanding bargains.
GSK,GSK:US,BBG000BLB481,Merck's Cancer Drug Keytruda Positive in Clinical Studies,2017-06-07 00:18:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UIt4KeuMWh4/mercks-cancer-drug-keytruda-positive-in-clinical-studies-cm799739,Merck amp Co Inc MRK announced positive data from a phase III study KEYNOTE 024 evaluating its anti PD 1 therapy Keytruda pembrolizumab for first line treatment of patients with metastatic non small cell lung cancer NSCLC with high levels of PD L1 In Aug 2016 Keytruda
GSK,GSK:US,BBG000BLB481,"Novartis, Bristol-Myers Collaborate for Opdivo Combination",2017-06-07 00:16:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d8OUTMPlgXQ/novartis-bristol-myers-collaborate-for-opdivo-combination-cm799724,Novartis AG NVS announced that it has entered into clinical research collaboration with Bristol Myers Squibb Company BMY Per the terms of the agreement Bristol Myers will investigate the safety tolerability and efficacy of Novartis s Mekinist in combination with its own Opdivo
GSK,GSK:US,BBG000BLB481,"Novartis, Bristol-Myers Collaborate for Opdivo Combination",2017-06-06 22:12:10 +0000,https://finance.yahoo.com/news/novartis-bristol-myers-collaborate-opdivo-221210611.html?.tsrc=rss,Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.
GSK,GSK:US,BBG000BLB481,"2 giant drugmakers are racing to make a breakthrough in treating HIV, and there's $22 billion on the line",2017-06-06 16:06:01 +0000,https://finance.yahoo.com/news/2-giant-drugmakers-racing-breakthrough-160601803.html?.tsrc=rss,The $22 billion HIV drug market is gearing up for a major shake-up over the next year...
GSK,GSK:US,BBG000BLB481,Novartis Presents Data on Tafinlar-Mekinist Combination,2017-06-06 00:00:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sfZTIliA3Ek/novartis-presents-data-on-tafinlar-mekinist-combination-cm799050,Novartis AG NVS announced results from a phase II study BRF113220 on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology ASCO The results from the study showed a durable survival benefit for some patients with BRAF
GSK,GSK:US,BBG000BLB481,Implied PPH Analyst Target Price: $64,2017-06-05 14:01:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l-QGm57ExMA/implied-pph-analyst-target-price-64-cm798545,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
GSK,GSK:US,BBG000BLB481,Novartis Reports Positive Data on Breast Cancer Drug Kisqali,2017-06-02 17:32:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7O3SKS8XtGk/novartis-reports-positive-data-on-breast-cancer-drug-kisqali-cm798080,Novartis AG NVS announced positive data from the phase III study MONALEESA 2 on breast cancer drug Kisqali The study reinforced the efficacy and safety of Kisqali plus letrozole in postmenopausal women with hormone receptor positive human epidermal growth factor receptor 2
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Positive Data from Lilly & Teva, BMY's Deals & More",2017-06-02 14:36:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zyOvflCjBeA/pharma-stock-roundup-positive-data-from-lilly-teva-bmys-deals-more-cm797951,This week there were quite a few regulatory and pipeline updates with Lilly LLY reporting positive results on its cancer drug Cyramza while the FDA expanded the label of Merck s MRK HIV drug Isentress Recap of the Week s Most Important Stories Lilly s Cyramza Hits Primary
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Shares Boosted By Renewed Push In HIV Treatment,2017-06-02 09:08:00 +0000,http://finance.yahoo.com/r/5f5c1779-5a6c-3b32-b895-618c48a45791/glaxosmithkline-shares-boosted-by-renewed-push-in-hiv-treatment.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Glaxo was boosted Friday after its HIV joint-venture filed an application in the U.S. and EU for a new combination tablet, in a continued push for dominance in the field"
GSK,GSK:US,BBG000BLB481,GSK Reports EU & US Submissions For First HIV Maintenance Regimen - Quick Facts,2017-06-02 02:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R0WVb6nFbiY/gsk-reports-eu--us-submissions-for-first-hiv-maintenance-regimen--quick-facts-20170602-00049,GSK Reports EU & US Submissions For First HIV Maintenance Regimen - Quick Facts
GSK,GSK:US,BBG000BLB481,"Deed records reveal sale price, billionaire buyer of GSK’s RTP campus",2017-06-01 20:15:10 +0000,http://finance.yahoo.com/r/918e599a-6a4d-3d49-9cc7-b7035cb186e1/deed-records-reveal-sale-price-billionaire-buyer.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"New details surrounding the previously announced sale and partial leaseback of GlaxoSmithKline’s (GSK) sprawling research and administration campus in Research Triangle Park are beginning to shed light on the new owner’s plans to turn the campus into the Triangle’s next center for innovation.  Real estate records filed June 1 show that the new owner of the campus, Parmer RTP LLC, paid $110 million for the assemblage, which includes all of the 20 research, office and laboratory buildings located on GSK’s North and South campuses on Moore Drive in RTP and the campuses’ 470 acres of land."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Vaccines Segment in 1Q17,2017-06-01 13:08:45 +0000,http://finance.yahoo.com/r/b6988781-f4bf-3baf-a763-2dac6ebd8552/glaxosmithklines-vaccines-segment-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s (GSK) Vaccines segment reported a 16.0% operational growth and a 15.0% positive impact of foreign exchange in 1Q17.
GSK,GSK:US,BBG000BLB481,What Happened to Novartis’s Valuation after 1Q17?,2017-06-01 11:38:52 +0000,http://finance.yahoo.com/r/4539076a-c0cd-3f2b-b885-aaaa0f1709f7/what-happened-to-novartiss-valuation-after-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis reported EPS of $1.13 on revenues of $11.54 billion for 1Q17, which represents 2% YoY operational growth in revenues."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Pharmaceuticals Segment in 1Q17,2017-06-01 11:38:39 +0000,http://finance.yahoo.com/r/e36f379b-b552-3e5d-a8df-daf149748604/glaxosmithklines-pharmaceuticals-segment-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues."
GSK,GSK:US,BBG000BLB481,Gilead Single Tablet Regiment for HIV Good in Phase III,2017-05-31 23:31:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xoAPx9RqbG0/gilead-single-tablet-regiment-for-hiv-good-in-phase-iii-cm797146,Gilead Sciences Inc GILD announced positive results on four phase III studies evaluating bictegravir in combination with FTC TAF as a single tablet regimen for HIV infection The four phase III studies evaluating a fixed dose combination of bictegravir 50mg BIC an experimental
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Segment Performances in 1Q17,2017-05-31 21:35:52 +0000,http://finance.yahoo.com/r/85c26082-5c7b-392a-b450-a049a599946e/glaxosmithklines-segment-performances-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline (GSK) reported a 19.0% rise in 1Q17 revenues to ~7.4 billion pounds, driven by an operational rise of 5.0% and a favorable currency impact of 14.0%."
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline’s Valuation Changed after 1Q17,2017-05-31 20:04:24 +0000,http://finance.yahoo.com/r/92fe962a-1a40-37ed-be73-fb75eab75d9c/how-glaxosmithklines-valuation-changed-after-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline is trading at a forward PE multiple of 15.4x, which is lower than the industry average of 16.4x as of May 31, 2017."
GSK,GSK:US,BBG000BLB481,3 Top Dividend Stocks in Diabetes Treatment,2017-05-31 19:44:00 +0000,http://finance.yahoo.com/r/8d33268a-71f6-30e9-ace4-82b737807232/3-top-dividend-stocks-in-diabetes-treatment.aspx?yptr=yahoo&.tsrc=rss,"Looking for great dividend stocks of drugmakers with diabetes treatments? Check out AstraZeneca, Pfizer, and Sanofi."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Surges to New Highs,2017-05-31 19:17:00 +0000,http://finance.yahoo.com/r/6ec2bffe-e02f-38e5-bde7-d0972c839d5a/glaxosmithkline-surges-to-new-highs.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,GSK is trading at 2017 highs today as investors continue to aggressively accumulate shares.
GSK,GSK:US,BBG000BLB481,Pfizer's Trumenba Vaccine Approved by European Commission,2017-05-31 17:32:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lvvC164hgNA/pfizers-trumenba-vaccine-approved-by-european-commission-cm796942,Pfizer Inc PFE announced that its Trumenba vaccine received approval from the European Commission EC for active immunization of people aged 10 years and older for the prevention of invasive disease caused by Neisseria meningitidis serogroup B MenB Shares of Pfizer have underperformed
GSK,GSK:US,BBG000BLB481,"European Stocks Mixed on Cocktail of Deal Speculation, Politics and Economic Data",2017-05-31 16:30:00 +0000,http://finance.yahoo.com/r/9129025f-3470-383a-87db-bc304d06d03f/european-stocks-mixed-on-cocktail-of-deal-speculation-politics-and-economic-data.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"European stocks were mixed Wednesday as investors responded to a mixture of M&A speculation, economic data and other individual company news."
GSK,GSK:US,BBG000BLB481,European ADRs Advance as Pharmaceutical Stocks' Gains Offset Manufacturers' Contractions,2017-05-31 15:51:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SPVRmzhMrX8/european-adrs-advance-as-pharmaceutical-stocks-gains-offset-manufacturers-contractions-cm796880,American depository receipts of European stocks were 0 5 higher at 135 41 on the Bank of New York Mellon Europe ADR Index on Wednesday morning American depository receipts of European stocks were 0 5 higher at 135 41 on the Bank of New York Mellon Europe ADR Index on Wednesday morning Gainers
GSK,GSK:US,BBG000BLB481,"Gilead&apos;s HIV Combo Passes Muster, But Can It Stand Up To Glaxo, Merck?",2017-05-30 20:21:13 +0000,http://finance.yahoo.com/r/b32ce480-ec32-3dae-85ee-e556f5a5a3d8/gileads-hiv-combo-passes-muster-but-can-it-stand-up-to-glaxo-merck?src=A00220&yptr=yahoo&.tsrc=rss,"Gilead&apos;s HIV drug-combination met its goal in four late-stage trials, the No. 3 biotech said Tuesday."
GSK,GSK:US,BBG000BLB481,"Medtronic, GlaxoSmithKline team up in $40M equity deal for back-pain startup",2017-05-30 20:20:13 +0000,http://finance.yahoo.com/r/7358c1b0-35a9-38b5-8327-bd30a743ef9e/medtronic-glaxosmithkline-team-up-in-40m-equity.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Medtronic has joined in a $40 million round of equity financing for Saluda Medical, a med-tech company with operations in the Twin Cities.  Saluda is developing an implantable medical device to treat chronic back pain and other conditions using electrical pulses.  The company plans to expand its Twin Cities operation following the round of funding, Saluda Medical Senior Vice President Dan Brounstein said in an email."
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories",2017-05-30 15:37:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_ZIxBFVb75Q/the-zacks-analyst-blog-highlights-visa-general-electric-glaxosmithkline-morgan-stanley-and-abbott-laboratories-cm796199,For Immediate Release Chicago IL May 30 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include
GSK,GSK:US,BBG000BLB481,Biotech And Pharma Industry And Stock News,2017-05-30 15:21:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Shares Gain After HIV Treatment Appears To Hold Lead Over Rival Gilead,2017-05-30 14:21:00 +0000,http://finance.yahoo.com/r/8e87caaf-d486-346d-8b83-02782b66265f/glaxosmithkline-shares-gain-after-hiv-treatment-appears-to-hold-lead-over-rival-gilead.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,GlaxoSmithKline shares outperformed the market Tuesday after clinical trials data for Gilead's Bictegravir HIV treatment appeared to reduce the threat of a superior rival to GSK's Dolutegravir.
GSK,GSK:US,BBG000BLB481,Gilead's HIV drug meets goal in four late-stage studies,2017-05-30 13:37:41 +0000,https://finance.yahoo.com/news/gileads-hiv-drug-meets-goal-133741256.html?.tsrc=rss,"Gilead Sciences Inc said on  Tuesday a combination of its experimental HIV drug with existing  therapies met the main goal in four late-stage studies.  Gilead, which already has approved treatments for HIV, is  pinning its hope on the combination to better compete with  Britain's GlaxoSmithKline Plc, which is working on  two-drug treatment regimen for controlling the virus behind  AIDS.  The U.S. drugmaker evaluated the addition of its  experimental drug, bictegravir, to emtricitabine/tenofovir  alafenamide (FTC/TAF), which are already in use to treat HIV."
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories",2017-05-30 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-visa-133001913.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Visa, General Electric, GlaxoSmithKline, Morgan Stanley and Abbott Laboratories"
GSK,GSK:US,BBG000BLB481,[$$] GSK among biggest gainers as weak pound lifts FTSE 100,2017-05-26 21:44:15 +0000,"http://finance.yahoo.com/r/ee7b4ef2-28d9-3ae7-bd15-a9fd20209d9d/fe7c4644-421a-11e7-9d56-25f963e998b2,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","GlaxoSmithKline was among the gainers on Friday as the FTSE 100 set a new closing high. GSK was up 1.4 per cent to £16.41 after Berenberg turned positive with an £18.85 price trarget. ""The market ..."
GSK,GSK:US,BBG000BLB481,Genvoya Could Drive Gilead Sciences’ Revenue Growth in 2017,2017-05-26 20:23:23 +0000,http://finance.yahoo.com/r/4c319575-b0f7-3987-abab-c59cd9859954/genvoya-could-drive-gilead-sciences-revenue-growth-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Gilead Sciences’ (GILD) Genvoya generated revenues of around $769 million. The drug has seen double-digit sequential sales growth in every quarter since its launch in November 2015."
GSK,GSK:US,BBG000BLB481,"Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others",2017-05-26 19:34:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ll-r-eIDK1M/top-analyst-reports-for-visa-ge-glaxosmithkline-others-cm795555,Friday May 26 2017 Today s Research Daily features new research reports on 16 major stocks including Visa V General Electric Company GE and GlaxoSmithKline plc GSK You can see all of today s research reports here gt gt gt Visa shares have outperformed the
GSK,GSK:US,BBG000BLB481,"Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others",2017-05-26 16:44:04 +0000,https://finance.yahoo.com/news/top-analyst-reports-visa-ge-164404872.html?.tsrc=rss,"Top Analyst Reports for Visa, GE, GlaxoSmithKline & Others"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's New CEO Is Off to a Good Start,2017-05-26 16:33:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4cnUpEigjhg/glaxosmithklines-new-ceo-is-off-to-a-good-start-cm795322,Sir Andrew Witty s last quarter as CEO of GlaxoSmithKline plc NYSE GSK produced positive results and incoming leader Emma Walmsley gave some clues as to how things will be changing or not Q1 2017 marked the eighth reporting period since the closure of a 20 billion asset
GSK,GSK:US,BBG000BLB481,3 Stocks With iRobot-Like Return Potential,2017-05-26 15:33:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i7QNdQrvTBE/3-stocks-with-irobot-like-return-potential-cm795249,Which stocks have the potential to be the next iRobot NASDAQ IRBT First let s explain what we re asking Shares of home robot maker iRobot have surged over the last year rising about 135 thanks to terrific global demand for its latest Roomba 900 series vacuums and
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline&apos;s New CEO Is Off to a Good Start,2017-05-26 15:06:00 +0000,http://finance.yahoo.com/r/36d3d5a9-700d-3903-939b-87a171e848fa/glaxosmithklines-new-ceo-is-off-to-a-good-start.aspx?yptr=yahoo&.tsrc=rss,The latest quarter gave investors in this dividend stock an encouraging glimpse into the future.
GSK,GSK:US,BBG000BLB481,"FTSE 100 at all-time high, with the pound knocked below $1.29",2017-05-26 08:30:33 +0000,http://finance.yahoo.com/r/9927067c-f29a-3d64-8524-5d0a7384aa99/Story.aspx?guid=476512FA-41DF-11E7-BA12-2EF43906EB08&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"The FTSE 100 was at an all-time high Friday, as the pound dropped against major rivals after a poll showed a further narrowing of the Conservative Party’s lead before the general election."
GSK,GSK:US,BBG000BLB481,Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers,2017-05-24 16:35:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RB6NfVhUAp4/mercks-mrk-keytruda-gets-fda-nod-for-solid-tumor-cancers-cm793978,Merck amp Co Inc MRK announced that its anti PD 1 therapy Keytruda has received accelerated approval for the treatment of microsatellite instability high MSI H or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no
GSK,GSK:US,BBG000BLB481,Gardasil and Merck’s Vaccines Business in 1Q17,2017-05-24 13:06:37 +0000,http://finance.yahoo.com/r/f4aa9880-2411-3070-8d9b-31372a8ac307/gardasil-and-mercks-vaccines-business-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Gardasil is Merck's (MRK) leading vaccine franchise. Total sales for Gardasil in 1Q17 were $532.0 million, a ~41.0% rise over $378.0 million in 1Q16."
GSK,GSK:US,BBG000BLB481,A Close Look at Merck & Co.’s Valuation after 1Q17 Earnings,2017-05-23 12:14:17 +0000,http://finance.yahoo.com/r/98635744-f9af-3720-a331-9bc88c71d697/a-close-look-at-merck-co-s-valuation-after-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Merck stock has risen nearly 16.0% over the last 12 months. Analysts estimate that the stock has a potential to return 10.0% over the next 12 months.
GSK,GSK:US,BBG000BLB481,Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion,2017-05-23 00:11:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ymxyvSK-Pe0/novartis-nvs-lung-cancer-drug-gets-positive-chmp-opinion-cm792969,Novartis NVS recently announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has recommended the approval of a label expansion of Zykadia ceritinib to include the first line treatment of patients with advanced non small cell lung
GSK,GSK:US,BBG000BLB481,"Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc.",2017-05-21 12:12:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lXpqW5bKSRY/better-buy-celldex-therapeutics-inc-vs-agenus-inc-cm792315,Immuno oncology I O development is a sizzling hot area of focus for drug development these days While many major pharmaceutical companies have either launched or are testing I O drugs several clinical stage biotechs also are developing promising candidates Celldex
GSK,GSK:US,BBG000BLB481,"Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc.",2017-05-21 10:41:00 +0000,http://finance.yahoo.com/r/ad3c301e-564e-334b-ace1-2494fa9878cd/better-buy-celldex-therapeutics-inc-vs-agenus.aspx?yptr=yahoo&.tsrc=rss,"Celldex Therapeutics and Agenus have promising oncology pipelines, but which is the better stock right now?"
GSK,GSK:US,BBG000BLB481,Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications,2017-05-19 16:13:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kKAjfHTYVv0/mercks-mrk-keytruda-gets-fda-nod-for-two-new-indications-cm791934,Merck amp Co Inc MRK announced that the FDA has approved two new indications for Keytruda pembrolizumab the company s anti PD 1 therapy 160 The drug is now approved for the first line treatment of patients with locally advanced or metastatic urothelial carcinoma who
GSK,GSK:US,BBG000BLB481,Ionis (IONS) Stock Falls Despite Positive Inotersen Data,2017-05-17 00:16:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qowCjGDm2DA/ionis-ions-stock-falls-despite-positive-inotersen-data-cm790290,Ionis Pharmaceuticals Inc IONS announced that the phase III study NEURO TTR on inotersen IONIS TTRRx in patients with familial amyloid polyneuropathy FAP met both primary endpoints Inotersen is potentially a first in class and best in class candidate being developed for the treatment
GSK,GSK:US,BBG000BLB481,Ionis (IONS) Stock Falls Despite Positive Inotersen Data,2017-05-16 21:57:09 +0000,https://finance.yahoo.com/news/ionis-ions-stock-falls-despite-215709340.html?.tsrc=rss,"Ionis Pharmaceuticals, Inc. (IONS) announced that the phase III study NEURO-TTR on inotersen (IONIS-TTRRx) in patients with familial amyloid polyneuropathy (FAP) met both primary endpoints."
GSK,GSK:US,BBG000BLB481,Citi Prefers These 4 Stocks Over Pfizer On Bottom-Line Concerns,2017-05-16 15:15:54 +0000,https://finance.yahoo.com/news/citi-prefers-4-stocks-over-151554227.html?.tsrc=rss,Shares of Pfizer Inc. (NYSE: PFE ) were trading lower by nearly 2 percent Tuesday morning after analysts at Citi downgraded the stock and offered three alternative recommendations. Citi's Andrew Baum downgraded ...
GSK,GSK:US,BBG000BLB481,Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis,2017-05-16 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000494.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 16, 2017 / GlaxoSmithKline and Novartis shares traded flat on Monday despite news revealing that Glaxo could be ready to buy out Novartis' stake in their joint venture for ..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Could Buy Out Partner Novartis,2017-05-15 12:27:00 +0000,http://finance.yahoo.com/r/af361fbc-a555-3c03-b885-2213bf61d409/glaxosmithkline-could-buy-out-partner-novartis.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis holds a 36.5% stake in the healthcare company.
GSK,GSK:US,BBG000BLB481,"Top-10 Glaxo investor Woodford sells out, criticises board",2017-05-12 15:56:31 +0000,http://finance.yahoo.com/news/top-10-glaxo-investor-woodford-112907633.html?.tsrc=rss,"British fund manager Neil Woodford said on Friday he had sold out of pharma company GlaxoSmithKline (GSK.L) after a ""frustrating"" stint as an investor spanning more than 15 years.  In a strongly worded blog post on the firm's website entitled 'Glaxit', Woodford said neither growth nor shareholder value had met his expectations, while the board had consistently refused to listen to his plans to break up the company.  Woodford, famous for avoiding the dot.com crash and financial crisis during a 25-year stint at Invesco Perpetual,  and who now runs around 10 billion pounds ($12.8 billion) at his own firm, said three of GSK's four units had been ""perennial underperformers""."
GSK,GSK:US,BBG000BLB481,Glaxit: GlaxoSmithKline Sees a Top Investor Dump Stock out of 'Frustration',2017-05-12 13:59:00 +0000,http://finance.yahoo.com/r/039e3823-2696-3e27-87e6-b11da70b70ec/glaxit-glaxosmithkline-sees-a-top-investor-dump-stock-out-of-frustration.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline shares traded firmly higher Friday after one of its biggest shareholders said he was dumping his holding after fifteen years out of ""frustration""."
GSK,GSK:US,BBG000BLB481,Woodford Turns Bullish on Lloyds as He Cuts Ties With Glaxo,2017-05-12 12:05:23 +0000,http://finance.yahoo.com/r/5004f341-fd8b-331c-8571-bca412a9df48/woodford-turns-bullish-on-lloyds-bank-as-he-cuts-ties-with-glaxo?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Neil Woodford has turned bullish on the U.K. economy and bought a stake in Lloyds Banking Group Plc as the money manager pivots his fund toward domestic-focused companies. To fund the buying, he sold his ..."
GSK,GSK:US,BBG000BLB481,[$$] SuperGroup's wholesale change translates into sales,2017-05-11 19:16:48 +0000,"http://finance.yahoo.com/r/28935004-8017-3528-8e7d-f3685a5374cb/c8b0c0aa-3656-11e7-bce4-9023f8c0fd2e,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","""Discern Dwarf Bravery 1859, Come Over Exhilarate Kitten"". ""Smooth Trooper Lovers Yo Mammas Flapjacks."" ""Don't Choice A Wicked Want Funny."" Any readers hoping this proves ..."
GSK,GSK:US,BBG000BLB481,Hikma Shares Plunge After It Says 'Low Likelihood' of 2017 Generic Advair Approval,2017-05-11 07:38:00 +0000,http://finance.yahoo.com/r/b93b0b8f-9d2e-35c1-a7c7-ac7bd124e7fe/hikma-shares-plunge-after-it-says-low-likelihood-of-2017-generic-advair-approval.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Hikma shares plunged the most in nine months inLondon trading Thursday after the drugmaker said that approval of its generic Advair Diskus asthma treatment faces delays from the FDA.
GSK,GSK:US,BBG000BLB481,"Mylan (MYL) Beats on Q1 Earnings, Revenues Miss Estimates",2017-05-10 20:03:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F_6v_ezJ1uU/mylan-myl-beats-on-q1-earnings-revenues-miss-estimates-cm787448,Mylan N V MYL reported first quarter 2017 results wherein earnings of 93 cents per share beat the Zacks Consensus Estimate by a penny and was up from 76 cents reported in the year ago quarter We note that shares of Mylan have outperformed the Zacks categorized Medical Generic
GSK,GSK:US,BBG000BLB481,Mylan disagrees with FDA over generic Advair delay,2017-05-10 19:25:11 +0000,http://finance.yahoo.com/news/epipen-maker-mylans-profit-edges-121227943.html?.tsrc=rss,"Generic drug maker Mylan NV on  Wednesday said it disagrees with the reasoning behind the U.S.  Food and Drug Administration's decision not to approve its  generic for GlaxoSmithKline Plc's blockbuster Advair in  March.  Mylan President Rajiv Malik said the FDA was asking it to  comply with standards set out in draft guidance the agency  issued, but that it believes it is not required to do so.  An FDA  spokeswoman declined to comment, saying she was prohibited by  law from discussing a pending application."
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline vs. Johnson & Johnson,2017-05-10 18:03:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OuDHx88rOyA/better-buy-glaxosmithkline-vs-johnson-johnson-cm787352,The stocks of big pharmaceutical companies are usually not very exciting but that s just fine for savvy investors who value safe dividends and the fact that these stocks often outperform the market in downturns GlaxoSmithKline NYSE GSK and Johnson amp Johnson NYSE JNJ
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : May 12th, 2017 (record date) : By the numbers : May 10, 2017",2017-05-10 17:25:21 +0000,http://finance.yahoo.com/r/7ced5222-b3d8-356b-a487-cf0fdeed1156/glaxosmithkline-plc-gsk-us-dividend-analysis-may-12th-2017-record-date-by-the-numbers-may-10-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing GlaxoSmithKline Plc with the following peers – Astrazeneca PLC Sponsored ADR, Merck & Co., Inc., Pfizer Inc., Novartis AG Sponsored ADR, Sanofi Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Shire PLC Sponsored ADR, Dynavax Technologies Corporation and Innoviva, Inc. (AZN-US, MRK-US, PFE-US, NVS-US, SNY-US, ... Read more
<b>(Read more...)</b>"
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline vs. Johnson & Johnson,2017-05-10 16:28:00 +0000,http://finance.yahoo.com/r/b422e10b-0448-33a3-8f4f-acbd85ac9df7/better-buy-glaxosmithkline-plc-vs-johnson-johnson.aspx?yptr=yahoo&.tsrc=rss,Which healthcare giant is right for your portfolio? It depends.
GSK,GSK:US,BBG000BLB481,Mylan says disagrees with FDA over generic Advair delay,2017-05-10 15:37:50 +0000,http://finance.yahoo.com/news/mylan-says-disagrees-fda-over-153750712.html?.tsrc=rss,"Drugmaker Mylan Inc , which is trying to launch a generic form of GlaxoSmithKline's Advair asthma treatment, on Wednesday said it is in disagreement with the U.S. Food and Drug Administration over the ..."
GSK,GSK:US,BBG000BLB481,FTSE 100 flirts with 7-week high as oil shares climb,2017-05-10 14:59:10 +0000,http://finance.yahoo.com/r/a6fd0c8f-dff2-3134-a6c2-b8931fb45222/Story.aspx?guid=70A1CA8A-354D-11E7-8F9B-E711D5D35B3E&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"U.K. stocks advanced toward a seven-week high Wednesday, as commodity shares rose and as the pound’s march toward a six-month high slowed."
GSK,GSK:US,BBG000BLB481,Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1,2017-05-09 16:05:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GdbcVj9uMNQ/epizyme-epzm-incurs-narrower-than-expected-loss-in-q1-cm786541,Epizyme Inc EPZM reported a loss of 56 cents per share in the first quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 63 cents but wider than the year ago loss of 41 cents Epizyme s share price decreased around 7 on Monday However the stock has gained 26 1 so
GSK,GSK:US,BBG000BLB481,Epizyme (EPZM) Incurs Narrower-than-Expected Loss in Q1,2017-05-09 13:50:01 +0000,http://finance.yahoo.com/news/epizyme-epzm-incurs-narrower-expected-135001296.html?.tsrc=rss,"Epizyme, Inc. (EPZM) reported a loss of 56 cents per share in the first quarter of 2017, narrower than the Zacks Consensus Estimate of loss of 63 cents but wider than the year-ago loss of 41 cents."
GSK,GSK:US,BBG000BLB481,"Notable ETF Inflow Detected - VGK, TOT, RDS.B, GSK",2017-05-08 16:03:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G4RRNCjbXwA/notable-etf-inflow-detected-vgk-tot-rdsb-gsk-cm785904,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 238 4 million dollar inflow that s a 1 9 increase week over week in outstanding
GSK,GSK:US,BBG000BLB481,Which Big Pharma Is the Best Dividend Stock?,2017-05-06 13:25:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y_z33vuoRT8/which-big-pharma-is-the-best-dividend-stock-cm785415,Dividend paying pharma stocks tend to be great long term investing vehicles because of their stellar free cash flows strong growth prospects and ability to weather most markets Even so there are literally dozens of names to choose from when it comes to this particular group making
GSK,GSK:US,BBG000BLB481,Which Big Pharma Is the Best Dividend Stock?,2017-05-06 11:25:00 +0000,http://finance.yahoo.com/r/bea1116d-18c1-38ee-b992-c37433f309ac/which-big-pharma-is-the-best-dividend-stock.aspx?yptr=yahoo&.tsrc=rss,This dividend-paying pharma stock is in a class by itself.
GSK,GSK:US,BBG000BLB481,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1,2017-05-05 19:24:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VChjX9F-Vc4/agenus-agen-reports-narrower-than-expected-loss-in-q1-cm785164,Agenus Inc AGEN reported first quarter 2017 loss of 18 cents per share including non cash expenses narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year ago loss of 37 cents The decline was due to the accelerated milestone payment received from Incyte Corporation
GSK,GSK:US,BBG000BLB481,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q1,2017-05-05 17:12:05 +0000,http://finance.yahoo.com/news/agenus-agen-reports-narrower-expected-171205358.html?.tsrc=rss,"Agenus Inc. (AGEN) reported first-quarter 2017 loss of 18 cents per share (including non-cash expenses), narrower than the Zacks Consensus Estimate of a loss of 32 cents and the year-ago loss of 37 cents."
GSK,GSK:US,BBG000BLB481,GSK 'real world' drug test has second success in asthma,2017-05-05 12:23:14 +0000,http://finance.yahoo.com/news/gsk-real-world-drug-test-122314818.html?.tsrc=rss,"GlaxoSmithKline notched up  a second win for its pioneering ""real world"" approach to testing  new drugs on Friday as its inhaled medicine Breo proved  significantly better than standard care in helping people with  asthma.  The success of the 4,233-patient trial, which tested Breo in  day-to-day practice across the town of Salford in northern  England, follows a similar win for the medicine in chronic  obstructive pulmonary disease (COPD) a year ago.  The study showed the drug, which is marketed as Relvar in  Europe, was superior in controlling symptoms of asthma compared  to usual care, based on a standardised questionnaire filled out  by patients."
GSK,GSK:US,BBG000BLB481,Relvar Ellipta Significantly Improved Asthma Control in Salford Lung Study Patients Compared with Their Usual Care,2017-05-05 11:38:00 +0000,http://finance.yahoo.com/news/relvar-ellipta-significantly-improved-asthma-113800160.html?.tsrc=rss,"GlaxoSmithKline plc and Innoviva Inc today announced positive results from the innovative Salford Lung Study in asthma, carried out amongst 4,233 patients treated by their own General Practitioner in everyday clinical practice."
GSK,GSK:US,BBG000BLB481,GSK And Innoviva Announce Positive Results From SLS In Asthma,2017-05-05 07:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e29Cq__FOOw/gsk-and-innoviva-announce-positive-results-from-sls-in-asthma-20170505-00348,GSK And Innoviva Announce Positive Results From SLS In Asthma
GSK,GSK:US,BBG000BLB481,Here's What Wiped $3 Billion Off GlaxoSmithKline's Market Cap in April,2017-05-04 13:14:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SHxVbFxbGoM/heres-what-wiped-3-billion-off-glaxosmithklines-market-cap-in-april-cm783978,What happened Shares of GlaxoSmithKline NYSE GSK a U K based pharmaceutical giant had 3 billion in market cap wiped away in April according to data from S amp P Global Market Intelligence Though it was a generally quiet month on the news front the company
GSK,GSK:US,BBG000BLB481,What's Behind Ionis Pharmaceuticals' 20% Rally In April,2017-05-04 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wMhgkgqm32U/whats-behind-ionis-pharmaceuticals-20-rally-in-april-cm783948,What happened Shares of Ionis Pharmaceuticals NASDAQ IONS 160 rallied 20 in April according to S amp P Global Market Intelligence following news that sales of Spinraza are off to a solid start and that it had inked a collaboration deal to develop therapeutics for use
GSK,GSK:US,BBG000BLB481,Here&apos;s What Wiped $3 Billion Off GlaxoSmithKline&apos;s Market Cap in April,2017-05-04 11:40:00 +0000,http://finance.yahoo.com/r/0db47ea2-4add-3da2-b9e9-457b5ab990f0/heres-what-wiped-3-billion-off-glaxosmithklines-ma.aspx?yptr=yahoo&.tsrc=rss,Advair&apos;s long-awaited generic competition has arrived.
GSK,GSK:US,BBG000BLB481,What’s GlaxoSmithKline’s Valuation after 1Q17 Earnings?,2017-05-03 11:36:07 +0000,http://finance.yahoo.com/r/ca459700-828c-3a94-ae2f-4e212c702104/whats-glaxosmithklines-valuation-after-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of April 27, 2017, GlaxoSmithKline is trading at a forward PE multiple of 15.1x, which is slightly lower than the industry average of 16.0x."
GSK,GSK:US,BBG000BLB481,GSK Makes Bullish Cross Above Critical Moving Average,2017-05-02 21:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oAoQw5Ryh2E/gsk-makes-bullish-cross-above-critical-moving-average-cm783034,In trading on Tuesday shares of GlaxoSmithKline plc Symbol GSK crossed above their 200 day moving average of 41 27 changing hands as high as 41 43 per share GlaxoSmithKline plc shares are currently trading up about 1 4 on the day The chart below shows the one year performance of
GSK,GSK:US,BBG000BLB481,"Cambridge's bluebird bio licenses delivery tech to Novartis, GSK",2017-05-02 15:10:09 +0000,http://finance.yahoo.com/r/dc8397be-ec6b-343a-b367-1cca935128d2/cambridges-bluebird-bio-licenses-delivery-tech-to.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Cambridge-based bluebird bio said Tuesday that Novartis and GlaxoSmithKline will pay undisclosed sums to license its technology for delivering genetic material into cells.  Bluebird bio (BLUE) announced that it's selling the non-exclusive rights to the patents covering the technology, called lentiviral vectors, to Novartis (NVS) for use in developing cancer treatments and to GSK (GSK) for drugs targeting rare genetic diseases."
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline’s Consumer Healthcare Segment Fared in 1Q17,2017-05-02 14:36:57 +0000,http://finance.yahoo.com/r/013a07ff-2e7d-3d83-94d6-a73fb8f82f92/how-glaxosmithklines-consumer-healthcare-segment-fared-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"With improvements in the supply chain and the successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance in coming years."
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline’s Vaccines Business Performed in 1Q17,2017-05-02 13:07:32 +0000,http://finance.yahoo.com/r/13e0908e-c61f-333c-9fab-14ebd28c89d3/how-glaxosmithklines-vaccines-business-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired the meningitis and other vaccines business from Novartis (NVS)."
GSK,GSK:US,BBG000BLB481,Analyzing GlaxoSmithKline’s Global Pharmaceutical Performance,2017-05-02 11:38:07 +0000,http://finance.yahoo.com/r/14ee1916-e872-32b1-a60e-d082ac09c112/analyzing-glaxosmithklines-global-pharmaceutical-performance?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The global pharmaceutical segment reported revenues of 3,204 million pounds in 1Q17."
GSK,GSK:US,BBG000BLB481,"ETFs with exposure to GlaxoSmithKline Plc : May 1, 2017",2017-05-01 19:57:11 +0000,http://finance.yahoo.com/r/38927d58-baeb-342e-9e82-2bee16741ba9/etfs-with-exposure-to-glaxosmithkline-plc-may-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to GlaxoSmithKline Plc Here are 5 ETFs with the largest exposure to GSK-US. Comparing the performance and risk of GlaxoSmithKline Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
GSK,GSK:US,BBG000BLB481,3 Bargain-Bin High-Yield Dividend Stocks You've Overlooked This Spring,2017-05-01 19:27:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MsTy9djbGrw/3-bargain-bin-high-yield-dividend-stocks-youve-overlooked-this-spring-cm782208,Regardless of how well or poorly the stock market is performing one thing is for certain Dividend stocks are always in style I ve often said that dividend stocks are the foundation of a great retirement portfolio and for good reason For starters companies that pay
GSK,GSK:US,BBG000BLB481,3 Bargain-Bin High-Yield Dividend Stocks You&apos;ve Overlooked This Spring,2017-05-01 17:41:00 +0000,http://finance.yahoo.com/r/9c13a86c-0154-325a-a46c-a1b82ba8e99b/3-bargain-bin-high-yield-dividend-stocks-youve-ove.aspx?yptr=yahoo&.tsrc=rss,These under-the-radar income stocks could pack a punch for your portfolio.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline making $139M investment in Rockville plant,2017-05-01 16:36:42 +0000,http://finance.yahoo.com/r/45462aef-3740-3619-ae7c-52b68b9f22eb/glaxosmithkline-announces-139-million-investment.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"British drug giant GlaxoSmithKline PLC (GSK) is investing $139 million to expand its Rockville manufacturing site, saying it needs extra capacity there to meet anticipated demand for its lupus drug.  The expansion would allow the company to boost bulk production of a substance used in several of its drugs, including Benlysta, by about 50 percent.  The expansion comes as the pharmaceutical giant is awaiting Food and Drug Administration approval to sell a new self-injectable form of Benlysta."
GSK,GSK:US,BBG000BLB481,Is This Big Pharma Stock's Sky-High Dividend Yield Sustainable?,2017-05-01 15:30:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5bH10Mp5b4Y/is-this-big-pharma-stocks-sky-high-dividend-yield-sustainable-cm781982,At nearly 5 GlaxoSmithKline NYSE GSK offers one of the richest dividend yields among major drug manufacturers The catch if you will is that this seemingly attractive yield is largely a byproduct of Glaxo s falling share price stemming from the ongoing weakness within its
GSK,GSK:US,BBG000BLB481,"Triad college awarded $25,000 STEM grant",2017-05-01 15:30:12 +0000,http://finance.yahoo.com/r/ad115013-7a17-3838-bb07-ff120ec9d06b/triad-college-awarded-25-000-stem-grant.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Davidson County Community College recently announced that it has been awarded a $25,000 “Ribbon of Hope grant from the North Carolina GlaxoSmithKline Foundation ((GSK) to boost the number of women students  pursuing degrees in science, technology, engineering and mathematics subject areas.  The Females in Math and Science (FeMS) project will provide a comprehensive set of academic and student support services to increase female students’ enrollment, success, and completion of the Associate in Science degree at DCCC.  The strategies include DCCC faculty working with local high school science and math teachers and counselors to earlier identify female students showing academic potential and interest in STEM majors and careers."
GSK,GSK:US,BBG000BLB481,How Did GlaxoSmithKline’s HIV Business Perform in 1Q17?,2017-05-01 14:39:07 +0000,http://finance.yahoo.com/r/59124c89-0243-37b8-8c9b-46e714c2e9a7/how-did-glaxosmithklines-hiv-business-perform-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline’s (GSK) HIV business is managed by ViiV Healthcare, a global specialist company in HIV medicines."
GSK,GSK:US,BBG000BLB481,Implied PPH Analyst Target Price: $64,2017-05-01 14:28:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ua6zPY-t2qg/implied-pph-analyst-target-price-64-cm781880,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
GSK,GSK:US,BBG000BLB481,Is This Big Pharma Stock&apos;s Sky-High Dividend Yield Sustainable?,2017-05-01 13:42:00 +0000,http://finance.yahoo.com/r/2320715a-581a-3e01-a2a0-1ed50d3bc438/is-this-big-pharma-stocks-sky-high-dividend-yield.aspx?yptr=yahoo&.tsrc=rss,GlaxoSmithKline should abandon its sky-high dividend and double down on growth. Here&apos;s why.
GSK,GSK:US,BBG000BLB481,How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 1Q17?,2017-05-01 13:09:18 +0000,http://finance.yahoo.com/r/1cf415fe-9708-3183-a88a-605746943519/how-did-glaxosmithklines-pharmaceuticals-segment-do-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s (GSK) pharmaceuticals segment revenues reported growth of 17% to ~4.2 billion pounds in 1Q17 as compared to 1Q16.
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline’s Business Segments Performed in 1Q17,2017-05-01 11:40:30 +0000,http://finance.yahoo.com/r/d754436c-0e29-3307-ba7d-de45b98e7ea1/how-glaxosmithklines-business-segments-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The company reported operational growth of 5% in its revenues to 7.4 billion pounds for 1Q17.
GSK,GSK:US,BBG000BLB481,Novartis’s Valuation after 1Q17 Earnings,2017-05-01 11:37:08 +0000,http://finance.yahoo.com/r/d9099371-d2e2-3e5b-9eab-4bc4858fd2a1/novartiss-valuation-after-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On April 27, 2017, Novartis was trading at a forward PE multiple of ~15.8x. The industry currently trades at a forward PE multiple of ~15.9x."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 1Q17 Earnings Surpass Analysts’ Estimates,2017-04-28 20:45:13 +0000,http://finance.yahoo.com/r/93b33933-a7c8-3e21-a061-7f160edb23b9/glaxosmithklines-1q17-earnings-surpass-analysts-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline (GSK) reported revenue growth of 19% to 7.4 billion pounds in 1Q17.
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017",2017-04-28 15:12:48 +0000,http://finance.yahoo.com/r/58d2b573-59cc-3210-ab5d-cb7baaf077ce/glaxosmithkline-plc-gsk-us-earnings-analysis-q1-2017-by-the-numbers-april-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis GlaxoSmithKline Plc reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of GlaxoSmithKline Plc – Novartis AG Sponsored ADR (NVS-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 9,237.24 million, Net Earnings of USD 1,308.53 million. ... Read more
<b>(Read more...)</b>"
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View",2017-04-27 22:28:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NuUrzVzDjnU/glaxo-gsk-reports-in-line-q1-earnings-reiterates-view-cm780722,GlaxoSmithKline plc s GSK first quarter results came roughly in line with expectations Glaxo reported first quarter 2017 core earnings of 62 cents per American Depositary Share ADS in line with the Zacks Consensus Estimate Earnings were up 9 year over year at constant exchange rates
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View",2017-04-27 20:37:08 +0000,http://finance.yahoo.com/news/glaxo-gsk-reports-line-q1-203708194.html?.tsrc=rss,"GlaxoSmithKline plc&apos;s (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate."
GSK,GSK:US,BBG000BLB481,New Glaxo Boss Emma Walmsley Seeks Sharper R&D Edge,2017-04-27 04:05:57 +0000,http://finance.yahoo.com/r/ba224dbe-d437-30bc-bf55-540a9e5e9159/glaxos-new-boss-emma-walmsley-seeks-sharper-r-d-edge-1493213171?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s new boss Emma Walmsley plans to narrow the company’s drug research to focus only on the biggest opportunities.
GSK,GSK:US,BBG000BLB481,Ionis Pharmaceuticals: Big Data Coming Soon,2017-04-26 16:07:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uO2pjcff4h4/ionis-pharmaceuticals-big-data-coming-soon-cm779528,Fresh on the heels of winning Food and Drug Administration FDA approval in December for what could be its first blockbuster drug Ionis Pharmaceuticals NASDAQ IONS should find out this quarter if another one of its drugs has what it takes Advancing to market In
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Beats Earnings and Revenues in Q1,2017-04-26 15:10:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aML946zfjpw/glaxo-gsk-beats-earnings-and-revenues-in-q1-cm779421,GlaxoSmithKline plc GSK one of the largest health care companies reshaped its business following the Mar 2015 completion of the three part inter conditional transaction with Novartis related to its Consumer Healthcare Vaccines and Oncology businesses Under the deal Glaxo sold its
GSK,GSK:US,BBG000BLB481,"New GlaxoSmithKline CEO wants fewer, bigger new drug launches",2017-04-26 14:55:56 +0000,http://finance.yahoo.com/news/glaxsmithkline-ceo-wants-fewer-bigger-123559663.html?.tsrc=rss,"GlaxoSmithKline's new  chief executive aims to improve returns in drug development, and  wants fewer but bigger new medicine launches.  In her first comments since taking over on April 1, Emma  Walmsley, 47, said on Wednesday that her priority was the  pharmaceuticals unit, where she wants commercial considerations  to be given greater weight in early investment decisions.  ""We'd like to have probably fewer and more focused  priorities, to have bigger launches,"" she told reporters, after  announcing first-quarter results, adding this would involve  tough choices and the closure of some research programmes."
GSK,GSK:US,BBG000BLB481,Analyst Ratings and Recommendations for GlaxoSmithKline,2017-04-26 14:36:53 +0000,http://finance.yahoo.com/r/5efccdb2-10ed-36f4-af98-fdf05dde3134/analyst-ratings-and-recommendations-for-glaxosmithkline?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s (GSK) stock price fell nearly 5.5% over the last 12 months and have risen ~5.9% in 2017 year-to-date.
GSK,GSK:US,BBG000BLB481,Glaxo meets 1Q profit forecasts,2017-04-26 14:26:45 +0000,http://finance.yahoo.com/news/glaxo-meets-1q-profit-forecasts-142645752.html?.tsrc=rss,"On a per-share basis, the Brentford, Britain-based company said it had profit of 53 cents. Earnings, adjusted for one-time gains and costs, came to 62 cents per share. The results met Wall Street expectations. ..."
GSK,GSK:US,BBG000BLB481,Ionis Pharmaceuticals: Big Data Coming Soon,2017-04-26 14:01:00 +0000,http://finance.yahoo.com/r/345b5ee7-e948-3af1-b127-046468e9b7f0/ionis-pharmaceuticals-big-data-coming-soon.aspx?yptr=yahoo&.tsrc=rss,Results from GlaxoSmithKline&apos;s phase 3 study of IONIS-TTR Rx are expected to be reported this quarter.
GSK,GSK:US,BBG000BLB481,Glaxo Stock Slumps as Investors Eye Advair Generics,2017-04-26 13:46:00 +0000,http://finance.yahoo.com/r/d0462052-3395-3986-95bd-c74daeb5715a/glaxo-stock-slumps-as-investors-eye-advair-generics.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Mylan's setback may not be enough to prevent generic Advair reaching the market in 2017
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Beats Earnings and Revenues in Q1,2017-04-26 13:11:01 +0000,http://finance.yahoo.com/news/glaxo-gsk-beats-earnings-revenues-131101302.html?.tsrc=rss,"Glaxo reported core earnings of 63 cents per American depositary share, which marginally beat our consensus estimate of 62 cents."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare,2017-04-26 13:07:19 +0000,http://finance.yahoo.com/r/8853c9ff-01c3-39db-aee4-2685afd11b03/glaxosmithklines-1q17-estimates-consumer-healthcare?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For the European markets, GSK's revenues are expected to grow in 1Q17, mainly due to increase in sales of wellness products like Voltaren and the Sensodyne products portfolio."
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Beats Q1 Estimates, Keeps Full Year Targets In Place",2017-04-26 12:57:00 +0000,http://finance.yahoo.com/r/62f17f77-610a-3f1b-80af-41fe3da788f2/glaxosmithkline.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,GlaxoSmithKline posted stronger-than-expected first quarter earnings and kept its full year profit and revenue figures in place as it awaits potential rivals to is Advair respiratory treatment.line
GSK,GSK:US,BBG000BLB481,GSK warns of impact from generic drugs after solid Q1,2017-04-26 12:31:36 +0000,http://finance.yahoo.com/r/b9c598c5-74aa-340b-ab1c-91da7812e14e/gsk-warns-impact-generic-drugs-123136464.html?.tsrc=rss,LONDON (AP) — GlaxoSmithKline says new products helped first-quarter sales rise 17 percent from the year before but warned that competition from generic drugs may weigh on earnings later this year.
GSK,GSK:US,BBG000BLB481,"[$$] GlaxoSmithKline Net Income Boosted by Strong Sales, Weak Pound",2017-04-26 12:25:47 +0000,http://finance.yahoo.com/r/f02679d9-620d-3039-8cca-f424f7018b61/glaxosmithkline-net-income-boosted-by-strong-sales-weak-pound-1493209544?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline said net income ballooned in the first quarter due to strong sales growth newer drugs, a boost from a weak pound, and a favorable year-earlier comparison."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business,2017-04-26 11:36:33 +0000,http://finance.yahoo.com/r/012cf927-5928-32a1-89dd-d4788d4f6fd1/glaxosmithklines-1q17-estimates-vaccines-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The Novartis acquisition has improved sales for GSK's Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe."
GSK,GSK:US,BBG000BLB481,"Glaxo Profit Jumps 31% as Sales of HIV, Lung Drugs Increase",2017-04-26 11:13:07 +0000,http://finance.yahoo.com/news/glaxo-profit-jumps-31-sales-111307001.html?.tsrc=rss,"GlaxoSmithKline Plc, the U.K.’s biggest drugmaker, posted a 31 percent gain in first-quarter profit, helped by a weaker pound and rising sales of its drugs including HIV treatments."
GSK,GSK:US,BBG000BLB481,Glaxo's New CEO Walmsley Pledges to Make Drugs the Priority,2017-04-26 11:13:07 +0000,http://finance.yahoo.com/r/0a432df7-543b-3aee-b01c-1419825a7755/glaxo-profit-jumps-31-as-sales-of-hiv-respiratory-drugs-climb?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Emma Walmsley pledged to spur growth at GlaxoSmithKline Plc’s pharmaceutical unit less than a month after taking over as chief executive officer of the U.K.’s largest drugmaker.
GSK,GSK:US,BBG000BLB481,Weak sterling boosts GlaxSmithKline as new CEO takes over,2017-04-26 11:10:05 +0000,http://finance.yahoo.com/news/weak-sterling-boosts-glaxsmithkline-ceo-111005539.html?.tsrc=rss,"GlaxoSmithKline's new  chief executive reported slightly better than expected  first-quarter results on Wednesday, keeping the drugmaker on  track to hit financial targets in 2017 as it braces for generic  competition to blockbuster lung drug Advair.  Analysts, on average, had forecast sales of 7.26 billion  pounds and EPS of 24.5p, according to Thomson Reuters data.  Under Witty, GSK built up a diversified business, with its  core pharmaceuticals operation buttressed by large consumer  health and vaccine units."
GSK,GSK:US,BBG000BLB481,[$$] GlaxoSmithKline 1Q Results Expected to Get Boost From Weak Pound,2017-04-25 19:01:11 +0000,http://finance.yahoo.com/r/f92896d4-236b-3371-873b-d6f37d99f889/glaxosmithkline-1q-results-expected-to-get-boost-from-weak-pound-earnings-preview-1493146867?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline is expected to post revenue of GBP7.25 billion for the first quarter, up 16% from the year-earlier period, when it reports results Wednesday."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 1Q17 Estimates: Pharmaceuticals Segment,2017-04-25 14:39:22 +0000,http://finance.yahoo.com/r/1c88da02-5bd7-3eb1-adb6-ec01e19be822/glaxosmithklines-1q17-estimates-pharmaceuticals-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GlaxoSmithKline’s (GSK) Pharmaceuticals segment revenues have declined substantially in 2015 due to the divestment of its Oncology business to Novartis (NVS) in March 2015.
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 1Q17 Estimates: Revenues Expected to Grow,2017-04-25 13:09:37 +0000,http://finance.yahoo.com/r/34d38ef7-3d1d-32f3-95c2-fd0c90343f15/glaxosmithklines-1q17-estimates-revenues-expected-to-grow?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Analysts expect ~16.5% growth in GlaxoSmithKline’s (GSK) 1Q17 revenues to ~7.3 billion pounds following strong product launches, acquired products from Novartis (NVS), and improvement in the supply chain...."
GSK,GSK:US,BBG000BLB481,"Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More",2017-04-25 13:08:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ghSfv9yzOB4/drug-stocks-q1-earnings-releases-on-apr-26-amgn-gsk-more-cm778424,The Q1 earnings season is in full swing and we believe this quarter is on track to see the highest growth in almost three years According to the Earnings Preview report 95 S amp P 500 members accounting for 24 9 of the index s total market capitalization have reported results as of Apr
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 1Q17 Earnings: Analysts’ Estimates,2017-04-25 11:40:14 +0000,http://finance.yahoo.com/r/1fc3c0f6-0b48-3e41-8dda-b953131d0913/glaxosmithklines-1q17-earnings-analysts-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline is set to release its 1Q17 earnings on April 26, 2017. Analysts estimate GSK's earnings per share to reach 0.25 pounds for 1Q17."
GSK,GSK:US,BBG000BLB481,"Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More",2017-04-25 10:50:10 +0000,http://finance.yahoo.com/news/drug-stocks-q1-earnings-releases-105010141.html?.tsrc=rss,Here we have four pharma companies that are set to report first-quarter results on Apr 26. Let&apos;s see how things are shaping up for this quarter.
GSK,GSK:US,BBG000BLB481,"First malaria vaccine to be tested in Africa, with boost from Lexington's Agenus",2017-04-24 16:30:12 +0000,http://finance.yahoo.com/r/c4208d9e-497b-3332-adec-c61229195013/first-malaria-vaccine-to-be-tested-in-africa-with.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"The World Health Organization said Monday that the world’s first malaria vaccine, which features a key component made by Lexington biotech Agenus, will be available in parts of Africa beginning next year.  The WHO’s African regional office said that Ghana, Kenya and Malawi would participate in a pilot program for the injectable vaccine, which was developed by U.K. drug giant GlaxoSmithKline (GSK) with funding from the Bill & Melinda Gates Foundation.  The vaccine contains a so-called adjuvant made by Agenus (AGEN), which is designed to boost the body’s immune response."
GSK,GSK:US,BBG000BLB481,3 Dividend Stocks That Retirees Should Avoid,2017-04-22 18:03:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sUMqKi3X0fg/3-dividend-stocks-that-retirees-should-avoid-cm777529,Sometimes the most tempting stocks can be some of the most dangerous That appears to be the case for three stocks with seemingly attractive dividend yields CenturyLink NYSE CTL GlaxoSmithKline NYSE GSK and Teva Pharmaceutical Industries NYSE TEVA Here s
GSK,GSK:US,BBG000BLB481,3 Dividend Stocks That Retirees Should Avoid,2017-04-22 16:03:00 +0000,http://finance.yahoo.com/r/0b024976-bd14-367c-b517-dc50c8bbb525/3-dividend-stocks-that-retirees-should-avoid.aspx?yptr=yahoo&.tsrc=rss,"High dividend yields for CenturyLink, GlaxoSmithKline, and Teva look great, but there&apos;s more to the story for these stocks."
GSK,GSK:US,BBG000BLB481,Barclays -- Mired In Mud (Again) -- Should Dump Its CEO,2017-04-21 20:52:00 +0000,http://finance.yahoo.com/r/2265fad3-4420-3f0e-98a9-a2a1e4d175e0/barclays-mired-in-mud-again-should-dump-its-ceo?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,Barclays CEO Jes Staley's efforts to hunt down a whistleblower show that he was either incompetent or unfit to head the bank.
GSK,GSK:US,BBG000BLB481,Analyst Estimates for Novartis’s 1Q17 Earnings,2017-04-21 17:13:26 +0000,http://finance.yahoo.com/r/028d8940-3c92-3526-9ea1-50095dab59ab/analyst-estimates-for-novartiss-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis is set to release its 1Q17 earnings on April 25, 2017. Analysts estimate its 1Q17 EPS at $1.12 with revenues of ~$11.7 billion."
GSK,GSK:US,BBG000BLB481,What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?,2017-04-21 17:04:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LHnd6rIgHoY/whats-in-store-for-glaxosmithkline-gsk-in-q1-earnings-cm777139,GlaxoSmithKline plc GSK is scheduled to report first quarter 2017 results on Apr 26 before market opens Last quarter the company delivered a positive earnings surprise of 14 04 Glaxo s shares are up 5 7 this year so far outperforming the 4 increase witnessed by the Zacks
GSK,GSK:US,BBG000BLB481,What&apos;s in Store for GlaxoSmithKline (GSK) in Q1 Earnings?,2017-04-21 15:21:03 +0000,http://finance.yahoo.com/news/apos-store-glaxosmithkline-gsk-q1-152103586.html?.tsrc=rss,"GlaxoSmithKline plc (GSK) is scheduled to report first-quarter 2017 results on Apr 26 before market opens. Last quarter, the company delivered a positive earnings surprise of 14.04%."
GSK,GSK:US,BBG000BLB481,4 Stocks Are Showing Red Flags -- Here's When to Sell,2017-04-21 11:07:00 +0000,http://finance.yahoo.com/r/382d1649-0617-3bab-90ab-f690422d9953/4-stocks-are-showing-red-flags-here-s-when-to-sell.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,You don't want to own these four 'toxic stocks'.
GSK,GSK:US,BBG000BLB481,$3M award in suit against drug company over man's suicide,2017-04-21 04:00:02 +0000,http://finance.yahoo.com/news/3m-award-suit-against-drug-company-over-mans-040000131.html?.tsrc=rss,"A suburban Chicago woman has been awarded $3 million in a lawsuit against a pharmaceutical company she blamed for her husband's suicide. Wendy Dolin's husband, Stewart, stepped in front of a Chicago Transit ..."
GSK,GSK:US,BBG000BLB481,Here's Why Innoviva Inc. Lost 10% Today,2017-04-21 00:02:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tXr7ttLT6Wk/heres-why-innoviva-inc-lost-10-today-cm776783,What happened Shares of Innoviva NASDAQ INVA a biotechnology royalty company that develops respiratory therapeutics and is perhaps best known as GlaxoSmithKline s NYSE GSK development partner for its multiple next generation COPD and asthma products fell as much as
GSK,GSK:US,BBG000BLB481,Teva's new asthma inhaler poses first competition for GSK's Advair,2017-04-20 22:43:39 +0000,http://finance.yahoo.com/news/teva-launches-copy-asthma-inhaler-191218937.html?.tsrc=rss,"Teva Pharmaceutical Industries Ltd  on Thursday launched an asthma inhaler that  will be the first direct competition to GlaxoSmithKline's  best-selling Advair.  Teva, which won U.S. approval in January to make an inhaler  similar to Advair, also launched a generic version of its own  inhaler, AirDuo RespiClick.  AirDuo is not a true generic of Advair, but contains the  same two active ingredients, fluticasone propionate and  salmeterol."
GSK,GSK:US,BBG000BLB481,Here&apos;s Why Innoviva Inc. Lost 10% Today,2017-04-20 22:08:00 +0000,http://finance.yahoo.com/r/6df2a23e-7634-35da-ba57-4a118a715aa7/heres-why-innoviva-inc-lost-10-today.aspx?yptr=yahoo&.tsrc=rss,Innoviva&apos;s proxy battle with an activist hedge fund for board seats leaves shareholders disappointed.
GSK,GSK:US,BBG000BLB481,GSK must pay $3 million in generic Paxil suicide lawsuit: U.S. jury,2017-04-20 21:38:48 +0000,http://finance.yahoo.com/news/gsk-must-pay-3-million-213848018.html?.tsrc=rss,"The jury's award followed a trial in federal court in Chicago in a lawsuit over the death of Stewart Dolin, a partner at Reed Smith LLP who jumped in front of an oncoming commuter train in 2010 after taking a generic equivalent of GSK's Paxil.  The verdict by the nine-member jury in favor of Dolin's wife, Wendy Dolin, was confirmed by GSK, which said in a statement it was disappointed and planned to appeal."
GSK,GSK:US,BBG000BLB481,"As Price Falls, Vetr Upgrades GlaxoSmithKline To Buy",2017-04-20 18:35:32 +0000,http://finance.yahoo.com/news/price-falls-vetr-upgrades-glaxosmithkline-183532974.html?.tsrc=rss,"The Vetr crowd on Thursday upgraded its rating for GlaxoSmithKline plc (ADR) (NYSE: GSK ) from 3 stars (Hold), issued 527 days ago, to 4 stars (Buy). Crowd sentiment at the time of the upgrade was mostly ..."
GSK,GSK:US,BBG000BLB481,Teva launches copy of asthma inhaler Advair,2017-04-20 17:34:20 +0000,http://finance.yahoo.com/news/teva-launches-copy-asthma-inhaler-173420564.html?.tsrc=rss,"Teva Pharmaceutical Industries Ltd  launched its asthma inhaler and the  authorized generic of the drug on Thursday, nearly three months  after it got U.S. approval to market a copy of GlaxoSmithKline's  best-selling Advair.  Teva did not disclose the pricing of the inhalers.  Bernstein  analyst Erica Kazlow said the branded inhaler was priced at $285  wholesale acquisition cost, while the authorized generic was  priced at $90."
GSK,GSK:US,BBG000BLB481,Innoviva director vote drama hands last-minute loss to Sarissa,2017-04-20 13:42:12 +0000,http://finance.yahoo.com/news/innoviva-director-vote-drama-hands-134212274.html?.tsrc=rss,"Shareholders of Innoviva Inc.  handed a narrow victory to the U.S. respiratory drug  company, according to a person close to the matter, as its fight  against activist hedge fund Sarissa Capital saw several last  minute twists and turns.  Innoviva shareholders supported the company's three director  nominees at the annual meeting, according to the person who has  access to the preliminary voting totals.  Sarissa had nominated three of its own directors, after  months of pressuring changes at the company."
GSK,GSK:US,BBG000BLB481,ZappRX gets $25 million from Qiming US to expand into the U.S. drug prescription market,2017-04-20 04:30:26 +0000,http://finance.yahoo.com/r/f05de60d-a810-3fdc-93db-d735f6e9e12f/zapprx-gets-25-million-from-chinese-vcs-hoping-to-tap-into-the-u-s-drug-prescription-market?ncid=txtlnkusaolp00000591&yptr=yahoo&.tsrc=rss,"ZappRX, the app that aims to make it easier to manage specialty drug prescriptions, has pulled in $25 million in Series B funding led by Qiming US, the Chinese venture outfit's stateside health care fund.GV (formerly Google Ventures) and GlaxoSmithKline’s funding arm SR One were also in the round and Qiming US's Mark McDade will now join the..."
GSK,GSK:US,BBG000BLB481,Activist Sarissa says Innoviva backed out of proxy settlement deal,2017-04-20 02:09:01 +0000,http://finance.yahoo.com/news/activist-sarissa-says-innoviva-backed-020901838.html?.tsrc=rss,"Activist hedge fund Sarissa Capital  Management LP said on Wednesday that U.S. respiratory drug  company Innoviva Inc reneged on a proxy settlement deal  that was struck earlier in the day.  Sarissa, run by former Carl Icahn protege Alex Denner, said  in a statement that Innoviva had accepted an offer to settle the  proxy contest ahead of the shareholder vote scheduled for  Thursday by adding two Sarissa-nominated directors to the board."
GSK,GSK:US,BBG000BLB481,"There Have Been Few Losers Since The Brexit Vote, But It's About To Get Ugly",2017-04-19 01:39:00 +0000,http://finance.yahoo.com/r/1fd1e2a8-6041-30e2-aca5-73fcd0034a01/there-have-been-few-losers-since-the-brexit-vote-but-its-about-to-get-ugly?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"This has U.K. stocks down close to 2.5% today, closing in on the lows. And the pound has rallied about 2.5%--a reflection of a return of some chance of cold feet emerging. Does it change the outlook for Brexit?"
GSK,GSK:US,BBG000BLB481,[$$] Science looks to nucleic acids to create right genetic vaccine recipe,2017-04-18 23:15:27 +0000,"http://finance.yahoo.com/r/348667eb-ef00-3d54-9b0c-a004dcea3e4a/d0977172-155b-11e7-b0c1-37e417ee6c76,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The primary ingredients of vaccines have always been proteins, the molecular workhorses of biology. In traditional vaccines, which consist of whole pathogens - killed, weakened or inactivated micro-organisms ..."
GSK,GSK:US,BBG000BLB481,Blog Coverage Bristol-Myers and Nordic Announce an Agreement for Development of Fibrosis Biomarker Technology,2017-04-18 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-bristol-myers-nordic-121500616.html?.tsrc=rss,"Upcoming AWS Coverage on GlaxoSmithKline LONDON, UK / ACCESSWIRE / April 18, 2017 / Active Wall St. blog coverage looks at the headline from Bristol-Myers Squibb Co. (NYSE: BMY ) (""BMS"") as the ..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline JV Submits NDA For Candidate Shingles Vaccine Shingrix In Japan,2017-04-18 04:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ApTAwbRPzMo/glaxosmithkline-jv-submits-nda-for-candidate-shingles-vaccine-shingrix-in-japan-20170418-00149,GlaxoSmithKline JV Submits NDA For Candidate Shingles Vaccine Shingrix In Japan
GSK,GSK:US,BBG000BLB481,"OncoMed's lung cancer drug fails mid-stage study, shares tumble",2017-04-17 14:43:17 +0000,http://finance.yahoo.com/news/oncomeds-lung-cancer-drug-fails-125832045.html?.tsrc=rss,"OncoMed Pharmaceuticals Inc's  shares were jolted for a second time in a week after the company  said on Monday its experimental lung cancer drug failed a  mid-stage study.  Including those losses, OncoMed's market valuation has halved  since the company said last week it would discontinue a trial  testing another cancer drug.  ""Based on the events of today and last week, we will be  undertaking a comprehensive portfolio prioritization review  immediately,"" said Chief Executive Paul Hastings."
GSK,GSK:US,BBG000BLB481,"Tweedy Browne Global Value Buys Baidu, LG Electronics, Kia Motors, Sells Luen Thai Holdings, ...",2017-04-14 15:53:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zxfxYaUVA4U/tweedy-browne-global-value-buys-baidu-lg-electronics-kia-motors-sells-luen-thai-holdings-cm774245,Tweedy Browne Global Value New Purchases BIDU Added Positions 066570 000270 005380 GSK Reduced Positions CNP 8141 TMG Sold Out 00311 PSON HAS HEAD EKO New Purchases BIDU New Purchases BIDU Added Positions
GSK,GSK:US,BBG000BLB481,"Innoviva to review costs, executive pay following Sarissa pressure",2017-04-13 21:35:10 +0000,http://finance.yahoo.com/news/innoviva-review-costs-executive-pay-213510273.html?.tsrc=rss,"Drug company Innoviva Inc said  on Thursday it would undertake a review of its costs, including  executive compensation following pressure from activist investor  Sarissa Capital Management LP.  The news comes two weeks after hedge fund Sarissa Capital  called for a sharp cut in the compensation of Innoviva's chief  executive and the board.  The review will be conducted by a special committee of the  company's independent directors and is expected to be out by  third quarter of this year, Innoviva said."
GSK,GSK:US,BBG000BLB481,Why Juno Therapeutics' Stock Tumbled in the Past One Year,2017-04-13 16:57:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_WhBQ-gDtV0/why-juno-therapeutics-stock-tumbled-in-the-past-one-year-cm773876,Seattle WA based Juno Therapeutics Inc JUNO remains focused on the development of immuno oncology treatments The company is looking to revolutionize cancer treatments by engaging the body s immune system to treat the disease Juno is developing cell based cancer immunotherapies using CAR
GSK,GSK:US,BBG000BLB481,Mylan Down on FDA Warning Letter to Manufacturing Facility,2017-04-12 22:54:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hH0C-TAaIj8/mylan-down-on-fda-warning-letter-to-manufacturing-facility-cm773518,Shares of Mylan Inc MYL declined 2 after the company received a warning letter from the FDA for its manufacturing facility in India The FDA cited significant violations of current good manufacturing practice CGMP regulations for finished pharmaceuticals in the warning letter
GSK,GSK:US,BBG000BLB481,Inovio's Ebola Vaccine Positive in Expanded Phase I Study,2017-04-12 15:58:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UPPNC7jtFFk/inovios-ebola-vaccine-positive-in-expanded-phase-i-study-cm773271,Inovio Pharmaceuticals Inc INO recently reported positive preliminary results from the expanded stage of its phase I study EBOV 001 The study was conducted to evaluate the company s Ebola DNA vaccine INO 4212 The company has enrolled an additional 125 patients in the study The
GSK,GSK:US,BBG000BLB481,"This Survey's Bad News Could Be Good News for Inovio Pharmaceuticals, Inc.",2017-04-12 13:56:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kn65P26-KOU/this-surveys-bad-news-could-be-good-news-for-inovio-pharmaceuticals-inc-cm773106,Bad news for some can be good news for others That could be the case with a survey the 160 National Center for Health Statistics NCHS published last week There was definitely some bad news about the prevalence of genital human papillomavirus HPV in Americans Here s why
GSK,GSK:US,BBG000BLB481,"This Survey&apos;s Bad News Could Be Good News for Inovio Pharmaceuticals, Inc.",2017-04-12 12:04:00 +0000,http://finance.yahoo.com/r/47edecb7-cfad-3829-afad-4335c78418f1/this-surveys-bad-news-could-be-good-news-for-inovi.aspx?yptr=yahoo&.tsrc=rss,A surprisingly high number of Americans have HPV. That means the market for Inovio could be big -- if the company can achieve success with its experimental drugs.
GSK,GSK:US,BBG000BLB481,Hearing loss biotech Frequency Therapeutics dials up $32M round,2017-04-11 10:15:08 +0000,http://finance.yahoo.com/r/adaefb4e-b2e3-39b9-b72b-372ec5ae6fc7/hearing-loss-biotech-frequency-therapeutics-dials.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Frequency Therapeutics, a Woburn-based biotech co-founded by renowned MIT professor Bob Langer, came out of stealth mode earlier this year with a plan to treat hearing loss by stimulating the regrowth of hair cells in the inner ear.  On Tuesday, the 14-employee company pulled back the curtain on its early financing, announcing that it had closed a $32 million Series A round led by CoBro Ventures, a Virginia-based investment firm co-founded by Frequency board chairman and biotech entrepreneur Marc Cohen.  Other investors include Morningside Ventures, Emigrant Capital and Alexandria Real Estate Equities (ARE)."
GSK,GSK:US,BBG000BLB481,The State of Play in Axovant Sciences,2017-04-11 10:00:00 +0000,http://finance.yahoo.com/r/76115f5d-5183-38b1-9e69-2d99322c758d/state-play-axovant-sciences?partner=YahooSA&yptr=yahoo&.tsrc=rss,We take a deeper look at Axovant Sciences after the company named a new CEO.
GSK,GSK:US,BBG000BLB481,The 3 Best HIV Drug Stocks to Buy in 2017,2017-04-09 20:53:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-3PTyi0IbyM/the-3-best-hiv-drug-stocks-to-buy-in-2017-cm771872,An estimated 36 7 million people around the world have HIV Around 17 million of them are taking prescription drugs to treat their condition 160 The total global HIV drug market totals more than 20 billion annually There are several choices for investing in HIV drug stocks Three
GSK,GSK:US,BBG000BLB481,The 3 Best HIV Drug Stocks to Buy in 2017,2017-04-09 19:03:00 +0000,http://finance.yahoo.com/r/efa68392-9d57-3b00-8b33-9704f6ccb611/the-3-best-hiv-drug-stocks-to-buy-in-2017.aspx?yptr=yahoo&.tsrc=rss,"Gilead Sciences, GlaxoSmithKline, and Merck stand out as the top HIV drug stocks."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Dodges a Bullet... for Now,2017-04-08 17:53:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZpM7i2Hve6k/glaxosmithkline-dodges-a-bullet-for-now-cm771779,Incoming GlaxoSmithKline plc NYSE GSK CEO Emma Walmsley got a little welcoming gift from the Food and Drug Administration the week she took the reins of the venerable British healthcare company Mylan NASDAQ MYL received a notification that its application for a
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Dodges a Bullet... for Now,2017-04-08 16:03:00 +0000,http://finance.yahoo.com/r/ef1db4ab-512c-3340-abcf-01eeada9089a/glaxosmithkline-dodges-a-bullet-for-now.aspx?yptr=yahoo&.tsrc=rss,The drugmaker is breathing a little easier after generic competition for its blockbuster asthma drug hit a setback.
GSK,GSK:US,BBG000BLB481,3 Big Pharma Companies With the Best Pipelines,2017-04-08 12:54:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UhSqAjHfJ48/3-big-pharma-companies-with-the-best-pipelines-cm771718,It s not the current product lineups that matter the most for big pharma companies It s their pipelines Three big pharma companies boasting the strongest pipelines are Johnson amp Johnson NYSE JNJ Novartis NYSE NVS and Roche NASDAQOTH RHHBY Here s what
GSK,GSK:US,BBG000BLB481,3 Big Pharma Companies With the Best Pipelines,2017-04-08 11:22:00 +0000,http://finance.yahoo.com/r/9fec55fc-0049-3112-ade1-93863c0f877d/3-big-pharma-companies-with-the-best-pipelines.aspx?yptr=yahoo&.tsrc=rss,"Why the pipelines for Johnson & Johnson, Novartis, and Roche look especially strong."
GSK,GSK:US,BBG000BLB481,Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC,2017-04-07 22:53:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XNabRWKDviI/novartis-nvs-in-licenses-ophthalmic-drug-from-lubris-llc-cm771639,Novartis AG NVS recently announced that it has exercised an option to in license ECF843 for ophthalmic indications worldwide outside Europe from Lubris LLC A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks classified
GSK,GSK:US,BBG000BLB481,4 Big Reasons Mylan N.V. Shares Fell 7% in March,2017-04-06 14:57:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1KqM2of2byA/4-big-reasons-mylan-nv-shares-fell-7-in-march-cm770701,What happened Shares of Mylan NASDAQ MYL an embattled branded and generic drug developer perhaps best known for its allergic reaction injectable medication EpiPen fell 7 in March according to data from S amp P Global Market Intelligence Worries continue to mount
GSK,GSK:US,BBG000BLB481,4 Big Reasons Mylan N.V. Shares Fell 7% in March,2017-04-06 13:41:00 +0000,http://finance.yahoo.com/r/a61a0178-16fa-32ca-af08-29980963d7e6/4-big-reasons-mylan-nv-shares-fell-7-in-march.aspx?yptr=yahoo&.tsrc=rss,Many of Mylan&apos;s issues lead back to uncertainties surrounding EpiPen.
GSK,GSK:US,BBG000BLB481,Just How Much Is a Medical Miracle Worth?,2017-04-06 09:00:15 +0000,http://finance.yahoo.com/r/4f240da1-82e8-37d6-8342-95820bdd76f0/just-how-much-is-a-medical-miracle-worth?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Years of costly treatments could give way to pricier one-shot cures like Spark Therapeutics’ blindness drug. But insurers aren’t ready.
GSK,GSK:US,BBG000BLB481,Better Buy: AbbVie Inc. vs. GlaxoSmithKline,2017-04-05 21:55:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JJt9rCeVrjE/better-buy-abbvie-inc-vs-glaxosmithkline-cm770444,They re both big successful drugmakers but AbbVie NYSE ABBV and GlaxoSmithKline NYSE GSK haven t competed directly against each other all that much in the past That could potentially change in the future however with Glaxo s bid to enter the autoimmune disease
GSK,GSK:US,BBG000BLB481,Better Buy: AbbVie Inc. vs. GlaxoSmithKline,2017-04-05 20:21:00 +0000,http://finance.yahoo.com/r/3893a2c1-1c72-3d81-a8f0-e288441f46e3/better-buy-abbvie-inc-vs-glaxosmithkline.aspx?yptr=yahoo&.tsrc=rss,"Which stock is the better pick based on growth, valuation, and dividends: AbbVie or GlaxoSmithKline?"
GSK,GSK:US,BBG000BLB481,At Least 33 Companies Have Pulled Ads From 'The O'Reilly Factor' in Wake of Sexual Harassment Claims,2017-04-05 18:49:00 +0000,http://finance.yahoo.com/r/1da92010-7e52-3ef5-b7f2-10a00cf19521/26-companies-have-pulled-ads-from-the-o-reilly-factor-in-wake-of-sexual-harassment-claims.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The list of major advertisers that have either removed their ads completely or shifted them away from Fox's popular primetime program, 'The O'Reilly Factor,' continues to grow."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Is Voluntarily Recalling Asthma Inhalers in the U.S.,2017-04-05 12:50:00 +0000,http://finance.yahoo.com/r/4ede0d6d-740f-3cd8-95ea-ec15d6607e58/glaxosmithkline-is-voluntarily-recalling-asthma-inhalers-in-the-u-s.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,GlaxoSmithKline is recalling some asthma inhalers due to a leak in the pump.
GSK,GSK:US,BBG000BLB481,"Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC",2017-04-04 21:24:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O4lDwTmfOeY/novartis-tafinlar-mekinist-get-eu-approval-for-nsclc-cm769828,Novartis AG NVS recently announced that the European Commission has approved Tafinlar dabrafenib in combination with Mekinist trametinib for the treatment of patients with BRAF V600 positive advanced or metastatic non small cell lung cancer NSCLC A look at Novartis share
GSK,GSK:US,BBG000BLB481,"Consumer Sector Update for 04/04/2017: PIR,SHLD,CONN,KATE,COH,KORS",2017-04-04 17:43:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lQR-xMGOYRI/consumer-sector-update-for-04042017-pirshldconnkatecohkors-cm769698,Top Consumer StocksTop Consumer Stocks WMT 0 07 WMT 0 07 MCD 0 25 MCD 0 25 DIS 0 23 DIS 0 23 CVS 0 50 CVS 0 50 KO 0 24 KO 0 24 Consumer stocks were mixed during Tuesday trading with shares of consumer staples companies in the S amp P 500 climbing less than 0 1 while shares
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Initiates Phase III Study with Mepolizumab,2017-04-03 22:36:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4Or3uszHLo4/glaxosmithkline-initiates-phase-iii-study-with-mepolizumab-cm769292,GlaxoSmithKline plc GSK announced the initiation of a phase III study with Nucala mepolizumab in patients with severe hypereosinophilic syndrome HES The 32 week study aims to randomize about 18 20 patients The study will also assess the effects of mepolizumab 300 mg every four
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Initiates Phase III Study with Mepolizumab,2017-04-03 20:11:08 +0000,http://finance.yahoo.com/news/glaxosmithkline-initiates-phase-iii-study-201108898.html?.tsrc=rss,"GlaxoSmithKline plc (GSK) announced the initiation of a phase III study with Nucala (mepolizumab,) in patients with severe hypereosinophilic syndrome (HES)."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Initiates Phase III Study with Mepolizumab,2017-04-03 20:11:08 +0000,http://finance.yahoo.com/news/glaxosmithkline-initiates-phase-iii-study-201108898.html,GlaxoSmithKline Initiates Phase III Study with Mepolizumab
GSK,GSK:US,BBG000BLB481,2 FTSE 100 growth stars with dividend yields above 4%,2017-04-03 15:57:47 +0000,http://uk.finance.yahoo.com/news/2-ftse-100-growth-stars-155747165.html,2 FTSE 100 growth stars with dividend yields above 4%
GSK,GSK:US,BBG000BLB481,Why Dynavax Technologies Corporation Stock Briefly Spiked Today,2017-04-03 15:38:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JsefUeqk-kY/why-dynavax-technologies-corporation-stock-briefly-spiked-today-cm769033,What happened Shares of Dynavax Technologies Corporation NASDAQ DVAX 160 gained as much as 19 in pre market trading this morning on the news that the Food and Drug Administration s vaccines and related biological products advisory committee VRBPAC will review
GSK,GSK:US,BBG000BLB481,Novartis Expects to Witness Flat Revenue Growth in 2017,2017-04-03 13:06:48 +0000,http://marketrealist.com/2017/03/novartis-expects-witness-flat-revenue-growth-2017/?utm_source=yahoo&utm_medium=feed,Novartis Expects to Witness Flat Revenue Growth in 2017
GSK,GSK:US,BBG000BLB481,Wall Street Loves European Stocks: 5 Top Dividend Picks to Buy Now,2017-04-03 12:25:56 +0000,http://finance.yahoo.com/news/wall-street-loves-european-stocks-122556364.html,Wall Street Loves European Stocks: 5 Top Dividend Picks to Buy Now
GSK,GSK:US,BBG000BLB481,Wall Street Loves European Stocks: 5 Top Dividend Picks to Buy Now,2017-04-03 12:25:56 +0000,http://finance.yahoo.com/news/wall-street-loves-european-stocks-122556364.html?.tsrc=rss,"For the past couple of months, Wall Street strategists and portfolio managers has been championing European stocks as better buys now than U.S. stocks."
GSK,GSK:US,BBG000BLB481,How Eli Lilly’s New Products Performed in 2016,2017-04-03 11:36:16 +0000,http://marketrealist.com/2017/03/how-eli-lillys-new-products-performed-in-2016/?utm_source=yahoo&utm_medium=feed,How Eli Lilly’s New Products Performed in 2016
GSK,GSK:US,BBG000BLB481,"[$$] At Glaxo, a New CEO Steps In, Must Wring More From R&D",2017-04-02 16:18:44 +0000,https://www.wsj.com/articles/glaxos-new-ceo-is-a-steady-hand-in-pharmaceuticals-rolling-seas-1490952607?mod=yahoo_hs,"[$$] At Glaxo, a New CEO Steps In, Must Wring More From R&D"
GSK,GSK:US,BBG000BLB481,6:24 am GlaxoSmithKline starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome,2017-04-02 10:24:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#gsk,6:24 am GlaxoSmithKline starts phase III study with mepolizumab in patients with severe hypereosinophilic syndrome
GSK,GSK:US,BBG000BLB481,"50 Advertisers Boycott YouTube Advertising, And It Won't Mean More Than A 1% Dip In Google's Top Line",2017-04-01 12:45:52 +0000,http://finance.yahoo.com/news/50-advertisers-boycott-youtube-advertising-124552338.html,"50 Advertisers Boycott YouTube Advertising, And It Won't Mean More Than A 1% Dip In Google's Top Line"
GSK,GSK:US,BBG000BLB481,"50 Advertisers Boycott YouTube Advertising, And It Won't Mean More Than A 1% Dip In Google's Top Line",2017-04-01 12:45:52 +0000,http://finance.yahoo.com/news/50-advertisers-boycott-youtube-advertising-124552338.html?.tsrc=rss,"Alphabet Inc (NASDAQ: GOOG ) (NASDAQ: GOOGL ) shares have shed roughly 4 percent since the YouTube ad-boycott controversy erupted. Sell-side analysts for their part, raised red flags — lowering estimates, ..."
GSK,GSK:US,BBG000BLB481,"The Worst-Case Scenario for Gilead Sciences, Inc.",2017-04-01 11:59:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w73ccEexaXI/the-worst-case-scenario-for-gilead-sciences-inc-cm768651,The sun will come out tomorrow Like Little Orphan Annie Gilead Sciences NASDAQ GILD shareholders are hoping better things are right around the corner For the last year the days have certainly been gray for the big biotech I recently described a best case scenario
GSK,GSK:US,BBG000BLB481,"The Worst-Case Scenario for Gilead Sciences, Inc.",2017-04-01 10:41:00 +0000,http://finance.yahoo.com/r/6d2d40c8-b14c-32a3-a0fa-5ea076521827/the-worst-case-scenario-for-gilead-sciences-inc.aspx?yptr=yahoo&.tsrc=rss,Could nothing but doom and despair be ahead for Gilead Sciences?
GSK,GSK:US,BBG000BLB481,"The Worst-Case Scenario for Gilead Sciences, Inc.",2017-04-01 10:41:00 +0000,https://www.fool.com/investing/2017/04/01/the-worst-case-scenario-for-gilead-sciences-inc.aspx,"The Worst-Case Scenario for Gilead Sciences, Inc."
GSK,GSK:US,BBG000BLB481,[$$] Glaxo’s New CEO Is a Steady Hand in Pharmaceuticals’ Rolling Seas,2017-04-01 04:08:23 +0000,https://www.wsj.com/articles/glaxos-new-ceo-is-a-steady-hand-in-pharmaceuticals-rolling-seas-1490952607?ru=yahoo?mod=yahoo_itp,[$$] Glaxo’s New CEO Is a Steady Hand in Pharmaceuticals’ Rolling Seas
GSK,GSK:US,BBG000BLB481,[$$] Glaxo’s New CEO Is a Steady Hand in Pharmaceuticals’ Rolling Seas,2017-04-01 04:08:23 +0000,http://finance.yahoo.com/r/a9d14459-14ae-32a0-a164-fe288241bbae/glaxos-new-ceo-is-a-steady-hand-in-pharmaceuticals-rolling-seas-1490952607?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"At GlaxoSmithKline, the new chief, Emma Walmsley, arrives from the company’s consumer health products operations to focus on stoking the research pipeline of new drugs."
GSK,GSK:US,BBG000BLB481,Mylan Receives CRL for Generic Advair Diskus From the FDA,2017-03-31 22:59:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wA-hpJeyV30/mylan-receives-crl-for-generic-advair-diskus-from-the-fda-cm768585,Mylan N V MYL recently suffered a huge setback The company received a complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of GlaxoSmithKline s GSK asthma drug Advair Diskus The company is in the process of reviewing
GSK,GSK:US,BBG000BLB481,Understanding Sanofi’s Valuation Compared to Peers,2017-03-31 19:29:18 +0000,http://finance.yahoo.com/r/d04ead54-b36c-39ed-99bd-b95ded999823/understanding-sanofis-valuation-compared-to-peers?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Sanofi’s top line has risen on rising sales in its Genzyme, Animal Health, and Vaccines segments."
GSK,GSK:US,BBG000BLB481,Understanding Sanofi’s Valuation Compared to Peers,2017-03-31 19:29:18 +0000,http://marketrealist.com/2017/03/understanding-sanofis-valuation-compared-to-peers/?utm_source=yahoo&utm_medium=feed,Understanding Sanofi’s Valuation Compared to Peers
GSK,GSK:US,BBG000BLB481,The 2 Most Dangerous Types of Dividend Stocks,2017-03-30 15:03:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pITBDPDq_BM/the-2-most-dangerous-types-of-dividend-stocks-cm767708,More often than not dividend stocks are what form the foundation of the best retirement portfolios It s not hard to understand why either Over the long run dividend paying stocks have run circles around non dividend paying stocks in terms of overall return
GSK,GSK:US,BBG000BLB481,What Wall Street Analysts Estimate for GlaxoSmithKline,2017-03-30 14:36:33 +0000,http://marketrealist.com/2017/03/what-wall-street-analysts-estimate-for-glaxosmithkline/?utm_source=yahoo&utm_medium=feed,What Wall Street Analysts Estimate for GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,What Wall Street Analysts Estimate for GlaxoSmithKline,2017-03-30 14:36:33 +0000,http://finance.yahoo.com/r/f1448651-36cc-322e-91be-6c23f7c5648e/what-wall-street-analysts-estimate-for-glaxosmithkline?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline (GSK) is estimated to report EPS of 111.01 pence on revenues of ~30.0 billion pounds in 2017, 7.6% growth compared to 2016 revenues."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Consumer Healthcare Segment in 2016,2017-03-30 13:06:31 +0000,http://finance.yahoo.com/r/196ce309-8306-36c7-a3e0-b3f2553566ca/glaxosmithklines-consumer-healthcare-segment-in-2016?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GSK's Consumer Healthcare segment achieved growth of 9% to ~1.8 billion pounds in the US markets during 2016, highlighted by the strong performance of Flonase and new products under the Sensodyne brand...."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Consumer Healthcare Segment in 2016,2017-03-30 13:06:31 +0000,http://marketrealist.com/2017/03/glaxosmithklines-consumer-healthcare-segment-in-2016/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Consumer Healthcare Segment in 2016
GSK,GSK:US,BBG000BLB481,Performance of GlaxoSmithKline’s Vaccines Business in 2016,2017-03-30 11:36:26 +0000,http://finance.yahoo.com/r/8ff7fe06-2f30-3a99-a91c-1df11a2fa582/performance-of-glaxosmithklines-vaccines-business-in-2016?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,GSK's Vaccines business reported growth of 14% to ~4.6 billion pounds in 2016.
GSK,GSK:US,BBG000BLB481,Performance of GlaxoSmithKline’s Vaccines Business in 2016,2017-03-30 11:36:26 +0000,http://marketrealist.com/2017/03/performance-of-glaxosmithklines-vaccines-business-in-2016/?utm_source=yahoo&utm_medium=feed,Performance of GlaxoSmithKline’s Vaccines Business in 2016
GSK,GSK:US,BBG000BLB481,GSK's new CEO gets short-term win from generic Advair delay,2017-03-30 07:53:37 +0000,http://sg.finance.yahoo.com/news/gsks-ceo-gets-short-term-075337438.html,GSK's new CEO gets short-term win from generic Advair delay
GSK,GSK:US,BBG000BLB481,GSK's new CEO gets short-term win from generic Advair delay,2017-03-30 07:44:49 +0000,http://finance.yahoo.com/news/gsks-ceo-gets-short-term-074449578.html?.tsrc=rss,"GlaxoSmithKline's new  CEO Emma Walmsley, who takes over on April 1, has won a  short-term reprieve from the threat of generic Advair with a  delay in U.S. approval for Mylan's copy of the  blockbuster lung inhaler.  It is unclear how long Mylan will have to wait to get its  version of the asthma and chronic lung disease medicine on the  market, after receiving a so-called complete response letter  (CRL) from the U.S. Food and Drug Administration (FDA)."
GSK,GSK:US,BBG000BLB481,2 FTSE 100 stocks I’d buy with 4%+ dividend yields,2017-03-30 06:00:43 +0000,http://uk.finance.yahoo.com/news/2-ftse-100-stocks-d-060043197.html,2 FTSE 100 stocks I’d buy with 4%+ dividend yields
GSK,GSK:US,BBG000BLB481,"FDA Snubs MYL, Roche Wins FDA Panel Vote Hands Down, TNXP Falls After-hours",2017-03-30 02:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cJpX67g_YwY/fda-snubs-myl-roche-wins-fda-panel-vote-hands-down-tnxp-falls-afterhours-20170330-00075,"FDA Snubs MYL, Roche Wins FDA Panel Vote Hands Down, TNXP Falls After-hours"
GSK,GSK:US,BBG000BLB481,VBI Vaccines Emerges as Strong Biotech Stock,2017-03-29 20:01:00 +0000,https://www.thestreet.com/story/14064786/1/vbi-vaccines-emerges-as-strong-biotech-stock.html?puc=yahoo&cm_ven=YAHOO,VBI Vaccines Emerges as Strong Biotech Stock
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Continues to Strengthen,2017-03-29 19:00:00 +0000,http://realmoney.thestreet.com/articles/03/29/2017/glaxosmithkline-continues-strengthen?puc=yahoo&cm_ven=YAHOO,GlaxoSmithKline Continues to Strengthen
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Continues to Strengthen,2017-03-29 19:00:00 +0000,http://finance.yahoo.com/r/a036e055-9efc-377c-ae13-196bd046a9d8/glaxosmithkline-continues-strengthen?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Technical indicators suggest GSK can see further significant gains in 2017.
GSK,GSK:US,BBG000BLB481,FDA declines to approve Mylan's generic of GSK's Advair for now,2017-03-29 18:57:42 +0000,http://uk.finance.yahoo.com/news/fda-declines-approve-mylans-generic-185742242.html,"[Reuters - UK Focus] - Mylan NV said on Wednesday the U.S. Food and Drug Administration declined to approve its generic version of GlaxoSmithKline Plc (Other OTC: GLAXF - news) 's blockbuster Advair asthma treatment, but provided no details of the agency's concerns or how long the product might be delayed. Mylan (Hamburg: 27249935.HM - news) 's shares fell 2.9 percent to $40.50, while GSK's U.S.-traded shares rose 0.7 percent. Mylan said it received a so-called complete response letter (CRL) from the FDA, which had been expected to decide by Tuesday whether to approve the first generic copy of Advair, a two-part inhaled drug used to treat asthma and chronic lung disease."
GSK,GSK:US,BBG000BLB481,Mylan stock sinks 2% after FDA fails to approve its generic asthma medication,2017-03-29 18:04:46 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=01BFC7CF-AB2D-4A9C-A23C-FA1297B91BE9&siteid=yhoof2,Mylan stock sinks 2% after FDA fails to approve its generic asthma medication
GSK,GSK:US,BBG000BLB481,U.S. FDA rejects Mylan's generic version of GSK's Advair,2017-03-29 17:27:22 +0000,http://finance.yahoo.com/news/u-fda-rejects-mylans-generic-172722666.html,[Reuters] - Mylan NV said on Wednesday its application to market a generic copy of GlaxoSmithKline Plc's blockbuster inhaled lung drug Advair was rejected by the U.S. Food and Drug Administration. The drugmaker did ...
GSK,GSK:US,BBG000BLB481,U.S. FDA rejects Mylan's generic version of GSK's Advair,2017-03-29 17:27:22 +0000,http://finance.yahoo.com/news/u-fda-rejects-mylans-generic-172722666.html?.tsrc=rss,Mylan NV said on Wednesday its application to market a generic copy of GlaxoSmithKline Plc's blockbuster inhaled lung drug Advair was rejected by the U.S. Food and Drug Administration. The drugmaker did ...
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Advair May Escape Generics Challenge,2017-03-29 15:49:00 +0000,http://www.investopedia.com/news/gsks-advair-may-escape-generics-challenge-gsk/?partner=YahooSA,GlaxoSmithKline Advair May Escape Generics Challenge
GSK,GSK:US,BBG000BLB481,Performance of GlaxoSmithKline’s HIV Business in 2016,2017-03-29 14:36:23 +0000,http://marketrealist.com/2017/03/performance-of-glaxosmithklines-hiv-business-in-2016/?utm_source=yahoo&utm_medium=feed,Performance of GlaxoSmithKline’s HIV Business in 2016
GSK,GSK:US,BBG000BLB481,Performance of Key Pharmaceuticals Products for GlaxoSmithKline,2017-03-29 13:06:22 +0000,http://marketrealist.com/2017/03/performance-of-key-pharmaceuticals-products-for-glaxosmithkline/?utm_source=yahoo&utm_medium=feed,Performance of Key Pharmaceuticals Products for GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,"FDA, Mylan silence on generic Advair may be good news for GSK",2017-03-29 12:38:08 +0000,http://sg.finance.yahoo.com/news/fda-silence-generic-advair-may-081741836.html,"FDA, Mylan silence on generic Advair may be good news for GSK"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Pharmaceuticals Segment Performance,2017-03-29 11:37:09 +0000,http://marketrealist.com/2017/03/glaxosmithklines-pharmaceuticals-segment-performance/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Pharmaceuticals Segment Performance
GSK,GSK:US,BBG000BLB481,2 Footsie growth and income shares for your ISA,2017-03-29 09:30:29 +0000,http://uk.finance.yahoo.com/news/2-footsie-growth-income-shares-093029744.html,2 Footsie growth and income shares for your ISA
GSK,GSK:US,BBG000BLB481,FDA silence on generic Advair may be good news for GSK,2017-03-29 08:15:36 +0000,http://uk.finance.yahoo.com/news/fda-silence-generic-advair-may-081536423.html,FDA silence on generic Advair may be good news for GSK
GSK,GSK:US,BBG000BLB481,[$$] FDA Nominee Scott Gottlieb Plans Recusals From Decisions on Many Drug Firms,2017-03-29 04:21:53 +0000,https://www.wsj.com/articles/fda-nominee-plans-recusals-from-decisions-on-many-drug-firms-1490760063?ru=yahoo?mod=yahoo_itp,[$$] FDA Nominee Scott Gottlieb Plans Recusals From Decisions on Many Drug Firms
GSK,GSK:US,BBG000BLB481,[$$] FDA Nominee Plans Recusals From Decisions on Many Drug Firms,2017-03-29 04:01:10 +0000,https://www.wsj.com/articles/fda-nominee-plans-recusals-from-decisions-on-many-drug-firms-1490760063?mod=yahoo_hs,[$$] FDA Nominee Plans Recusals From Decisions on Many Drug Firms
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : February 24th, 2017 (record date) : By the numbers : March 28, 2017",2017-03-28 15:34:24 +0000,http://www.capitalcube.com/blog/index.php/glaxosmithkline-plc-gsk-us-dividend-analysis-february-24th-2017-record-date-by-the-numbers-march-28-2017/,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : February 24th, 2017 (record date) : By the numbers : March 28, 2017"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Segment-Wise Performance in 2016,2017-03-28 14:39:16 +0000,http://marketrealist.com/2017/03/glaxosmithklines-segment-wise-performance-in-2016/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Segment-Wise Performance in 2016
GSK,GSK:US,BBG000BLB481,Performance of GlaxoSmithKline in 2016,2017-03-28 13:08:28 +0000,http://marketrealist.com/2017/03/performance-of-glaxosmithkline-in-2016/?utm_source=yahoo&utm_medium=feed,Performance of GlaxoSmithKline in 2016
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Valuation Compared to Its Peers,2017-03-28 11:37:59 +0000,http://marketrealist.com/2017/03/glaxosmithklines-valuation-compared-to-its-peers-2/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Valuation Compared to Its Peers
GSK,GSK:US,BBG000BLB481,"First Trump Hiccups, Now Brexit Flare-Ups Coming For Stocks",2017-03-28 00:44:00 +0000,http://www.forbes.com/sites/bryanrich/2017/03/27/first-trump-hiccups-now-brexit-flare-ups-coming-for-stocks/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"First Trump Hiccups, Now Brexit Flare-Ups Coming For Stocks"
GSK,GSK:US,BBG000BLB481,J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe,2017-03-27 15:58:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BikrjRbgllY/jj-jnj-anaemia-drug-marketing-label-expanded-in-europe-cm765867,Johnson amp Johnson JNJ announced that the French health authority has granted approval to expand the label of its anaemia drug Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes MDS in the mutual recognition procedure
GSK,GSK:US,BBG000BLB481,Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma,2017-03-27 15:03:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uQJ_K9N2m6w/mercks-ketruda-gets-positive-chmp-opinion-for-lymphoma-cm765814,Merck amp Co Inc MRK recently announced that its anti PD 1 therapy Keytruda has received positive opinion from the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP for the treatment of patients with relapsed or refractory classical hodgkin
GSK,GSK:US,BBG000BLB481,J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe,2017-03-27 14:27:02 +0000,http://finance.yahoo.com/news/j-j-jnj-anaemia-drug-142702432.html,J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe
GSK,GSK:US,BBG000BLB481,"Coca-Cola, Walmart Latest to Pull Ads From Google Amid Concerns About Offensive Content",2017-03-24 21:52:00 +0000,https://www.thestreet.com/story/14056118/1/at-amp-t-and-verizon-pull-non-search-ads-from-google-amid-concerns-about-offensive-content.html?puc=yahoo&cm_ven=YAHOO,[at TheStreet] - Google faces some tough decisions as the boycott by advertisers continues to grow.
GSK,GSK:US,BBG000BLB481,Exploring Novartis’s 2016 Revenue,2017-03-24 21:05:50 +0000,http://marketrealist.com/2017/03/exploring-novartiss-2016-revenue/?utm_source=yahoo&utm_medium=feed,Exploring Novartis’s 2016 Revenue
GSK,GSK:US,BBG000BLB481,Why Google Has to Definitively Address Its Offensive Content Problem,2017-03-24 15:29:00 +0000,https://www.thestreet.com/story/14057812/1/why-google-needs-to-forcefully-address-its-video-ad-problem.html?puc=yahoo&cm_ven=YAHOO,Why Google Has to Definitively Address Its Offensive Content Problem
GSK,GSK:US,BBG000BLB481,Valeant Pharmaceuticals is Developing its Sales Force,2017-03-24 11:35:43 +0000,http://marketrealist.com/2017/03/valeant-pharmaceuticals-actively-developing-sales-force-2017/?utm_source=yahoo&utm_medium=feed,Valeant Pharmaceuticals is Developing its Sales Force
GSK,GSK:US,BBG000BLB481,"Jeff Auxier Reduces, Exits Multiple Positions in 4th Quarter",2017-03-23 17:58:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UeczcznloEs/jeff-auxier-reduces-exits-multiple-positions-in-4th-quarter-cm764828,Jeff Auxier Trades Portfolio is the founder of Auxier Asset Management His portfolio consists of 152 stocks with a total value of 460 million During the fourth quarter of 2016 the guru sold shares in the following stocks Jeff Auxier Trades Portfolio is the founder of
GSK,GSK:US,BBG000BLB481,GLAXOSMITHKLINE PLC Financials,2017-03-23 17:04:11 +0000,http://finance.yahoo.com/q/is?s=gsk&annual,GLAXOSMITHKLINE PLC Financials
GSK,GSK:US,BBG000BLB481,"Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency",2017-03-23 12:26:27 +0000,http://sg.finance.yahoo.com/news/crunch-week-looms-sanofi-roche-122627416.html,"Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency"
GSK,GSK:US,BBG000BLB481,"Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency",2017-03-23 11:21:54 +0000,http://uk.finance.yahoo.com/news/crunch-week-looms-sanofi-roche-112154840.html,"[Reuters - UK Focus] - Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline (Amsterdam: GO8.AS - news) braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent."
GSK,GSK:US,BBG000BLB481,Novartis' Acute Heart Failure Drug Fails in Late-Stage Study,2017-03-23 00:58:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B4vfKGlyqYU/novartis-acute-heart-failure-drug-fails-in-late-stage-study-cm764455,Novartis AG NVS recently suffered a setback on the announcement of disappointing data from a phase III study RELAX AHF 2 on pipeline candidate serelaxin RLX030 A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks
GSK,GSK:US,BBG000BLB481,"GSK and Regeneron to mine gene data from 500,000 Britons",2017-03-23 00:01:00 +0000,http://uk.finance.yahoo.com/news/gsk-regeneron-mine-gene-data-000100602.html,"GSK and Regeneron to mine gene data from 500,000 Britons"
GSK,GSK:US,BBG000BLB481,Relistor May Be Solid Growth Opportunity for Valeant in 2017,2017-03-22 14:36:52 +0000,http://marketrealist.com/2017/03/relistor-may-prove-solid-growth-opportunity-valeant-pharmaceuticals-2017/?utm_source=yahoo&utm_medium=feed,Relistor May Be Solid Growth Opportunity for Valeant in 2017
GSK,GSK:US,BBG000BLB481,Xifaxan Expected to Witness Robust Growth in 2017,2017-03-22 13:06:45 +0000,http://marketrealist.com/2017/03/xifaxan-expected-witness-robust-growth-trends-2017/?utm_source=yahoo&utm_medium=feed,Xifaxan Expected to Witness Robust Growth in 2017
GSK,GSK:US,BBG000BLB481,Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod,2017-03-21 21:08:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s3huNu9biqI/allergans-dermal-filler-for-wrinkle-correction-gets-fda-nod-cm763764,Allergan plc AGN announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21 The approval was based on the data from a U S pivotal clinical trial It showed that 59 of patients under test
GSK,GSK:US,BBG000BLB481,Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod,2017-03-21 18:58:06 +0000,http://finance.yahoo.com/news/allergans-dermal-filler-wrinkle-correction-185806943.html,Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
GSK,GSK:US,BBG000BLB481,Still Bullish on GlaxoSmithKline,2017-03-21 18:13:00 +0000,http://realmoney.thestreet.com/articles/03/21/2017/still-bullish-glaxosmithkline?puc=yahoo&cm_ven=YAHOO,Still Bullish on GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,2 safe FTSE 100 shares with dividend yields above 4%,2017-03-21 16:20:02 +0000,http://uk.finance.yahoo.com/news/2-safe-ftse-100-shares-162002259.html,2 safe FTSE 100 shares with dividend yields above 4%
GSK,GSK:US,BBG000BLB481,7 Pharma Plays With Emerging Market Potential,2017-03-21 16:13:00 +0000,http://blogs.barrons.com/emergingmarketsdaily/2017/03/21/7-pharma-plays-with-emerging-market-potential/?mod=yahoobarrons&ru=yahoo,7 Pharma Plays With Emerging Market Potential
GSK,GSK:US,BBG000BLB481,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017,2017-03-21 15:11:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q2AQHxA2koE/6-reasons-to-invest-in-glaxosmithkline-gsk-stock-in-2017-cm763381,GlaxoSmithKline plc GSK one of the largest health care companies reshaped its business following Mar 2015 completion of the three part inter conditional transaction with Novartis AG NVS Under the deal Glaxo sold oncology assets to Novartis and acquired Novartis Vaccines
GSK,GSK:US,BBG000BLB481,Lilly's Breast Cancer Combo Drug Phase III Results Positive,2017-03-21 14:09:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QSMsf3fTJMs/lillys-breast-cancer-combo-drug-phase-iii-results-positive-cm763321,Eli Lilly and Company LLY recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer met the primary endpoint of progression free survival PFS The double blind MONARCH 2 phase III study evaluated abemaciclib a CDK 4
GSK,GSK:US,BBG000BLB481,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017,2017-03-21 13:18:01 +0000,http://finance.yahoo.com/news/6-reasons-invest-glaxosmithkline-gsk-131801097.html,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
GSK,GSK:US,BBG000BLB481,Novartis (NVS) Announces Positive Data on Heart Failure Drug,2017-03-21 00:06:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rqAZrgxK2DA/novartis-nvs-announces-positive-data-on-heart-failure-drug-cm763197,Novartis AG NVS recently announced results of a new post hoc analysis from the PARADIGM HF study on Entresto in a subgroup of patients with reduced ejection fraction heart failure HFrEF and diabetes A look at Novartis share price movement over the past one year shows that the stock
GSK,GSK:US,BBG000BLB481,Novartis (NVS) Announces Positive Data on Heart Failure Drug,2017-03-20 22:22:10 +0000,http://finance.yahoo.com/news/novartis-nvs-announces-positive-data-222210122.html,Novartis (NVS) Announces Positive Data on Heart Failure Drug
GSK,GSK:US,BBG000BLB481,November 17th Options Now Available For GlaxoSmithKline (GSK),2017-03-20 17:09:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wncfEPxcNgI/november-17th-options-now-available-for-glaxosmithkline-gsk-cm763048,Investors in GlaxoSmithKline plc Symbol GSK saw new options become available today for the November 17th expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 242 days until expiration the newly available
GSK,GSK:US,BBG000BLB481,AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal,2017-03-20 17:08:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VD0jEST0MYE/astrazeneca-azn-gets-another-crl-for-zs-9-inks-copd-deal-cm763005,London based AstraZeneca plc AZN received a second Complete Response Letter CRL from the FDA for its new drug application NDA for investigational drug ZS 9 The company is looking to get ZS 9 sodium zirconium cyclosilicate approved for the treatment of hyperkalemia high potassium level
GSK,GSK:US,BBG000BLB481,Why Biotech Stock Gilead (GILD) Could Be a Value Trap,2017-03-20 16:10:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sKkKzx0FFk4/why-biotech-stock-gilead-gild-could-be-a-value-trap-cm762916,Gilead Sciences Inc GILD one of the key players in the biotech market has had a phenomenal run over the last five years with shares gaining 195 1 during this period compared to the Zacks categorized Medical Biomedical Genetics industry growth of 51 8 From a valuation
GSK,GSK:US,BBG000BLB481,AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal,2017-03-20 14:32:02 +0000,http://finance.yahoo.com/news/astrazeneca-azn-gets-another-crl-143202137.html,AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
GSK,GSK:US,BBG000BLB481,Why Biotech Stock Gilead (GILD) Could Be a Value Trap,2017-03-20 14:06:02 +0000,http://finance.yahoo.com/news/why-biotech-stock-gilead-gild-140602293.html,Why Biotech Stock Gilead (GILD) Could Be a Value Trap
GSK,GSK:US,BBG000BLB481,AstraZeneca Inks $230 Million COPD Drugs Deal,2017-03-17 13:45:00 +0000,http://www.investopedia.com/news/astrazeneca-inks-230m-copd-drugs-deal-azn-gsk/?partner=YahooSA,AstraZeneca Inks $230 Million COPD Drugs Deal
GSK,GSK:US,BBG000BLB481,A Look at Opdivo’s Performance in 2016,2017-03-17 11:38:01 +0000,http://marketrealist.com/2017/03/a-look-at-opdivos-performance-in-2016/?utm_source=yahoo&utm_medium=feed,A Look at Opdivo’s Performance in 2016
GSK,GSK:US,BBG000BLB481,Glaxo Seeks Label Expansion for Fluarix Vaccine,2017-03-16 16:00:00 +0000,http://www.investopedia.com/news/glaxo-flu-drug-fluarix-seeks-label-expansion-gsk/?partner=YahooSA,Glaxo Seeks Label Expansion for Fluarix Vaccine
GSK,GSK:US,BBG000BLB481,Glaxo Files for Label Expansion of Influenza Vaccine in US,2017-03-16 15:10:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_izUCg5xDV4/glaxo-files-for-label-expansion-of-influenza-vaccine-in-us-cm761595,GlaxoSmithKline plc GSK announced that it has submitted a supplemental Biologics License Application sBLA to the FDA seeking approval to expand the label of Fluarix Quadrivalent an influenza vaccine for infants six months or older At present this vaccine is approved for
GSK,GSK:US,BBG000BLB481,Glaxo Files for Label Expansion of Influenza Vaccine in US,2017-03-16 12:59:12 +0000,http://finance.yahoo.com/news/glaxo-files-label-expansion-influenza-125912149.html,Glaxo Files for Label Expansion of Influenza Vaccine in US
GSK,GSK:US,BBG000BLB481,Is a GlaxoSmithKline plc buyout back on the cards?,2017-03-16 11:41:17 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-plc-buyout-back-cards-114117998.html,Is a GlaxoSmithKline plc buyout back on the cards?
GSK,GSK:US,BBG000BLB481,Merck's (MRK) Keytruda Gets FDA Nod for Lymphoma Indication,2017-03-15 17:08:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BCm7XG_r2Sc/mercks-mrk-keytruda-gets-fda-nod-for-lymphoma-indication-cm761201,Merck amp Co Inc MRK announced that it has received FDA approval for its anti PD 1 therapy Keytruda for the treatment of patients with refractory classical Hodgkin lymphoma cHL or who had relapsed after three or more prior lines of therapy This is the first time that Merck has
GSK,GSK:US,BBG000BLB481,GSK: New Female CEO Gets 25% Less Than Predecessor,2017-03-15 16:07:00 +0000,http://www.investopedia.com/news/gsk-new-female-ceo-gets-25-less-predecessor/?partner=YahooSA,GSK: New Female CEO Gets 25% Less Than Predecessor
GSK,GSK:US,BBG000BLB481,7 Most Popular Diet Pills That Work Fast Without Exercise,2017-03-15 15:16:36 +0000,http://www.insidermonkey.com/blog/7-most-popular-diet-pills-that-work-fast-without-exercise-566573/,7 Most Popular Diet Pills That Work Fast Without Exercise
GSK,GSK:US,BBG000BLB481,GSK announces US regulatory submission seeking expanded indication for Fluarix® Quadrivalent (Influenza Vaccine) for infants 6 months and older,2017-03-15 15:13:00 +0000,http://finance.yahoo.com/news/gsk-announces-us-regulatory-submission-151300270.html,"[PR Newswire] - PHILADELPHIA, March 15, 2017 /PRNewswire/ -- GSK today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for ..."
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines",2017-03-15 15:10:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2vujdP-LHPo/the-zacks-analyst-blog-highlights-intel-glaxo-schwab-travelers-and-american-airlines-cm761150,For Immediate Release Chicago IL March 15 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines",2017-03-15 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-intel-133001630.html,"The Zacks Analyst Blog Highlights: Intel, Glaxo, Schwab, Travelers and American Airlines"
GSK,GSK:US,BBG000BLB481,Why I’d buy and hold Hikma Pharmaceuticals plc for the next decade,2017-03-15 12:08:58 +0000,http://uk.finance.yahoo.com/news/why-d-buy-hold-hikma-120858025.html,Why I’d buy and hold Hikma Pharmaceuticals plc for the next decade
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's New Woman CEO To Make Less Than Male Predecessor,2017-03-15 11:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yIchlbTuPsQ/glaxosmithklines-new-woman-ceo-to-make-less-than-male-predecessor-20170315-00839,GlaxoSmithKline's New Woman CEO To Make Less Than Male Predecessor
GSK,GSK:US,BBG000BLB481,"Once paid by Vertex, Trump's FDA pick would be tasked with regulating it",2017-03-15 09:45:08 +0000,http://www.bizjournals.com/boston/news/2017/03/15/once-paid-by-vertex-trumps-fda-pick-would-be.html?ana=yahoo,"Once paid by Vertex, Trump's FDA pick would be tasked with regulating it"
GSK,GSK:US,BBG000BLB481,GSK's new female CEO to get 25 percent less after pay policy review,2017-03-15 08:25:15 +0000,http://sg.finance.yahoo.com/news/gsks-female-ceo-25-percent-081817372.html,GSK's new female CEO to get 25 percent less after pay policy review
GSK,GSK:US,BBG000BLB481,GSK's new female CEO to get 25 pct less after pay policy review,2017-03-15 08:14:55 +0000,http://uk.finance.yahoo.com/news/gsks-female-ceo-25-pct-081455651.html,"[Reuters - UK Focus] - Incoming GlaxoSmithKline Chief Executive Emma Walmsley, the first woman to lead a top global drugmaker, will get a pay package worth a quarter less than her predecessor, following a company rethink on remuneration. Walmsley, who takes over next month, will be paid a base salary of 1,003,000 pounds ($1.23 million), or 10 percent less than outgoing CEO Andrew Witty. ""Taking into account the fact that this is Emma's first CEO role, reductions have been made to all elements of her remuneration package in comparison to Sir Andrew's current arrangements,"" the report stated."
GSK,GSK:US,BBG000BLB481,"Top Research Reports for Intel, Schwab & Glaxo",2017-03-14 22:07:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g27MOB0Mqk8/top-research-reports-for-intel-schwab-glaxo-cm760823,Tuesday March 14 2017 Today s Research Daily features new research reports on 16 major stocks including Intel 160 INTC Glaxo GSK and Schwab SCHW Intel shares have gained only 1 2 since election results were announced on Nov 8 lagging the broader Tech sector up 8 8 as
GSK,GSK:US,BBG000BLB481,"Top Research Reports for Intel, Schwab & Glaxo",2017-03-14 19:23:07 +0000,http://finance.yahoo.com/news/top-research-reports-intel-schwab-192307698.html,"Top Research Reports for Intel, Schwab & Glaxo"
GSK,GSK:US,BBG000BLB481,How a Major Drugmaker Plans to Cure Disease... Without Drugs,2017-03-14 17:07:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LhyBph8rBY4/how-a-major-drugmaker-plans-to-cure-disease-without-drugs-cm760610,Pharmaceutical giant GlaxoSmithKline plc NYSE GSK has the resources to pursue long term bets in medicine that could eventually change the course of disease treatment and yield large payoffs Three and half years ago the company announced its plans for an audacious goal to
GSK,GSK:US,BBG000BLB481,Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy,2017-03-14 17:07:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KA66CW70WE8/novartis-breast-cancer-drug-okd-by-fda-as-first-line-therapy-cm760615,Swiss pharma giant Novartis AG NVS announced that the FDA has approved Kisqali formerly known as ribociclib LEE011 for use in combination with an aromatase inhibitor for the first line treatment of postmenopausal women with hormone receptor positive human epidermal growth factor receptor
GSK,GSK:US,BBG000BLB481,2 shares with explosive growth potential,2017-03-14 16:18:44 +0000,http://uk.finance.yahoo.com/news/2-shares-explosive-growth-potential-161844821.html,2 shares with explosive growth potential
GSK,GSK:US,BBG000BLB481,Couple sue pharma giant for work that led to prison in China,2017-03-14 15:38:19 +0000,http://finance.yahoo.com/news/couple-sue-pharma-giant-led-153807011.html,Couple sue pharma giant for work that led to prison in China
GSK,GSK:US,BBG000BLB481,Couple sue pharma giant for work that led to prison in China,2017-03-14 15:38:07 +0000,http://sg.finance.yahoo.com/news/couple-sue-pharma-giant-led-153807863.html,Couple sue pharma giant for work that led to prison in China
GSK,GSK:US,BBG000BLB481,How a Major Drugmaker Plans to Cure Disease... Without Drugs,2017-03-14 15:12:00 +0000,http://www.fool.com/investing/2017/03/14/how-a-major-drugmaker-plans-to-cure-disease-withou.aspx,How a Major Drugmaker Plans to Cure Disease... Without Drugs
GSK,GSK:US,BBG000BLB481,"Glaxo to Pay First Woman CEO Less, Cites Lack of Experience",2017-03-14 14:29:51 +0000,https://www.bloomberg.com/news/articles/2017-03-14/glaxo-to-pay-first-woman-ceo-less-citing-a-lack-of-experience?cmpid=yhoo.headline,"Glaxo to Pay First Woman CEO Less, Cites Lack of Experience"
GSK,GSK:US,BBG000BLB481,It’s time to vaccinate your investments against a deadly bird flu,2017-03-14 13:28:17 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=9C179F36-05B5-11E7-8E99-0F3C31BBB02B&siteid=yhoof2,It’s time to vaccinate your investments against a deadly bird flu
GSK,GSK:US,BBG000BLB481,TradeKing vs. Merrill Edge: Best Choice for an IRA Account,2017-03-13 02:10:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lguQnm33bbI/tradeking-vs-merrill-edge-best-choice-for-an-ira-account-cm759760,IRAs can be a powerful savings tool as they allow your savings some protection from Uncle Sam while giving you an incredible level of flexibility to invest how you want to But you shouldn t jump in with both feet by opening an IRA at the first broker you see The brokerage you
GSK,GSK:US,BBG000BLB481,"Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus",2017-03-11 00:16:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I4sIny95Xis/epizyme-epzm-reports-narrower-q4-loss-pipeline-in-focus-cm759478,Epizyme Inc EPZM reported a loss of 60 cents per share in the fourth quarter of 2016 narrower than the Zacks Consensus Estimate of 64 cents but wider than the year ago loss of 53 cents Epizyme s share price has outperformed the Zacks classified Medical Biomedical Genetics industry
GSK,GSK:US,BBG000BLB481,Alexion's sBLA for Soliris Receives FDA Acknowledgement,2017-03-11 00:14:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XC95fOoMveg/alexions-sbla-for-soliris-receives-fda-acknowledgement-cm759433,Alexion Pharmaceuticals Inc ALXN announced that the FDA on Mar 9 has accepted the supplemental Biologics License Application sBLA to expand the indication for Soliris for the potential treatment of 160 patients with refractory generalized myasthenia gravis gMG who
GSK,GSK:US,BBG000BLB481,"Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus",2017-03-10 15:30:03 +0000,http://finance.yahoo.com/news/epizyme-epzm-reports-narrower-q4-163004733.html,"Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus"
GSK,GSK:US,BBG000BLB481,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4,2017-03-10 15:12:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KAjukKJ8K8g/agenus-agen-reports-narrower-than-expected-loss-in-q4-cm759239,Agenus Inc AGEN reported fourth quarter 2016 loss of 30 cents per share including non cash expenses narrower than the Zacks Consensus Estimate of a loss of 33 cents but wider than the year ago loss of 18 cents Moreover revenues declined 27 year over year to 5 5 million slightly
GSK,GSK:US,BBG000BLB481,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4,2017-03-10 14:21:02 +0000,http://finance.yahoo.com/news/agenus-agen-reports-narrower-expected-142102754.html,Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4
GSK,GSK:US,BBG000BLB481,2 FTSE 100 stocks I’d happily buy and never sell,2017-03-10 11:17:27 +0000,http://uk.finance.yahoo.com/news/2-ftse-100-stocks-d-111727655.html,2 FTSE 100 stocks I’d happily buy and never sell
GSK,GSK:US,BBG000BLB481,Why Ionis Pharmaceuticals Rallied 12% in February,2017-03-09 23:14:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fX9j-7eUk4o/why-ionis-pharmaceuticals-rallied-12-in-february-cm758894,What happened After reporting better than expected results in the fourth quarter and providing investors with an update on its R amp D progress 160 shares in Ionis Pharmaceuticals NASDAQ IONS increased more than 12 last month 160 according to S amp P Global
GSK,GSK:US,BBG000BLB481,"Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?",2017-03-09 19:35:49 +0000,http://www.investors.com/news/technology/merck-glaxo-undercut-gileads-hiv-mt-everest-as-hepatitis-c-topples/?src=A00220A,"Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?"
GSK,GSK:US,BBG000BLB481,GSK April 28th Options Begin Trading,2017-03-09 17:13:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wJ2J8M_kQ78/gsk-april-28th-options-begin-trading-cm758561,Investors in GlaxoSmithKline plc Symbol GSK saw new options begin trading today for the April 28th expiration At Stock Options Channel our YieldBoost formula has looked up and down the GSK options chain for the new April 28th contracts and identified the following call contract
GSK,GSK:US,BBG000BLB481,"Gilead: ""Stuck Between A Rock And A Hard Place?""",2017-03-09 16:02:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/09/gilead-stuck-between-a-rock-and-a-hard-place/?mod=yahoobarrons&ru=yahoo,"Gilead: ""Stuck Between A Rock And A Hard Place?"""
GSK,GSK:US,BBG000BLB481,Coverage initiated on GlaxoSmithKline by Kepler and Liberum,2017-03-09 13:49:11 +0000,http://finance.yahoo.com/q/ud?s=GSK,Coverage initiated on GlaxoSmithKline by Kepler and Liberum
GSK,GSK:US,BBG000BLB481,"Valeant (VRX) Issues Notes, Restructures Debt; Shares Down",2017-03-09 00:12:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2lxcIv02zR0/valeant-vrx-issues-notes-restructures-debt-shares-down-cm758221,Valeant Pharmaceuticals International Inc VRX commenced an offer to purchase cash up to 600 million of aggregate principal amount of the outstanding 6 75 senior notes due 2018 On Mar 3 the company had announced the divesture of its skincare products The company used the net proceeds
GSK,GSK:US,BBG000BLB481,"Aerie (AERI) Q4 Loss Widens, Rhopressa NDA Resubmitted",2017-03-08 22:13:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mudvyGdh2h4/aerie-aeri-q4-loss-widens-rhopressa-nda-resubmitted-cm758135,Aerie Pharmaceuticals Inc AERI posted fourth quarter 2016 loss of 87 cents per share including stock based compensation wider than both the Zacks Consensus Estimate of a loss of 65 cents and the year ago loss of 76 cents Being a development stage company Aerie has not generated
GSK,GSK:US,BBG000BLB481,"Trump rally on pause: Stocks, Dow Jones sluggish despite strong ADP jobs report: Snap, Goldman, BofA, Urban Outfitters on the move",2017-03-08 15:35:09 +0000,http://www.bizjournals.com/phoenix/news/2017/03/08/trump-rally-on-pausestocks-dow-jones-sluggish.html?ana=yahoo,"Trump rally on pause: Stocks, Dow Jones sluggish despite strong ADP jobs report: Snap, Goldman, BofA, Urban Outfitters on the move"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's Nucala Positive in Label Expansion Study,2017-03-07 23:13:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VpNn37c56l0/glaxosmithklines-nucala-positive-in-label-expansion-study-cm757591,GlaxoSmithKline plc 160 GSK announced that a phase IIIb study evaluating its respiratory drug Nucala mepolizumab met all its primary and secondary endpoints 160 The 160 MUSCA study showed that patients with severe asthma driven by eosinophilic inflammation when treated with the
GSK,GSK:US,BBG000BLB481,Novartis (NVS) Reports Positive Data on Biosimilar Humira,2017-03-07 23:13:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XQQrS0hUvXM/novartis-nvs-reports-positive-data-on-biosimilar-humira-cm757583,Novartis AG NVS announced encouraging data for its proposed biosimilar verison of AbbVie s ABBV Humira adalimumab namely GP2017 from a phase III study A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks classified Large
GSK,GSK:US,BBG000BLB481,Novartis (NVS) Reports Positive Data on Biosimilar Humira,2017-03-07 21:21:09 +0000,http://finance.yahoo.com/news/novartis-nvs-reports-positive-data-212109555.html,Novartis (NVS) Reports Positive Data on Biosimilar Humira
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's Nucala Positive in Label Expansion Study,2017-03-07 21:08:09 +0000,http://finance.yahoo.com/news/glaxosmithklines-nucala-positive-label-expansion-210809378.html,GlaxoSmithKline's Nucala Positive in Label Expansion Study
GSK,GSK:US,BBG000BLB481,"NOVN Moves Ahead, PTCT Finally Achieves It, TGTX Gets GENUINE Reaction",2017-03-07 01:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dzsBSqo3jPg/novn-moves-ahead-ptct-finally-achieves-it-tgtx-gets-genuine-reaction-20170307-00031,"NOVN Moves Ahead, PTCT Finally Achieves It, TGTX Gets GENUINE Reaction"
GSK,GSK:US,BBG000BLB481,Why GlaxoSmithKline plc Edged Higher in February,2017-03-06 18:15:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QLxo6Ge-PB0/why-glaxosmithkline-plc-edged-higher-in-february-cm756724,What happened According to data from S amp P Global Market Intelligence shares of the British drugmaker GlaxoSmithKline NYSE GSK rose by 7 36 last month The exact reason for Glaxo s strong February however isn t altogether clear After all the market barely reacted
GSK,GSK:US,BBG000BLB481,Why GlaxoSmithKline plc Edged Higher in February,2017-03-06 16:43:00 +0000,http://www.fool.com/investing/2017/03/06/why-glaxosmithkline-plc-edged-higher-in-february.aspx,Why GlaxoSmithKline plc Edged Higher in February
GSK,GSK:US,BBG000BLB481,3 Neil Woodford stocks I’d buy in March,2017-03-06 15:31:56 +0000,http://uk.finance.yahoo.com/news/3-neil-woodford-stocks-d-153156961.html,3 Neil Woodford stocks I’d buy in March
GSK,GSK:US,BBG000BLB481,GSK's MUSCA study shows Nucala® (mepolizumab) significantly improves quality of life and lung function in severe asthma patients with an eosinophilic phenotype,2017-03-06 15:20:00 +0000,http://finance.yahoo.com/news/gsks-musca-study-shows-nucala-152000874.html,"[PR Newswire] - LONDON, March 6, 2017 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with ..."
GSK,GSK:US,BBG000BLB481,3 Tempting High-Yield Dividend Stocks You Should Avoid,2017-03-06 15:18:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i3rj0JR7Xws/3-tempting-high-yield-dividend-stocks-you-should-avoid-cm756531,Stocks with better than average dividends can provide a tremendous boost to your portfolio The harsh reality though is that a large proportion of stocks that offer elevated yields do so because of fundamental weaknesses in their underlying business making them extremely risky
GSK,GSK:US,BBG000BLB481,3 Tempting High-Yield Dividend Stocks You Should Avoid,2017-03-06 13:23:00 +0000,http://www.fool.com/investing/2017/03/06/3-tempting-high-yield-dividend-stocks-you-should-a.aspx,3 Tempting High-Yield Dividend Stocks You Should Avoid
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Reports MUSCA Study Results On Nucala,2017-03-06 10:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/evzfDjfruB8/glaxosmithkline-reports-musca-study-results-on-nucala-20170306-00809,GlaxoSmithKline Reports MUSCA Study Results On Nucala
GSK,GSK:US,BBG000BLB481,Retire early on these 3 stocks,2017-03-04 08:40:08 +0000,http://uk.finance.yahoo.com/news/retire-early-3-stocks-084008733.html,Retire early on these 3 stocks
GSK,GSK:US,BBG000BLB481,GSK's Board Faces Pressure Over Incoming CEO's Pay,2017-03-03 10:08:00 +0000,https://www.thestreet.com/story/14025607/1/gsk-s-board-faces-pressure-over-incoming-ceo-s-pay.html?puc=yahoo&cm_ven=YAHOO,GSK's Board Faces Pressure Over Incoming CEO's Pay
GSK,GSK:US,BBG000BLB481,"Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View",2017-03-03 00:14:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EWt_rQWboks/mylan-myl-beats-on-q4-earnings-stock-up-on-strong-view-cm755721,Shares of Mylan N V s MYL were up 7 2 after the company beat expectations in the fourth quarter 2016 and provided a strong outlook for 2017 amid challenging conditions The company reported fourth quarter 2016 earnings of 1 57 per share beating the Zacks Consensus Estimate of 1 41 and
GSK,GSK:US,BBG000BLB481,"Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat",2017-03-03 00:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J1EvPSghvFI/keryx-kerx-q4-loss-wider-than-expected-revenues-beat-cm755717,Keryx Biopharmaceuticals Inc KERX reported fourth quarter 2016 loss of 32 cents per share narrower than the year ago loss of 36 cents However the loss was wider than the Zacks Consensus Estimate of a loss of 27 cents per share Revenues came in at 9 53 million in the quarter
GSK,GSK:US,BBG000BLB481,"Impax (IPXL) Q4 Earnings in Line, Revenues Miss Estimates",2017-03-03 00:13:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nZyy1U2ILHA/impax-ipxl-q4-earnings-in-line-revenues-miss-estimates-cm755709,Impax Laboratories Inc IPXL posted fourth quarter 2016 adjusted earnings of 16 cents per share in line with the Zacks Consensus Estimate Earnings were also down 74 2 from 62 cents in the year ago period due to lower generic product sales The company s share price fell 34 74 following
GSK,GSK:US,BBG000BLB481,"Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View",2017-03-02 21:46:09 +0000,http://finance.yahoo.com/news/mylan-myl-beats-q4-earnings-214609602.html,"Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View"
GSK,GSK:US,BBG000BLB481,These 3 Big Pharma Stocks Are Exceptionally Cheap,2017-03-02 19:13:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T-WkI4p5oKs/these-3-big-pharma-stocks-are-exceptionally-cheap-cm755561,For retirees and income seeking investors there are few industries that offer more promise than big pharma There s a lot to like about investing in some of the steadiest drug innovators Their portfolios are often dozens of products deep which provides the diversification
GSK,GSK:US,BBG000BLB481,Investors pile pressure on GSK over new chief’s pay deal,2017-03-02 18:56:00 +0000,http://uk.finance.yahoo.com/news/investors-pile-pressure-gsk-over-182800487.html,Investors pile pressure on GSK over new chief’s pay deal
GSK,GSK:US,BBG000BLB481,These 3 Big Pharma Stocks Are Exceptionally Cheap,2017-03-02 17:12:00 +0000,http://www.fool.com/investing/2017/03/02/these-3-big-pharma-stocks-are-exceptionally-cheap.aspx,These 3 Big Pharma Stocks Are Exceptionally Cheap
GSK,GSK:US,BBG000BLB481,3 big yielders I’d buy and hold for the next 5 years,2017-03-02 17:01:01 +0000,http://uk.finance.yahoo.com/news/3-big-yielders-d-buy-170101944.html,3 big yielders I’d buy and hold for the next 5 years
GSK,GSK:US,BBG000BLB481,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis",2017-03-02 16:16:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dIeJghG0Oak/zacks-industry-outlook-highlights-glaxosmithkline-celgene-and-exelixis-cm755339,For Immediate Release Chicago IL March 02 2017 Today Zacks Equity Research discusses the Industry Pharma Part 2 including GlaxoSmithKline plc NYSE GSK Free Report Celgene Corporation NASDAQ CELG Free Report and Exelixis Inc NASDAQ
GSK,GSK:US,BBG000BLB481,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis",2017-03-02 14:30:02 +0000,http://finance.yahoo.com/news/zacks-industry-outlook-highlights-glaxosmithkline-143002187.html,"Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis"
GSK,GSK:US,BBG000BLB481,"Valeant (VRX) Tops Q4 Earnings, Shares Down on Tepid View",2017-03-02 00:13:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iTHTVBxt89w/valeant-vrx-tops-q4-earnings-shares-down-on-tepid-view-cm755148,Shares of Valeant Pharmaceuticals Inc VRX fell over 13 9 following the company s dismal guidance for 2017 concurrent with the fourth quarter 2016 earnings We note that the shares of Valeant have underperformed the Zacks classified Medical Drugs industry in the last one year The
GSK,GSK:US,BBG000BLB481,"M&As, Pipeline Catalysts to Drive Pharma Sector",2017-03-01 23:14:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N3pJezp3vK8/mas-pipeline-catalysts-to-drive-pharma-sector-cm755151,Although pharma and biotech stocks are facing challenges in the form of increasing focus on the high prices of drugs a changing competitive scenario and mixed results the sector s fundamentals remain strong innovation mergers and acquisitions M amp As product approvals and positive
GSK,GSK:US,BBG000BLB481,"M&As, Pipeline Catalysts to Drive Pharma Sector",2017-03-01 20:19:08 +0000,http://finance.yahoo.com/news/m-pipeline-catalysts-drive-pharma-201908607.html,"M&As, Pipeline Catalysts to Drive Pharma Sector"
GSK,GSK:US,BBG000BLB481,"Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low",2017-02-28 18:50:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1OSAmTex0LM/endo-endp-beats-on-q4-earnings-revenues-guides-low-cm754295,Endo International plc s ENDP fourth quarter 2016 earnings of 1 77 per share beat the Zacks Consensus Estimate of 1 63 Reported earnings were also above the year ago figure of 1 36 Revenues came in at 1 24 billion in fourth quarter of 2016 up 15 6 year over year Revenues were also
GSK,GSK:US,BBG000BLB481,"Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low",2017-02-28 17:17:05 +0000,http://finance.yahoo.com/news/endo-endp-beats-q4-earnings-171705428.html,"Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low"
GSK,GSK:US,BBG000BLB481,"Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen's and Lilly",2017-02-28 16:52:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x3veEitpvqg/zacks-industry-outlook-highlights-johnson-johnson-pfizer-glaxo-amgens-and-lilly-cm754237,For Immediate Release Chicago IL February 28 2017 Today Zacks Equity Research discusses the Industry Pharma Part 1 including Johnson amp Johnson NYSE JNJ Free Report Pfizer NYSE PFE Free Report Glaxo NYSE GSK Free Report Amgen s NASDAQ
GSK,GSK:US,BBG000BLB481,"Januvia, Vaccines May Drive Merck’s Revenue Growth in 2017",2017-02-28 15:37:24 +0000,http://marketrealist.com/2017/02/januvia-franchise-vaccines-business-may-drive-mercks-revenue-growth-2017/?utm_source=yahoo&utm_medium=feed,"Januvia, Vaccines May Drive Merck’s Revenue Growth in 2017"
GSK,GSK:US,BBG000BLB481,"Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen's and Lilly",2017-02-28 14:30:02 +0000,http://finance.yahoo.com/news/zacks-industry-outlook-highlights-johnson-143002844.html,"Zacks Industry Outlook Highlights: Johnson & Johnson, Pfizer, Glaxo, Amgen's and Lilly"
GSK,GSK:US,BBG000BLB481,PAREXEL Names Simon Harford SVP & CFO - Quick Facts,2017-02-28 07:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/omnT7RI7bkA/parexel-names-simon-harford-svp--cfo--quick-facts-20170228-00562,PAREXEL Names Simon Harford SVP & CFO - Quick Facts
GSK,GSK:US,BBG000BLB481,Pharma Industry Outlook - February/March 2017,2017-02-28 06:50:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JnCkTN4-Fz8/pharma-industry-outlook-februarymarch-2017-cm753953,There is no doubt that 2016 was a tough year for pharma and biotech stocks with the sector facing a lot of criticism for rising drug prices Although shares did rally post election in November on hopes that drug pricing would not be a key focus area under a Trump presidency the rally turned
GSK,GSK:US,BBG000BLB481,Why I'm Optimistic About GlaxoSmithKline,2017-02-27 16:23:00 +0000,http://realmoney.thestreet.com/articles/02/27/2017/why-im-optimistic-about-glaxosmithkline?puc=yahoo&cm_ven=YAHOO,Why I'm Optimistic About GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,Eli Lilly and Co.’s New Products Portfolio,2017-02-27 15:36:48 +0000,http://marketrealist.com/2017/02/eli-lilly-and-co-s-new-products-portfolio/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s New Products Portfolio
GSK,GSK:US,BBG000BLB481,Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc,2017-02-25 15:50:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jvoMBOYO904/better-buy-eli-lilly-and-co-vs-glaxosmithkline-plc-cm753201,A couple recent events helped shares of Eli Lilly and Co NYSE LLY bounce back from a big clinical trial failure that sent the stock tumbling late last year Despite some ups and downs over the past year the big pharma stock notched an 12 gain Lilly s peer across the
GSK,GSK:US,BBG000BLB481,Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc,2017-02-25 14:34:40 +0000,http://www.fool.com/investing/2017/02/25/better-buy-eli-lilly-and-co-vs-glaxosmithkline-plc.aspx,Better Buy: Eli Lilly and Co vs. GlaxoSmithKline plc
GSK,GSK:US,BBG000BLB481,Radius Health (RDUS) Posts Wider Loss in Q4,2017-02-24 22:51:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MM6qRtO6g14/radius-health-rdus-posts-wider-loss-in-q4-cm753108,Radius Health Inc RDUS posted a loss of 1 22 per share in the fourth quarter of 2016 compared with a loss of 77 cents per share in the year ago quarter and wider than the Zacks Consensus Estimate loss of 1 16 The year over year increase in net loss was attributable to an increase
GSK,GSK:US,BBG000BLB481,"Intercept (ICPT) Q4 Loss Wider than Expected, Revenues Beat",2017-02-24 22:51:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UP_ug5KF3q0/intercept-icpt-q4-loss-wider-than-expected-revenues-beat-cm753091,Intercept Pharmaceuticals Inc ICPT posted a loss of 4 84 per share in the fourth quarter of 2016 wider than the Zacks Consensus Estimate of a loss of 3 58 and the year ago loss of 3 62 Quarterly revenues came in at 13 8 million up significantly from 0 4 million in the year ago
GSK,GSK:US,BBG000BLB481,"PPH, GSK, SNY, AZN: Large Inflows Detected at ETF",2017-02-24 17:50:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BJ5twBr7Fl8/pph-gsk-sny-azn-large-inflows-detected-at-etf-cm752853,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 58 7 million dollar inflow that s a 18 8 increase week over week in outstanding units
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs",2017-02-24 12:27:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-bmy-next-122712720.html,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Breaks Above 200-Day Moving Average - Bullish for GSK,2017-02-23 22:50:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UJLGK2QcKmQ/glaxosmithkline-breaks-above-200-day-moving-average-bullish-for-gsk-cm752421,In trading on Thursday shares of GlaxoSmithKline plc Symbol GSK crossed above their 200 day moving average of 41 38 changing hands as high as 41 60 per share GlaxoSmithKline plc shares are currently trading up about 1 2 on the day The chart below shows the one year performance of
GSK,GSK:US,BBG000BLB481,Top Ranked Growth Stocks to Buy for February 23rd,2017-02-23 15:12:03 +0000,http://finance.yahoo.com/news/top-ranked-growth-stocks-buy-151203653.html,Top Ranked Growth Stocks to Buy for February 23rd
GSK,GSK:US,BBG000BLB481,Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line,2017-02-23 14:58:02 +0000,http://finance.yahoo.com/news/bayer-bayry-misses-q4-earnings-145802802.html,Bayer (BAYRY) Misses on Q4 Earnings; Revenues in Line
GSK,GSK:US,BBG000BLB481,Positive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma,2017-02-23 10:00:00 +0000,http://finance.yahoo.com/news/positive-results-relvar-ellipta-lung-100000186.html,"[Business Wire] - GlaxoSmithKline plc and Innoviva, Inc. today announced positive headline results from a non-inferiority lung function study, which demonstrated that patients with well-controlled asthma were able to switch to the once-daily Relvar® Ellipta® 100/25, an inhaled corticosteroid /long-acting beta2 agonist combination, from the twice-daily Seretide® Accuhaler® 250/50, without compromising their lung function...."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Reports Positive Resultsfrom Relvar Ellipta Lung Function Study,2017-02-23 05:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aI2F7b6DN1E/glaxosmithkline-reports-positive-resultsfrom-relvar-ellipta-lung-function-study-20170223-00268,GlaxoSmithKline Reports Positive Resultsfrom Relvar Ellipta Lung Function Study
GSK,GSK:US,BBG000BLB481,Pfizer's Leukemia Candidate Gets Priority Review in U.S.,2017-02-23 00:50:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M_MRKdPZ84s/pfizers-leukemia-candidate-gets-priority-review-in-us-cm751705,Pfizer Inc PFE announced that its Biologics License Application BLA for leukemia candidate inotuzumab ozogamicin has been accepted for priority review by the FDA Inotuzumab ozogamicin is being evaluated for the treatment of adult patients with relapsed or refractory B cell precursor
GSK,GSK:US,BBG000BLB481,3 Things Gilead Sciences' CEO Just Said That You'll Want to Know,2017-02-22 22:51:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mdnZgkahpHw/3-things-gilead-sciences-ceo-just-said-that-youll-want-to-know-cm751674,When John Milligan speaks people listen especially if they re Gilead Sciences NASDAQ GILD shareholders The big biotech s CEO and its CFO Robin Washington sat down to field questions at the RBC Capital Markets 2017 Healthcare Conference in New York City on
GSK,GSK:US,BBG000BLB481,Troubling Trial Data Weighed on Agenus Inc Stock Today,2017-02-22 22:49:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HgXG2tZy59Y/troubling-trial-data-weighed-on-agenus-inc-stock-today-cm751656,What happened Shares of Agenus Inc NASDAQ AGEN a biopharmaceutical company developing cancer therapies had fallen about 14 5 as of 3 20 p m EST on Wednesday Investors weren t too thrilled about its cancer vaccine s recent clinical trial failure So what The
GSK,GSK:US,BBG000BLB481,Pfizer's Leukemia Candidate Gets Priority Review in U.S.,2017-02-22 22:08:10 +0000,http://finance.yahoo.com/news/pfizers-leukemia-candidate-gets-priority-220810266.html,Pfizer's Leukemia Candidate Gets Priority Review in U.S.
GSK,GSK:US,BBG000BLB481,"Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs",2017-02-22 21:31:19 +0000,http://www.investors.com/news/technology/gilead-gsk-pitted-in-hiv-battle-both-struggle-vs-standard-drugs/,"Gilead, Glaxo Pitted In HIV Battle; Both Struggle Vs. Standard Drugs"
GSK,GSK:US,BBG000BLB481,"Biotech: What's Next For Gilead, Glaxo, and Merck HIV Treatments",2017-02-22 17:42:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/22/biotech-whats-next-for-gilead-glaxo-and-merck-hiv-treatments/?mod=yahoobarrons&ru=yahoo,"Biotech: What's Next For Gilead, Glaxo, and Merck HIV Treatments"
GSK,GSK:US,BBG000BLB481,Korn Ferry Futurestep Partners with GlaxoSmithKline to Support Talent Acquisition,2017-02-21 18:38:00 +0000,http://finance.yahoo.com/news/korn-ferry-futurestep-partners-glaxosmithkline-183800948.html,"[Business Wire] - Futurestep division of Korn Ferry , the preeminent global people and organisational advisory firm, has been appointed by GlaxoSmithKline , one of the world's largest science-led global healthcare companies, to provide a Flexible Delivery Solution for recruitment support across the United Kingdom, United States and Latin America."
GSK,GSK:US,BBG000BLB481,"If You Want Yield, Look to the UK",2017-02-20 03:14:22 +0000,http://finance.yahoo.com/news/want-yield-look-uk-031422768.html,"If You Want Yield, Look to the UK"
GSK,GSK:US,BBG000BLB481,2 High-Yield Dividend Stocks That Are Ridiculously Cheap,2017-02-18 18:53:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lc05pSs3qWE/2-high-yield-dividend-stocks-that-are-ridiculously-cheap-cm750041,If you re looking for high quality dividend stocks that pay a better than average yield the pharmaceutical industry is definitely worth checking out Because of the political turmoil surrounding drug prices after all numerous pharma stocks are presently trading at
GSK,GSK:US,BBG000BLB481,2 High-Yield Dividend Stocks That Are Ridiculously Cheap,2017-02-18 17:09:32 +0000,http://www.fool.com/investing/2017/02/18/2-high-yield-dividend-stocks-that-are-ridiculously.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 High-Yield Dividend Stocks That Are Ridiculously Cheap
GSK,GSK:US,BBG000BLB481,Inside Sanofi’s Revenues in 4Q16,2017-02-17 21:46:44 +0000,http://marketrealist.com/2017/02/inside-sanofis-revenues-in-4q16/?utm_source=yahoo&utm_medium=feed,Inside Sanofi’s Revenues in 4Q16
GSK,GSK:US,BBG000BLB481,Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Is Turning Around,2017-02-17 20:54:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H-QVWdYjaQ8/teva-pharmaceutical-industries-ltd-adr-teva-is-turning-around-cm749851,InvestorPlace Stock Market News Stock Advice amp Trading Tips Teva Pharmaceutical Industries Ltd ADR 160 NYSE TEVA has been dealing with a lot challenges over the past 12 18 months Source Open Grid Scheduler Modified It has been trying to incorporate its
GSK,GSK:US,BBG000BLB481,"Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View",2017-02-17 20:52:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZnWcegqUYUY/shire-shpg-beats-on-q4-earnings-sales-gives-upbeat-view-cm749789,Shire plc SHPG reported fourth quarter 2016 earnings of 3 37 per American Depositary Share ADS beating the Zacks Consensus Estimate of 3 25 and down from the year ago tally of 2 97 Revenues on the other hand surged 121 8 to 3 8 billion and beat the Zacks Consensus Estimate of 3
GSK,GSK:US,BBG000BLB481,"Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View",2017-02-17 19:04:07 +0000,http://finance.yahoo.com/news/shire-shpg-beats-q4-earnings-190407809.html,"Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View"
GSK,GSK:US,BBG000BLB481,Could BP plc and GlaxoSmithKline plc help you retire early?,2017-02-17 16:15:26 +0000,http://uk.finance.yahoo.com/news/could-bp-plc-glaxosmithkline-plc-161526491.html,Could BP plc and GlaxoSmithKline plc help you retire early?
GSK,GSK:US,BBG000BLB481,"Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook",2017-02-16 23:54:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5B9iR-TqOug/zoetis-zts-beats-q4-earnings-estimates-lowers-outlook-cm749278,Zoetis Inc ZTS fourth quarter 2016 earnings of 47 cents per share surpassed the Zacks Consensus Estimate of 45 cents Earnings were also up from 43 cents reported in the year ago period Total revenue growth was relatively flat year over year at 1 28 billion in fourth quarter 2016 in
GSK,GSK:US,BBG000BLB481,"Alkermes (ALKS) Q4 Loss Narrower than Expectations, Sales Beat",2017-02-16 22:55:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l2kOwCDSJo8/alkermes-alks-q4-loss-narrower-than-expectations-sales-beat-cm749226,Alkermes plc ALKS reported loss of 4 cents per share including the impact of share based compensation expense in the fourth quarter of 2016 narrower than the Zacks Consensus Estimate of a loss of 19 cents The reported loss was however narrower than the year ago loss of 34 cents
GSK,GSK:US,BBG000BLB481,"Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y",2017-02-16 22:54:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZD47EscK3gY/alexion-alxn-q4-earnings-in-line-sales-rise-yy-cm749218,Alexion Pharmaceuticals Inc s ALXN fourth quarter 2016 earnings including stock based compensation expense of 1 10 cents per share compared with the year ago earnings of 78 cents Earnings were in line with the Zacks Consensus Estimate of 1 10 Revenues on the other hand rose 19
GSK,GSK:US,BBG000BLB481,"Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook",2017-02-16 21:25:09 +0000,http://finance.yahoo.com/news/zoetis-zts-beats-q4-earnings-212509353.html,"Zoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook"
GSK,GSK:US,BBG000BLB481,"Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y",2017-02-16 21:19:09 +0000,http://finance.yahoo.com/news/alexion-alxn-q4-earnings-line-211909291.html,"Alexion (ALXN) Q4 Earnings In-Line, Sales Rise Y/Y"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Valuation Compared to Its Peers,2017-02-16 14:05:53 +0000,http://marketrealist.com/2017/02/glaxosmithklines-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Valuation Compared to Its Peers
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16,2017-02-16 12:35:58 +0000,http://marketrealist.com/2017/02/glaxosmithklines-consumer-healthcare-reports-growth-in-4q16/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16
GSK,GSK:US,BBG000BLB481,3 hot dividend stocks I’d buy in March,2017-02-16 10:33:46 +0000,http://uk.finance.yahoo.com/news/3-hot-dividend-stocks-d-103346040.html,3 hot dividend stocks I’d buy in March
GSK,GSK:US,BBG000BLB481,British Blue Chips Snub Investor Calls to Show CEO Pay Ratio,2017-02-16 08:29:24 +0000,http://www.bloomberg.com/news/articles/2017-02-16/british-blue-chips-snub-investor-calls-to-reveal-ceo-pay-ratios?cmpid=yhoo.headline,British Blue Chips Snub Investor Calls to Show CEO Pay Ratio
GSK,GSK:US,BBG000BLB481,"AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates",2017-02-15 16:55:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ypyywPRg92w/amag-pharma-amag-incurs-loss-in-q4-revenues-lag-estimates-cm748317,AMAG Pharmaceuticals Inc AMAG reported adjusted earnings of 1 36 per share in the fourth quarter of 2016 up from 1 04 in the year ago quarter Moreover including one time and special items reported loss was 31 cents per share in the fourth quarter of 2016 against profit of 21 cents in
GSK,GSK:US,BBG000BLB481,"Drug Stocks Q4 Earnings Slated for Feb 16: ALXN, ZTS & More",2017-02-15 15:58:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aAFdX6KF4O4/drug-stocks-q4-earnings-slated-for-feb-16-alxn-zts-more-cm748281,The Q4 earnings season is on its last legs as results from 358 S amp P 500 members or 71 6 of the index s total membership is already out As of Feb 15 2017 358 S amp P 500 members that account for 81 2 of the index s total market capitalization have reported results according to the
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16,2017-02-15 15:36:29 +0000,http://marketrealist.com/2017/02/glaxosmithklines-vaccines-business-reported-growth-in-4q16/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16
GSK,GSK:US,BBG000BLB481,"AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates",2017-02-15 15:08:03 +0000,http://finance.yahoo.com/news/amag-pharma-amag-incurs-loss-150803626.html,"AMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s HIV Business in 4Q16,2017-02-15 12:37:29 +0000,http://marketrealist.com/2017/02/glaxosmithklines-hiv-business-in-4q16/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s HIV Business in 4Q16
GSK,GSK:US,BBG000BLB481,Gilead (GILD) Announces Data on Combination Therapy for HIV,2017-02-14 23:17:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pTiMuj31wIE/gilead-gild-announces-data-on-combination-therapy-for-hiv-cm747948,Gilead Sciences Inc GILD recently announced data from a phase II study The study evaluated the efficacy safety and tolerability of bictegravir 75 mg BIC in combination of emtricitabine tenofovir alafenamide 200 25 mg FTC TAF versus dolutegravir 50 mg DTG
GSK,GSK:US,BBG000BLB481,"ETFs with exposure to GlaxoSmithKline Plc : February 14, 2017",2017-02-14 21:39:59 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-glaxosmithkline-plc-february-14-2017/,"ETFs with exposure to GlaxoSmithKline Plc : February 14, 2017"
GSK,GSK:US,BBG000BLB481,"Gilead HIV Drug Tops GSK Combo, But Rivalry 'Intense' With GSK Doublet",2017-02-14 21:19:45 +0000,http://www.investors.com/news/technology/gilead-hiv-drug-tops-gsk-combo-but-rivalry-intense-with-gsk-doublet/,"Gilead HIV Drug Tops GSK Combo, But Rivalry 'Intense' With GSK Doublet"
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming",2017-02-14 21:18:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IAcJhypQHE0/glaxosmithkline-performance-continues-but-generic-competition-may-finally-be-coming-cm747883,British drugmaker GlaxoSmithKline plc NYSE GSK turned in the latest in a string of good quarters The restructuring set in motion in 2015 continues to take hold and revenue is on the rise But management tamped down the enthusiasm by warning that the long awaited
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming",2017-02-14 20:19:01 +0000,http://www.fool.com/investing/2017/02/14/glaxosmithkline-performance-continues-but-generic.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"GlaxoSmithKline Performance Continues, but Generic Competition May Finally Be Coming"
GSK,GSK:US,BBG000BLB481,Performance of GlaxoSmithKline’s Pharmaceuticals Segment in 4Q16,2017-02-14 20:05:43 +0000,http://marketrealist.com/2017/02/performance-of-glaxosmithklines-pharmaceuticals-segment-in-4q16/?utm_source=yahoo&utm_medium=feed,Performance of GlaxoSmithKline’s Pharmaceuticals Segment in 4Q16
GSK,GSK:US,BBG000BLB481,4Q16 Performance of GlaxoSmithKline’s Business Segments,2017-02-14 18:35:43 +0000,http://marketrealist.com/2017/02/4q16-performance-of-glaxosmithklines-business-segments/?utm_source=yahoo&utm_medium=feed,4Q16 Performance of GlaxoSmithKline’s Business Segments
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline PLC (ADR) (GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake,2017-02-14 17:10:20 +0000,http://www.insidermonkey.com/blog/glaxosmithkline-plc-adr-gsk-two-drug-cocktail-aims-decrease-hiv-patient-pill-intake-552297/,GlaxoSmithKline PLC (ADR) (GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Revenue Trend for 4Q16,2017-02-14 16:46:53 +0000,http://marketrealist.com/2017/02/glaxosmithklines-revenue-trend-for-4q16/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Revenue Trend for 4Q16
GSK,GSK:US,BBG000BLB481,Lilly's Olumiant Gets Marketing Authorization in Europe,2017-02-14 16:21:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7u1obRM1WQA/lillys-olumiant-gets-marketing-authorization-in-europe-cm747595,Eli Lilly and Company LLY along with its partner Incyte Corporation INCY announced that the European Commission has granted marketing authorization to once daily baricitinib in Europe for the treatment of adults with moderate to severe active rheumatoid arthritis RA 160 The drug will
GSK,GSK:US,BBG000BLB481,Gilead Sciences: Not Out of the Woods Yet?,2017-02-14 16:17:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/14/gilead-sciences-not-out-of-the-woods-yet/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: Not Out of the Woods Yet?
GSK,GSK:US,BBG000BLB481,Lilly's Olumiant Gets Marketing Authorization in Europe,2017-02-14 14:32:02 +0000,http://finance.yahoo.com/news/lillys-olumiant-gets-marketing-authorization-143202479.html,Lilly's Olumiant Gets Marketing Authorization in Europe
GSK,GSK:US,BBG000BLB481,Gilead challenges GSK with strong HIV drug data,2017-02-14 08:52:04 +0000,http://sg.finance.yahoo.com/news/gilead-challenges-gsk-strong-hiv-085204001.html,Gilead challenges GSK with strong HIV drug data
GSK,GSK:US,BBG000BLB481,9 Top Pharmaceutical Stocks to Buy for the Dividends,2017-02-14 04:17:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vOX7JeqtEYM/9-top-pharmaceutical-stocks-to-buy-for-the-dividends-cm747392,InvestorPlace Stock Market News Stock Advice amp Trading Tips When investors are on the hunt for income driving dividend stocks they often gravitate toward utilities or consumer staples names And well they should Those businesses are essentially recession proof so the income in
GSK,GSK:US,BBG000BLB481,GSK: ViiV Healthcare Shows Positive Study Results For Two-drug Regimen For HIV,2017-02-14 02:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C-EST0XPqS8/gsk-viiv-healthcare-shows-positive-study-results-for-twodrug-regimen-for-hiv-20170214-00080,GSK: ViiV Healthcare Shows Positive Study Results For Two-drug Regimen For HIV
GSK,GSK:US,BBG000BLB481,"Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference",2017-02-14 01:40:00 +0000,https://www.thestreet.com/story/14000534/1/gilead-and-good-news-make-a-rare-joint-appearance-at-hiv-conference.html?puc=yahoo&cm_ven=YAHOO,"Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference"
GSK,GSK:US,BBG000BLB481,PRESS DIGEST- Financial Times - Feb 14,2017-02-14 00:55:42 +0000,http://finance.yahoo.com/news/press-digest-financial-times-feb-005542789.html,PRESS DIGEST- Financial Times - Feb 14
GSK,GSK:US,BBG000BLB481,[$$] GSK claims new HIV combination therapy will be 'less harmful',2017-02-13 23:45:58 +0000,"http://www.ft.com/cms/s/c3a90b3c-f20c-11e6-95ee-f14e55513608,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - GlaxoSmithKline claimed that its new HIV treatment would be ""less harmful and less hassle"" than current therapies, as it unveiled clinical trial results for a two-drug cocktail designed to reduce ..."
GSK,GSK:US,BBG000BLB481,"Can Gilead Swivel To HIV Amid Floundering Hep C Sales, GSK Rivalry?",2017-02-13 21:25:44 +0000,http://www.investors.com/news/technology/can-gilead-swivel-to-hiv-amid-floundering-hep-c-sales-gsk-rivalry/,"Can Gilead Swivel To HIV Amid Floundering Hep C Sales, GSK Rivalry?"
GSK,GSK:US,BBG000BLB481,Analysts See 18% Gains Ahead For The Holdings of PPH,2017-02-13 16:20:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GYPOvYrPr44/analysts-see-18-gains-ahead-for-the-holdings-of-pph-cm746963,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017",2017-02-13 15:41:17 +0000,http://www.capitalcube.com/blog/index.php/glaxosmithkline-plc-gsk-us-earnings-analysis-2016-by-the-numbers-february-13-2017/,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017"
GSK,GSK:US,BBG000BLB481,Don’t take 1.15% from Premium Bonds when these 2 income stocks pay over 5%,2017-02-13 07:30:53 +0000,http://uk.finance.yahoo.com/news/don-t-1-15-premium-073053845.html,Don’t take 1.15% from Premium Bonds when these 2 income stocks pay over 5%
GSK,GSK:US,BBG000BLB481,Pharmaceutical ETF Experiences Big Inflow,2017-02-10 17:17:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5GJSjpw6n2c/pharmaceutical-etf-experiences-big-inflow-cm746340,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 66 7 million dollar inflow that s a 28 8 increase week over week in outstanding units
GSK,GSK:US,BBG000BLB481,Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017,2017-02-10 16:09:55 +0000,http://ir.baystreet.ca/article.aspx?id=475&1486742995,Actinium Pharmaceuticals (ATNM) has Considerable Potential in 2017
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi",2017-02-10 14:20:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UTFQRQy9O5I/pharma-stock-roundup-allergan-gsk-top-4q-earnings-praluent-breather-for-sanofi-cm746062,Major pharma companies like Allergan AGN and GlaxoSmithKline GSK reported better than expected fourth quarter results this week Meanwhile French pharma giant Sanofi SNY got a breather in the PCSK9 inhibitor patent infringement lawsuit with a court allowing the company to continue selling
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017",2017-02-10 14:06:01 +0000,http://www.capitalcube.com/blog/index.php/glaxosmithkline-plc-gsk-us-earnings-analysis-q4-2016-by-the-numbers-february-10-2017/,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017"
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi",2017-02-10 11:44:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-allergan-gsk-114411776.html,"Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi"
GSK,GSK:US,BBG000BLB481,Is this the most undervalued stock on the FTSE 100 today?,2017-02-10 07:20:39 +0000,http://uk.finance.yahoo.com/news/most-undervalued-stock-ftse-100-072039652.html,Is this the most undervalued stock on the FTSE 100 today?
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View",2017-02-09 18:19:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2rDh7poyDb0/glaxo-gsk-beats-on-q4-earnings-posts-dismal-17-view-cm745674,GlaxoSmithKline s GSK fourth quarter beat estimates but the outlook for 2017 was weak amid a potential entry of generics for Advair Glaxo reported fourth quarter 2016 core earnings of 0 70 per American Depositary Share ADS beating the Zacks Consensus Estimate of 0 57 Core earnings
GSK,GSK:US,BBG000BLB481,Gilead to Battle GlaxoSmithKline for HIV Cure,2017-02-09 17:58:00 +0000,http://www.investopedia.com/news/gilead-glaxosmithkline-race-hiv-cure-gildgsk/?partner=YahooSA,Gilead to Battle GlaxoSmithKline for HIV Cure
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View",2017-02-09 15:36:03 +0000,http://finance.yahoo.com/news/glaxo-gsk-beats-q4-earnings-153603977.html,"Glaxo (GSK) Beats on Q4 Earnings, Posts Dismal '17 View"
GSK,GSK:US,BBG000BLB481,Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now,2017-02-09 15:21:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JymZOcKnaXw/sanofi-sny-q4-earnings-in-line-can-sell-praulent-for-now-cm745382,Sanofi SNY reported fourth quarter 2016 earnings of 67 cents per American depositary share which were in line with the Zacks Consensus Estimate Earnings declined 4 6 on a reported basis and 1 5 at constant currency rates CER Fourth quarter 2016 net sales rose 3 3 on
GSK,GSK:US,BBG000BLB481,PRESS DIGEST- British Business - Feb 9,2017-02-09 01:30:20 +0000,http://finance.yahoo.com/news/press-digest-british-business-feb-013020472.html,PRESS DIGEST- British Business - Feb 9
GSK,GSK:US,BBG000BLB481,"Allergan Leads Drug Stocks On View-Crushing Q4, 2016, 2017 Guidance",2017-02-08 21:21:27 +0000,http://www.investors.com/news/technology/allergan-leads-drug-stocks-on-view-crushing-q4-2016-2017-guidance/,"Allergan Leads Drug Stocks On View-Crushing Q4, 2016, 2017 Guidance"
GSK,GSK:US,BBG000BLB481,[$$] GSK beats forecasts but braces for asthma drug challenge,2017-02-08 18:30:17 +0000,"http://www.ft.com/cms/s/ff80a2cc-ee02-11e6-930f-061b01e23655,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - GlaxoSmithKline full-year results exceeded market expectations on Wednesday, allowing Sir Andrew Witty to end his near decade-long tenure at the helm of the UK's biggest drugmaker on a relatively strong ..."
GSK,GSK:US,BBG000BLB481,Gilead: Where's the Bottom?,2017-02-08 18:28:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/08/gilead-wheres-the-bottom/?mod=yahoobarrons&ru=yahoo,Gilead: Where's the Bottom?
GSK,GSK:US,BBG000BLB481,FTSE 100 ekes out a slight gain ahead of key Brexit vote,2017-02-08 17:22:43 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=47839218-EDD2-11E6-A511-11CD4998B6A5&siteid=yhoof2,"[at MarketWatch] - U.K. stocks end little-changed on Wednesday, with traders appearing to be avoiding big bets as they watch for a final vote in parliament on a key Brexit bill."
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y",2017-02-08 17:22:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BqMIFtKk49A/glaxo-gsk-misses-q4-earnings-revenues-rise-yy-cm744971,GlaxoSmithKline plc GSK one of the largest health care companies reshaped its business following the Mar 2015 completion of the three part inter conditional transaction with Novartis related to its Consumer Healthcare Vaccines and Oncology businesses This UK based company now focuses
GSK,GSK:US,BBG000BLB481,"Vaccine Sales Help GSK Results, Shares Up",2017-02-08 17:22:00 +0000,http://www.investopedia.com/news/glaxosmithkline-slightly-after-results-gsk/?partner=YahooSA,"Vaccine Sales Help GSK Results, Shares Up"
GSK,GSK:US,BBG000BLB481,"Strong Q4 Earnings Ahead of the Bell: TWX, GSK, ALK",2017-02-08 17:21:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iddLO53uGLQ/strong-q4-earnings-ahead-of-the-bell-twx-gsk-alk-cm744956,Wednesday February 8 2017 A slew of new Q4 earnings reports hit the tape this morning covering a wide range of industries from pharma to airlines to media Included among these are some buy rated companies according to our trusted Zacks Rank including GlaxoSmithKline GSK
GSK,GSK:US,BBG000BLB481,GSK warns profits to be hit by generic drugs competition,2017-02-08 16:57:15 +0000,http://sg.finance.yahoo.com/news/gsk-warns-profits-hit-generic-165715188.html,GSK warns profits to be hit by generic drugs competition
GSK,GSK:US,BBG000BLB481,[$$] GlaxoSmithKline Warns of Hit From Advair Copycat,2017-02-08 16:54:52 +0000,https://www.wsj.com/articles/glaxosmithkline-shares-fall-on-advair-copycat-warning-1486563777?mod=yahoo_hs,[$$] GlaxoSmithKline Warns of Hit From Advair Copycat
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline and Gilead to face off at HIV meeting next week,2017-02-08 16:50:39 +0000,http://finance.yahoo.com/news/glaxosmithkline-gilead-face-off-hiv-165039039.html,GlaxoSmithKline and Gilead to face off at HIV meeting next week
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline and Gilead to face off at HIV meeting next week,2017-02-08 16:50:37 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-gilead-face-off-hiv-165037934.html,GlaxoSmithKline and Gilead to face off at HIV meeting next week
GSK,GSK:US,BBG000BLB481,Are shares in GlaxoSmithKline plc now in bargain territory?,2017-02-08 15:40:00 +0000,http://uk.finance.yahoo.com/news/shares-glaxosmithkline-plc-now-bargain-154000363.html,Are shares in GlaxoSmithKline plc now in bargain territory?
GSK,GSK:US,BBG000BLB481,GW Pharma (GWPH) Posts Narrower-than-Expected Loss in Q1,2017-02-08 15:21:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pEEwWq4SJBw/gw-pharma-gwph-posts-narrower-than-expected-loss-in-q1-cm744858,GW Pharmaceuticals plc GWPH reported first quarter fiscal 2017 loss of 77 cents per share much narrower than both the Zacks Consensus Estimate of a loss of 1 35 and the year ago figure of 82 cents The company s shares gained 4 6 following the release of first quarter fiscal
GSK,GSK:US,BBG000BLB481,Amgen's Secondary Hyperparathyroidism Drug Approved in U.S.,2017-02-08 15:21:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NOkk6--Ko-A/amgens-secondary-hyperparathyroidism-drug-approved-in-us-cm744857,Amgen Inc AMGN announced that the FDA has approved Parsabiv etelcalcetide for the treatment of secondary hyperparathyroidism HPT in adult patients with chronic kidney disease CKD on hemodialysis Parsabiv is the first therapy in 12 years to be approved for this condition The drug has
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y",2017-02-08 14:51:02 +0000,http://finance.yahoo.com/news/glaxo-gsk-misses-q4-earnings-145102422.html,"Glaxo (GSK) Misses Q4 Earnings, Revenues Rise Y/Y"
GSK,GSK:US,BBG000BLB481,"GSK CEO on Drug Pricing, Regulation, Succession",2017-02-08 14:47:40 +0000,http://finance.yahoo.com/video/gsk-ceo-drug-pricing-regulation-144740502.html,"GSK CEO on Drug Pricing, Regulation, Succession"
GSK,GSK:US,BBG000BLB481,Weak pound buoys GSK but drugmaker warns on 2017 generic threat,2017-02-08 13:50:40 +0000,http://sg.finance.yahoo.com/news/weak-pound-buoys-gsk-drugmaker-123946648.html,Weak pound buoys GSK but drugmaker warns on 2017 generic threat
GSK,GSK:US,BBG000BLB481,Glaxo posts 4Q profit,2017-02-08 13:48:58 +0000,http://sg.finance.yahoo.com/news/glaxo-posts-4q-profit-133548770.html,Glaxo posts 4Q profit
GSK,GSK:US,BBG000BLB481,GSK CEO: US health-care system could benefit from more tr...,2017-02-08 13:17:00 +0000,http://finance.yahoo.com/video/gsk-ceo-us-health-care-131700745.html,GSK CEO: US health-care system could benefit from more tr...
GSK,GSK:US,BBG000BLB481,GSK beats Street on top and bottom line,2017-02-08 13:16:00 +0000,http://finance.yahoo.com/video/gsk-beats-street-top-bottom-131600956.html,GSK beats Street on top and bottom line
GSK,GSK:US,BBG000BLB481,GSK warns profits to be hit by generic drugs competition,2017-02-08 13:09:46 +0000,http://finance.yahoo.com/news/gsk-warns-profits-hit-generic-drugs-competition-130937873--finance.html,GSK warns profits to be hit by generic drugs competition
GSK,GSK:US,BBG000BLB481,Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns,2017-02-08 12:31:00 +0000,https://www.thestreet.com/story/13994061/1/glaxo-beats-expectations-for-q4-earnings-shares-fall-on-advair-concerns.html?puc=yahoo&cm_ven=YAHOO,Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns
GSK,GSK:US,BBG000BLB481,CEO Witty will leave GSK on a high: Novasecta,2017-02-08 06:28:00 +0000,http://finance.yahoo.com/video/ceo-witty-leave-gsk-high-062800764.html,CEO Witty will leave GSK on a high: Novasecta
GSK,GSK:US,BBG000BLB481,"Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More",2017-02-07 16:23:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pPEt0dlJZec/drug-stock-q4-earnings-to-watch-on-feb-8-agn-gsk-more-cm744195,We are in the thick of the Q4 reporting cycle with quarterly numbers of several companies already on board Growth is likely to be the highest in two years Total earnings may even set a new quarterly record Approximately 275 S amp P 500 members representing 55 of the index s total
GSK,GSK:US,BBG000BLB481,"Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc.",2017-02-07 14:45:20 +0000,http://www.fool.com/investing/2017/02/06/better-buy-agenus-inc-vs-alnylam-pharmaceuticals-i.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc."
GSK,GSK:US,BBG000BLB481,"Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More",2017-02-07 14:06:02 +0000,http://finance.yahoo.com/news/drug-stock-q4-earnings-watch-140602999.html,"Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More"
GSK,GSK:US,BBG000BLB481,Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus,2017-02-07 13:53:00 +0000,https://www.thestreet.com/story/13992272/1/earnings-preview-glaxosmithkline-likely-to-see-currency-boost-advair-sales-in-focus.html?puc=yahoo&cm_ven=YAHOO,Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus
GSK,GSK:US,BBG000BLB481,Better Buy: Merck & Co. Inc. vs. GlaxoSmithKline,2017-02-07 13:18:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wY8cCMm9L4w/better-buy-merck-co-inc-vs-glaxosmithkline-cm743975,They re two of the biggest pharmaceutical companies in the world but Merck NYSE MRK and GlaxoSmithKline NYSE GSK have had very different paths lately While Merck s stock is up close to 30 over the last 12 months shares of GlaxoSmithKline have declined Which is
GSK,GSK:US,BBG000BLB481,Better Buy: Merck & Co. Inc. vs. GlaxoSmithKline,2017-02-07 12:16:49 +0000,http://www.fool.com/investing/2017/02/07/better-buy-merck-co-inc-vs-glaxosmithkline.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Merck & Co. Inc. vs. GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,"Better Buy: Agenus Inc. vs. Alnylam Pharmaceuticals, Inc.",2017-02-06 16:19:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nN9vHYf5ODQ/better-buy-agenus-inc-vs-alnylam-pharmaceuticals-inc-cm743584,Agenus NASDAQ AGEN and Alnylam Pharmaceuticals NASDAQ ALNY are both clinical stage biotechs developing drugs that hold the potential to make a big difference for patients Shares of both companies have dropped dramatically since October Which biotech stock is now the
GSK,GSK:US,BBG000BLB481,Merck???s Keytruda Gets Priority Review for Bladder Cancer,2017-02-06 14:17:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SkPm72X343I/mercks-keytruda-gets-priority-review-for-bladder-cancer-cm743496,Merck amp Co Inc s MRK two supplemental Biologics License Applications sBLA for its anti PD 1 therapy Keytruda have been accepted under priority review by the FDA This time the company is looking to expand the label of Keytruda for the treatment of patients with locally advanced
GSK,GSK:US,BBG000BLB481,"New GlaxoSmithKline CEO prepares for R&D choices, potential deals",2017-02-06 12:59:16 +0000,http://sg.finance.yahoo.com/news/glaxosmithkline-ceo-prepares-r-d-125718160.html,"New GlaxoSmithKline CEO prepares for R&D choices, potential deals"
GSK,GSK:US,BBG000BLB481,2 FTSE 100 stocks I’d buy in February and 1 I’d sell,2017-02-06 12:58:02 +0000,http://uk.finance.yahoo.com/news/2-ftse-100-stocks-d-125802675.html,2 FTSE 100 stocks I’d buy in February and 1 I’d sell
GSK,GSK:US,BBG000BLB481,"Brexit Already Having a Negative Impact, Business Leaders Say",2017-02-06 11:22:00 +0000,https://www.thestreet.com/story/13990535/1/brexit-already-having-a-negative-impact-business-leaders-say.html?puc=yahoo&cm_ven=YAHOO,"Brexit Already Having a Negative Impact, Business Leaders Say"
GSK,GSK:US,BBG000BLB481,"GSK North American president: Health care spending in N.C. will crowd out education, transportation needs",2017-02-03 21:30:21 +0000,http://www.bizjournals.com/triangle/news/2017/02/03/gsk-north-american-president-health-care-spending.html?ana=yahoo,"GSK North American president: Health care spending in N.C. will crowd out education, transportation needs"
GSK,GSK:US,BBG000BLB481,2 dividends I’d buy before Vodafone Group plc,2017-02-03 15:10:26 +0000,http://uk.finance.yahoo.com/news/2-dividends-d-buy-vodafone-151026281.html,2 dividends I’d buy before Vodafone Group plc
GSK,GSK:US,BBG000BLB481,Why the Majority of Analysts Deem Novartis a ‘Buy’,2017-02-03 14:06:16 +0000,http://marketrealist.com/2017/02/why-the-majority-of-analysts-deem-novartis-a-buy/?utm_source=yahoo&utm_medium=feed,Why the Majority of Analysts Deem Novartis a ‘Buy’
GSK,GSK:US,BBG000BLB481,"Advair, Armonair From Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets FDA Approval",2017-02-02 16:03:31 +0000,http://www.insidermonkey.com/blog/advair-armonair-from-teva-pharmaceutical-industries-ltd-adr-teva-gets-fda-approval-530510/,"Advair, Armonair From Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets FDA Approval"
GSK,GSK:US,BBG000BLB481,Ignore Gilead Sciences Inc.: Here Are 2 Better Stocks,2017-02-02 15:53:56 +0000,http://www.fool.com/investing/2017/02/02/ignore-gilead-sciences-inc-here-are-2-better-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Ignore Gilead Sciences Inc.: Here Are 2 Better Stocks
GSK,GSK:US,BBG000BLB481,Ignore Gilead Sciences Inc.: Here Are 2 Better Stocks,2017-02-02 15:35:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uOBVjTxW5s8/ignore-gilead-sciences-inc-here-are-2-better-stocks-cm742147,Because of the anemic outlook for its hepatitis C franchise and recent clinical setbacks Gilead Sciences NASDAQ GILD may not be the outright bargain that its rock bottom forward price to earnings ratio of about seven would seem to indicate In fact Pfizer NYSE PFE
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?,2017-02-02 13:34:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VuCl5k6L758/glaxosmithkline-gsk-q4-earnings-whats-in-the-cards-cm741985,GlaxoSmithKline plc GSK is scheduled to report fourth quarter 2016 and full year results on Feb 8 Last quarter the company delivered a positive earnings surprise of 7 79 Glaxo s share price was up 2 4 this year so far outperforming the 0 6 decline witnessed by the Zacks
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?,2017-02-02 11:42:11 +0000,http://finance.yahoo.com/news/glaxosmithkline-gsk-q4-earnings-whats-114211770.html,GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?
GSK,GSK:US,BBG000BLB481,Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16,2017-02-01 20:05:43 +0000,http://marketrealist.com/2017/02/weighing-the-foreign-exchange-impact-on-novartiss-revenues-in-4q16/?utm_source=yahoo&utm_medium=feed,Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16
GSK,GSK:US,BBG000BLB481,Pharmaceutical ETF Experiences Big Outflow,2017-02-01 17:31:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FpBHpO9uXdU/pharmaceutical-etf-experiences-big-outflow-cm741625,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 28 7 million dollar outflow that s a 9 9 decrease week over week from 5 538 138
GSK,GSK:US,BBG000BLB481,"Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys",2017-02-01 14:34:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PCmmYD-cZnQ/forget-celldex-therapeutics-inc-these-2-stocks-are-better-buys-cm741322,If ultra high risk high reward biotech stocks are your thing then Celldex Therapeutics NASDAQ CLDX is probably on your radar right now This beaten down biotech stock after all could blast northward in a hurry if its experimental 160 triple negative breast
GSK,GSK:US,BBG000BLB481,Merck Keytruda Gets EU Approval for First-Line Lung Cancer,2017-02-01 13:31:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_AHtvJrgM6s/merck-keytruda-gets-eu-approval-for-first-line-lung-cancer-cm741323,Merck amp Co Inc MRK announced that its anti PD 1 therapy Keytruda has been approved by the European Commission for the first line treatment of adult patients with metastatic non small cell lung cancer NSCLC In Aug 2016 Keytruda was approved in the EU for the second line treatment
GSK,GSK:US,BBG000BLB481,Healthcare Names Rally as Pharma Meets with Trump,2017-01-31 16:29:00 +0000,http://www.investopedia.com/news/trump-meets-pharma-ceos-stocks-pop-pfe-lly/?partner=YahooSA,Healthcare Names Rally as Pharma Meets with Trump
GSK,GSK:US,BBG000BLB481,Trump says drug prices are 'astronomical',2017-01-31 14:48:07 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=A18FAF41-1B41-4FB3-A3D2-8DA9D94CCCC3&siteid=yhoof2,Trump says drug prices are 'astronomical'
GSK,GSK:US,BBG000BLB481,How a 300-Year Old Drug Company Is Changing the World,2017-01-31 14:33:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EJNaH2lXlVE/how-a-300-year-old-drug-company-is-changing-the-world-cm740625,GlaxoSmithKline plc NYSE GSK traces its roots back to a London apothecary in 1715 But when Fortune Magazine compiled its Change the World list the top 50 companies that are making money by tackling society s biggest problems the venerable British drugmaker beat out all
GSK,GSK:US,BBG000BLB481,How a 300-Year Old Drug Company Is Changing the World,2017-01-31 13:28:08 +0000,http://www.fool.com/investing/2017/01/31/how-a-300-year-old-drug-company-is-changing-the-wo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How a 300-Year Old Drug Company Is Changing the World
GSK,GSK:US,BBG000BLB481,"As Teva wins U.S. approval for GSK Advair copy, main fight yet to come",2017-01-30 16:33:32 +0000,http://sg.finance.yahoo.com/news/teva-wins-u-approval-gsk-163332660.html,"As Teva wins U.S. approval for GSK Advair copy, main fight yet to come"
GSK,GSK:US,BBG000BLB481,"As Teva wins US approval for GSK Advair copy, main fight yet to come",2017-01-30 16:24:50 +0000,http://uk.finance.yahoo.com/news/teva-wins-us-approval-gsk-162450130.html,"[Reuters - UK Focus] - Israel's Teva Pharmaceutical Industries has won U.S. approval to market a copy of GlaxoSmithKline (Other OTC: GLAXF - news) 's best-selling Advair inhaler, although the real battle is still to come. Teva's version of GSK's blockbuster medicine, called AirDuo RespiClick, is not directly substitutable for Advair and is only approved for asthma, while Advair is also widely used for chronic obstructive pulmonary disease (COPD)."
GSK,GSK:US,BBG000BLB481,TAF-Based HIV Strategy May Boost Gilead Sciences’s Long-Term Growth,2017-01-30 12:37:46 +0000,http://marketrealist.com/2017/01/taf-based-hiv-strategy-may-contribute-significantly-gilead-sciences-long-term-growth/?utm_source=yahoo&utm_medium=feed,TAF-Based HIV Strategy May Boost Gilead Sciences’s Long-Term Growth
GSK,GSK:US,BBG000BLB481,These 3 income stocks could make you long-term rich,2017-01-30 10:13:30 +0000,http://uk.finance.yahoo.com/news/3-income-stocks-could-long-101330983.html,These 3 income stocks could make you long-term rich
GSK,GSK:US,BBG000BLB481,[$$] Looking for a new chief? Let the office 'Hunger Games' begin,2017-01-30 05:00:27 +0000,"http://www.ft.com/cms/s/e8f2eeb6-e30d-11e6-9645-c9357a75844a,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Chief executive is a highly paid, high-profile role, for which highly motivated pretenders have prepared for years. The only surprise is why anyone is surprised that recruiting a new one often descends ..."
GSK,GSK:US,BBG000BLB481,What’s the Secret Ingredient in That Pizza Crust? Antacid,2017-01-30 04:26:23 +0000,http://www.wsj.com/articles/whats-the-secret-ingredient-in-that-pizza-crust-antacid-1485714201?ru=yahoo?mod=yahoo_itp,"[at The Wall Street Journal] - A bubbling antacid called Eno is intended to relieve upset stomachs, but some use it in recipes, from traditional Indian dishes to Oreo cake."
GSK,GSK:US,BBG000BLB481,Can Novavax Stay Ahead of the Competition?,2017-01-28 21:58:52 +0000,http://www.fool.com/investing/2017/01/27/can-novavax-stay-ahead-of-the-competition.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Can Novavax Stay Ahead of the Competition?
GSK,GSK:US,BBG000BLB481,Can Novavax Stay Ahead of the Competition?,2017-01-27 23:31:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YRtybBvDgMk/can-novavax-stay-ahead-of-the-competition-cm739662,Last September Novavax NASDAQ NVAX stunned investors with a spectacular pivotal trial failure The clinical stage biotech s lead candidate was miles ahead of possible competitors from GlaxoSmithKline NYSE GSK and AstraZeneca NYSE AZN but the upsetting results threw
GSK,GSK:US,BBG000BLB481,2017 Small-Cap Biotech Watchlist: Takeaways for Investors,2017-01-27 22:33:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5-voNMzxd_8/2017-small-cap-biotech-watchlist-takeaways-for-investors-cm739688,Submitted by The Life Sciences Report as part of our contributors program Submitted bySubmitted by The Life Sciences ReportThe Life Sciences Report as part of ouras part of our contributorscontributors programprogram 2017 Small Cap Biotech Watchlist Takeaways
GSK,GSK:US,BBG000BLB481,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint",2017-01-27 11:04:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-110411214.html,"Pharma Stock Roundup: J&J to Buy Actelion, Bristol-Myers' 4Q Results Disappoint"
GSK,GSK:US,BBG000BLB481,"With new Bay Area presence, Singapore fund invests $800M in Alphabet-created Verily",2017-01-26 22:50:09 +0000,http://www.bizjournals.com/sanfrancisco/news/2017/01/26/verily-google-temasek-singapore-fund-alphabet-goog.html?ana=yahoo,"With new Bay Area presence, Singapore fund invests $800M in Alphabet-created Verily"
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline's Dividend Sustainable?,2017-01-26 21:32:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8CpptES9Mzc/is-glaxosmithklines-dividend-sustainable-cm738948,British drugmaker GlaxoSmithKline plc NYSE GSK is one of the top yielding dividend stocks in the medical sector Company management has committed to paying a quarterly dividend through 2017 that amounts to a yield of 4 7 160 at today s exchange rate A rich payout like
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline's Dividend Sustainable?,2017-01-26 20:28:43 +0000,http://www.fool.com/investing/2017/01/26/is-glaxosmithklines-dividend-sustainable.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is GlaxoSmithKline's Dividend Sustainable?
GSK,GSK:US,BBG000BLB481,Alphabet's life science spinoff raises $800M from Singapore investor,2017-01-26 18:30:08 +0000,http://www.bizjournals.com/sanjose/news/2017/01/26/alphabets-life-science-spinoff-raises-800m-from.html?ana=yahoo,Alphabet's life science spinoff raises $800M from Singapore investor
GSK,GSK:US,BBG000BLB481,11 Largest Pharmaceutical Companies In The World,2017-01-26 14:28:39 +0000,http://www.insidermonkey.com/blog/11-largest-pharmaceutical-companies-in-the-world-523960/,11 Largest Pharmaceutical Companies In The World
GSK,GSK:US,BBG000BLB481,"GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000",2017-01-26 11:02:00 +0000,https://www.thestreet.com/story/13967133/1/gm-nike-microsoft-are-hot-now-that-dow-has-hit-20-000.html?puc=yahoo&cm_ven=YAHOO,"GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000"
GSK,GSK:US,BBG000BLB481,"Q4 Earnings Scorecard and Analyst Reports for Tesla, Verizon & Others",2017-01-25 19:31:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QQEOTFRZU68/q4-earnings-scorecard-and-analyst-reports-for-tesla-verizon-others-cm738263,Wednesday January 25 2017 Today s Research Daily features an updated scorecard for the ongoing Q4 earnings season and fresh research reports on 16 major stocks including Verizon VZ and Tesla TSLA To see of all of the 70 or so research reports issued by our analyst team
GSK,GSK:US,BBG000BLB481,"Q4 Earnings Scorecard and Analyst Reports for Tesla, Verizon & Others",2017-01-25 17:08:05 +0000,http://finance.yahoo.com/news/q4-earnings-scorecard-analyst-reports-170805595.html,"Q4 Earnings Scorecard and Analyst Reports for Tesla, Verizon & Others"
GSK,GSK:US,BBG000BLB481,Uh-Oh: This Could Be Johnson & Johnson's Biggest Risk in 2017,2017-01-25 00:31:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ab1L-5zHkIQ/uh-oh-this-could-be-johnson-johnsons-biggest-risk-in-2017-cm737710,Johnson amp Johnson NYSE JNJ released its fourth quarter 2016 financials and the numbers show that the launch of a Remicade biosimilar by Pfizer Inc NYSE PFE could pose a big threat to the company s growth in 2017 Image source Getty Images A massive
GSK,GSK:US,BBG000BLB481,Gilead Sciences Stock: What Could Go Wrong?,2017-01-24 22:32:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rT-Mcp74rJs/gilead-sciences-stock-what-could-go-wrong-cm737646,In the wake of weakening hepatitis C drug revenue and key trial disappointments Gilead Sciences NASDAQ GILD shares have tumbled over the past year Is now a good time to buy Before you decide it could help to understand what risks remain for the company and its
GSK,GSK:US,BBG000BLB481,What Do Analysts Recommend for Johnson & Johnson?,2017-01-24 12:36:01 +0000,http://marketrealist.com/2017/01/what-do-analysts-recommend-for-johnson-johnson/?utm_source=yahoo&utm_medium=feed,What Do Analysts Recommend for Johnson & Johnson?
GSK,GSK:US,BBG000BLB481,Analysts Expect Negative Growth for Novartis in 4Q16,2017-01-23 12:38:52 +0000,http://marketrealist.com/2017/01/analysts-expect-negative-growth-for-novartis-in-4q16/?utm_source=yahoo&utm_medium=feed,Analysts Expect Negative Growth for Novartis in 4Q16
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson,2017-01-22 20:24:13 +0000,http://www.fool.com/investing/2017/01/21/better-buy-glaxosmithkline-plc-vs-johnson-johnson.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline PLC vs. Johnson & Johnson,2017-01-21 21:36:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/goYVctdZjd4/better-buy-glaxosmithkline-plc-vs-johnson-johnson-cm736396,Two big drugmakers have seen their stocks go in opposite directions over the last five years GlaxoSmithKline NYSE GSK shareholders lost more than 10 during the period while Johnson amp Johnson NYSE JNJ shareholders have enjoyed gains of over 75 Which of
GSK,GSK:US,BBG000BLB481,5 Drugs That Are Way Cheaper in Canada,2017-01-21 20:37:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LAI1U5myHdo/5-drugs-that-are-way-cheaper-in-canada-cm736393,A lot of the discussion related to curbing runaway drug prices in the United States has focused on the importation of drugs from neighboring Canada But are drugs really less expensive there Often the answer is yes For instance here are five common medicines that are much cheaper to
GSK,GSK:US,BBG000BLB481,5 Drugs That Are Way Cheaper in Canada,2017-01-21 19:02:06 +0000,http://www.fool.com/investing/2017/01/21/5-drugs-that-are-way-cheaper-in-canada.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,5 Drugs That Are Way Cheaper in Canada
GSK,GSK:US,BBG000BLB481,3 Footsie giants you should consider buying before it’s too late,2017-01-21 08:00:54 +0000,http://uk.finance.yahoo.com/news/3-footsie-giants-consider-buying-080054431.html,3 Footsie giants you should consider buying before it’s too late
GSK,GSK:US,BBG000BLB481,Novartis’s 4Q16 Earnings: What Is Expected?,2017-01-20 22:41:30 +0000,http://marketrealist.com/2017/01/novartiss-4q16-earnings-what-is-expected/?utm_source=yahoo&utm_medium=feed,Novartis’s 4Q16 Earnings: What Is Expected?
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?,2017-01-20 17:38:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v6lthsuY290/is-glaxosmithkline-gsk-a-great-stock-for-value-investors-cm736073,Value investing is easily one of the most popular ways to find great stocks in any market environment After all who wouldn t want to find stocks that are either flying under the radar and are compelling buys or offer up tantalizing discounts when compared to fair value One way to find
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?,2017-01-20 15:00:03 +0000,http://finance.yahoo.com/news/glaxosmithkline-gsk-great-stock-value-150003111.html,Is GlaxoSmithKline (GSK) a Great Stock for Value Investors?
GSK,GSK:US,BBG000BLB481,Why is Pharma Struggling to Grow EPS?,2017-01-19 18:15:00 +0000,http://www.investopedia.com/news/transition-continues-glaxosmithkline-gsk-lly/?partner=YahooSA,Why is Pharma Struggling to Grow EPS?
GSK,GSK:US,BBG000BLB481,Glaxo CEO Seeks Greater Transparency on Drug Pricing,2017-01-19 11:55:29 +0000,http://finance.yahoo.com/video/glaxo-ceo-seeks-greater-transparency-115529402.html,Glaxo CEO Seeks Greater Transparency on Drug Pricing
GSK,GSK:US,BBG000BLB481,GSK grabs Astra executive to replace pharma head,2017-01-19 10:15:34 +0000,http://sg.finance.yahoo.com/news/gsk-grabs-astra-executive-replace-071940361.html,GSK grabs Astra executive to replace pharma head
GSK,GSK:US,BBG000BLB481,GSK grabs Astra executive to replace exiting pharma head,2017-01-19 07:57:36 +0000,http://in.finance.yahoo.com/news/gsk-grabs-astra-executive-replace-075736766.html,GSK grabs Astra executive to replace exiting pharma head
GSK,GSK:US,BBG000BLB481,"Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics",2017-01-18 22:00:00 +0000,http://www.bloomberg.com/news/articles/2017-01-18/ebola-zika-push-drugmakers-to-join-effort-to-avert-pandemics?cmpid=yhoo.headline,"Ebola, Zika Push Drugmakers Into Effort to Avert Pandemics"
GSK,GSK:US,BBG000BLB481,In This Case Silence Could be Golden,2017-01-17 18:38:00 +0000,http://www.investopedia.com/news/healthcare-red-again-pfe-lly/?partner=YahooSA,In This Case Silence Could be Golden
GSK,GSK:US,BBG000BLB481,5 Trump-Proof Pharma Dividend Stocks to Buy,2017-01-17 16:38:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C0k6xbz5rvs/5-trump-proof-pharma-dividend-stocks-to-buy-cm734299,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Donald Trump needed just 20 minutes to knock 24 6 billion in value from the nine biggest Big Pharma companies That was the statistic bandied about recently when the president elect at
GSK,GSK:US,BBG000BLB481,Does this pharma’s 56% sales growth make it a better buy than GlaxoSmithKline plc?,2017-01-17 12:50:21 +0000,http://uk.finance.yahoo.com/news/does-pharma-56-sales-growth-125021524.html,Does this pharma’s 56% sales growth make it a better buy than GlaxoSmithKline plc?
GSK,GSK:US,BBG000BLB481,How Is Novartis’s Revenue Trending?,2017-01-16 15:37:03 +0000,http://marketrealist.com/2017/01/what-are-novartiss-revenue-trends/?utm_source=yahoo&utm_medium=feed,How Is Novartis’s Revenue Trending?
GSK,GSK:US,BBG000BLB481,How Did Novartis Perform in 3Q16?,2017-01-16 14:07:34 +0000,http://marketrealist.com/2017/01/how-did-novartis-perform-in-3q16/?utm_source=yahoo&utm_medium=feed,How Did Novartis Perform in 3Q16?
GSK,GSK:US,BBG000BLB481,5 Trump-Proof Pharma Dividends Up To 5.3%,2017-01-16 13:38:00 +0000,http://www.forbes.com/sites/brettowens/2017/01/16/5-trump-proof-pharma-dividends-up-to-5-3/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,5 Trump-Proof Pharma Dividends Up To 5.3%
GSK,GSK:US,BBG000BLB481,How Does Novartis’s Valuation Compare to Peers?,2017-01-16 12:37:38 +0000,http://marketrealist.com/2017/01/how-does-novartiss-valuation-compare-to-peers/?utm_source=yahoo&utm_medium=feed,How Does Novartis’s Valuation Compare to Peers?
GSK,GSK:US,BBG000BLB481,Two 5% dividend yields you’d be crazy to pass up,2017-01-15 08:20:39 +0000,http://uk.finance.yahoo.com/news/two-5-dividend-yields-d-082039239.html,Two 5% dividend yields you’d be crazy to pass up
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016?,2017-01-14 20:57:15 +0000,http://www.fool.com/investing/2017/01/13/is-glaxosmithklines-stock-a-bargain-after-dropping.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016?
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016?,2017-01-13 22:37:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yItGjeKr5gU/is-glaxosmithklines-stock-a-bargain-after-dropping-48-in-2016-cm733521,Image source Getty Images What happened According to data from S amp P Global Market Intelligence shares of the British pharma giant GlaxoSmithKline NYSE GSK slid by 4 8 in 2016 GSK data by YCharts The drugmaker s woes can
GSK,GSK:US,BBG000BLB481,4 Signs Glaxo's Turnaround Is Taking Hold,2017-01-13 16:40:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lp6ofo5jfAQ/4-signs-glaxos-turnaround-is-taking-hold-cm733298,British healthcare giant GlaxoSmithKline plc NYSE GSK embarked on a major restructuring when it announced a multipart deal with Novartis AG NYSE NVS in 2014 The agreement involved swapping Glaxo s current portfolio of oncology drugs for most of Novartis vaccine assets
GSK,GSK:US,BBG000BLB481,4 Signs Glaxo's Turnaround Is Taking Hold,2017-01-13 14:55:43 +0000,http://www.fool.com/investing/2017/01/13/4-signs-glaxos-turnaround-is-taking-hold.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Signs Glaxo's Turnaround Is Taking Hold
GSK,GSK:US,BBG000BLB481,Implied PPH Analyst Target Price: $64,2017-01-12 15:56:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cxHkT8afl6s/implied-pph-analyst-target-price-64-cm732651,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
GSK,GSK:US,BBG000BLB481,Full Show: What'd You Miss? (01/11),2017-01-12 00:29:33 +0000,http://www.bloomberg.com/news/videos/2017-01-12/full-show-what-d-you-miss-01-11?cmpid=yhoo.headline,Full Show: What'd You Miss? (01/11)
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's Redfern on Drug Pricing,2017-01-11 21:53:51 +0000,http://finance.yahoo.com/video/glaxosmithklines-redfern-drug-pricing-215351887.html,GlaxoSmithKline's Redfern on Drug Pricing
GSK,GSK:US,BBG000BLB481,7 Blue-Chip Dividend Stocks That Are Dead Weight Right Now,2017-01-10 22:50:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6vqHdxRjLRA/7-blue-chip-dividend-stocks-that-are-dead-weight-right-now-cm731927,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips With the likelihood of a trio of rate hikes expected this year dividend stocks have earned a little more than their fair share of bad press See as is the case with bond prices higher interest rates push
GSK,GSK:US,BBG000BLB481,3 Big Reasons (and 8 Smaller Ones) to Buy Ionis Pharmaceuticals Stock,2017-01-10 16:54:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FEyk7s7HQNU/3-big-reasons-and-8-smaller-ones-to-buy-ionis-pharmaceuticals-stock-cm731674,If you were looking for a reason to buy Ionis Pharmaceuticals NASDAQ IONS stock the biotech s CEO gave several in his presentation at the J P Morgan Healthcare Conference on Monday Here are three big reasons to buy Ionis shares in 2017 and eight smaller
GSK,GSK:US,BBG000BLB481,"Bristol-Myers, GeneCentric Tie Up for Opdivo Biomarker Study",2017-01-09 14:52:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EsOt2GXfvik/bristol-myers-genecentric-tie-up-for-opdivo-biomarker-study-cm730896,Bristol Myers Squibb Company BMY inked a biomarker research collaboration with GeneCentric Diagnostics Inc under which application of the latter s proprietary core technology Cancer Subtype Platform CSP will be explored for the identification of translational biomarkers for Bristol
GSK,GSK:US,BBG000BLB481,Does EKF Diagnostics Holding plc have more upside than GlaxoSmithKline plc after beating expectations?,2017-01-09 14:46:21 +0000,http://uk.finance.yahoo.com/news/does-ekf-diagnostics-holding-plc-144621881.html,Does EKF Diagnostics Holding plc have more upside than GlaxoSmithKline plc after beating expectations?
GSK,GSK:US,BBG000BLB481,Adaptimmune confirms GSK Nomination of Second Adaptimmune Target under Strategic Multi-Target Collaboration,2017-01-09 13:01:00 +0000,http://finance.yahoo.com/news/adaptimmune-confirms-gsk-nomination-second-130100929.html,"[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, Jan. 09, 2017-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that GlaxoSmithKline plc has nominated a second target, ..."
GSK,GSK:US,BBG000BLB481,Gilead Sciences Must Answer to Investors After a Disappointing 2016,2017-01-06 16:36:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VSnrFoVCQek/gilead-sciences-must-answer-to-investors-after-a-disappointing-2016-cm730418,Gilead Sciences Inc GILD delivered a poor performance last year The stock lost over 24 in 2016 caused by a drop in sales of products that treat hepatitis C According to Ben Levinsohn in a Barron s article the decline was also attributed to the company s lack of a plan for
GSK,GSK:US,BBG000BLB481,"NeRRe, A GlaxoSmithKline PLC (ADR) (GSK) Spinout Raises £23 Million For NK Antagonists",2017-01-06 16:00:07 +0000,http://www.insidermonkey.com/blog/nerre-a-glaxosmithkline-plc-adr-gsk-spinout-raises-23-million-for-nk-antagonists-514967/,"NeRRe, A GlaxoSmithKline PLC (ADR) (GSK) Spinout Raises £23 Million For NK Antagonists"
GSK,GSK:US,BBG000BLB481,"Bristol-Myers, J&J Ink Immunotherapy Research Collaboration",2017-01-06 14:40:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WFlI3XUuJQs/bristol-myers-jj-ink-immunotherapy-research-collaboration-cm730346,Bristol Myers Squibb Company BMY announced a new clinical research collaboration with Johnson amp Johnson s JNJ Janssen Biotech Inc under which its immuno oncology drug Opdivo will be evaluated in combination with the latter s Darzalex in phase Ib phase II studies for multiple myeloma
GSK,GSK:US,BBG000BLB481,The Best Thing About Glaxo's Next Vaccine (Hint: It's Not the Billion-Dollar Sales Estimate),2017-01-06 14:40:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oBPt1Wc1F10/the-best-thing-about-glaxos-next-vaccine-hint-its-not-the-billion-dollar-sales-estimate-cm730227,British pharmaceutical giant GlaxoSmithKline plc NYSE GSK 160 recently submitted a license application to the Food and Drug Administration for its new shingles vaccine Shingrix forging ahead in its effort to launch a new billion dollar product The vaccine has a high
GSK,GSK:US,BBG000BLB481,The Best Thing About Glaxo's Next Vaccine (Hint: It's Not the Billion-Dollar Sales Estimate),2017-01-06 13:24:59 +0000,http://www.fool.com/investing/2017/01/06/the-best-thing-about-glaxos-next-vaccine-hint-its.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Best Thing About Glaxo's Next Vaccine (Hint: It's Not the Billion-Dollar Sales Estimate)
GSK,GSK:US,BBG000BLB481,"Bristol-Myers, J&J Ink Immunotherapy Research Collaboration",2017-01-06 13:17:01 +0000,http://finance.yahoo.com/news/bristol-myers-j-j-ink-131701835.html,"Bristol-Myers, J&J Ink Immunotherapy Research Collaboration"
GSK,GSK:US,BBG000BLB481,"Mylan, Novartis, Hikma Take On GSK In Generic Asthma Battle",2017-01-05 21:41:32 +0000,http://www.investors.com/news/technology/mylan-novartis-hikma-take-on-gsk-in-generic-asthma-battle/,"Mylan, Novartis, Hikma Take On GSK In Generic Asthma Battle"
GSK,GSK:US,BBG000BLB481,Is today’s 10% riser Churchill China plc the perfect way to profit from Brexit?,2017-01-05 10:42:44 +0000,http://uk.finance.yahoo.com/news/today-10-riser-churchill-china-104244680.html,Is today’s 10% riser Churchill China plc the perfect way to profit from Brexit?
GSK,GSK:US,BBG000BLB481,4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017,2017-01-04 13:38:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5WHf6QhBzvY/4-reasons-why-pfizer-pfe-could-be-a-great-pick-in-2017-cm729081,Pfizer Inc PFE is one of the most prominent names in the pharmaceutical sector not just for its medicines and vaccines but also for its consumer healthcare products This New York based company is known for products like Prevnar Lyrica Lipitor and Celebrex among others Pfizer s
GSK,GSK:US,BBG000BLB481,4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017,2017-01-04 11:25:11 +0000,http://finance.yahoo.com/news/4-reasons-why-pfizer-pfe-112511393.html,4 Reasons Why Pfizer (PFE) Could be a Great Pick in 2017
GSK,GSK:US,BBG000BLB481,Are these the ultimate safety shares for a turbulent 2017?,2017-01-04 07:00:51 +0000,http://uk.finance.yahoo.com/news/ultimate-safety-shares-turbulent-2017-070051418.html,Are these the ultimate safety shares for a turbulent 2017?
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 04th, 2016 (record date) : By the numbers : January 3, 2017",2017-01-03 16:09:07 +0000,http://www.capitalcube.com/blog/index.php/glaxosmithkline-plc-gsk-us-dividend-analysis-november-04th-2016-record-date-by-the-numbers-january-3-2017/,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : November 04th, 2016 (record date) : By the numbers : January 3, 2017"
GSK,GSK:US,BBG000BLB481,Total Voting Rights,2017-01-03 10:43:06 +0000,http://www.publicnow.com/view/F8FA689A0E87D629C5C5A69FA908561DE1E41CAD,"[at noodls] - GlaxoSmithKline plc and Capital Inconformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital ..."
GSK,GSK:US,BBG000BLB481,GSK confirms closure of agreement to divests non-core assets to Aspen,2017-01-03 09:33:10 +0000,http://www.publicnow.com/view/D321277055F2960A1EFBBC3CA8813B651639C8BA,"[at noodls] - GlaxoSmithKline today announced the closure of one of its series of agreements with Aspen Pharmacare Holdings Limited (JSE: APN) and certain of its subsidiaries ('Aspen'), which were the subject of announcements ..."
GSK,GSK:US,BBG000BLB481,2 beginner stocks to kick-start a portfolio,2017-01-03 07:53:10 +0000,http://uk.finance.yahoo.com/news/2-beginner-stocks-kick-start-075310663.html,2 beginner stocks to kick-start a portfolio
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Vaccines Business,2017-01-02 14:06:08 +0000,http://marketrealist.com/2016/12/glaxosmithklines-vaccines-business/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Vaccines Business
GSK,GSK:US,BBG000BLB481,Top stocks for January,2017-01-01 07:00:09 +0000,http://uk.finance.yahoo.com/news/top-stocks-january-070009574.html,Top stocks for January
GSK,GSK:US,BBG000BLB481,Top Ranked Income Stocks to Buy for December 30th,2016-12-30 19:57:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jUk7e52urZ0/top-ranked-income-stocks-to-buy-for-december-30th-cm728088,Here are four stocks with buy rank and strong income characteristics for investors to consider today December 30 th GlaxoSmithKline plc GSK This pharmaceutical company has a Zacks Rank 2 Buy and witnessed the Zacks Consensus Estimate for its current year earnings improving 0 1
GSK,GSK:US,BBG000BLB481,10 Famous Corporate Whistleblowers in Publicly-Traded Companies,2016-12-30 18:19:16 +0000,http://www.insidermonkey.com/blog/10-famous-corporate-whistleblowers-in-publicly-traded-companies-513406/,10 Famous Corporate Whistleblowers in Publicly-Traded Companies
GSK,GSK:US,BBG000BLB481,Top Ranked Income Stocks to Buy for December 30th,2016-12-30 17:05:05 +0000,http://finance.yahoo.com/news/top-ranked-income-stocks-buy-170505082.html,Top Ranked Income Stocks to Buy for December 30th
GSK,GSK:US,BBG000BLB481,A Look at GlaxoSmithKline’s HIV Business,2016-12-30 15:36:44 +0000,http://marketrealist.com/2016/12/a-look-at-glaxosmithklines-hiv-business/?utm_source=yahoo&utm_medium=feed,A Look at GlaxoSmithKline’s HIV Business
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed,2016-12-30 14:07:11 +0000,http://marketrealist.com/2016/12/how-glaxosmithklines-pharmaceuticals-segment-has-performed/?utm_source=yahoo&utm_medium=feed,How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed
GSK,GSK:US,BBG000BLB481,Merck (MRK) Does Well in 2016: Reasons for Outperformance,2016-12-30 14:00:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XKoQqVV0l3g/merck-mrk-does-well-in-2016-reasons-for-outperformance-cm727759,New Jersey based leading pharma company Merck amp Co Inc s MRK share price is up 11 8 so far this year This is impressive given that the year was fraught with challenges for the pharma biotech sector which faced immense flak for steep drug prices The company s price movement
GSK,GSK:US,BBG000BLB481,Exploring GlaxoSmithKline’s Business Segments,2016-12-30 12:38:05 +0000,http://marketrealist.com/2016/12/exploring-glaxosmithklines-business-segments/?utm_source=yahoo&utm_medium=feed,Exploring GlaxoSmithKline’s Business Segments
GSK,GSK:US,BBG000BLB481,Merck (MRK) Does Well in 2016: Reasons for Outperformance,2016-12-30 11:37:11 +0000,http://finance.yahoo.com/news/merck-mrk-does-well-2016-113711809.html,Merck (MRK) Does Well in 2016: Reasons for Outperformance
GSK,GSK:US,BBG000BLB481,Why I’m bullish on GlaxoSmithKline plc for 2017,2016-12-30 08:20:02 +0000,http://uk.finance.yahoo.com/news/why-m-bullish-glaxosmithkline-plc-082002996.html,Why I’m bullish on GlaxoSmithKline plc for 2017
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Revenue Trend,2016-12-29 22:05:32 +0000,http://marketrealist.com/2016/12/glaxosmithklines-revenue-trend/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Revenue Trend
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline’s Valuation Compares to Its Peers’,2016-12-29 20:27:42 +0000,http://marketrealist.com/2016/12/how-glaxosmithklines-valuation-compares-to-its-peers/?utm_source=yahoo&utm_medium=feed,How GlaxoSmithKline’s Valuation Compares to Its Peers’
GSK,GSK:US,BBG000BLB481,FTSE 100 clocks all-time closing high,2016-12-29 17:05:36 +0000,http://uk.finance.yahoo.com/news/ftse-100-clocks-time-closing-111136230.html,FTSE 100 clocks all-time closing high
GSK,GSK:US,BBG000BLB481,United Therapeutics’ Robust Research Pipeline,2016-12-29 12:36:09 +0000,http://marketrealist.com/2016/12/robust-research-pipeline-expected-boost-united-therapeutics-revenues-future-years/?utm_source=yahoo&utm_medium=feed,United Therapeutics’ Robust Research Pipeline
GSK,GSK:US,BBG000BLB481,No Quick Wins for GSK,2016-12-29 06:00:17 +0000,http://www.bloomberg.com/gadfly/articles/2016-12-29/gsk-s-new-ceo-emma-walmsley-finds-the-low-hanging-fruit-has-gone?cmpid=yhoo.headline,No Quick Wins for GSK
GSK,GSK:US,BBG000BLB481,2 Top High-Yield Dividend Stocks to Buy Now,2016-12-28 23:57:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h5FW5AR1TPE/2-top-high-yield-dividend-stocks-to-buy-now-cm727198,One of the easiest ways to find quality companies that pay better than average dividends is to focus on industries that have multiple tailwinds at their proverbial backs The pharmaceutical industry for example is experiencing a renaissance of sorts due to the aging and ever
GSK,GSK:US,BBG000BLB481,2 Top High-Yield Dividend Stocks to Buy Now,2016-12-28 22:38:11 +0000,http://www.fool.com/investing/2016/12/28/2-top-high-yield-dividend-stocks-to-buy-now-2.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 Top High-Yield Dividend Stocks to Buy Now
GSK,GSK:US,BBG000BLB481,VRX’s Gastrointestinal Segment Saw Robust Revenue Growth in 2016,2016-12-28 14:06:36 +0000,http://marketrealist.com/2016/12/valeant-pharmaceuticals-gastro-intestinal-segment-continues-report-robust-revenue-growth-2016/?utm_source=yahoo&utm_medium=feed,VRX’s Gastrointestinal Segment Saw Robust Revenue Growth in 2016
GSK,GSK:US,BBG000BLB481,Is this under-the-radar pharma stock the next GlaxoSmithKline plc?,2016-12-28 08:00:16 +0000,http://uk.finance.yahoo.com/news/under-radar-pharma-stock-next-080016813.html,Is this under-the-radar pharma stock the next GlaxoSmithKline plc?
GSK,GSK:US,BBG000BLB481,"ETFs with exposure to GlaxoSmithKline Plc : December 27, 2016",2016-12-27 18:03:26 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-glaxosmithkline-plc-december-27-2016-3/,"ETFs with exposure to GlaxoSmithKline Plc : December 27, 2016"
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q3, 2016 By the Numbers : December 26, 2016",2016-12-26 13:57:56 +0000,http://www.capitalcube.com/blog/index.php/glaxosmithkline-plc-gsk-us-earnings-analysis-q3-2016-by-the-numbers-december-26-2016/,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q3, 2016 By the Numbers : December 26, 2016"
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline, Vodafone Hit ‘-Year Low Prices",2016-12-25 19:56:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dKaOJ6wgqj0/glaxosmithkline-vodafone-hit-year-low-prices-cm726035,GlaxoSmithKline PLC GSK Diageo PLC DEO V odafone Group PLC VOD and National Grid PLC NGG have reached their three year low prices GlaxoSmithKline PLC GSK reached 8 5 The prices of GlaxoSmithKline shares have declined to 8 5 which is only
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline, Vodafone Hit 3-Year Low Prices",2016-12-24 23:09:25 +0000,http://finance.yahoo.com/news/glaxosmithkline-vodafone-hit-3-low-230925257.html,"GlaxoSmithKline, Vodafone Hit 3-Year Low Prices"
GSK,GSK:US,BBG000BLB481,Teva Settles Charges in U.S. -- WSJ,2016-12-23 02:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YQHyE8PJxiM/teva-settles-charges-in-us--wsj-20161223-00054,Teva Settles Charges in U.S. -- WSJ
GSK,GSK:US,BBG000BLB481,"Noteworthy ETF Inflows: VGK, TOT, RDS.B, GSK",2016-12-22 16:57:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pV-jQUhoy50/noteworthy-etf-inflows-vgk-tot-rdsb-gsk-cm725110,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 94 9 million dollar inflow that s a 0 9 increase week over week in outstanding
GSK,GSK:US,BBG000BLB481,Teva Settles Foreign Corruption Probe for $519 Million -- 2nd Update,2016-12-22 15:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qAtreSCEbc0/teva-settles-foreign-corruption-probe-for-519-million--2nd-update-20161222-00642,Teva Settles Foreign Corruption Probe for $519 Million -- 2nd Update
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline PLC (ADR) (GSK) Phase 3 Trials Looks Positive: Will Gilead Sciences, Inc. (GILD) Endure?",2016-12-21 18:27:15 +0000,http://www.insidermonkey.com/blog/glaxosmithkline-plc-adr-gsk-phase-3-trials-looks-positive-will-gilead-sciences-inc-gild-endure-512585/,"GlaxoSmithKline PLC (ADR) (GSK) Phase 3 Trials Looks Positive: Will Gilead Sciences, Inc. (GILD) Endure?"
GSK,GSK:US,BBG000BLB481,Gilead Sciences: How Bad is the Glaxo News?,2016-12-20 16:25:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/20/gilead-sciences-how-bad-is-the-glaxo-news/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: How Bad is the Glaxo News?
GSK,GSK:US,BBG000BLB481,GSK launches big study to test new injection for HIV prevention,2016-12-20 14:28:08 +0000,http://uk.finance.yahoo.com/news/gsk-launches-big-study-test-142808455.html,GSK launches big study to test new injection for HIV prevention
GSK,GSK:US,BBG000BLB481,ViiV starts HIV prevention study with cabotegravir,2016-12-20 14:22:09 +0000,http://www.publicnow.com/view/C6E172436FF57F959A6783D7439247FADA020C53,"[at noodls] - ViiV Healthcare announces start of phase III studyevaluating long-acting cabotegravir for HIV prevention First injectable to be studiedfor efficacy in pre-exposure prophylaxis London, UK 20 December 2016-ViiV ..."
GSK,GSK:US,BBG000BLB481,GSK's two-drug HIV therapy shines in two big studies,2016-12-20 09:42:57 +0000,http://uk.finance.yahoo.com/news/gsks-two-drug-hiv-therapy-094257034.html,"[Reuters - UK Focus] - LONDON, Dec (Shanghai: 600875.SS - news) 20 (Reuters) - GlaxoSmithKline (Other OTC: GLAXF - news) 's already fast-growing HIV drug business has received an important boost after two major clinical studies successfully tested a new two-drug treatment regimen to control the virus that causes AIDS. Antiretroviral therapy has turned HIV from a death sentence into a manageable condition but patients need to stay on treatment for life, so there is a growing focus on making medication as well-tolerated as possible. GSK has developed the new two-drug cocktail through its majority-owned ViiV Healthcare, in which Pfizer (NYSE: PFE - news) and Shionogi also hold stakes."
GSK,GSK:US,BBG000BLB481,Blocklisting Application,2016-12-20 08:22:17 +0000,http://www.publicnow.com/view/55195338F0A4DDD645B13548CBD0665BC561FB75,"[at noodls] - GlaxoSmithKline plc Application has been made to the Financial Conduct Authority and the London Stock Exchange Plc for a total of 4,000,000 Ordinary shares of 25p each (shares) to be admitted to the Official ..."
GSK,GSK:US,BBG000BLB481,3 stocks you can buy with dividends yielding more than 5%,2016-12-20 07:10:58 +0000,http://uk.finance.yahoo.com/news/3-stocks-buy-dividends-yielding-071058490.html,3 stocks you can buy with dividends yielding more than 5%
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline''s New Drug Challenges HIV Treatment Orthodoxy -- Update,2016-12-20 06:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6gScNb4NZR0/glaxosmithklines-new-drug-challenges-hiv-treatment-orthodoxy--update-20161220-00152,GlaxoSmithKline''s New Drug Challenges HIV Treatment Orthodoxy -- Update
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's New Drug Challenges AIDS Treatment Orthodoxy,2016-12-20 05:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IVPxx7aWf4Q/glaxosmithklines-new-drug-challenges-aids-treatment-orthodoxy-20161220-00106,GlaxoSmithKline's New Drug Challenges AIDS Treatment Orthodoxy
GSK,GSK:US,BBG000BLB481,GSK: ViiV Reports Positive Trial Results Of Two-drug HIV Treatment Regimen,2016-12-20 02:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qUU3a18m5Jk/gsk-viiv-reports-positive-trial-results-of-twodrug-hiv-treatment-regimen-20161220-00055,GSK: ViiV Reports Positive Trial Results Of Two-drug HIV Treatment Regimen
GSK,GSK:US,BBG000BLB481,GSK boosts board-level science as new CEO prepares to take over,2016-12-19 16:33:52 +0000,http://in.finance.yahoo.com/news/gsk-boosts-board-level-science-163352959.html,GSK boosts board-level science as new CEO prepares to take over
GSK,GSK:US,BBG000BLB481,Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer,2016-12-19 16:02:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tOrdc2H6TkI/merck-keytruda-gets-chmp-nod-for-first-line-lung-cancer-cm723243,Merck amp Co Inc MRK announced that its anti PD 1 therapy Keytruda was rendered a positive opinion in the EU for the first line treatment of metastatic lung cancer The European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP recommended marketing
GSK,GSK:US,BBG000BLB481,Directorate Change,2016-12-19 15:41:16 +0000,http://www.publicnow.com/view/C29F35EC2F89D6A248C9D72A5374E8C09F0E5737,"[at noodls] - Issued: 19 December 2016, London, UK - LSE Announcement GSK announces Board changes GSK today announced the creation of a new Board committee and a number of changes to the membership of the Board and ..."
GSK,GSK:US,BBG000BLB481,Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data,2016-12-19 15:00:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tOqzHAb24EE/pfizer-chantix-label-warning-lifted-in-us-to-add-new-data-cm723249,Pfizer Inc PFE announced that the FDA has lifted a boxed warning about neuropsychiatric side effects from the label of its smoking cessation drug Chantix We remind investors that Chantix s label included a boxed warning regarding serious neuropsychiatric adverse events reported in
GSK,GSK:US,BBG000BLB481,Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer,2016-12-19 13:30:01 +0000,http://finance.yahoo.com/news/merck-keytruda-gets-chmp-nod-133001511.html,Merck Keytruda Gets CHMP Nod for First-Line Lung Cancer
GSK,GSK:US,BBG000BLB481,Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data,2016-12-19 13:26:01 +0000,http://finance.yahoo.com/news/pfizer-chantix-label-warning-lifted-132601817.html,Pfizer Chantix Label Warning Lifted in U.S.; to Add New Data
GSK,GSK:US,BBG000BLB481,Phase III study start for closed triple in asthma,2016-12-19 10:11:10 +0000,http://www.publicnow.com/view/5B3CD2DC017CAC3EA7AD246433C1529BEAA2782D,"[at noodls] - Issued: Monday, 19 December 2016, London UK - LSE Announcement GSK starts phase III study of once-daily closed triple combination therapy FF/UMEC/VI in patients with asthma GlaxoSmithKline plc (LSE/NYSE: ..."
GSK,GSK:US,BBG000BLB481,GSK Starts Phase III Study of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI in Patients with Asthma,2016-12-19 09:30:00 +0000,http://uk.finance.yahoo.com/news/gsk-starts-phase-iii-study-093000250.html,GSK Starts Phase III Study of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI in Patients with Asthma
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline, Innoviva Start Phase III Study for Triple Combination Asthma Therapy",2016-12-19 04:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u5mMoGNbzm4/glaxosmithkline-innoviva-start-phase-iii-study-for-triple-combination-asthma-therapy-20161219-00084,"GlaxoSmithKline, Innoviva Start Phase III Study for Triple Combination Asthma Therapy"
GSK,GSK:US,BBG000BLB481,Glaxo Begins Phase III Study Of Triple Combination Therapy In Asthma Patients,2016-12-19 04:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dj1TzEBPL7c/glaxo-begins-phase-iii-study-of-triple-combination-therapy-in-asthma-patients-20161219-00080,Glaxo Begins Phase III Study Of Triple Combination Therapy In Asthma Patients
GSK,GSK:US,BBG000BLB481,"US drops bold warning from anti-smoking pills Chantix, Zyban",2016-12-16 21:56:56 +0000,http://sg.finance.yahoo.com/news/pfizer-says-us-drops-bold-194944573.html,"US drops bold warning from anti-smoking pills Chantix, Zyban"
GSK,GSK:US,BBG000BLB481,[$$] FDA Drops Stringent Warning on Smoking-Cessation Drug Chantix,2016-12-16 20:28:17 +0000,http://www.wsj.com/articles/fda-drops-stringent-warning-on-smoking-cessation-drug-chantix-1481918026?mod=yahoo_hs,[$$] FDA Drops Stringent Warning on Smoking-Cessation Drug Chantix
GSK,GSK:US,BBG000BLB481,Treasury Stock,2016-12-16 17:40:09 +0000,http://www.publicnow.com/view/F547623CB9171C19870D9A66AE9619A854535A62,"[at noodls] - GlaxoSmithKline plc (the 'Company') Notification of Transfer of Shares out of Treasury Pursuant to the Financial Conduct Authority's Listing Rule 12.6.4, the Company hereby notifies the market of the following: ..."
GSK,GSK:US,BBG000BLB481,Correction to FDA Chantix Warning Story,2016-12-16 15:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tbUczRELrvU/correction-to-fda-chantix-warning-story-20161216-00612,Correction to FDA Chantix Warning Story
GSK,GSK:US,BBG000BLB481,FDA Drops Stringent Warning on Smoking-Cessation Drug Chantix,2016-12-16 15:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Smc_WFAHLiQ/fda-drops-stringent-warning-on-smokingcessation-drug-chantix-20161216-00596,FDA Drops Stringent Warning on Smoking-Cessation Drug Chantix
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-12-16 11:28:10 +0000,http://www.publicnow.com/view/405419964162DF612CBFC0F6C7A953DADC787C2B,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 16 December ...
GSK,GSK:US,BBG000BLB481,Big Pharma Face Off: Is Merck More Attractive than J&J?,2016-12-15 23:57:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hxdmlUydiwg/big-pharma-face-off-is-merck-more-attractive-than-jj-cm722243,The year has been fraught with challenges for the pharma biotech sector which has faced immense flak for steep drug prices Democratic presidential candidate Hillary Clinton had pledged to find ways to curb drug prices and lower prescription drug costs for all Americans Naturally with Trump
GSK,GSK:US,BBG000BLB481,Big Pharma Face Off: Is Merck More Attractive than J&J?,2016-12-15 21:22:09 +0000,http://finance.yahoo.com/news/big-pharma-face-off-merck-212209033.html,Big Pharma Face Off: Is Merck More Attractive than J&J?
GSK,GSK:US,BBG000BLB481,Blockchain Technology Can Help Reduce Flow Of Counterfeit Drugs,2016-12-14 16:03:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0vO34HgMIso/blockchain-technology-can-help-reduce-flow-of-counterfeit-drugs-cm721230,"Biotech (Shutterstock photo)    The global pharmaceutical industry is faced with a thriving counterfeit drugs market, a source of unfair competition that harms innovative and generic industries, and most importantly, puts millions of lives at risk. Despite strict enforcement efforts and policies, the problem of"
GSK,GSK:US,BBG000BLB481,How You Can Profit as the Market for COPD Drugs Grows,2016-12-13 19:12:00 +0000,https://www.thestreet.com/story/13924244/1/how-you-can-profit-as-the-market-for-copd-drugs-grows.html?puc=yahoo&cm_ven=YAHOO,How You Can Profit as the Market for COPD Drugs Grows
GSK,GSK:US,BBG000BLB481,GSK's Witty: We need to get drug pricing right,2016-12-13 19:10:00 +0000,http://finance.yahoo.com/video/gsks-witty-drug-pricing-191000613.html,GSK's Witty: We need to get drug pricing right
GSK,GSK:US,BBG000BLB481,"With Obamacare repealed, 1 in 4 adults could be uninsurable due to a pre-existing condition",2016-12-12 17:46:15 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=4D292502-C078-11E6-9CE4-1CAA3DBD2E2E&siteid=yhoof2,"With Obamacare repealed, 1 in 4 adults could be uninsurable due to a pre-existing condition"
GSK,GSK:US,BBG000BLB481,3 reasons to buy GlaxoSmithKline plc’s 5.5% yield before the market catches on,2016-12-12 08:56:41 +0000,http://uk.finance.yahoo.com/news/3-reasons-buy-glaxosmithkline-plc-085641805.html,3 reasons to buy GlaxoSmithKline plc’s 5.5% yield before the market catches on
GSK,GSK:US,BBG000BLB481,How drugs like Tylenol and Flonase are saving the US $102 billion,2016-12-11 18:00:00 +0000,http://finance.yahoo.com/news/drugs-tylenol-flonase-saving-us-180000057.html,How drugs like Tylenol and Flonase are saving the US $102 billion
GSK,GSK:US,BBG000BLB481,"Bayer, Versant Mount New Stem-Cell Venture -- WSJ",2016-12-10 02:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lP-DKqr5Wtw/bayer-versant-mount-new-stemcell-venture--wsj-20161210-00011,"Bayer, Versant Mount New Stem-Cell Venture -- WSJ"
GSK,GSK:US,BBG000BLB481,A new Lyme disease vaccine will soon be tested on Americans and Europeans,2016-12-10 02:16:19 +0000,http://finance.yahoo.com/news/lyme-disease-vaccine-soon-tested-021619373.html,A new Lyme disease vaccine will soon be tested on Americans and Europeans
GSK,GSK:US,BBG000BLB481,10 Dangerous High-Yield Dividend Stocks to Avoid,2016-12-09 21:57:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/29FYNOjVblQ/10-dangerous-high-yield-dividend-stocks-to-avoid-cm719605,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips With interest rates at historic lows income investors have naturally gravitated to high yield dividend stocks in recent years Source StockSnap io But while dividend investing has historically proven
GSK,GSK:US,BBG000BLB481,Bayer Teams Up With Versant to Develop Stem-Cell Therapies--Update,2016-12-09 08:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tr-RFWusXD8/bayer-teams-up-with-versant-to-develop-stemcell-therapiesupdate-20161209-00203,Bayer Teams Up With Versant to Develop Stem-Cell Therapies--Update
GSK,GSK:US,BBG000BLB481,Here’s my top stock pick for 2017,2016-12-08 10:47:31 +0000,http://uk.finance.yahoo.com/news/top-stock-pick-2017-104731774.html,Here’s my top stock pick for 2017
GSK,GSK:US,BBG000BLB481,"Asset Sales, New Projects Fuel 6.7% Yield",2016-12-07 16:47:38 +0000,http://finance.yahoo.com/news/asset-sales-projects-fuel-6-151742275.html,"Asset Sales, New Projects Fuel 6.7% Yield"
GSK,GSK:US,BBG000BLB481,Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug,2016-12-07 14:21:00 +0000,https://www.thestreet.com/story/13917037/1/pfizer-takes-106-million-fine-from-u-k-for-price-hike-of-epilepsy-drug.html?puc=yahoo&cm_ven=YAHOO,Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug
GSK,GSK:US,BBG000BLB481,Has GlaxoSmithKline Finally Turned the Corner?,2016-12-06 12:02:06 +0000,http://www.fool.com/investing/2016/12/06/has-glaxosmithkline-finally-turned-the-corner.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Has GlaxoSmithKline Finally Turned the Corner?
GSK,GSK:US,BBG000BLB481,Robust Pipeline Supports 5.5% Dividend Yield,2016-12-05 15:33:23 +0000,http://finance.yahoo.com/news/robust-pipeline-supports-5-5-153323430.html,Robust Pipeline Supports 5.5% Dividend Yield
GSK,GSK:US,BBG000BLB481,GSK insider Waterhouse to head drugmaker's HIV unit ViiV,2016-12-05 14:36:02 +0000,http://uk.finance.yahoo.com/news/gsk-insider-waterhouse-head-drugmakers-143602260.html,GSK insider Waterhouse to head drugmaker's HIV unit ViiV
GSK,GSK:US,BBG000BLB481,Better buy: GlaxoSmithKline plc vs Shire plc,2016-12-05 12:55:47 +0000,http://uk.finance.yahoo.com/news/better-buy-glaxosmithkline-plc-vs-125547360.html,Better buy: GlaxoSmithKline plc vs Shire plc
GSK,GSK:US,BBG000BLB481,Adaptimmune Announces Initiation of Myxoid/Round Cell Liposarcoma Study,2016-12-05 12:30:00 +0000,http://finance.yahoo.com/news/adaptimmune-announces-initiation-myxoid-round-123000979.html,"[GlobeNewswire] - PHILADELPHIA and OXFORD, United Kingdom, Dec. 05, 2016-- Adaptimmune Therapeutics plc, a leader in T-cell therapy to treat cancer, today announced that it has initiated a study of its NY‑ ESO SPEAR™ T‑ ..."
GSK,GSK:US,BBG000BLB481,What Smart Money Thinks About GlaxoSmithKline plc (ADR) (GSK),2016-12-04 22:08:10 +0000,http://www.insidermonkey.com/blog/what-smart-money-thinks-about-glaxosmithkline-plc-adr-gsk-491777/,What Smart Money Thinks About GlaxoSmithKline plc (ADR) (GSK)
GSK,GSK:US,BBG000BLB481,How to Buy GlaxoSmithKline at a 15% Discount,2016-12-02 19:59:00 +0000,https://www.thestreet.com/story/13912669/1/how-to-buy-glaxosmithkline-at-a-15-discount.html?puc=yahoo&cm_ven=YAHOO,How to Buy GlaxoSmithKline at a 15% Discount
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline PLC (ADR) (GSK) Wins Approval Of Its Asthma Drug Nucala,2016-12-02 18:26:13 +0000,http://www.insidermonkey.com/blog/glaxosmithkline-plc-adr-gsk-wins-approval-of-its-asthma-drug-nucala-497035/,GlaxoSmithKline PLC (ADR) (GSK) Wins Approval Of Its Asthma Drug Nucala
GSK,GSK:US,BBG000BLB481,"Glaxo and Innoviva Get Positive News (GSK, INVA)",2016-12-02 16:27:00 +0000,http://www.investopedia.com/news/glaxo-files-copd-drug-europe-gsk-inva/?partner=YahooSA,[at Investopedia] - Glaxo and Innoviva are moving higher on the heels of positive news in both Europe and Japan for a COPD drug.
GSK,GSK:US,BBG000BLB481,"How China Makes Money (BABA, PFE)",2016-12-02 16:23:00 +0000,http://www.investopedia.com/articles/investing/042815/fundamentals-how-china-makes-its-money.asp?partner=YahooSA,"How China Makes Money (BABA, PFE)"
GSK,GSK:US,BBG000BLB481,GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD,2016-12-02 14:15:00 +0000,http://uk.finance.yahoo.com/news/gsk-files-regulatory-submission-european-141500956.html,GSK Files Regulatory Submission in European Union for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Files for Approval of Three Drugs,2016-12-02 09:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5cSfCw_4g3M/glaxosmithkline-files-for-approval-of-three-drugs-20161202-00360,GlaxoSmithKline Files for Approval of Three Drugs
GSK,GSK:US,BBG000BLB481,GSK Files Regulatory Submission In EU For Triple Combination Therapy On COPD,2016-12-02 09:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/INIWWtmbzuw/gsk-files-regulatory-submission-in-eu-for-triple-combination-therapy-on-copd-20161202-00348,GSK Files Regulatory Submission In EU For Triple Combination Therapy On COPD
GSK,GSK:US,BBG000BLB481,Relvar® Ellipta® 100/25 mcg Gains Approval in Japan for Use in Patients with COPD,2016-12-02 07:00:00 +0000,http://au.finance.yahoo.com/news/relvar-ellipta-100-25-mcg-070000366.html,"[Business Wire] - LONDON & BRISBANE, Calif.--(BUSINESSWIRE)-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ:INVA - News) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptoms with chronic obstructive pulmonary disease (chronic bronchitis, pulmonary emphysema) (in the case where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required). Relvar is a combination of the inhaled corticosteroid (ICS), fluticasone furoate ‘FF’, and the long-acting beta2 agonist (LABA), vilanterol ‘VI’. The approved dose of FF/VI in chronic obstructive pulmonary disease (COPD) is 100/25 mcg administered once-daily using the Ellipta dry powder inhaler (DPI)."
GSK,GSK:US,BBG000BLB481,GSK & Innoviva Announce Approval Of Relvar Ellipta In Japan For COPD,2016-12-02 02:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yM7jIQ_BhIA/gsk--innoviva-announce-approval-of-relvar-ellipta-in-japan-for-copd-20161202-00031,GSK & Innoviva Announce Approval Of Relvar Ellipta In Japan For COPD
GSK,GSK:US,BBG000BLB481,Here's the Best Dividend Stock in Big Pharma,2016-12-01 23:34:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iavayLtxyM0/heres-the-best-dividend-stock-in-big-pharma-cm716721,When looking for the best pharma dividend stocks there are a few metrics investors should look for High dividend yield Reasonable dividend payout ratio History of dividend increases High likelihood of increase in share price All four categories are
GSK,GSK:US,BBG000BLB481,Oramed Vs. Novo Nordisk In Race For Oral GLP-1,2016-12-01 22:35:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cGK8LuoB9po/oramed-vs-novo-nordisk-in-race-for-oral-glp-1-cm715418,By Sharon di Stefano BySharon di Stefano As diabetes drug frontrunners scramble to create the next best thing GLP 1 a powerful hormone designed to tell the pancreas when to release insulin brings face to face two strong contenders for an oral version Oramed Pharmaceuticals Inc
GSK,GSK:US,BBG000BLB481,Here's the Best Dividend Stock in Big Pharma,2016-12-01 21:48:37 +0000,http://www.fool.com/investing/2016/12/01/heres-the-best-dividend-stock-in-big-pharma.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Here's the Best Dividend Stock in Big Pharma
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-12-01 15:22:39 +0000,http://www.publicnow.com/view/0B5F4926C4A86BF532DB714A89C526213C61CFB6,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 30 November ...
GSK,GSK:US,BBG000BLB481,Total Voting Rights,2016-12-01 15:21:31 +0000,http://www.publicnow.com/view/82DC4A27FFF55FC7E144F6409D22DD85AF5081D8,"[at noodls] - GlaxoSmithKline plc and Capital Inconformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital ..."
GSK,GSK:US,BBG000BLB481,GSK biotech asthma drug wins UK approval after extra price cut,2016-12-01 00:14:57 +0000,http://sg.finance.yahoo.com/news/gsk-biotech-asthma-drug-wins-000733613.html,GSK biotech asthma drug wins UK approval after extra price cut
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline PLC (ADR) (GSK) Targeting Blockbuster Sales With Shingles Vaccine On EU Approval,2016-11-30 17:56:23 +0000,http://www.insidermonkey.com/blog/glaxosmithkline-plc-adr-gsk-targeting-blockbuster-sales-with-shingles-vaccine-on-eu-approval-495279/,GlaxoSmithKline PLC (ADR) (GSK) Targeting Blockbuster Sales With Shingles Vaccine On EU Approval
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Plans Nigeria Health Boost After Drinks Sale,2016-11-29 21:00:01 +0000,http://www.bloomberg.com/news/articles/2016-11-29/glaxosmithkline-plans-nigeria-expansion-after-suntory-disposal?cmpid=yhoo.headline,GlaxoSmithKline Plans Nigeria Health Boost After Drinks Sale
GSK,GSK:US,BBG000BLB481,Should You Buy 3M Co (MMM)?,2016-11-29 15:35:31 +0000,http://www.insidermonkey.com/blog/should-you-buy-3m-co-mmm-490962/,Should You Buy 3M Co (MMM)?
GSK,GSK:US,BBG000BLB481,"Injections, implants tested as new weapons to prevent HIV",2016-11-29 14:17:26 +0000,http://uk.finance.yahoo.com/news/injections-implants-tested-weapons-prevent-141726631.html,"Injections, implants tested as new weapons to prevent HIV"
GSK,GSK:US,BBG000BLB481,Merck: Keytruda's Priority Review for New Cancer Indication,2016-11-29 12:53:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YZgnHQ10nVs/merck-keytrudas-priority-review-for-new-cancer-indication-cm714874,Merck amp Co Inc s MRK yet another supplemental Biologics License Application sBLA for its anti PD 1 therapy Keytruda has been accepted for priority review by the FDA This time the company is looking to expand the label for the treatment of previously treated patients with
GSK,GSK:US,BBG000BLB481,[$$] Big data promise exponential change in healthcare,2016-11-29 12:00:10 +0000,"http://www.ft.com/cms/s/1b614d10-9a03-11e6-8f9b-70e3cabccfae,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Big data promise exponential change in healthcare
GSK,GSK:US,BBG000BLB481,[$$] Pharma giants see future of lower healthcare profits,2016-11-29 12:00:10 +0000,"http://www.ft.com/cms/s/1dfd4f60-9a03-11e6-8f9b-70e3cabccfae,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[$$] Pharma giants see future of lower healthcare profits
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Files Regulatory Application for Shingrix in EU,2016-11-28 15:32:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IG0W80pmvlc/glaxo-gsk-files-regulatory-application-for-shingrix-in-eu-cm714438,GlaxoSmithKline plc GSK announced that it has filed a Marketing Authorisation Application MAA in the EU for its shingles vaccine candidate Shingrix The company is seeking an approval of the vaccine for intramuscularly use in two doses with a two to six month interval between doses
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Files Regulatory Application for Shingrix in EU,2016-11-28 13:29:01 +0000,http://finance.yahoo.com/news/glaxo-gsk-files-regulatory-application-132901439.html,Glaxo (GSK) Files Regulatory Application for Shingrix in EU
GSK,GSK:US,BBG000BLB481,2 FTSE 100 stars you should consider buying before it’s too late,2016-11-28 07:00:38 +0000,http://uk.finance.yahoo.com/news/2-ftse-100-stars-consider-070038177.html,2 FTSE 100 stars you should consider buying before it’s too late
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Studies EPO-Like Anemia Drug (GSK),2016-11-25 16:33:00 +0000,http://www.investopedia.com/news/glaxosmithkline-launches-anemia-drug-trial-gsk/?partner=YahooSA,GlaxoSmithKline Studies EPO-Like Anemia Drug (GSK)
GSK,GSK:US,BBG000BLB481,Is AstraZeneca plc or GlaxoSmithKline plc the best Black Friday buy?,2016-11-25 12:22:10 +0000,http://uk.finance.yahoo.com/news/astrazeneca-plc-glaxosmithkline-plc-best-122210169.html,Is AstraZeneca plc or GlaxoSmithKline plc the best Black Friday buy?
GSK,GSK:US,BBG000BLB481,GSK Announces EU Regulatory Submission Of Shingles Candidate Vaccine,2016-11-25 09:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I7PG_jN5u60/gsk-announces-eu-regulatory-submission-of-shingles-candidate-vaccine-20161125-00140,GSK Announces EU Regulatory Submission Of Shingles Candidate Vaccine
GSK,GSK:US,BBG000BLB481,Glaxo Nucala Favorable in Rare Vasculitis Disease Study,2016-11-24 15:06:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gRmZfyO6ZG0/glaxo-nucala-favorable-in-rare-vasculitis-disease-study-cm713650,GlaxoSmithKline plc GSK announced encouraging data from a pivotal phase III study on Nucala an IL 5 antagonist in patients with relapsing and refractory eosinophilic granulomatosis with polyangiitis EGPA previously known as Churg Strauss syndrome The randomized double blinded study
GSK,GSK:US,BBG000BLB481,Glaxo Nucala Favorable in Rare Vasculitis Disease Study,2016-11-24 13:11:01 +0000,http://finance.yahoo.com/news/glaxo-nucala-favorable-rare-vasculitis-131101462.html,Glaxo Nucala Favorable in Rare Vasculitis Disease Study
GSK,GSK:US,BBG000BLB481,GSK chases Astra with start of big anaemia drug trials,2016-11-24 12:13:59 +0000,http://finance.yahoo.com/news/gsk-chases-astra-start-big-121359335.html,"[Reuters] - GlaxoSmithKline has started pivotal trials of an experimental anaemia drug, chasing AstraZeneca in the race to develop a medicine that mimics the body's response to high altitude. GSK's daprodustat, given as a pill, is designed to displace injectable EPO products that are used widely in patients with chronic kidney disease. GSK said on Thursday its two Phase III clinical studies would enrol a combined total of 7,500 patients with kidney disease."
GSK,GSK:US,BBG000BLB481,"3 Potentially Huge Catalysts for Ionis Pharmaceuticals, Inc. in 2017",2016-11-23 23:04:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V40d4B-x-g0/3-potentially-huge-catalysts-for-ionis-pharmaceuticals-inc-in-2017-cm713564,To say that 2016 has been an up and down year for Ionis Pharmaceuticals Inc NASDAQ IONS is an understatement In the first half of the year shares of the biotech plunged more than 60 Since July though Ionis stock has rebounded by over 75 Next year could be critical for
GSK,GSK:US,BBG000BLB481,Smart Money Continues to Lose Confidence In McDonald’s Corporation (MCD),2016-11-23 16:20:00 +0000,http://www.insidermonkey.com/blog/smart-money-continues-to-lose-confidence-in-mcdonalds-corporation-mcd-490120/,Smart Money Continues to Lose Confidence In McDonald’s Corporation (MCD)
GSK,GSK:US,BBG000BLB481,5 Very Safe Dividend Stocks to Buy Now and Hold Forever,2016-11-23 13:41:59 +0000,http://247wallst.com/investing/2016/11/23/5-very-safe-dividend-stocks-to-buy-now-and-hold-forever/,5 Very Safe Dividend Stocks to Buy Now and Hold Forever
GSK,GSK:US,BBG000BLB481,"After recent declines, is this one of the FTSE 100’s best bargains?",2016-11-23 09:13:15 +0000,http://uk.finance.yahoo.com/news/recent-declines-one-ftse-100-091315846.html,"After recent declines, is this one of the FTSE 100’s best bargains?"
GSK,GSK:US,BBG000BLB481,Mepolizumab meets endpoints in phase 3 EGPA study,2016-11-23 07:50:05 +0000,http://www.publicnow.com/view/1A173398DC15514688FBA2CCCCEF22DEE2D21D58,"[at noodls] - Issued: Wednesday 23 November 2016, London UK - LSE Announcement GSK announces phase lll study of mepolizumab meets co-primary endpoints and all secondary endpoints in patients with eosinophilic granulomatosis ..."
GSK,GSK:US,BBG000BLB481,"GSK : Mepolizumab Phase Lll Study Meets Co-primary Endpoints,secondary Endpoints",2016-11-23 02:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fFzD69enE3A/gsk--mepolizumab-phase-lll-study-meets-coprimary-endpointssecondary-endpoints-20161123-00035,"GSK : Mepolizumab Phase Lll Study Meets Co-primary Endpoints,secondary Endpoints"
GSK,GSK:US,BBG000BLB481,6 Worthy Dividend Stocks Down 10% or More,2016-11-22 23:30:10 +0000,http://finance.yahoo.com/news/6-worthy-dividend-stocks-down-233010777.html,6 Worthy Dividend Stocks Down 10% or More
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Seeks FDA OK for COPD Inhaler (GSK),2016-11-22 20:56:00 +0000,http://www.investopedia.com/news/glaxosmithkline-files-triple-copd-inhaler-gsk/?partner=YahooSA,GlaxoSmithKline Seeks FDA OK for COPD Inhaler (GSK)
GSK,GSK:US,BBG000BLB481,Glaxo Files for COPD Drug; FluLaval Approved for Infants,2016-11-22 16:21:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6m67yQ5fy4k/glaxo-files-for-copd-drug-flulaval-approved-for-infants-cm712665,GlaxoSmithKline plc GSK and partner Innoviva Inc INVA announced filing of a regulatory submission in the U S for a once daily closed triple combination therapy fluticasone furoate FF umeclidinium UMEC vilanterol VI for chronic obstructive pulmonary disease COPD Encouragingly
GSK,GSK:US,BBG000BLB481,Here’s Our Take On Theravance Biopharma Inc (TBPH) And GlaxoSmithKline PLC (ADR) (GSK)’s Latest Submission,2016-11-22 14:49:00 +0000,http://www.insidermonkey.com/blog/heres-our-take-on-theravance-biopharma-inc-tbph-and-glaxosmithkline-plc-adr-gsks-latest-submission-489531/,Here’s Our Take On Theravance Biopharma Inc (TBPH) And GlaxoSmithKline PLC (ADR) (GSK)’s Latest Submission
GSK,GSK:US,BBG000BLB481,Glaxo Files for COPD Drug; FluLaval Approved for Infants,2016-11-22 14:00:02 +0000,http://finance.yahoo.com/news/glaxo-files-copd-drug-flulaval-140002406.html,Glaxo Files for COPD Drug; FluLaval Approved for Infants
GSK,GSK:US,BBG000BLB481,Blog Coverage GlaxoSmithKline Files for US Approval for Triple Combination Lung Cancer Therapy,2016-11-22 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-glaxosmithkline-files-us-131500639.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / November 22, 2016 / Active Wall St. blog coverage looks at the headline from GlaxoSmithKline PLC (NYSE: GSK ) and Innoviva, Inc. (NASDAQ: INVA ) as both companies announced on ..."
GSK,GSK:US,BBG000BLB481,2 stocks for your grandchildren to inherit,2016-11-22 07:15:43 +0000,http://uk.finance.yahoo.com/news/2-stocks-grandchildren-inherit-071543149.html,2 stocks for your grandchildren to inherit
GSK,GSK:US,BBG000BLB481,"ACOR Fails To Walk The Talk, SNY Gets FDA Nod, New Use For Genmab''s Old Drug",2016-11-22 00:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U_tDZlS06Pk/acor-fails-to-walk-the-talk-sny-gets-fda-nod-new-use-for-genmabs-old-drug-20161122-00001,"ACOR Fails To Walk The Talk, SNY Gets FDA Nod, New Use For Genmab''s Old Drug"
GSK,GSK:US,BBG000BLB481,2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio,2016-11-21 19:04:00 +0000,https://www.thestreet.com/story/13901060/1/2-excellent-dividend-paying-drug-stocks-to-add-to-your-portfolio.html?puc=yahoo&cm_ven=YAHOO,2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio
GSK,GSK:US,BBG000BLB481,GSK seeking FDA approval for 'triple combination' COPD therapy,2016-11-21 16:15:08 +0000,http://www.bizjournals.com/philadelphia/news/2016/11/21/gsk-fda-approval-innoviva-triple-inhaler-copd.html?ana=yahoo,"[at American City Business Journals] - GlaxoSmithKline filed an application Monday with the Food and Drug Administration seeking approval for a triple combination therapy for patients with chronic obstructive pulmonary disease (COPD). The product was developed by GlaxoSmithKline (GSK) in a partnership with South San Francisco-based Innoviva (INVA), which formerly operated as Theravance. Dave Allen, head of respiratory research and development at GlaxoSmithkline, said treatment is geared to COPD patients who are often must take multiple therapies requiring multiple inhalers."
GSK,GSK:US,BBG000BLB481,GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older,2016-11-21 13:28:00 +0000,http://finance.yahoo.com/news/gsk-receives-fda-approval-expanded-132800621.html,"[PR Newswire] - PHILADELPHIA, Nov. 21, 2016 /PRNewswire/ -- GSK [LSE/NYSE: GSK] announced today it has received approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research expanding the indication for FluLaval® Quadrivalent (Influenza Vaccine) to include use in children 6 months and older. Prior to this, the vaccine was only approved for active immunization against influenza A subtype viruses and type B viruses, in persons 3 years of age and older. ""The flu is a serious disease with a significant impact on public health and can lead to thousands of deaths in the US every flu season,"" said Patrick Desbiens, Senior Vice President, US Vaccines."
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline plc’s first-mover advantage could power future profits,2016-11-21 12:29:02 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-plc-first-mover-advantage-122902331.html,How GlaxoSmithKline plc’s first-mover advantage could power future profits
GSK,GSK:US,BBG000BLB481,GSK files regulatory submission in US for once-daily closed triple combination therapy FF/UMEC/VI for patients with COPD,2016-11-21 12:00:00 +0000,http://finance.yahoo.com/news/gsk-files-regulatory-submission-us-120000855.html,"[PR Newswire] - LONDON, Nov. 21, 2016 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration ..."
GSK,GSK:US,BBG000BLB481,GSK Announces FDA Approval Of Expanded Age Indication For Influenza Vaccine,2016-11-21 08:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/14PMpvzDFaQ/gsk-announces-fda-approval-of-expanded-age-indication-for-influenza-vaccine-20161121-00430,GSK Announces FDA Approval Of Expanded Age Indication For Influenza Vaccine
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline seeks U.S. approval for triple lung drug,2016-11-21 08:13:17 +0000,http://sg.finance.yahoo.com/news/glaxosmithkline-seeks-u-approval-triple-080520191.html,"[Reuters] - GlaxoSmithKline (GSK.L) said on Monday it had filed its new three-in-one inhaled lung drug for U.S. approval, putting it on track to reach the market ahead of rivals in 2017, assuming it wins a green light. Britain's biggest drugmaker is vying with competitors including AstraZeneca (AZN.L) and Novartis (NOVN.S) to develop so-called ""closed triple"" therapies, offering a single inhaler for patients with chronic obstructive pulmonary disease (COPD). Outgoing Chief Executive Andrew Witty has said it could be an ""absolute clincher"" for its respiratory business."
GSK,GSK:US,BBG000BLB481,GSK Files Regulatory Submission in US for Once-Daily Closed Triple Combination Therapy FF/UMEC/VI for Patients with COPD,2016-11-21 07:00:00 +0000,http://finance.yahoo.com/news/gsk-files-regulatory-submission-us-070000346.html,"[Business Wire] - GlaxoSmithKline plc and Innoviva, Inc. today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol for patients with chronic obstructive pulmonary disease ."
GSK,GSK:US,BBG000BLB481,GSK Files For Triple Combination Therapy FF/UMEC/VI For Patients With COPD,2016-11-21 02:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/67M8ihCD25Y/gsk-files-for-triple-combination-therapy-ffumecvi-for-patients-with-copd-20161121-00038,GSK Files For Triple Combination Therapy FF/UMEC/VI For Patients With COPD
GSK,GSK:US,BBG000BLB481,"The Hidden Upside In The Coming Mexican Crisis (HPQ, GE, GSK)",2016-11-18 21:52:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9o0bxQ2bD9o/the-hidden-upside-in-the-coming-mexican-crisis-hpq-ge-gsk-cm711255,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips If there is one certainty during a Trump presidency it s that America s relationship with its southern neighbor will be changing President elect Trump has not only promised to
GSK,GSK:US,BBG000BLB481,GSK receives FDA approval for expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and older,2016-11-18 20:50:14 +0000,http://www.publicnow.com/view/56E4F0029D4165B3B2AD7DCF87CCB3F03E37A195,[at noodls] - GSK announced today it has received approval from the US Food and Drug Administration's (FDA) Center for Biologics Evaluation and Research expanding the indication for FluLaval Quadrivalent ...
GSK,GSK:US,BBG000BLB481,Innovative Research in Vaccines May Boost Pfizer’s Revenues,2016-11-18 15:04:40 +0000,http://marketrealist.com/2016/11/innovative-research-programs-vaccines-segment-may-boost-pfizers-revenues-future-years/?utm_source=yahoo&utm_medium=feed,Innovative Research in Vaccines May Boost Pfizer’s Revenues
GSK,GSK:US,BBG000BLB481,Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC,2016-11-18 14:52:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IeuVXN-niL0/better-buy-abbvie-inc-vs-glaxosmithkline-plc-cm711102,During most of 2016 when shares of AbbVie NYSE ABBV went up so did shares of GlaxoSmithKline NYSE GSK However after the U S election surprise the paths of these two drugmakers stocks have diverged AbbVie is up but Glaxo isn t That s just a short term snapshot
GSK,GSK:US,BBG000BLB481,ViiV starts PhIII LA injectable treatment regimen,2016-11-18 14:50:12 +0000,http://www.publicnow.com/view/AC4B2B3409ABAA6EE462C302751FA383D357D98B,"[at noodls] - PRESS RELEASE ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine ..."
GSK,GSK:US,BBG000BLB481,Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC,2016-11-18 13:16:57 +0000,http://www.fool.com/investing/2016/11/18/better-buy-abbvie-inc-vs-glaxosmithkline.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: AbbVie Inc. vs. GlaxoSmithKline PLC
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta,2016-11-18 05:51:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Mv1A_MpQePI/glaxo-gsk-presents-phase-iii-data-on-sirukumab-benlysta-cm710965,GlaxoSmithKline plc GSK reported results from two pivotal phase III studies SIRROUND T and SIRROUND H on subcutaneous sirukumab anti interleukin 6 monoclonal antibody for the treatment of adults with moderate to severely active rheumatoid arthritis RA SIRROUND T evaluated
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta,2016-11-18 03:51:03 +0000,http://finance.yahoo.com/news/glaxo-gsk-presents-phase-iii-035103762.html,Glaxo (GSK) Presents Phase III Data on Sirukumab & Benlysta
GSK,GSK:US,BBG000BLB481,WHO says funds secured for Africa pilots of world's first malaria vaccine,2016-11-17 18:23:27 +0000,http://uk.finance.yahoo.com/news/says-funds-secured-africa-pilots-182327810.html,"[Reuters - UK Focus] - Funding for phase one of pilot deployments of the world's first malaria vaccine in sub-Saharan Africa has been secured and immunisation campaigns will begin in 2018, the World Health Organization (WHO) said on Thursday. Pedro Alonso, director of the WHO's Global Malaria Programme, said on Thursday that securing funding and being able to trial the vaccine in Africa pilots would be a milestone in the fight against malaria. The go-ahead (Frankfurt: 908670 - news) comes after the Global Fund to Fight AIDS, Tuberculosis and Malaria on Thursday approved $15 million for the malaria vaccine pilots, assuring full funding for the first phase of the programme."
GSK,GSK:US,BBG000BLB481,Is this an unmissable opportunity to buy these 2 FTSE 100 heroes?,2016-11-17 17:58:08 +0000,http://uk.finance.yahoo.com/news/unmissable-opportunity-buy-2-ftse-175808059.html,Is this an unmissable opportunity to buy these 2 FTSE 100 heroes?
GSK,GSK:US,BBG000BLB481,How Sandoz Performed for Novartis in 3Q16,2016-11-17 16:04:31 +0000,http://marketrealist.com/2016/11/how-sandoz-performed-for-novartis-in-3q16/?utm_source=yahoo&utm_medium=feed,How Sandoz Performed for Novartis in 3Q16
GSK,GSK:US,BBG000BLB481,Novartis’s 3Q16 Earnings Surpass Analyst Estimates,2016-11-16 22:04:08 +0000,http://marketrealist.com/2016/11/novartiss-3q16-earnings-surpass-analyst-estimates/?utm_source=yahoo&utm_medium=feed,Novartis’s 3Q16 Earnings Surpass Analyst Estimates
GSK,GSK:US,BBG000BLB481,Ex-sleuths sue GlaxoSmithKline over imprisonment in China,2016-11-16 17:29:26 +0000,http://in.finance.yahoo.com/news/ex-sleuths-sue-glaxosmithkline-over-172926169.html,Ex-sleuths sue GlaxoSmithKline over imprisonment in China
GSK,GSK:US,BBG000BLB481,Suit Says Glaxo's Conduct Led to Couple's Imprisonment in China,2016-11-15 20:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IDKGeFT2UTU/suit-says-glaxos-conduct-led-to-couples-imprisonment-in-china-20161115-01467,Suit Says Glaxo's Conduct Led to Couple's Imprisonment in China
GSK,GSK:US,BBG000BLB481,"Sanofi, GSK expect further price pressure, more M&A under Trump",2016-11-15 15:52:42 +0000,http://sg.finance.yahoo.com/news/sanofi-gsk-expect-further-price-155242490.html,"Sanofi, GSK expect further price pressure, more M&A under Trump"
GSK,GSK:US,BBG000BLB481,Trump-induced share weakness is an opportunity with these 2 firms,2016-11-15 12:17:48 +0000,http://uk.finance.yahoo.com/news/trump-induced-share-weakness-opportunity-121748745.html,Trump-induced share weakness is an opportunity with these 2 firms
GSK,GSK:US,BBG000BLB481,"New Phase IV Data On VBI Vaccines, Inc. (VBIV) HBV Vaccine Show It Can Carve Out A Market From GlaxoSmithKline PLC (ADR) (GSK)",2016-11-14 16:02:33 +0000,http://www.insidermonkey.com/blog/new-phase-iv-data-on-vbi-vaccines-inc-vbiv-hbv-vaccine-show-it-can-carve-out-a-market-from-glaxosmithkline-plc-adr-gsk-487849/,"New Phase IV Data On VBI Vaccines, Inc. (VBIV) HBV Vaccine Show It Can Carve Out A Market From GlaxoSmithKline PLC (ADR) (GSK)"
GSK,GSK:US,BBG000BLB481,Could GlaxoSmithKline plc learn something from Carr’s Group plc?,2016-11-14 14:21:35 +0000,http://uk.finance.yahoo.com/news/could-glaxosmithkline-plc-learn-something-142135745.html,Could GlaxoSmithKline plc learn something from Carr’s Group plc?
GSK,GSK:US,BBG000BLB481,New Pharma Rankings On Global Access To Medicine Released,2016-11-14 02:28:00 +0000,http://www.forbes.com/sites/judystone/2016/11/13/new-pharma-rankings-on-global-access-to-medicine/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,New Pharma Rankings On Global Access To Medicine Released
GSK,GSK:US,BBG000BLB481,A massive nonprofit rejected a bunch of donated vaccines from Pfizer — and now the drug giant is offering them at a lower price,2016-11-11 19:09:00 +0000,http://finance.yahoo.com/news/massive-nonprofit-rejected-bunch-donated-181800481.html,A massive nonprofit rejected a bunch of donated vaccines from Pfizer — and now the drug giant is offering them at a lower price
GSK,GSK:US,BBG000BLB481,Pfizer offers cut-price pneumonia shot for humanitarian crises,2016-11-11 19:08:12 +0000,http://uk.finance.yahoo.com/news/pfizer-offers-cut-price-pneumonia-190812891.html,Pfizer offers cut-price pneumonia shot for humanitarian crises
GSK,GSK:US,BBG000BLB481,Pfizer offers cut-price pneumonia shot for humanitarian crises,2016-11-11 11:17:34 +0000,http://uk.finance.yahoo.com/news/pfizer-offers-cut-price-pneumonia-111734711.html,"[Reuters - UK Focus] - U.S. pharmaceuticals giant Pfizer is to offer its pneumococcal vaccine at the lowest possible price to non-governmental organisations seeking to protect vulnerable people from illness in humanitarian crises. In what it called a major expansion of its humanitarian assistance work, the drugmaker said its Prevenar 13 shot, which protects babies and children against pneumonia and other diseases, would be offered in a new multi-dose vial at the lowest prevailing global price, currently $3.10 per dose. ""In addition, given the acute need for aid on the ground, Pfizer will donate all sales proceeds for the first year of this program to humanitarian groups undertaking the difficult work of reaching vulnerable populations in emergency settings,"" the company said in a statement."
GSK,GSK:US,BBG000BLB481,These stocks are the FTSE’s true growth greats,2016-11-11 07:15:50 +0000,http://uk.finance.yahoo.com/news/stocks-ftse-true-growth-greats-071550898.html,These stocks are the FTSE’s true growth greats
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts",2016-11-10 21:17:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8OiOYOelc2M/the-zacks-analyst-blog-highlights-chevron-glaxo-aflac-novo-nordisk-and-mgm-resorts-cm707155,For Immediate Release Chicago IL November 10 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
GSK,GSK:US,BBG000BLB481,Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit,2016-11-10 17:04:00 +0000,https://www.thestreet.com/story/13888690/1/here-s-which-pharma-giants-might-want-to-buy-pfizer-s-consumer-health-unit.html?puc=yahoo&cm_ven=YAHOO,Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit
GSK,GSK:US,BBG000BLB481,Tracing Benjamin Graham's Descendants,2016-11-10 17:00:00 +0000,http://realmoney.thestreet.com/articles/11/10/2016/tracing-benjamin-grahams-descendants?puc=yahoo&cm_ven=YAHOO,Tracing Benjamin Graham's Descendants
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-11-10 15:21:06 +0000,http://www.publicnow.com/view/8B0AFC4C7B6EEF208597187FF802948062F2729E,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 10 November ...
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts",2016-11-10 14:30:02 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-chevron-143002150.html,"The Zacks Analyst Blog Highlights: Chevron, Glaxo, Aflac, Novo Nordisk and MGM Resorts"
GSK,GSK:US,BBG000BLB481,Why AstraZeneca plc may still not be cheap enough to beat this upstart,2016-11-10 11:59:30 +0000,http://uk.finance.yahoo.com/news/why-astrazeneca-plc-may-still-115930461.html,Why AstraZeneca plc may still not be cheap enough to beat this upstart
GSK,GSK:US,BBG000BLB481,"Top Research Reports for 9th November, 2016",2016-11-10 06:53:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wSFNEq_M2Ag/top-research-reports-for-9th-november-2016-cm706859,Wednesday November 9 2016 Today s Research Daily features new research reports on 16 major stocks including Chevron CVX Glaxo GSK and Aflac AFL Chevron s shares have gained more than 19 year to date The analyst emphasizes that the company s current oil and gas development
GSK,GSK:US,BBG000BLB481,Donald Trump Election Victory Boosts Some Stocks and Sectors,2016-11-09 17:00:00 +0000,http://realmoney.thestreet.com/articles/11/09/2016/donald-trump-election-victory-boosts-some-stocks-and-sectors?puc=yahoo&cm_ven=YAHOO,Donald Trump Election Victory Boosts Some Stocks and Sectors
GSK,GSK:US,BBG000BLB481,"LONDON MARKETS: FTSE 100 Ends Roller-coaster Day Higher As Trump Win Boosts Pharma, Gold Shares",2016-11-09 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ifSZfYO5wGA/london-markets-ftse-100-ends-rollercoaster-day-higher-as-trump-win-boosts-pharma-gold-shares-20161109-00898,"LONDON MARKETS: FTSE 100 Ends Roller-coaster Day Higher As Trump Win Boosts Pharma, Gold Shares"
GSK,GSK:US,BBG000BLB481,Corporate Winners and Losers Start to Emerge After Trump's Victory -- 2nd Update,2016-11-09 07:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3DxXqaE7nq0/corporate-winners-and-losers-start-to-emerge-after-trumps-victory--2nd-update-20161109-00499,Corporate Winners and Losers Start to Emerge After Trump's Victory -- 2nd Update
GSK,GSK:US,BBG000BLB481,Corporate Winners and Losers Emerge After Trump Win,2016-11-09 05:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cA3T8MbGHwQ/corporate-winners-and-losers-emerge-after-trump-win-20161109-00161,Corporate Winners and Losers Emerge After Trump Win
GSK,GSK:US,BBG000BLB481,Rewarding Client Service Over Sales -- WSJ,2016-11-09 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qzUgwwrPFhE/rewarding-client-service-over-sales--wsj-20161109-00090,Rewarding Client Service Over Sales -- WSJ
GSK,GSK:US,BBG000BLB481,Rewarding Client Service Over Sales -- WSJ,2016-11-09 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/usIA8U9zszc/rewarding-client-service-over-sales--wsj-20161109-00091,Rewarding Client Service Over Sales -- WSJ
GSK,GSK:US,BBG000BLB481,Better Buy: Amgen Inc. vs. Johnson & Johnson,2016-11-08 20:40:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZCtfhk-YaG4/better-buy-amgen-inc-vs-johnson-johnson-cm705910,They re two of the premiere long term winners among healthcare stocks They both have deep pipelines and deep pocketbooks And they both reward investors with nice dividends The track records of Amgen NASDAQ AMGN and Johnson amp Johnson NYSE JNJ so far in 2016
GSK,GSK:US,BBG000BLB481,"Drug Stock Earnings to Watch on Nov 9: MYL, IONS & More",2016-11-08 18:15:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iAhLrDR2TQ8/drug-stock-earnings-to-watch-on-nov-9-myl-ions-more-cm705436,It s nearing the closing bell of the third quarter 2016 earnings season with approximately 423 S amp P 500 members representing 84 6 of the index s total market capitalization having reported quarterly results as of Nov 4 An impressive 72 8 of these companies managed to record an
GSK,GSK:US,BBG000BLB481,Better Buy: Amgen Inc. vs. Johnson & Johnson,2016-11-08 17:37:34 +0000,http://www.fool.com/investing/2016/11/08/better-buy-amgen-inc-vs-johnson-johnson.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Amgen Inc. vs. Johnson & Johnson
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-11-08 17:17:07 +0000,http://www.publicnow.com/view/C795245EA1333BE07F2A651F6142B263BCA84EB8,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 08 November ...
GSK,GSK:US,BBG000BLB481,Block listing Interim Review,2016-11-08 17:17:07 +0000,http://www.publicnow.com/view/BCC003BC97235A48DA05BB92E5CF080A0630EFD7,[at noodls] - BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris. ... This is an abstract of the original noodl. To continue reading this ...
GSK,GSK:US,BBG000BLB481,US FDA Clears Propeller Integration With GlaxoSmithKline PLC (ADR) (GSK)’s Ellipta,2016-11-08 13:49:24 +0000,http://www.insidermonkey.com/blog/us-fda-clears-propeller-integration-with-glaxosmithkline-plc-adr-gsks-ellipta-485776/,US FDA Clears Propeller Integration With GlaxoSmithKline PLC (ADR) (GSK)’s Ellipta
GSK,GSK:US,BBG000BLB481,5 Healthcare Stocks Kahn Brothers Is Bullish On,2016-11-08 13:44:21 +0000,http://www.insidermonkey.com/blog/5-healthcare-stocks-kahn-brothers-is-bullish-on-485758/,5 Healthcare Stocks Kahn Brothers Is Bullish On
GSK,GSK:US,BBG000BLB481,Here’s how investors can profit from a Brexit-driven slowdown,2016-11-08 13:24:50 +0000,http://uk.finance.yahoo.com/news/investors-profit-brexit-driven-slowdown-132450760.html,Here’s how investors can profit from a Brexit-driven slowdown
GSK,GSK:US,BBG000BLB481,Companies Rethink Sales Rewards in Favor of Service,2016-11-08 11:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iB2NumNtkdo/companies-rethink-sales-rewards-in-favor-of-service-20161108-00820,Companies Rethink Sales Rewards in Favor of Service
GSK,GSK:US,BBG000BLB481,"Drug Prices to Drop Regardless of U.S. Vote Outcome, Witty Says",2016-11-08 10:52:23 +0000,http://www.bloomberg.com/news/articles/2016-11-08/drug-prices-to-drop-regardless-of-u-s-vote-outcome-witty-says?cmpid=yhoo.headline,"Drug Prices to Drop Regardless of U.S. Vote Outcome, Witty Says"
GSK,GSK:US,BBG000BLB481,Why did shares in Hikma Pharmaceuticals plc and GlaxoSmithKline plc crash last week?,2016-11-08 10:08:27 +0000,http://uk.finance.yahoo.com/news/why-did-shares-hikma-pharmaceuticals-100827872.html,Why did shares in Hikma Pharmaceuticals plc and GlaxoSmithKline plc crash last week?
GSK,GSK:US,BBG000BLB481,Why Agenus Inc. Stock Plummeted 44.7% in October,2016-11-07 16:01:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0px2rmdY3sw/why-agenus-inc-stock-plummeted-447-in-october-cm704907,Image source Getty Images What happened Shares of tiny immunotherapy developer Agenus Inc NASDAQ AGEN tumbled 44 7 in October according to data from S amp P Global Market Intelligence A larger than expected loss in its third quarter earnings report overshadowed
GSK,GSK:US,BBG000BLB481,5 Out-of-Favor Buy-Rated Stocks Yielding 5% or More,2016-11-07 13:25:37 +0000,http://247wallst.com/investing/2016/11/07/5-out-of-favor-buy-rated-stocks-yielding-5-or-more/,5 Out-of-Favor Buy-Rated Stocks Yielding 5% or More
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-11-04 17:21:09 +0000,http://www.publicnow.com/view/8904858FC5DC55EC5C019F0AD7E444FE00221738,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 04 November ...
GSK,GSK:US,BBG000BLB481,Epizyme (EPZM) Reports Narrower-than-Expected Loss in Q3,2016-11-04 14:15:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qkk5q6vE7Bo/epizyme-epzm-reports-narrower-than-expected-loss-in-q3-cm704067,Epizyme Inc EPZM reported a loss of 42 cents per share in the third quarter of 2016 narrower than both the Zacks Consensus Estimate and the year ago loss of 56 cents FindTheCompany Graphiq Quarter in Detail The company earned collaboration revenues of 6 6 million
GSK,GSK:US,BBG000BLB481,How Does Pfizer's Dividend Stack Up?,2016-11-04 14:14:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hzHw1WyEIeU/how-does-pfizers-dividend-stack-up-cm703861,Image source Getty Images After the company reported disappointing third quarter results Pfizer s NYSE PFE dividend is starting to look like the primary reason to buy or hold this megacap pharma stock After all the drugmaker s earnings release was
GSK,GSK:US,BBG000BLB481,How Does Pfizer's Dividend Stack Up?,2016-11-04 12:05:11 +0000,http://www.fool.com/investing/2016/11/04/how-does-pfizers-dividend-stack-up.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How Does Pfizer's Dividend Stack Up?
GSK,GSK:US,BBG000BLB481,Kahn Brothers Adds to 4 Holdings in ‘rd Quarter,2016-11-04 11:19:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gmV5_27X9uk/kahn-brothers-adds-to-4-holdings-in-rd-quarter-cm703542,Kahn Brothers Trades Portfolio added to four holdings in its portfolio in the third quarter The largest was the purchase of 5 7 5 shares in GlaxoSmithKline PLC GSK a London based pharmaceutical company for an average price of 4 86 per share The transaction had a
GSK,GSK:US,BBG000BLB481,"European Stocks Mixed on Corporate Earnings, Brexit News",2016-11-03 17:23:00 +0000,https://www.thestreet.com/story/13880067/1/european-stocks-mixed-on-corporate-earnings-brexit-news.html?puc=yahoo&cm_ven=YAHOO,"European Stocks Mixed on Corporate Earnings, Brexit News"
GSK,GSK:US,BBG000BLB481,How Tresiba Helps Novo Achieve Its Growth Targets,2016-11-03 14:04:21 +0000,http://marketrealist.com/2016/11/how-tresiba-helps-novo-achieve-its-growth-targets/?utm_source=yahoo&utm_medium=feed,How Tresiba Helps Novo Achieve Its Growth Targets
GSK,GSK:US,BBG000BLB481,3 High-Yield Dividend Stocks to Buy in November,2016-11-03 13:09:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AG8DkPYdWXs/3-high-yield-dividend-stocks-to-buy-in-november-cm703058,Image source Getty Images All high yield dividend stocks aren t created equal There are plenty of stocks available that sport above average yields but there aren t many that also feature a low risk of a dividend cut and the potential to grow the dividend over time Buying
GSK,GSK:US,BBG000BLB481,Sterling’s collapse makes GlaxoSmithKline plc an attractive takeover target,2016-11-03 12:12:29 +0000,http://uk.finance.yahoo.com/news/sterling-collapse-makes-glaxosmithkline-plc-121229618.html,Sterling’s collapse makes GlaxoSmithKline plc an attractive takeover target
GSK,GSK:US,BBG000BLB481,3 High-Yield Dividend Stocks to Buy in November,2016-11-03 11:38:19 +0000,http://www.fool.com/investing/2016/11/03/3-high-yield-dividend-stocks-to-buy-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 High-Yield Dividend Stocks to Buy in November
GSK,GSK:US,BBG000BLB481,Gilead Science - Buy Hepatitis C Get HIV for Free,2016-11-03 02:41:57 +0000,http://finance.yahoo.com/tumblr/blog-gilead-science-buy-hepatitis-c-get-hiv-for-free-024203143.html,Gilead Science - Buy Hepatitis C Get HIV for Free
GSK,GSK:US,BBG000BLB481,Kahn Brothers Adds to 4 Holdings in 3rd Quarter,2016-11-02 23:01:57 +0000,http://finance.yahoo.com/news/kahn-brothers-adds-4-holdings-230157090.html,Kahn Brothers Adds to 4 Holdings in 3rd Quarter
GSK,GSK:US,BBG000BLB481,GSK statement in response to New York Times article on China,2016-11-02 18:00:13 +0000,http://www.publicnow.com/view/E23A5DD3E5B099B491677DAD0BBBB4C3936E5F4B,[at noodls] - Issued: London These matters relating to our operations in China were deeply disappointing to GSK. They have previously been the subject of investigation by authorities in China and the United States. ...
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-11-02 17:00:04 +0000,http://www.publicnow.com/view/C4A5085006EF6D51C39A3B6DDAEADB00C82F6C72,[at noodls] - Released : 02.11.2016 16:49 RNS Number : 1825O GlaxoSmithKline PLC 02 November 2016 GlaxoSmithKline plc (the 'Company') Transaction notification 1. ... This is an abstract of the original noodl. To continue ...
GSK,GSK:US,BBG000BLB481,Here Are Johnson & Johnson's Next 10 Potential Blockbuster Drugs,2016-11-01 18:16:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8XZQmUNMLrA/here-are-johnson-johnsons-next-10-potential-blockbuster-drugs-cm701935,Image source Getty Images When it comes to steady investments there may be no rock more solid in the healthcare space than Johnson amp Johnson NYSE JNJ Johnson amp Johnson s stability arises from the diversity of its sales and the inelasticity of its products J amp
GSK,GSK:US,BBG000BLB481,Total Voting Rights,2016-11-01 10:33:05 +0000,http://www.publicnow.com/view/D9632E9A8E621645F5895CBFDFE4F62655D07530,"[at noodls] - GlaxoSmithKline plc and Capital Inconformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital ..."
GSK,GSK:US,BBG000BLB481,4 Healthcare Stocks to Buy With Dividends Yielding More Than 4%,2016-10-31 11:33:31 +0000,http://www.fool.com/investing/2016/10/30/4-healthcare-stocks-to-buy-with-dividends-yielding.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Healthcare Stocks to Buy With Dividends Yielding More Than 4%
GSK,GSK:US,BBG000BLB481,"The Good, the Bad and the Ugly of pharma stocks",2016-10-31 07:10:30 +0000,http://uk.finance.yahoo.com/news/good-bad-ugly-pharma-stocks-071030607.html,"The Good, the Bad and the Ugly of pharma stocks"
GSK,GSK:US,BBG000BLB481,Crown Case Reverberates Beyond China -- WSJ,2016-10-31 02:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_jPlRXfYU1Q/crown-case-reverberates-beyond-china--wsj-20161031-00045,Crown Case Reverberates Beyond China -- WSJ
GSK,GSK:US,BBG000BLB481,Drugmakers Turn Cheap Generics Into Expensive Pills,2016-10-30 13:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IozYak-W0yk/drugmakers-turn-cheap-generics-into-expensive-pills-20161030-00018,Drugmakers Turn Cheap Generics Into Expensive Pills
GSK,GSK:US,BBG000BLB481,4 Healthcare Stocks to Buy With Dividends Yielding More Than 4%,2016-10-30 12:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sjs-XensvOA/4-healthcare-stocks-to-buy-with-dividends-yielding-more-than-4-cm700722,Looking for high yielding dividend stocks Healthcare s got em GlaxoSmithKline NYSE GSK Kindred Healthcare NYSE KND Medical Properties Trust NYSE MPW and Sanofi NYSE SNY have at least two things in common They re all healthcare stocks
GSK,GSK:US,BBG000BLB481,China's Crown Probe Seen as Warning Shot to Foreign Firms,2016-10-30 09:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nVMLEz3bFng/chinas-crown-probe-seen-as-warning-shot-to-foreign-firms-20161030-00009,China's Crown Probe Seen as Warning Shot to Foreign Firms
GSK,GSK:US,BBG000BLB481,China's Crown Probe Seen as Warning Shot to Foreign Firms,2016-10-30 09:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MiIsuHbQanQ/chinas-crown-probe-seen-as-warning-shot-to-foreign-firms-20161030-00086,China's Crown Probe Seen as Warning Shot to Foreign Firms
GSK,GSK:US,BBG000BLB481,Here's Why Biogen Should Buy Ionis Pharmaceuticals,2016-10-28 22:32:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HIbpcisBAFk/heres-why-biogen-should-buy-ionis-pharmaceuticals-cm700584,Despite the uncertainly created by the forthcoming retirement of Biogen s NASDAQ BIIB longtime CEO George Scangos the biotech is reportedly continuing to hunt for deals that would diversify its clinical and product portfolios The things is it may not have to
GSK,GSK:US,BBG000BLB481,3 Retirement Stocks to Buy in November,2016-10-28 19:02:26 +0000,http://www.fool.com/investing/2016/10/28/3-retirement-stocks-to-buy-in-november.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Retirement Stocks to Buy in November
GSK,GSK:US,BBG000BLB481,3 Retirement Stocks to Buy in November,2016-10-28 14:54:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E-DaJ0kBtdg/3-retirement-stocks-to-buy-in-november-cm700026,Image source Getty Images Most retirees don t want to spend their Novembers worrying about their investment portfolios They have more important things to focus on like spending time with family and friends and preparing for a huge Thanksgiving dinner If you too would like
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-28 13:28:01 +0000,http://www.publicnow.com/view/34B956065311FB6681A8D8EB7EF7A1979C295927,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 28 October ...
GSK,GSK:US,BBG000BLB481,Why Fret Over Agenus Inc. Q3 Results?,2016-10-27 19:42:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v_CgvhQH-fs/why-fret-over-agenus-inc-q3-results-cm699697,Agenus Inc NASDAQ AGEN announced its third quarter results on Thursday Shares of the biotech promptly fell by more than 11 in early trading Why would anyone fret over Agenus financial results They shouldn t Image source Getty Images Ugly numbers
GSK,GSK:US,BBG000BLB481,Why Fret Over Agenus Inc. Q3 Results?,2016-10-27 18:17:23 +0000,http://www.fool.com/investing/2016/10/27/why-fret-over-agenus-inc-q3-results.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Fret Over Agenus Inc. Q3 Results?
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View",2016-10-27 17:42:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MSHBkLyUhYo/glaxo-gsk-beats-q3-earnings-estimates-keeps-2016-view-cm699551,GlaxoSmithKline plc GSK reported third quarter 2016 core earnings of 85 cents per American Depositary Share ADS beating the Zacks Consensus Estimate of 77 cents Core earnings were also up 12 year over year at constant exchange rates CER Quarterly revenues were up 8 at CER to 7
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-27 16:46:13 +0000,http://www.publicnow.com/view/F833EB5F912724E8389F1A351710DF5A53AF8746,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 27 October ...
GSK,GSK:US,BBG000BLB481,Does GlaxoSmithKline's Sales Surge Make It An Unmissable 'Buy'?,2016-10-27 15:53:00 +0000,http://www.forbes.com/sites/roystonwild/2016/10/27/does-glaxosmithklines-sales-surge-make-it-an-unmissable-buy/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Does GlaxoSmithKline's Sales Surge Make It An Unmissable 'Buy'?
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View",2016-10-27 15:42:03 +0000,http://finance.yahoo.com/news/glaxo-gsk-beats-q3-earnings-154203289.html,"Glaxo (GSK) Beats Q3 Earnings Estimates, Keeps 2016 View"
GSK,GSK:US,BBG000BLB481,GSK expands meningitis B vaccine production in Germany,2016-10-27 13:28:06 +0000,http://uk.finance.yahoo.com/news/gsk-expands-meningitis-b-vaccine-132806643.html,GSK expands meningitis B vaccine production in Germany
GSK,GSK:US,BBG000BLB481,3 Bargain Bin High-Yield Dividend Stocks You've Overlooked This Fall,2016-10-27 12:43:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PhwsbWQPF2U/3-bargain-bin-high-yield-dividend-stocks-youve-overlooked-this-fall-cm699113,Image source Getty Images Regardless of how well or poorly the stock market is performing one thing is for certain Dividend stocks are always in style I ve often said that dividend stocks are the foundation of a great retirement portfolio and for good reason
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Pharmaceuticals Limited announces a 12% Sales growth for the quarter ended 30 September, 2016",2016-10-27 12:16:24 +0000,http://www.publicnow.com/view/FFC207E9361AC65A03DA23BEA2ACA2F419E6CE85,"[at noodls] - PRESS RELEASE Thursday, 27thOctober 2016, Mumbai ------------------------------------------------------------------------------- GlaxoSmithKline Pharmaceuticals Limited today declared its financial results ..."
GSK,GSK:US,BBG000BLB481,3 Bargain Bin High-Yield Dividend Stocks You've Overlooked This Fall,2016-10-27 11:26:03 +0000,http://www.fool.com/investing/2016/10/27/3-bargain-bin-high-yield-dividend-stocks-youve-ove.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Bargain Bin High-Yield Dividend Stocks You've Overlooked This Fall
GSK,GSK:US,BBG000BLB481,Glaxo's Brexit Profit Bounce Shows Why The FTSE 100 Is Strong,2016-10-27 08:14:00 +0000,http://www.forbes.com/sites/timworstall/2016/10/27/glaxos-brexit-profit-bounce-show-why-the-ftse-100-is-strong/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Glaxo's Brexit Profit Bounce Shows Why The FTSE 100 Is Strong
GSK,GSK:US,BBG000BLB481,Business Watch -- WSJ,2016-10-27 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zgCq-bgCjuQ/business-watch--wsj-20161027-00086,Business Watch -- WSJ
GSK,GSK:US,BBG000BLB481,"Drugmaker GSK posts profits jump, boosted by vaccines",2016-10-26 18:22:45 +0000,http://uk.finance.yahoo.com/news/drugmaker-gsk-posts-profits-jump-182245577.html,"Drugmaker GSK posts profits jump, boosted by vaccines"
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline CEO Touts HIV Medicines, Pipeline",2016-10-26 16:14:48 +0000,http://finance.yahoo.com/video/glaxosmithkline-ceo-touts-hiv-medicines-161448075.html,"GlaxoSmithKline CEO Touts HIV Medicines, Pipeline"
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-26 14:55:03 +0000,http://www.publicnow.com/view/B7ADA992D8CE1133523A0A749417B7313B4FB6C3,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 26 October ...
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q3 Earnings, Revenues Rise Y/Y",2016-10-26 14:53:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C-nroUkgSJ8/glaxo-gsk-beats-q3-earnings-revenues-rise-yy-cm698430,GlaxoSmithKline plc GSK one of the largest health care companies reshaped its business following the Mar 2015 completion of the three part inter conditional transaction with Novartis related to its Consumer Healthcare Vaccines and Oncology businesses This UK based company now focuses
GSK,GSK:US,BBG000BLB481,Drugmaker GSK returns to growth in China after torrid time,2016-10-26 14:28:03 +0000,http://uk.finance.yahoo.com/news/drugmaker-gsk-returns-growth-china-142803512.html,Drugmaker GSK returns to growth in China after torrid time
GSK,GSK:US,BBG000BLB481,British imports of cheap medicines dry up as pound falls,2016-10-26 14:07:16 +0000,http://uk.finance.yahoo.com/news/british-imports-cheap-medicines-dry-140716797.html,British imports of cheap medicines dry up as pound falls
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline PLC (ADR) (GSK) Teams Up With Fimbrion Therapeutics, Inc.",2016-10-26 14:00:15 +0000,http://www.insidermonkey.com/blog/glaxosmithkline-plc-adr-gsk-teams-up-with-fimbrion-therapeutics-inc-483305/,"GlaxoSmithKline PLC (ADR) (GSK) Teams Up With Fimbrion Therapeutics, Inc."
GSK,GSK:US,BBG000BLB481,Is GlaxoSmithKline plc about to crash?,2016-10-26 13:44:09 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-plc-crash-134409791.html,Is GlaxoSmithKline plc about to crash?
GSK,GSK:US,BBG000BLB481,[$$] Glaxo Profit Jumps on Weaker Pound,2016-10-26 13:28:00 +0000,http://www.wsj.com/articles/glaxo-profit-jumps-on-weaker-pound-1477483206?mod=yahoo_hs,[$$] Glaxo Profit Jumps on Weaker Pound
GSK,GSK:US,BBG000BLB481,Glaxo beats 3Q profit forecasts,2016-10-26 13:24:49 +0000,http://sg.finance.yahoo.com/news/glaxo-beats-3q-profit-forecasts-132449525.html,Glaxo beats 3Q profit forecasts
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline beats forecasts as weak pound provides windfall,2016-10-26 13:08:32 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-beats-forecasts-weak-pound-113131133.html,GlaxoSmithKline beats forecasts as weak pound provides windfall
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q3 Earnings, Revenues Rise Y/Y",2016-10-26 13:07:01 +0000,http://finance.yahoo.com/news/glaxo-gsk-beats-q3-earnings-130701284.html,"Glaxo (GSK) Beats Q3 Earnings, Revenues Rise Y/Y"
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. Eli Lilly and Company,2016-10-26 12:43:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HZ2Qgc5SuMw/better-buy-glaxosmithkline-plc-vs-eli-lilly-and-company-cm698365,Image source Getty Images Don t think that Big Pharma stocks march in lockstep GlaxoSmithKline s NYSE GSK stock price is lower than it was five years ago During the same period the share price of Eli Lilly NYSE LLY has more than doubled But which of these
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. Eli Lilly and Company,2016-10-26 12:27:59 +0000,http://www.fool.com/investing/2016/10/26/better-buy-glaxosmithkline-plc-vs-eli-lilly.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: GlaxoSmithKline plc vs. Eli Lilly and Company
GSK,GSK:US,BBG000BLB481,European Economy Improving Fast: 4 Top Dividend Stocks to Buy Now,2016-10-26 12:25:13 +0000,http://247wallst.com/investing/2016/10/26/european-economy-improving-fast-4-top-dividend-stocks-to-buy-now/,European Economy Improving Fast: 4 Top Dividend Stocks to Buy Now
GSK,GSK:US,BBG000BLB481,GSK CEO: Focus on affordable pricing,2016-10-26 12:20:00 +0000,http://finance.yahoo.com/video/gsk-ceo-focus-affordable-pricing-122000903.html,GSK CEO: Focus on affordable pricing
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Beats Estimates in Strong Third Quarter,2016-10-26 12:14:00 +0000,https://www.thestreet.com/story/13867315/1/glaxosmithkline-beats-estimates-in-strong-third-quarter.html?puc=yahoo&cm_ven=YAHOO,GlaxoSmithKline Beats Estimates in Strong Third Quarter
GSK,GSK:US,BBG000BLB481,GSK CEO on 'very good quarter',2016-10-26 12:12:00 +0000,http://finance.yahoo.com/video/gsk-ceo-very-good-quarter-121200746.html,GSK CEO on 'very good quarter'
GSK,GSK:US,BBG000BLB481,GSK sees earnings rise amid good demand for vaccines,2016-10-26 12:03:42 +0000,http://sg.finance.yahoo.com/news/gsk-sees-earnings-rise-amid-120342535.html,GSK sees earnings rise amid good demand for vaccines
GSK,GSK:US,BBG000BLB481,Price Monitoring Extension,2016-10-26 11:15:13 +0000,http://www.publicnow.com/view/70AFD037D229ABFC0483CEB5880938D195927C76,[at noodls] - Price Monitoring Extension The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 26 October ...
GSK,GSK:US,BBG000BLB481,Second Price Monitoring Extn,2016-10-26 11:15:02 +0000,http://www.publicnow.com/view/E424197712B201A04A0BBFF374308822CAFD3795,[at noodls] - Second Price Monitoring Extn The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 26 ...
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline enjoys big windfall as pound slides,2016-10-26 11:07:47 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-enjoys-big-windfall-pound-110747847.html,"[Reuters - UK Focus] - Drugmaker GlaxoSmithKline said on Wednesday it expected even bigger profit gains in 2016 thanks to a weak pound, which has continued to fall after Britain's vote in June to leave the European Union, as ..."
GSK,GSK:US,BBG000BLB481,Glaxo Sticks to 2016 Forecast as U.S. Pricing Pressure Continues,2016-10-26 11:04:03 +0000,http://www.bloomberg.com/news/articles/2016-10-26/glaxo-s-earnings-beat-estimates-sales-of-newer-products-rise?cmpid=yhoo.headline,Glaxo Sticks to 2016 Forecast as U.S. Pricing Pressure Continues
GSK,GSK:US,BBG000BLB481,Glaxo’s Earnings Beat Estimates Sales of Newer Products Rise,2016-10-26 11:04:03 +0000,http://finance.yahoo.com/news/glaxo-earnings-beat-estimates-sales-110403726.html,Glaxo’s Earnings Beat Estimates Sales of Newer Products Rise
GSK,GSK:US,BBG000BLB481,"Drugmaker GSK posts profits jump, boosted by vaccines",2016-10-26 08:22:45 +0000,http://au.finance.yahoo.com/news/drugmaker-gsk-posts-profits-jump-082245930.html,"[AFP] - British drugs giant GlaxoSmithKline said Wednesday that net profits soared 50 percent in the group's third quarter, buoyed by a bright performance at its vaccines division. In September, GSK promoted its consumer healthcare head Emma Walmsley to chief executive, a move which will make her the most powerful woman on the FTSE 100."
GSK,GSK:US,BBG000BLB481,"GSK Q3 Profit Rises, Sales Up 8% CER; Affirms 2016 Core EPS Growth Guidance",2016-10-26 07:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nCcJfVoj_Gc/gsk-q3-profit-rises-sales-up-8-cer-affirms-2016-core-eps-growth-guidance-20161026-01146,"GSK Q3 Profit Rises, Sales Up 8% CER; Affirms 2016 Core EPS Growth Guidance"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 3Q16 Revenues Are Expected to Rise,2016-10-25 17:04:08 +0000,http://marketrealist.com/2016/10/glaxosmithklines-3q16-revenues-are-expected-to-rise/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s 3Q16 Revenues Are Expected to Rise
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s 3Q16 Earnings: What to Expect,2016-10-25 14:56:53 +0000,http://marketrealist.com/2016/10/glaxosmithklines-3q16-earnings-what-to-expect/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s 3Q16 Earnings: What to Expect
GSK,GSK:US,BBG000BLB481,Merck Keytruda Gets FDA Approval for First-Line Lung Cancer,2016-10-25 14:27:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FKUGu8s5ZTY/merck-keytruda-gets-fda-approval-for-first-line-lung-cancer-cm697709,Merck amp Co Inc MRK announced that the FDA has approved a label expansion of its PD 1 therapy Keytruda to include the first line treatment of patients whose tumors have high PD L1 expression with no EGFR or ALK genomic tumor aberrations Keytruda is approved for the treatment
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-25 13:25:05 +0000,http://www.publicnow.com/view/C4DBA7A2650FC361D95DEFD7A109AE2823B556CC,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 25 October ...
GSK,GSK:US,BBG000BLB481,Have you forgotten how good these 2 income heroes are?,2016-10-25 13:02:11 +0000,http://uk.finance.yahoo.com/news/forgotten-good-2-income-heroes-130211382.html,Have you forgotten how good these 2 income heroes are?
GSK,GSK:US,BBG000BLB481,[$$] Novartis Profit Helped by GlaxoSmithKline Joint Venture,2016-10-25 07:23:40 +0000,http://www.wsj.com/articles/novartis-profit-helped-by-glaxosmithkline-joint-venture-1477374676?mod=yahoo_hs,[$$] Novartis Profit Helped by GlaxoSmithKline Joint Venture
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline seeking U.S. approval for shingles vaccine,2016-10-24 14:55:11 +0000,http://www.bizjournals.com/philadelphia/news/2016/10/24/glaxosmithkline-gsk-shingles-vaccine-us-approval.html?ana=yahoo,GlaxoSmithKline seeking U.S. approval for shingles vaccine
GSK,GSK:US,BBG000BLB481,Will Shingrix be GlaxoSmithKline plc’s next blockbuster?,2016-10-24 13:23:10 +0000,http://uk.finance.yahoo.com/news/shingrix-glaxosmithkline-plc-next-blockbuster-132310139.html,Will Shingrix be GlaxoSmithKline plc’s next blockbuster?
GSK,GSK:US,BBG000BLB481,GSK files potential $1 billion shingles vaccine for U.S. approval,2016-10-24 07:22:09 +0000,http://sg.finance.yahoo.com/news/gsk-seeks-u-approval-shingles-064026949.html,GSK files potential $1 billion shingles vaccine for U.S. approval
GSK,GSK:US,BBG000BLB481,GSK files potential $1 billion shingles vaccine for U.S. approval,2016-10-24 07:19:22 +0000,http://in.finance.yahoo.com/news/gsk-files-potential-1-billion-071922190.html,GSK files potential $1 billion shingles vaccine for U.S. approval
GSK,GSK:US,BBG000BLB481,GSK files potential $1 bln shingles vaccine for U.S. approval,2016-10-24 07:13:16 +0000,http://uk.finance.yahoo.com/news/gsk-files-potential-1-bln-071316594.html,"[Reuters - UK Focus] - GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market. Shingrix is ..."
GSK,GSK:US,BBG000BLB481,GSK seeks U.S. approval for shingles vaccine Shingrix,2016-10-24 06:17:36 +0000,http://uk.finance.yahoo.com/news/gsk-seeks-u-approval-shingles-061736743.html,"[Reuters - UK Focus] - GlaxoSmithKline said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market. Shingrix is viewed by analysts as among ..."
GSK,GSK:US,BBG000BLB481,Glaxo Seeks FDA Approval for Experimental Shingles Vaccine,2016-10-24 06:12:32 +0000,http://www.bloomberg.com/news/articles/2016-10-24/glaxo-seeks-approval-in-u-s-for-experimental-shingles-vaccine?cmpid=yhoo.headline,Glaxo Seeks FDA Approval for Experimental Shingles Vaccine
GSK,GSK:US,BBG000BLB481,US FDA submission of shingles candidate vaccine,2016-10-24 06:11:10 +0000,http://www.publicnow.com/view/5A50085494F6600444839B4B269AF1A3D0EBEC73,"[at noodls] - Issued: 24 October 2016, London UK - LSE Announcement GSK announces US regulatory submission of candidate vaccine for prevention of shingles - Regulatory submissions in the EU and Canada remain on track ..."
GSK,GSK:US,BBG000BLB481,GSK announces US regulatory submission of candidate vaccine for prevention of shingles,2016-10-24 06:11:09 +0000,http://www.publicnow.com/view/D8E2445322498162A11131F4C3BA566416CBCDE2,[at noodls] - Regulatory submissions in the EU and Canada remain on track for 2016 GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has submitted a Biologics License Application (BLA) for its candidate shingles ...
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Seeks US Regulatory Approval for Shingles Vaccine,2016-10-24 02:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4yJQiPMP2xc/glaxosmithkline-seeks-us-regulatory-approval-for-shingles-vaccine-20161024-00036,GlaxoSmithKline Seeks US Regulatory Approval for Shingles Vaccine
GSK,GSK:US,BBG000BLB481,"GSK Submits BLA For Its Candidate Shingles Vaccine, Shingrix - Quick Facts",2016-10-24 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2jRk-jaUp9M/gsk-submits-bla-for-its-candidate-shingles-vaccine-shingrix--quick-facts-20161024-01141,"GSK Submits BLA For Its Candidate Shingles Vaccine, Shingrix - Quick Facts"
GSK,GSK:US,BBG000BLB481,"No Cure Yet for Breast Cancer, but 3 Big Advances in 2016",2016-10-23 18:24:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FnBBI7_t0XI/no-cure-yet-for-breast-cancer-but-3-big-advances-in-2016-cm696885,In the U S one in eight women will be diagnosed with breast cancer in her lifetime I became one of those eight women a decade ago and endured the go to treatment at the time for breast cancer chemotherapy surgery radiation with ensuing hair loss and constant nausea But there
GSK,GSK:US,BBG000BLB481,Do Analysts Expect Negative Growth for Novartis in 3Q16?,2016-10-21 22:04:10 +0000,http://marketrealist.com/2016/10/do-analysts-expect-negative-growth-for-novartis-in-3q16/?utm_source=yahoo&utm_medium=feed,Do Analysts Expect Negative Growth for Novartis in 3Q16?
GSK,GSK:US,BBG000BLB481,What’s to Be Expected from Novartis’s 3Q16 Earnings?,2016-10-21 19:47:21 +0000,http://marketrealist.com/2016/10/whats-to-be-expected-from-novartiss-3q16-earnings/?utm_source=yahoo&utm_medium=feed,What’s to Be Expected from Novartis’s 3Q16 Earnings?
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-21 15:29:01 +0000,http://www.publicnow.com/view/D2DD59BB67A05C414C85033EA66ABDA40D409212,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 21 October ...
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline (GSK) Q3 Earnings: What's in the Cards?,2016-10-21 15:27:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5-rUMmrAk_g/glaxosmithkline-gsk-q3-earnings-whats-in-the-cards-cm696591,GlaxoSmithKline plc GSK is scheduled to report third quarter 2016 results on Oct 26 Last quarter the company delivered a positive earnings surprise of 27 27 Let s see how things are shaping up for this quarter Factors at Play Glaxo focuses on its three core
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline (GSK) Q3 Earnings: What's in the Cards?,2016-10-21 13:27:01 +0000,http://finance.yahoo.com/news/glaxosmithkline-gsk-q3-earnings-whats-132701834.html,GlaxoSmithKline (GSK) Q3 Earnings: What's in the Cards?
GSK,GSK:US,BBG000BLB481,Which is the better buy? GlaxoSmithKline plc vs Shire plc,2016-10-21 10:58:08 +0000,http://uk.finance.yahoo.com/news/better-buy-glaxosmithkline-plc-vs-105808134.html,Which is the better buy? GlaxoSmithKline plc vs Shire plc
GSK,GSK:US,BBG000BLB481,Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc,2016-10-20 14:51:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HLX0hoH3a_E/better-buy-pfizer-inc-vs-glaxosmithkline-plc-cm695872,Image source Getty Images You don t want to go buy just any big pharma stock Some are definitely better than others But figuring out which big pharma stock to go with requires checking out the companies product lineups pipelines and financial health Digging into those details
GSK,GSK:US,BBG000BLB481,Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc,2016-10-20 14:24:39 +0000,http://www.fool.com/investing/2016/10/20/better-buy-pfizer-inc-vs-glaxosmithkline.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Pfizer Inc. vs. GlaxoSmithKline plc
GSK,GSK:US,BBG000BLB481,"[video]These 5 Big-Cap Stocks Are Breaking Out After the Debate: Alphabet, Visa and More",2016-10-20 12:17:00 +0000,https://www.thestreet.com/story/13860053/1/these-5-big-cap-stocks-are-breaking-out-after-the-debate-alphabet-visa-and-more.html?puc=yahoo&cm_ven=YAHOO,"[video]These 5 Big-Cap Stocks Are Breaking Out After the Debate: Alphabet, Visa and More"
GSK,GSK:US,BBG000BLB481,Lackluster Sales Growth Puts Publicis on Defensive,2016-10-20 06:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dx8CTBgTGkk/lackluster-sales-growth-puts-publicis-on-defensive-20161020-00160,Lackluster Sales Growth Puts Publicis on Defensive
GSK,GSK:US,BBG000BLB481,WHO seeks new mechanism for crisis vaccine supplies at low cost,2016-10-19 14:27:59 +0000,http://uk.finance.yahoo.com/news/seeks-mechanism-crisis-vaccine-supplies-142759573.html,"[Reuters - UK Focus] - LONDON, Oct (HKSE: 3366-OL.HK - news) 19 (Reuters) - The World Health Organization, drugmakers and humanitarian groups are hammering out details of a new vaccine supply system aimed at getting vital shots to vulnerable people in crises such as wars or natural disasters. The mechanism, which so far has British drugmaker GlaxoSmithKline (Other OTC: GLAXF - news) signed up to provide its pneumonia vaccine at the lowest possible price, will ask other major pharmaceutical firms including Pfizer (NYSE: PFE - news) and Merck (Jakarta: 28586808.JK - news) to make similar cut-price agreements for emergencies only. ""The idea is that this will set a model in place for other manufacturers to put their vaccines on the table,"" said Greg Elder, a medical coordinator with the international charity Medecins Sans Frontieres (MSF) which joined talks on the issue at the WHO's Geneva headquarters last week."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Plc (GSK) Shrugs Skeptics Concerns To Launch Cold Flu Tracker App,2016-10-19 04:05:44 +0000,http://www.insidermonkey.com/blog/glaxosmithkline-plc-gsk-shrugs-skeptics-concerns-to-launch-cold-flu-tracker-app-482066/,GlaxoSmithKline Plc (GSK) Shrugs Skeptics Concerns To Launch Cold Flu Tracker App
GSK,GSK:US,BBG000BLB481,Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.,2016-10-18 22:10:17 +0000,http://www.fool.com/investing/2016/10/18/better-buy-agenus-inc-vs-bellicum.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.
GSK,GSK:US,BBG000BLB481,Better Buy: Agenus Inc. vs. Bellicum Pharmaceuticals Inc.,2016-10-18 21:48:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hHkafuNI_74/better-buy-agenus-inc-vs-bellicum-pharmaceuticals-inc-cm695041,Image source Getty Images It s been a good year for clinical stage biotech Agenus Inc NASDAQ AGEN Its shares are up over 20 in 2016 160 Meanwhile shares of peer Bellicum Pharmaceuticals NASDAQ BLCM 160 have sunk more than 20 Which of these two biotech
GSK,GSK:US,BBG000BLB481,Eli Lilly’s 3Q16 Earnings: What to Expect,2016-10-18 21:21:03 +0000,http://marketrealist.com/2016/10/eli-lillys-3q16-earnings-what-to-expect/?utm_source=yahoo&utm_medium=feed,Eli Lilly’s 3Q16 Earnings: What to Expect
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-18 06:03:10 +0000,http://www.publicnow.com/view/ACE055CF8CA1DA79590632A9A4C7F7BAF77A51AA,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 18 October ...
GSK,GSK:US,BBG000BLB481,Why You Should Wait to Buy These 3 Stocks,2016-10-17 18:25:06 +0000,http://www.fool.com/investing/2016/10/16/why-you-should-wait-to-buy-these-3-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why You Should Wait to Buy These 3 Stocks
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-17 17:23:06 +0000,http://www.publicnow.com/view/3710EE6094A9ABE40EF0ED139365975562C30658,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 17 October ...
GSK,GSK:US,BBG000BLB481,GSK January 2019 Options Begin Trading,2016-10-17 16:43:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7Aoc2m5_XAY/gsk-january-2019-options-begin-trading-cm694221,Investors in GlaxoSmithKline plc Symbol GSK saw new options begin trading today for the January 2019 expiration One of the key data points that goes into the price an option buyer is willing to pay is the time value so with 823 days until expiration the newly trading contracts represent
GSK,GSK:US,BBG000BLB481,Why You Should Wait to Buy These 3 Stocks,2016-10-16 19:40:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tu_-FaZRci0/why-you-should-wait-to-buy-these-3-stocks-cm693874,Source image Getty Images Stocks that appear worth buying sometimes aren t Any number of things can derail an otherwise promising stock and that means investors need to do their fair share of digging before buying To help identify stocks that investors ought to approach
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-14 16:21:02 +0000,http://www.publicnow.com/view/572013295615A04A8F89E7E972B14F8F3BDBF7FF,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 14 October ...
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : August 12th, 2016 (record date) : By the numbers : October 14, 2016",2016-10-14 15:43:57 +0000,http://www.capitalcube.com/blog/index.php/glaxosmithkline-plc-gsk-us-dividend-analysis-august-12th-2016-record-date-by-the-numbers-october-14-2016/,"GlaxoSmithKline Plc : GSK-US: Dividend Analysis : August 12th, 2016 (record date) : By the numbers : October 14, 2016"
GSK,GSK:US,BBG000BLB481,Shark Tank's O'Leary Bullish on GlaxoSmithKline (GSK),2016-10-13 17:20:00 +0000,https://www.thestreet.com/story/13852654/1/shark-tank-s-o-leary-bullish-on-glaxosmithkline-gsk.html?puc=yahoo&cm_ven=YAHOO,Shark Tank's O'Leary Bullish on GlaxoSmithKline (GSK)
GSK,GSK:US,BBG000BLB481,"Zacks Value Investor Highlights: GlaxoSmithKline, AstraZeneca, British American Tobacco, iShares United Kingdom ETF and Ishares MSCI United Kingdom Small Cap ETF",2016-10-13 16:46:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EGa1HROjo6k/zacks-value-investor-highlights-glaxosmithkline-astrazeneca-british-american-tobacco-ishares-united-kingdom-etf-and-ishares-msci-united-kingdom-small-cap-etf-cm692961,For Immediate Release Chicago IL October 13 2016 Zacks Value Investor is a podcast hosted weekly by Zacks Stock Strategist Tracey Ryniec Every week Tracey will be joined by guests to discuss the hottest investing topics in stocks bonds and ETFs and how it impacts your life To listen
GSK,GSK:US,BBG000BLB481,BofA: Expect upside to Merck estimates,2016-10-13 16:24:00 +0000,http://finance.yahoo.com/video/bofa-expect-upside-merck-estimates-162400174.html,BofA: Expect upside to Merck estimates
GSK,GSK:US,BBG000BLB481,Here’s What We Want To See From Adaptimmune Therapeutics PLC – ADR (ADAP),2016-10-13 14:40:29 +0000,http://www.insidermonkey.com/blog/heres-what-we-want-to-see-from-adaptimmune-therapeutics-plc-adr-adap-481062/,Here’s What We Want To See From Adaptimmune Therapeutics PLC – ADR (ADAP)
GSK,GSK:US,BBG000BLB481,World Health Organization warns that global tuberculosis fight is billions of dollars behind,2016-10-13 14:00:46 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=0160EDAA-7AC7-476B-B40B-8B788BA2D307&siteid=yhoof2,World Health Organization warns that global tuberculosis fight is billions of dollars behind
GSK,GSK:US,BBG000BLB481,Defensive stocks showdown: GlaxoSmithKline plc vs Reckitt Benckiser Group plc,2016-10-13 10:42:14 +0000,http://uk.finance.yahoo.com/news/defensive-stocks-showdown-glaxosmithkline-plc-104214577.html,Defensive stocks showdown: GlaxoSmithKline plc vs Reckitt Benckiser Group plc
GSK,GSK:US,BBG000BLB481,Is Brexit a Buying Opportunity?,2016-10-12 23:40:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/udIMNRXtAWo/is-brexit-a-buying-opportunity-cm692616,Welcome to Episode 13 of the Value Investor Podcast Every week Zacks value stock strategist and the Editor of Zacks Value Investor portfolio service Tracey Ryniec talks about all things happening in the value stock universe including her top stock picks This week Tracey discusses how
GSK,GSK:US,BBG000BLB481,Is Brexit a Buying Opportunity?,2016-10-12 21:18:09 +0000,http://finance.yahoo.com/news/brexit-buying-opportunity-211809594.html,Is Brexit a Buying Opportunity?
GSK,GSK:US,BBG000BLB481,"Tweedy Browne Adds to 5 Holdings, Trims — Others in ‘rd Quarter",2016-10-12 19:40:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fRUssXXBqTw/tweedy-browne-adds-to-5-holdings-trims-others-in-rd-quarter-cm692521,Tweedy Browne Trades Portfolio made five modest additions to holdings in its portfolio and two reductions that were more substantial during the third quarter The guru s most significant addition was the purchase of 646 4 shares in HSBC Holdings PLC LSE HBA a London
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-12 16:39:06 +0000,http://www.publicnow.com/view/BA1F684E22A46EE4132B03416EF6D46049EBCCE9,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 12 October ...
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Chevron, Cisco Systems, GlaxoSmithKline, NIKE and BP",2016-10-12 14:41:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B74rZdcpzQ8/the-zacks-analyst-blog-highlights-chevron-cisco-systems-glaxosmithkline-nike-and-bp-cm692358,For Immediate Release Chicago IL October 12 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Chevron, Cisco Systems, GlaxoSmithKline, NIKE and BP",2016-10-12 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-chevron-133001518.html,"The Zacks Analyst Blog Highlights: Chevron, Cisco Systems, GlaxoSmithKline, NIKE and BP"
GSK,GSK:US,BBG000BLB481,4 Contrarian Stocks to Buy Yielding 5% or More With Big Upside Potential,2016-10-12 12:35:37 +0000,http://247wallst.com/investing/2016/10/12/4-contrarian-stocks-to-buy-yielding-5-or-more-with-big-upside-potential/,4 Contrarian Stocks to Buy Yielding 5% or More With Big Upside Potential
GSK,GSK:US,BBG000BLB481,Is this stock a buy after reporting a 150% increase in revenue?,2016-10-12 11:11:32 +0000,http://uk.finance.yahoo.com/news/stock-buy-reporting-150-increase-111132973.html,Is this stock a buy after reporting a 150% increase in revenue?
GSK,GSK:US,BBG000BLB481,"Tweedy Browne Adds to 5 Holdings, Trims 2 Others in 3rd Quarter",2016-10-11 22:17:22 +0000,http://finance.yahoo.com/news/tweedy-browne-adds-5-holdings-221722833.html,"Tweedy Browne Adds to 5 Holdings, Trims 2 Others in 3rd Quarter"
GSK,GSK:US,BBG000BLB481,"Top Research Reports for Chevron, Cisco & GlaxoSmithKline",2016-10-11 20:18:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rmxfj1ZMSDE/top-research-reports-for-chevron-cisco-glaxosmithkline-cm692043,Tuesday October 11 2016 Today s Research Daily features research reports on 8 major stocks including Chevron Corp CVX Cisco Systems Inc CSCO and GlaxoSmithKline plc GSK Chevron shares have responded more positively to the recent oil price momentum than some of its
GSK,GSK:US,BBG000BLB481,Why Doctors Without Borders is turning down a million free pneumonia vaccines from Pfizer,2016-10-11 17:36:22 +0000,http://finance.yahoo.com/news/why-doctors-without-borders-turning-173622188.html,Why Doctors Without Borders is turning down a million free pneumonia vaccines from Pfizer
GSK,GSK:US,BBG000BLB481,"Top Research Reports for Chevron, Cisco & GlaxoSmithKline",2016-10-11 16:19:04 +0000,http://finance.yahoo.com/news/top-research-reports-chevron-cisco-161904143.html,"Top Research Reports for Chevron, Cisco & GlaxoSmithKline"
GSK,GSK:US,BBG000BLB481,Which Big Pharma Is the Best Dividend Stock?,2016-10-10 16:08:28 +0000,http://www.fool.com/investing/2016/10/09/which-big-pharma-is-the-best-dividend-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Which Big Pharma Is the Best Dividend Stock?
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-10-10 15:53:02 +0000,http://www.publicnow.com/view/6BB2C9225FFFCE622EB90BADBCDAECD37D7EAF58,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 10 October ...
GSK,GSK:US,BBG000BLB481,Which Big Pharma Is the Best Dividend Stock?,2016-10-09 17:18:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGmWRS42cQ8/which-big-pharma-is-the-best-dividend-stock-cm690785,Image source Getty Images Big pharma stocks have historically been among investors favorite dividend stocks Which major drugmaker stock is the best of all I think turning to Charles Dickens can help answer the question Before you think I ve lost my mind let me explain
GSK,GSK:US,BBG000BLB481,How Much Potential Does Idera Pharmaceuticals' Pipeline Really Have?,2016-10-09 15:44:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QLSLAetIYUc/how-much-potential-does-idera-pharmaceuticals-pipeline-really-have-cm690771,Image source Getty Images Shares of Idera Pharmaceuticals NASDAQ IDRA are down around 15 year to date And that s a good thing relatively speaking The clinical stage biotech s stock was down by more than 55 just a few months ago Idera s current market cap of over
GSK,GSK:US,BBG000BLB481,How Much Potential Does Idera Pharmaceuticals' Pipeline Really Have?,2016-10-09 13:43:31 +0000,http://www.fool.com/investing/2016/10/09/how-much-potential-does-idera-pharmaceuticals-pipe.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How Much Potential Does Idera Pharmaceuticals' Pipeline Really Have?
GSK,GSK:US,BBG000BLB481,BioDelivery Sciences (BDSI) Board Appoints New Members,2016-10-07 16:45:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hY9ZfCD8DrE/biodelivery-sciences-bdsi-board-appoints-new-members-cm690413,BioDelivery Sciences International Inc BDSI announced a couple of changes in its management While Timothy C Tyson has been appointed to the company s board of directors as an independent member Dr Mark A Sirgo the present President and Chief Executive Officer CEO and board member
GSK,GSK:US,BBG000BLB481,Will Gilead (GILD) Stock Fall as RBC Warns of HIV Competition?,2016-10-05 17:37:00 +0000,https://www.thestreet.com/story/13842555/1/will-gilead-gild-stock-fall-as-rbc-warns-of-hiv-competition.html?puc=yahoo&cm_ven=YAHOO,Will Gilead (GILD) Stock Fall as RBC Warns of HIV Competition?
GSK,GSK:US,BBG000BLB481,How Much Return Could Gilead Offer in the Next Year?,2016-10-05 14:04:20 +0000,http://marketrealist.com/2016/09/how-much-return-could-gilead-offer-in-the-next-year/?utm_source=yahoo&utm_medium=feed,How Much Return Could Gilead Offer in the Next Year?
GSK,GSK:US,BBG000BLB481,Gilead Sciences: More Competition?!?!,2016-10-05 13:56:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/05/gilead-sciences-more-competition/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: More Competition?!?!
GSK,GSK:US,BBG000BLB481,Could these FTSE 100 giants boost your portfolio higher?,2016-10-05 07:51:26 +0000,http://uk.finance.yahoo.com/news/could-ftse-100-giants-boost-075126686.html,Could these FTSE 100 giants boost your portfolio higher?
GSK,GSK:US,BBG000BLB481,"Pound Slump Highlights Brexit Concerns, Lifts FTSE to Near Record",2016-10-04 16:12:00 +0000,https://www.thestreet.com/story/13841014/1/pound-slump-highlights-brexit-concerns-lifts-ftse-to-near-record.html?puc=yahoo&cm_ven=YAHOO,"Pound Slump Highlights Brexit Concerns, Lifts FTSE to Near Record"
GSK,GSK:US,BBG000BLB481,Pound Drops to 31-Year Low Against Dollar on Brexit Concerns,2016-10-04 12:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/StqxLAAitGM/pound-drops-to-31year-low-against-dollar-on-brexit-concerns-20161004-00857,Pound Drops to 31-Year Low Against Dollar on Brexit Concerns
GSK,GSK:US,BBG000BLB481,Genvoya Could Be Gilead Sciences’ Potential Growth Driver,2016-10-04 12:05:02 +0000,http://marketrealist.com/2016/09/genvoya-could-be-gilead-sciences-potential-growth-driver/?utm_source=yahoo&utm_medium=feed,Genvoya Could Be Gilead Sciences’ Potential Growth Driver
GSK,GSK:US,BBG000BLB481,Zika vaccine race spurred by crisis and profit potential,2016-10-04 11:22:51 +0000,http://finance.yahoo.com/news/zika-vaccine-race-spurred-crisis-051317237.html,Zika vaccine race spurred by crisis and profit potential
GSK,GSK:US,BBG000BLB481,Are dividends set to soar at these FTSE 100 favourites?,2016-10-04 09:45:55 +0000,http://uk.finance.yahoo.com/news/dividends-set-soar-ftse-100-094555268.html,Are dividends set to soar at these FTSE 100 favourites?
GSK,GSK:US,BBG000BLB481,Zika vaccine race spurred by crisis and profit potential,2016-10-04 05:13:46 +0000,http://sg.finance.yahoo.com/news/zika-vaccine-race-spurred-crisis-051118240.html,Zika vaccine race spurred by crisis and profit potential
GSK,GSK:US,BBG000BLB481,Novartis Is Surviving,2016-10-03 16:44:24 +0000,http://finance.yahoo.com/news/novartis-surviving-164424371.html,Novartis Is Surviving
GSK,GSK:US,BBG000BLB481,Gilead: Will New HIV Drugs Overshadow Hep C Worries?,2016-10-03 15:03:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/10/03/gilead-will-new-hiv-drugs-overshadow-hep-c-worries/?mod=yahoobarrons&ru=yahoo,Gilead: Will New HIV Drugs Overshadow Hep C Worries?
GSK,GSK:US,BBG000BLB481,"ETF’s with exposure to GlaxoSmithKline Plc : October 3, 2016",2016-10-03 14:50:56 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-glaxosmithkline-plc-october-3-2016/,"ETF’s with exposure to GlaxoSmithKline Plc : October 3, 2016"
GSK,GSK:US,BBG000BLB481,Bond Bull Market Is Over: Switch to These 4 Top Dividend Stocks Now,2016-10-03 14:15:04 +0000,http://247wallst.com/investing/2016/10/03/bond-bull-market-is-over-switch-to-these-4-top-dividend-stocks-now/,Bond Bull Market Is Over: Switch to These 4 Top Dividend Stocks Now
GSK,GSK:US,BBG000BLB481,2 FTSE stocks I’m tipping to take off in October!,2016-10-03 13:23:57 +0000,http://uk.finance.yahoo.com/news/2-ftse-stocks-m-tipping-132357957.html,2 FTSE stocks I’m tipping to take off in October!
GSK,GSK:US,BBG000BLB481,Total Voting Rights,2016-10-03 09:16:04 +0000,http://www.publicnow.com/view/1794CC5BC223CF40DC26003A30CECA3AAE544781,"[at noodls] - GlaxoSmithKline plc and Capital Inconformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital ..."
GSK,GSK:US,BBG000BLB481,Novo Nordisk Bets on Riskier Insulin Research,2016-10-02 23:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FG75k0yXfyc/novo-nordisk-bets-on-riskier-insulin-research-20161002-00060,Novo Nordisk Bets on Riskier Insulin Research
GSK,GSK:US,BBG000BLB481,Strong Revenue Points to Gains at GlaxoSmithKline,2016-10-02 00:45:12 +0000,http://finance.yahoo.com/news/strong-revenue-points-gains-glaxosmithkline-004512966.html,Strong Revenue Points to Gains at GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson,2016-10-01 17:21:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VA9Xj3xKm0I/better-buy-glaxosmithkline-plc-vs-johnson-johnson-cm687482,Image source Johnson amp Johnson Many investors gravitate to large company stocks in the pharmaceutical space because of the combination of growth and reliable dividend income that they offer GlaxoSmithKline NYSE GSK and Johnson amp Johnson NYSE JNJ are giants in
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson,2016-10-01 15:42:05 +0000,http://www.fool.com/investing/2016/10/01/better-buy-glaxosmithkline-plc-vs-johnson-johnson.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: GlaxoSmithKline plc vs. Johnson & Johnson
GSK,GSK:US,BBG000BLB481,Glaxo paying $20M to resolve SEC charges of China bribery,2016-09-30 22:45:19 +0000,http://sg.finance.yahoo.com/news/glaxo-paying-20m-resolve-sec-222829478.html,Glaxo paying $20M to resolve SEC charges of China bribery
GSK,GSK:US,BBG000BLB481,[$$] GlaxoSmithKline to Pay $20 Million to Settle SEC Bribery Probe,2016-09-30 21:05:27 +0000,http://www.wsj.com/articles/glaxosmithkline-to-pay-20-million-to-settle-sec-bribery-probe-1475268346?mod=yahoo_hs,[$$] GlaxoSmithKline to Pay $20 Million to Settle SEC Bribery Probe
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline to pay $20 mln to settle U.S. foreign bribery case,2016-09-30 19:04:46 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-pay-20-mln-settle-190446196.html,"[Reuters - UK Focus] - GlaxoSmithKline Plc (Other OTC: GLAXF - news) will pay $20 million to settle civil charges that it masked bribes to foreign officials in China by disguising them as legitimate travel, entertainment and marketing expenses, U.S. regulators said on Friday. The pharmaceutical company agreed to settle the case with the Securities and Exchange Commission without admitting or denying any wrongdoing. In a statement, the company said it had cooperated with the SEC and it had received credit for taking steps to improve its operations, such as changing how sales representatives are paid and stopping the practice of paying healthcare professionals to speak to doctors about the company's products."
GSK,GSK:US,BBG000BLB481,Glaxo to Pay $20 Million SEC Fine Over Bribery in China,2016-09-30 18:18:49 +0000,http://www.bloomberg.com/news/articles/2016-09-30/glaxo-to-pay-20-million-sec-fine-over-bribing-chinese-officials?cmpid=yhoo.headline,Glaxo to Pay $20 Million SEC Fine Over Bribery in China
GSK,GSK:US,BBG000BLB481,Glaxo to Pay $20 Million SEC Fine Over Bribing Chinese Officials,2016-09-30 18:18:49 +0000,http://finance.yahoo.com/news/glaxo-pay-20-million-sec-181849990.html,Glaxo to Pay $20 Million SEC Fine Over Bribing Chinese Officials
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline to pay $20 mln to settle foreign bribery related charges,2016-09-30 18:18:30 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-pay-20-mln-settle-181830640.html,"[Reuters - UK Focus] - GlaxoSmithKline will pay $20 million to settle civil charges that it masked improper bribes to foreign officials in China on its books by disguising them as legitimate travel, entertainment and marketing ..."
GSK,GSK:US,BBG000BLB481,The Highest-Yielding Drug Stocks,2016-09-30 17:25:20 +0000,http://www.fool.com/investing/2016/09/29/the-highest-yielding-drug-stocks.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Highest-Yielding Drug Stocks
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline to Pay $20 Million to Settle SEC Bribery Probe,2016-09-30 17:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YX8Dw-COg_M/glaxosmithkline-to-pay-20-million-to-settle-sec-bribery-probe-20160930-00745,GlaxoSmithKline to Pay $20 Million to Settle SEC Bribery Probe
GSK,GSK:US,BBG000BLB481,Which Pfizer Products Reported Declining Sales?,2016-09-30 15:05:21 +0000,http://marketrealist.com/2016/09/which-pfizer-products-reported-declining-sales/?utm_source=yahoo&utm_medium=feed,Which Pfizer Products Reported Declining Sales?
GSK,GSK:US,BBG000BLB481,Understanding Strong Growth Trends in Insulin and Novo Nordisk’s Profitability,2016-09-30 15:05:09 +0000,http://marketrealist.com/2016/09/strong-growth-trends-insulin-market-expected-boost-novo-nordisks-profitability/?utm_source=yahoo&utm_medium=feed,Understanding Strong Growth Trends in Insulin and Novo Nordisk’s Profitability
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline completes sale of remaining Aspen shares,2016-09-29 14:20:05 +0000,http://www.publicnow.com/view/223C321D2C314BDAAC0C2DE13DD6679061A5F23B,"[at noodls] - Issued: London Further to the announcement by GlaxoSmithKline on 28 September 2016, GlaxoSmithKline has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ('Aspen') at ..."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline announces intention to sell remaining holding in Aspen,2016-09-29 14:20:04 +0000,http://www.publicnow.com/view/880DA02E560DD10A3FE10A35C2EA3A0DDF161F79,[at noodls] - Issued: London GlaxoSmithKline announces that it intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd ('Aspen'). The disposal will be through a placing of ordinary shares in Aspen to institutional ...
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline (GSK) Stock Down, McNamara Named CEO of Consumer Healthcare Unit",2016-09-29 13:52:00 +0000,https://www.thestreet.com/story/13836020/1/glaxosmithkline-gsk-stock-down-mcnamara-named-ceo-of-consumer-healthcare-unit.html?puc=yahoo&cm_ven=YAHOO,"GlaxoSmithKline (GSK) Stock Down, McNamara Named CEO of Consumer Healthcare Unit"
GSK,GSK:US,BBG000BLB481,Glaxo Appoints Brian McNamara Chief of Consumer Health Division,2016-09-29 12:40:34 +0000,http://www.bloomberg.com/news/articles/2016-09-29/glaxo-appoints-brian-mcnamara-chief-of-consumer-health-division?cmpid=yhoo.headline,Glaxo Appoints Brian McNamara Chief of Consumer Health Division
GSK,GSK:US,BBG000BLB481,"After CEO move, GSK picks ex-Novartis executive to head consumer unit",2016-09-29 12:24:13 +0000,http://sg.finance.yahoo.com/news/ceo-move-gsk-picks-ex-122413740.html,"After CEO move, GSK picks ex-Novartis executive to head consumer unit"
GSK,GSK:US,BBG000BLB481,"After CEO move, GSK picks ex-Novartis exec to head consumer unit",2016-09-29 12:20:03 +0000,http://uk.finance.yahoo.com/news/ceo-move-gsk-picks-ex-122003806.html,"After CEO move, GSK picks ex-Novartis exec to head consumer unit"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare,2016-09-29 11:40:09 +0000,http://www.publicnow.com/view/650CFD50C5FA1BB915173B38693CFC62FECC27D0,"[at noodls] - Issued: London, UK GSK today announced that Brian McNamara, is appointed Chief Executive Officer (CEO) of GSK's Consumer Healthcare division effective immediately. ... This is an abstract of the original ..."
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-09-29 09:30:08 +0000,http://www.publicnow.com/view/05FB872A040C6BB2B6A25FE3426185CA8E732ADD,[at noodls] - Released :29.09.2016 10:17 RNS Number : 2016L GlaxoSmithKline PLC 29 September 2016 GlaxoSmithKline plc(the 'Company') Transaction notification 1. ... This is an abstract of the original noodl. To continue ...
GSK,GSK:US,BBG000BLB481,Aspen Sinks to Four-Month Low as Volumes Surge After Glaxo Sells,2016-09-29 08:16:37 +0000,http://finance.yahoo.com/news/aspen-sinks-four-month-low-081637041.html,Aspen Sinks to Four-Month Low as Volumes Surge After Glaxo Sells
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Plans To Sell Remaining Holding In Aspen,2016-09-28 23:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fpe9ukzNZUQ/glaxosmithkline-plans-to-sell-remaining-holding-in-aspen-20160928-01122,GlaxoSmithKline Plans To Sell Remaining Holding In Aspen
GSK,GSK:US,BBG000BLB481,Ariel Funds Comments on GlaxoSmithKline plc,2016-09-28 19:14:25 +0000,http://finance.yahoo.com/news/ariel-funds-comments-glaxosmithkline-plc-191425005.html,Ariel Funds Comments on GlaxoSmithKline plc
GSK,GSK:US,BBG000BLB481,John Rogers' Ariel Global Fund 2nd Quarter Commentary,2016-09-28 17:58:46 +0000,http://finance.yahoo.com/news/john-rogers-ariel-global-fund-175846072.html,John Rogers' Ariel Global Fund 2nd Quarter Commentary
GSK,GSK:US,BBG000BLB481,Glaxo Sells Stake in South Africa’s Aspen for $619 Million,2016-09-28 16:21:51 +0000,http://www.bloomberg.com/news/articles/2016-09-28/glaxo-to-sell-rest-of-stake-in-south-africa-s-aspen-to-investors?cmpid=yhoo.headline,Glaxo Sells Stake in South Africa’s Aspen for $619 Million
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: General Electric, GlaxoSmithKline and McDonald",2016-09-28 15:24:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nil5qH_80Vo/the-zacks-analyst-blog-highlights-general-electric-glaxosmithkline-and-mcdonald-cm685903,For Immediate Release Chicago IL September 28 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Vaccines for Malaria, Zika Make It a Likely Winner",2016-09-28 13:55:00 +0000,https://www.thestreet.com/story/13753689/1/glaxosmithkline-vaccines-for-malaria-zika-make-it-a-likely-winner.html?puc=yahoo&cm_ven=YAHOO,"GlaxoSmithKline Vaccines for Malaria, Zika Make It a Likely Winner"
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: General Electric, GlaxoSmithKline and McDonald",2016-09-28 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-general-133001338.html,"The Zacks Analyst Blog Highlights: General Electric, GlaxoSmithKline and McDonald"
GSK,GSK:US,BBG000BLB481,Battle of the Pharmaceutical Bigwigs: GlaxoSmithKline vs. Pfizer,2016-09-28 13:29:00 +0000,https://www.thestreet.com/story/13753462/1/battle-of-the-pharmaceutical-bigwigs-glaxosmithkline-vs-pfizer.html?puc=yahoo&cm_ven=YAHOO,Battle of the Pharmaceutical Bigwigs: GlaxoSmithKline vs. Pfizer
GSK,GSK:US,BBG000BLB481,3 Stocks to Avoid in Healthcare,2016-09-28 13:21:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sZ-YXVngQbk/3-stocks-to-avoid-in-healthcare-cm685768,Image source Getty Images Sometimes it can be just as important to know which stocks you shouldn t buy as it is to know which ones you should To help you separate the good from the bad we asked a team of Fools to highlight a healthcare stock they think should be avoided Read on
GSK,GSK:US,BBG000BLB481,3 Stocks to Avoid in Healthcare,2016-09-28 12:03:00 +0000,http://www.fool.com/investing/2016/09/28/3-stocks-to-avoid-in-healthcare.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Stocks to Avoid in Healthcare
GSK,GSK:US,BBG000BLB481,"New Research Reports for GE, McDonald's & GSK",2016-09-27 19:21:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/45sSPXdV0LU/new-research-reports-for-ge-mcdonalds-gsk-cm685538,Tuesday September 27 2016 Stocks started the Tuesday session modestly in the green after two down sessions with many seeing the tightening presidential election as adding to market uncertainty Oil gold the U S dollar and the 10 year Treasury bond yield lost ground in the morning with
GSK,GSK:US,BBG000BLB481,"New Research Reports for GE, McDonald's & GSK",2016-09-27 15:45:03 +0000,http://finance.yahoo.com/news/research-reports-ge-mcdonalds-gsk-154503451.html,"New Research Reports for GE, McDonald's & GSK"
GSK,GSK:US,BBG000BLB481,France’s Essilor Said to Hire Glaxo’s Halper as Head of M&A,2016-09-26 21:50:57 +0000,http://www.bloomberg.com/news/articles/2016-09-26/france-s-essilor-said-to-hire-glaxo-s-halper-as-new-head-of-m-a?cmpid=yhoo.headline,France’s Essilor Said to Hire Glaxo’s Halper as Head of M&A
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-09-26 16:09:07 +0000,http://www.publicnow.com/view/087F62236C75D1283ECB29927FBC938D1F032490,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 26 September ...
GSK,GSK:US,BBG000BLB481,The Internet of Medical Things: 6 Stocks in Focus,2016-09-26 15:24:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lzQhfP0_jp4/the-internet-of-medical-things-6-stocks-in-focus-cm684443,The Internet of Medical Things IoMT is fast gaining pace as pharma companies look to innovate and keep up with technology to help patients and physicians better monitor and track diseases With a couple of deals being announced this month IoMT seems like the future of healthcare IoMT
GSK,GSK:US,BBG000BLB481,Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.,2016-09-26 14:23:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K9Ax-4UKSbk/glaxojj-file-bla-for-rheumatoid-arthritis-drug-in-the-us-cm684479,GlaxoSmithKline plc GSK and Johnson amp Johnson s JNJ Janssen Biotech Inc announced the submission of a Biologics License Application BLA for sirukumab for the treatment of adults with moderate to severely active rheumatoid arthritis RA The companies are seeking approval for
GSK,GSK:US,BBG000BLB481,The Internet of Medical Things: 6 Stocks in Focus,2016-09-26 13:33:01 +0000,http://finance.yahoo.com/news/internet-medical-things-6-stocks-133301649.html,The Internet of Medical Things: 6 Stocks in Focus
GSK,GSK:US,BBG000BLB481,Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.,2016-09-26 12:56:12 +0000,http://finance.yahoo.com/news/glaxo-j-j-file-bla-125612704.html,Glaxo/J&J File BLA for Rheumatoid Arthritis Drug in the U.S.
GSK,GSK:US,BBG000BLB481,Apple iPhone Calling Big Pharma: We Can Help You Develop Better Drugs,2016-09-26 10:25:05 +0000,http://www.fool.com/investing/2016/09/25/apple-iphone-calling-big-pharma-we-can-help-you-de.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Apple iPhone Calling Big Pharma: We Can Help You Develop Better Drugs
GSK,GSK:US,BBG000BLB481,Apple iPhone Calling Big Pharma: We Can Help You Develop Better Drugs,2016-09-25 19:20:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OPiBdXoDZYc/apple-iphone-calling-big-pharma-we-can-help-you-develop-better-drugs-cm684253,Image source Getty Images Apple s NASDAQ AAPL iPhone just scored its first big drug deal Okay I m kidding but not really Through an app called PARADE short for Pa tient R heumatoid A rthritis D ata from the R e al World global
GSK,GSK:US,BBG000BLB481,3 Bold Bets on the Future of Biotechnology,2016-09-25 16:21:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7y-GJVbrQlM/3-bold-bets-on-the-future-of-biotechnology-cm684232,Image source Getty Images While we Fools generally invest in companies that are established and generating cash we also recognize that there s room for speculation in almost any portfolio After all companies that go on to create the next big thing can produce life changing
GSK,GSK:US,BBG000BLB481,3 Bold Bets on the Future of Biotechnology,2016-09-25 15:10:05 +0000,http://www.fool.com/investing/2016/09/25/3-bold-bets-on-the-future-of-biotechnology.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Bold Bets on the Future of Biotechnology
GSK,GSK:US,BBG000BLB481,5 Stocks to Sell Now Before It's Too Late,2016-09-24 14:00:00 +0000,https://www.thestreet.com/story/13749826/1/5-stocks-to-sell-now-before-it-s-too-late.html?puc=yahoo&cm_ven=YAHOO,5 Stocks to Sell Now Before It's Too Late
GSK,GSK:US,BBG000BLB481,GSK announces US regulatory submission for sirukumab in rheumatoid arthritis,2016-09-23 12:22:04 +0000,http://www.publicnow.com/view/B2A1066D3E0D9E2E76264BAA7C62E5367B4F1469,[at noodls] - Issued:London UK - LSE Announcement GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) by ...
GSK,GSK:US,BBG000BLB481,US Regulatory Submission for sirukumab in RA,2016-09-23 12:12:04 +0000,http://www.publicnow.com/view/9C97BD5FF9EA7DA65C1383A3C6016C75937154D0,"[at noodls] - Issued: 23 September 2016, London UK - LSE Announcement GSK announces US regulatory submission for sirukumab in rheumatoid arthritis GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of ..."
GSK,GSK:US,BBG000BLB481,[$$] GSK's 'fiercely competitive' Emma Walmsley faces test of experience,2016-09-23 11:54:25 +0000,"http://www.ft.com/cms/s/b59e537c-8168-11e6-bc52-0c7211ef3198,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - To most people who have encountered Emma Walmsley, her appointment this week as the next head of GlaxoSmithKline, the UK drugmaker, will probably come as little surprise. ""She's ruthlessly ambitious,"" ..."
GSK,GSK:US,BBG000BLB481,GSK Announces U.S. Regulatory Submission For Sirukumab In Rheumatoid Arthritis,2016-09-23 08:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JQ_ogRlrXcQ/gsk-announces-us-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis-20160923-00023,GSK Announces U.S. Regulatory Submission For Sirukumab In Rheumatoid Arthritis
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Files US Regulatory Application for Sirukumab in Rheumatoid Arthritis,2016-09-23 08:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TMbOobIuHtI/glaxosmithkline-files-us-regulatory-application-for-sirukumab-in-rheumatoid-arthritis-20160923-00020,GlaxoSmithKline Files US Regulatory Application for Sirukumab in Rheumatoid Arthritis
GSK,GSK:US,BBG000BLB481,The Pros and Cons of Buying Gilead Sciences Stock,2016-09-22 16:24:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O5MA38eTElM/the-pros-and-cons-of-buying-gilead-sciences-stock-cm683245,Image source Stockmonkeys com via Flickr Gilead Sciences NASDAQ GILD is a biotech Goliath generating 30 billion in annualized sales and 14 billion in annualized net income However shares have fallen in the past year Does Gilead Sciences falling share price offer
GSK,GSK:US,BBG000BLB481,Hard to swallow: emerging markets get tougher for drugmakers,2016-09-22 15:54:22 +0000,http://in.finance.yahoo.com/news/hard-swallow-emerging-markets-tougher-155422862.html,Hard to swallow: emerging markets get tougher for drugmakers
GSK,GSK:US,BBG000BLB481,Hard to swallow - emerging markets get tougher for drugmakers,2016-09-22 15:19:00 +0000,http://sg.finance.yahoo.com/news/hard-swallow-emerging-markets-tougher-151403852.html,Hard to swallow - emerging markets get tougher for drugmakers
GSK,GSK:US,BBG000BLB481,The Pros and Cons of Buying Gilead Sciences Stock,2016-09-22 14:48:00 +0000,http://www.fool.com/investing/2016/09/22/the-pros-and-cons-of-buying-gilead-sciences-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Pros and Cons of Buying Gilead Sciences Stock
GSK,GSK:US,BBG000BLB481,"HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target",2016-09-22 14:45:33 +0000,http://finance.yahoo.com/news/hc-wainwright-initiates-oncomed-pharmaceuticals-144533278.html,"HC Wainwright Initiates OncoMed Pharmaceuticals With Buy Rating, $20 Target"
GSK,GSK:US,BBG000BLB481,What GlaxoSmithKline plc’s choice of CEO means for shareholders,2016-09-22 10:44:16 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-plc-choice-ceo-means-104416627.html,What GlaxoSmithKline plc’s choice of CEO means for shareholders
GSK,GSK:US,BBG000BLB481,"Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment",2016-09-21 14:05:25 +0000,http://marketrealist.com/2016/09/ionis-glaxosmithkline-partner-on-abnormal-protein-treatment/?utm_source=yahoo&utm_medium=feed,"Ionis, GlaxoSmithKline Partner on Abnormal Protein Treatment"
GSK,GSK:US,BBG000BLB481,Is Sinclair Pharma plc a better bet than GlaxoSmithKline plc?,2016-09-21 11:32:03 +0000,http://uk.finance.yahoo.com/news/sinclair-pharma-plc-better-bet-113203733.html,Is Sinclair Pharma plc a better bet than GlaxoSmithKline plc?
GSK,GSK:US,BBG000BLB481,"Inside the 10-Year, $1 Billion Battle for the Next Critical Antibiotic",2016-09-21 05:01:06 +0000,http://www.bloomberg.com/news/articles/2016-09-21/inside-the-10-year-1-billion-battle-for-the-next-critical-antibiotic?cmpid=yhoo.headline,"Inside the 10-Year, $1 Billion Battle for the Next Critical Antibiotic"
GSK,GSK:US,BBG000BLB481,PRESS DIGEST- Financial Times - Sept 21,2016-09-20 23:38:19 +0000,http://finance.yahoo.com/news/press-digest-financial-times-sept-233819700.html,"[Reuters] - The chief executive of Wells Fargo & Co came under attack from Congress on Tuesday for denying that the U.S. bank's phantom accounts scandal was a co-ordinated ""scam"" and refusing to promise to claw back executive compensation. Airbus Group Chief Executive Tom Enders plans to complete the integration of the aerospace group by sweeping away overlapping functions and appointing Fabrice Bregier, the head of its planemaker Airbus, as the group's chief operating officer. GlaxoSmithKline said on Tuesday it had chosen Emma Walmsley, head of consumer healthcare, as its new chief executive, making her the only female chief executive of a major global pharmaceuticals company."
GSK,GSK:US,BBG000BLB481,Equities in waiting mode ahead of bank decisions,2016-09-20 22:06:11 +0000,http://uk.finance.yahoo.com/news/equities-waiting-mode-ahead-bank-164141635.html,Equities in waiting mode ahead of bank decisions
GSK,GSK:US,BBG000BLB481,Medecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix,2016-09-20 19:30:18 +0000,http://www.insidermonkey.com/blog/medecins-sans-frontieres-happy-with-glaxosmithkline-plc-adr-gsk-price-reduction-for-synflorix-475840/,Medecins Sans Frontieres Happy with GlaxoSmithKline PLC (ADR) (GSK) Price Reduction For Synflorix
GSK,GSK:US,BBG000BLB481,Glaxo becomes seventh female-led FTSE 100 firm,2016-09-20 17:49:05 +0000,http://uk.finance.yahoo.com/news/glaxo-becomes-seventh-female-led-174905321.html,Glaxo becomes seventh female-led FTSE 100 firm
GSK,GSK:US,BBG000BLB481,GSK appoints Emma Walmsley as Sir Andrew Witty's successor,2016-09-20 16:11:00 +0000,http://uk.finance.yahoo.com/news/gsk-appoints-emma-walmsley-sir-062700164.html,GSK appoints Emma Walmsley as Sir Andrew Witty's successor
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive,2016-09-20 15:25:00 +0000,http://www.forbes.com/sites/matthewherper/2016/09/20/glaxosmithkline-appoints-big-pharmas-first-woman-chief-executive/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,GlaxoSmithKline Appoints Big Pharma's First Woman Chief Executive
GSK,GSK:US,BBG000BLB481,Breaking the mould: GSK picks Big Pharma's first female CEO,2016-09-20 15:17:58 +0000,http://in.finance.yahoo.com/news/breaking-mould-gsk-picks-big-151758799.html,Breaking the mould: GSK picks Big Pharma's first female CEO
GSK,GSK:US,BBG000BLB481,Big Pharma’s Latest Breakthrough: Choosing Its First Female CEO,2016-09-20 15:05:09 +0000,http://finance.yahoo.com/news/big-pharma-latest-breakthrough-choosing-150509307.html,Big Pharma’s Latest Breakthrough: Choosing Its First Female CEO
GSK,GSK:US,BBG000BLB481,Equities drift higher ahead of bank decisions,2016-09-20 13:55:37 +0000,http://uk.finance.yahoo.com/news/equities-drift-higher-ahead-bank-135537740.html,Equities drift higher ahead of bank decisions
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline (GSK) Stock Lower, Names Walmsley CEO",2016-09-20 13:05:00 +0000,https://www.thestreet.com/story/13745468/1/glaxosmithkline-gsk-stock-lower-names-walmsley-ceo.html?puc=yahoo&cm_ven=YAHOO,"GlaxoSmithKline (GSK) Stock Lower, Names Walmsley CEO"
GSK,GSK:US,BBG000BLB481,LONDON MARKETS: FTSE 100 Climbs As Pound Drops To Lowest In More Than A Month,2016-09-20 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fDhU-XO9rLE/london-markets-ftse-100-climbs-as-pound-drops-to-lowest-in-more-than-a-month-20160920-00152,LONDON MARKETS: FTSE 100 Climbs As Pound Drops To Lowest In More Than A Month
GSK,GSK:US,BBG000BLB481,[$$] GlaxoSmithKline: a long look,2016-09-20 11:42:43 +0000,"http://www.ft.com/cms/s/4f26a0b0-7f1d-11e6-bc52-0c7211ef3198,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - For every organisation there comes a time for an unflinching look in the mirror. GlaxoSmithKline, the UK's largest pharmaceutical group, has gazed long and hard, and then embarked on a face-changing exercise. ..."
GSK,GSK:US,BBG000BLB481,Glaxo CEO's Potential Achilles Heel,2016-09-20 11:14:54 +0000,http://www.bloomberg.com/gadfly/articles/2016-09-20/glaxo-ceo-appointment-can-overcome-lack-of-science-pedigree?cmpid=yhoo.headline,Glaxo CEO's Potential Achilles Heel
GSK,GSK:US,BBG000BLB481,British pharma group GSK appoints new CEO,2016-09-20 11:09:11 +0000,http://uk.finance.yahoo.com/news/british-pharma-group-gsk-appoints-110911020.html,British pharma group GSK appoints new CEO
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Appoints Insider Walmsley as New CEO,2016-09-20 11:00:00 +0000,https://www.thestreet.com/story/13745080/1/glaxosmithkline-appoints-insider-walmsley-as-new-ceo.html?puc=yahoo&cm_ven=YAHOO,GlaxoSmithKline Appoints Insider Walmsley as New CEO
GSK,GSK:US,BBG000BLB481,Should you buy GlaxoSmithKline plc after its change in CEO?,2016-09-20 10:43:03 +0000,http://uk.finance.yahoo.com/news/buy-glaxosmithkline-plc-change-ceo-104303665.html,Should you buy GlaxoSmithKline plc after its change in CEO?
GSK,GSK:US,BBG000BLB481,5 Things You Must Know Before the Market Opens Tuesday,2016-09-20 10:22:00 +0000,https://www.thestreet.com/story/13743531/1/5-things-you-must-know-before-the-market-opens-tuesday.html?puc=yahoo&cm_ven=YAHOO,5 Things You Must Know Before the Market Opens Tuesday
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline names insider Emma Walmsley as new CEO,2016-09-20 10:10:36 +0000,http://finance.yahoo.com/news/glaxosmithkline-names-insider-emma-walmsley-090732231.html,GlaxoSmithKline names insider Emma Walmsley as new CEO
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline names insider Emma Walmsley as new CEO,2016-09-20 10:04:20 +0000,http://sg.finance.yahoo.com/news/glaxosmithkline-names-consumer-head-walmsley-062405405.html,GlaxoSmithKline names insider Emma Walmsley as new CEO
GSK,GSK:US,BBG000BLB481,UPDATE 2-GlaxoSmithKline names insider Emma Walmsley as new CEO,2016-09-20 09:04:15 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-names-consumer-head-walmsley-064135738.html,"[Reuters - UK Focus] - GlaxoSmithKline (Other OTC: GLAXF - news) said on Tuesday it had chosen Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates. Walmsley, who joined Britain's biggest drugmaker in 2010 from L'Oreal, will replace Andrew Witty who had previously announced his decision to retire on March 31, 2017. ""Under Andrew's leadership, GSK has successfully developed into a company with market-leading positions in pharmaceuticals, vaccines and consumer healthcare,"" Chairman Philip Hampton said."
GSK,GSK:US,BBG000BLB481,UPDATE 2-GlaxoSmithKline names insider Emma Walmsley as new CEO,2016-09-20 09:04:15 +0000,http://finance.yahoo.com/news/glaxosmithkline-names-consumer-head-walmsley-064135100.html,"[Reuters] - GlaxoSmithKline said on Tuesday it had chosen Emma Walmsley, head of consumer healthcare, as its new chief executive, after considering internal and external candidates. Walmsley, who joined Britain's biggest drugmaker in 2010 from L'Oreal, will replace Andrew Witty who had previously announced his decision to retire on March 31, 2017. The decision will disappoint investors such as Neil Woodford, a top shareholder and a critic of the drugmaker's current structure, who had wanted to see an outsider replace Witty."
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline names insider Emma Walmsley as new CEO,2016-09-20 08:30:20 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-picks-insider-emma-walmsley-074529523.html,GlaxoSmithKline names insider Emma Walmsley as new CEO
GSK,GSK:US,BBG000BLB481,GSK names Emma Walmsley as new chief executive,2016-09-20 08:16:51 +0000,http://sg.finance.yahoo.com/news/gsk-names-emma-walmsley-chief-075252119.html,GSK names Emma Walmsley as new chief executive
GSK,GSK:US,BBG000BLB481,British pharma group GSK picks new CEO,2016-09-20 07:04:46 +0000,http://uk.finance.yahoo.com/news/british-pharma-group-gsk-picks-070446460.html,British pharma group GSK picks new CEO
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline names consumer head Walmsley new CEO,2016-09-20 06:13:01 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-names-consumer-head-walmsley-061301262.html,GlaxoSmithKline names consumer head Walmsley new CEO
GSK,GSK:US,BBG000BLB481,GSK Appoints New CEO,2016-09-20 06:08:12 +0000,http://www.publicnow.com/view/FF13B3DFC22F4A747DA88BCD1357D18C9616B3D5,"[at noodls] - GlaxoSmithKline plc (the 'Company') Board change GSK appoints new CEO GSK today announces that Emma Walmsley, currently Chief Executive Officer (CEO) of GSK's Consumer Healthcare division, is appointed ..."
GSK,GSK:US,BBG000BLB481,Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline,2016-09-20 06:08:11 +0000,http://www.publicnow.com/view/A441BE390C978F01A9AC3831248D35FA47171DC4,"[at noodls] - Issued: London GSK today announces that Emma Walmsley, currently Chief Executive Officer (CEO) of GSK's Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK ..."
GSK,GSK:US,BBG000BLB481,Glaxo Names Consumer Head Emma Walmsley to Succeed Witty as CEO,2016-09-20 06:04:48 +0000,http://www.bloomberg.com/news/articles/2016-09-20/glaxo-names-emma-walmsley-as-new-chief-to-succeed-andrew-witty?cmpid=yhoo.headline,Glaxo Names Consumer Head Emma Walmsley to Succeed Witty as CEO
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline: Emma Walmsley To Succeed Andrew Witty As CEO In March 2017,2016-09-20 02:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pRWDqkcYNqw/glaxosmithkline-emma-walmsley-to-succeed-andrew-witty-as-ceo-in-march-2017-20160920-00703,GlaxoSmithKline: Emma Walmsley To Succeed Andrew Witty As CEO In March 2017
GSK,GSK:US,BBG000BLB481,"The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution",2016-09-19 15:01:01 +0000,http://www.fool.com/investing/general/2016/04/16/the-race-to-cure-the-zika-virus-is-on-and-this-com.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"The Race to Cure the Zika Virus is On, and This Company May Have the Best Solution"
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-09-19 14:18:05 +0000,http://www.publicnow.com/view/8CDB1DDDF03FC4529B2C32D9EDB0A522E4F572BF,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 19 September ...
GSK,GSK:US,BBG000BLB481,"GSK cuts vaccine price for refugees, bowing to pressure",2016-09-19 12:39:08 +0000,http://sg.finance.yahoo.com/news/gsk-cuts-vaccine-price-refugees-113811247.html,"GSK cuts vaccine price for refugees, bowing to pressure"
GSK,GSK:US,BBG000BLB481,GSK CEO: Pharma firms need to be empathetic,2016-09-18 22:46:00 +0000,http://finance.yahoo.com/video/gsk-ceo-pharma-firms-empathetic-224600028.html,GSK CEO: Pharma firms need to be empathetic
GSK,GSK:US,BBG000BLB481,Drugmakers Must Report Clinical Trial Results Once Kept Secret,2016-09-16 16:42:28 +0000,http://www.investors.com/news/technology/drugmakers-must-report-clinical-trial-results-once-kept-secret/,Drugmakers Must Report Clinical Trial Results Once Kept Secret
GSK,GSK:US,BBG000BLB481,Epizyme Receives Milestone from Glaxo for Lymphoma Drug,2016-09-16 15:22:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aOSodPnkzRM/epizyme-receives-milestone-from-glaxo-for-lymphoma-drug-cm680516,Epizyme Inc EPZM announced that the company has earned a milestone payment worth 6 million from GlaxoSmithKline GSK The payment was triggered by Glaxo s initiation of a phase I study on GSK3326595 formerly EPZ015938 The company initiated a phase I dose escalation study to
GSK,GSK:US,BBG000BLB481,Drugmakers Must Report Clinical Trial Results Once Kept Secret,2016-09-16 15:15:00 +0000,http://www.bloomberg.com/news/articles/2016-09-16/drugmakers-must-report-clinical-trial-results-once-kept-secret?cmpid=yhoo.headline,Drugmakers Must Report Clinical Trial Results Once Kept Secret
GSK,GSK:US,BBG000BLB481,Epizyme Receives Milestone from Glaxo for Lymphoma Drug,2016-09-16 13:05:01 +0000,http://finance.yahoo.com/news/epizyme-receives-milestone-glaxo-lymphoma-130501301.html,Epizyme Receives Milestone from Glaxo for Lymphoma Drug
GSK,GSK:US,BBG000BLB481,GSK closes UK factory due to flooding,2016-09-16 10:45:17 +0000,http://sg.finance.yahoo.com/news/gsk-closes-uk-factory-due-104259834.html,GSK closes UK factory due to flooding
GSK,GSK:US,BBG000BLB481,"Bullish on SoftBank, ASML, Royal Dutch Shell and GlaxoSmithKline",2016-09-15 19:44:00 +0000,https://www.thestreet.com/story/13741982/1/bullish-on-softbank-asml-royal-dutch-shell-and-glaxosmithkline.html?puc=yahoo&cm_ven=YAHOO,"Bullish on SoftBank, ASML, Royal Dutch Shell and GlaxoSmithKline"
GSK,GSK:US,BBG000BLB481,4 Foreign Stocks to Fire Up Your Portfolio,2016-09-15 18:21:00 +0000,http://www.thestreet.com/video/13741804/4-foreign-stocks-to-fire-up-your-portfolio.html?puc=yahoov&cm_ven=YAHOOV,4 Foreign Stocks to Fire Up Your Portfolio
GSK,GSK:US,BBG000BLB481,FDA Panel Suggests Removing Warning from Pfizer's Chantix,2016-09-15 17:16:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rFEzTKSezbw/fda-panel-suggests-removing-warning-from-pfizers-chantix-cm680084,Pfizer Inc PFE announced that the FDA advisory panels have recommended removing a serious warning about neuropsychiatric side effects on the label of its smoking cessation therapy Chantix We remind investors that Chantix s label includes a boxed warning regarding serious
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine,2016-09-15 16:18:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HQ9tcC7rQ6Y/glaxo-gsk-publishes-phase-iii-data-on-shingles-vaccine-cm680001,GlaxoSmithKline plc GSK announced that detailed results from a randomized phase III study ZOE 70 on its experimental shingles vaccine candidate Shingrix were published in the New England Journal of Medicine The study from which head line results were reported in Oct 2015 demonstrated
GSK,GSK:US,BBG000BLB481,FDA AdCom Votes on Pfizer and Spectrum Drugs - What Next?,2016-09-15 15:20:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YZF00y_bXfc/fda-adcom-votes-on-pfizer-and-spectrum-drugs-what-next-cm679963,Yesterday a couple of drugs came up before FDA advisory panels for review large cap pharma Pfizer Inc s PFE Chantix and biotech company Spectrum Pharmaceuticals Inc s SPPI Qapzola Chantix amp Qapzola under Review Data on Pfizer s smoking cessation product Chantix from
GSK,GSK:US,BBG000BLB481,Sanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price,2016-09-15 15:04:36 +0000,http://marketrealist.com/2016/09/sanofis-chase-for-zika-virus-vaccine-could-drive-its-share-price/?utm_source=yahoo&utm_medium=feed,Sanofi’s Chase for Zika Virus Vaccine Could Drive Its Share Price
GSK,GSK:US,BBG000BLB481,Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine,2016-09-15 14:27:02 +0000,http://finance.yahoo.com/news/glaxo-gsk-publishes-phase-iii-142702744.html,Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
GSK,GSK:US,BBG000BLB481,Epizyme Earns $6 Million Milestone Payment from GlaxoSmithKline for Initiation of Clinical Development with First-in-Class PRMT5 Inhibitor,2016-09-15 10:58:01 +0000,http://www.publicnow.com/view/2F862F59A0C921898A43AA8B0E8C69F72710B733,"[at noodls] - CAMBRIDGE, Mass., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapeutics, today announced it has earned a $6 million ..."
GSK,GSK:US,BBG000BLB481,These two large caps look seriously undervalued,2016-09-15 10:21:14 +0000,http://uk.finance.yahoo.com/news/two-large-caps-look-seriously-102114439.html,These two large caps look seriously undervalued
GSK,GSK:US,BBG000BLB481,GSK's candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM,2016-09-14 21:37:00 +0000,http://finance.yahoo.com/news/gsks-candidate-shingles-vaccine-shows-213700812.html,"[PR Newswire] - LONDON, Sept. 14, 2016 /PRNewswire/ -- GSK (LSE/NYSE: GSK) today announced the publication of detailed results from a randomised phase III study (ZOE-70) of its investigational shingles vaccine, Shingrix™, ..."
GSK,GSK:US,BBG000BLB481,GSK shingles vaccine remains effective after four years -study,2016-09-14 21:00:01 +0000,http://uk.finance.yahoo.com/news/gsk-shingles-vaccine-remains-effective-210001911.html,"[Reuters - UK Focus] - GlaxoSmithKline (Other OTC: GLAXF - news) 's experimental vaccine to prevent the intensely painful condition known as shingles remained 90 percent effective in people over age 70 even four years after receiving the injection, according to data published on Wednesday. In clinical trials, GSK's Shingrix has shown greater protection for older recipients than what has been demonstrated by Merck (Jakarta: 28586808.JK - news) & Co's rival Zostavax vaccine. The latest four-year data on Shingrix, which appears in the New England Journal of Medicine, shows it may also provide an additional significant advantage by maintaining its effectiveness over time."
GSK,GSK:US,BBG000BLB481,You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne,2016-09-14 14:42:59 +0000,http://www.fool.com/investing/2016/09/14/youll-never-guess-which-pharma-could-push-ahead-of.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne
GSK,GSK:US,BBG000BLB481,You'll Never Guess Which Pharma Could Knock Gilead Sciences Off Its HIV Throne,2016-09-14 13:47:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aFhBPwiwl6U/youll-never-guess-which-pharma-could-knock-gilead-sciences-off-its-hiv-throne-cm679245,Image source Getty Images If you re an HIV patient you know the drill You take three pills a day or a three drug cocktail every single day The triple combo which has been standard for HIV since the mid 1990s has transformed HIV from a death sentence into a more
GSK,GSK:US,BBG000BLB481,2 perfect FTSE 100 stocks for growth AND income investors!,2016-09-14 13:01:50 +0000,http://uk.finance.yahoo.com/news/2-perfect-ftse-100-stocks-130150017.html,2 perfect FTSE 100 stocks for growth AND income investors!
GSK,GSK:US,BBG000BLB481,How GlaxoSmithKline Took Its Medicine,2016-09-14 12:27:00 +0000,http://www.forbes.com/sites/matthewherper/2016/09/14/how-glaxosmithkline-took-its-medicine/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoomag,How GlaxoSmithKline Took Its Medicine
GSK,GSK:US,BBG000BLB481,"Glaxo, Astra Lead U.K. Drugmakers to Seek Continued EU Access",2016-09-14 10:56:30 +0000,http://www.bloomberg.com/news/articles/2016-09-14/u-k-drugmakers-led-by-glaxo-astra-seek-continued-eu-access?cmpid=yhoo.headline,"Glaxo, Astra Lead U.K. Drugmakers to Seek Continued EU Access"
GSK,GSK:US,BBG000BLB481,Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU,2016-09-13 15:48:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bEZLxcrE8Ek/glaxojj-file-for-rheumatoid-arthritis-drug-sirukumab-in-eu-cm678757,GlaxoSmithKline plc GSK and Johnson amp Johnson s JNJ Janssen Biologics announced the submission of a Marketing Authorisation Application MAA for sirukumab subcutaneous formulation for the treatment of adult patients with moderate to severely active rheumatoid arthritis RA
GSK,GSK:US,BBG000BLB481,GSK Optimistic about Future of Its Consumer Healthcare Segment,2016-09-13 15:04:30 +0000,http://marketrealist.com/2016/09/gsk-optimistic-about-future-of-its-consumer-healthcare-segment/?utm_source=yahoo&utm_medium=feed,GSK Optimistic about Future of Its Consumer Healthcare Segment
GSK,GSK:US,BBG000BLB481,Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU,2016-09-13 14:09:02 +0000,http://finance.yahoo.com/news/glaxo-j-j-file-rheumatoid-140902889.html,Glaxo/J&J File for Rheumatoid Arthritis Drug Sirukumab in EU
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Giving a Shot to Its Vaccines Business,2016-09-13 14:04:27 +0000,http://marketrealist.com/2016/09/glaxosmithkline-giving-a-shot-to-its-vaccines-business/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline Giving a Shot to Its Vaccines Business
GSK,GSK:US,BBG000BLB481,Performance of GSK’s Global Pharmaceuticals Franchises Mixed,2016-09-13 12:04:45 +0000,http://marketrealist.com/2016/09/performance-of-gsks-global-pharmaceuticals-franchises-mixed/?utm_source=yahoo&utm_medium=feed,Performance of GSK’s Global Pharmaceuticals Franchises Mixed
GSK,GSK:US,BBG000BLB481,Should you buy this healthcare company after its 39% fall?,2016-09-13 11:16:05 +0000,http://uk.finance.yahoo.com/news/buy-healthcare-company-39-fall-111605980.html,Should you buy this healthcare company after its 39% fall?
GSK,GSK:US,BBG000BLB481,Analysts Hit Reset Button On GlaxoSmithKline,2016-09-13 10:50:00 +0000,https://www.thestreet.com/story/13725980/1/analysts-hit-reset-button-on-glaxosmithkline.html?puc=yahoo&cm_ven=YAHOO,Analysts Hit Reset Button On GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,Companies Join To Fight Diabetes -- WSJ,2016-09-13 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NS64i4G0XnY/companies-join-to-fight-diabetes--wsj-20160913-00075,Companies Join To Fight Diabetes -- WSJ
GSK,GSK:US,BBG000BLB481,"Credit Markets: Apple, Daimler on BOE List -- WSJ",2016-09-13 02:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yHUPLACAsL4/credit-markets-apple-daimler-on-boe-list--wsj-20160913-00071,"Credit Markets: Apple, Daimler on BOE List -- WSJ"
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-09-12 16:08:19 +0000,http://www.publicnow.com/view/FAE505FB2C14CBA06582DEF8EB810D524268BD35,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 12 September ...
GSK,GSK:US,BBG000BLB481,"On Bank of England's Shopping List: Apple, Daimler Bonds",2016-09-12 15:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ggOeIuRmDA0/on-bank-of-englands-shopping-list-apple-daimler-bonds-20160912-01005,"On Bank of England's Shopping List: Apple, Daimler Bonds"
GSK,GSK:US,BBG000BLB481,Bank of England Lists Corporate Bonds Eligible for Purchase,2016-09-12 15:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3er-gcigbHw/bank-of-england-lists-corporate-bonds-eligible-for-purchase-20160912-00937,Bank of England Lists Corporate Bonds Eligible for Purchase
GSK,GSK:US,BBG000BLB481,The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working,2016-09-12 15:34:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/01l6Ki16PSM/the-only-thing-more-extraordinary-than-glaxosmithklines-growth-strategy-is-that-its-working-cm677964,Image source Getty Images Big pharma GlaxoSmithKline NYSE GSK is doubling down on cheaper meds Unlike its pharma peers many of which appear blind to the growing public outrage over sky high priced meds Glaxo is blazing a different trail The U K based pharma
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition,2016-09-12 15:04:41 +0000,http://marketrealist.com/2016/09/glaxosmithklines-combo-treatment-for-hiv-faces-stiff-competition/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition
GSK,GSK:US,BBG000BLB481,What’s the Problem with GSK’s Pharmaceutical Segment?,2016-09-12 14:04:50 +0000,http://marketrealist.com/2016/09/whats-the-problem-with-gsks-pharmaceutical-segment/?utm_source=yahoo&utm_medium=feed,What’s the Problem with GSK’s Pharmaceutical Segment?
GSK,GSK:US,BBG000BLB481,The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working,2016-09-12 13:54:47 +0000,http://www.fool.com/investing/2016/09/12/the-only-thing-more-extraordinary-than-glaxosmithk.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working
GSK,GSK:US,BBG000BLB481,"Of GSK’s Business Segments, This One Is the Sales Laggard",2016-09-12 12:05:08 +0000,http://marketrealist.com/2016/09/of-gsks-business-segments-this-one-is-the-sales-laggard/?utm_source=yahoo&utm_medium=feed,"Of GSK’s Business Segments, This One Is the Sales Laggard"
GSK,GSK:US,BBG000BLB481,GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis,2016-09-12 11:58:04 +0000,http://www.publicnow.com/view/E9D055E366F12CF148B45BFF04E72944DDE06A1E,[at noodls] - GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of subcutaneous formulation ...
GSK,GSK:US,BBG000BLB481,EU regulatory submission for sirukumab in RA,2016-09-12 11:38:06 +0000,http://www.publicnow.com/view/DD734A96547AFAF89DBF676FDFB96D2F05E31084,"[at noodls] - Issued: Monday 12 September 2016, London UK - LSE Announcement GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the regulatory ..."
GSK,GSK:US,BBG000BLB481,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--2nd Update,2016-09-12 08:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bWHK-ck9zbY/google-parent-and-sanofi-name-diabetes-joint-venture-onduo2nd-update-20160912-00502,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--2nd Update
GSK,GSK:US,BBG000BLB481,GSK Reports EU Regulatory Submission For Sirukumab In Rheumatoid Arthritis,2016-09-12 08:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I1_H-ldkRE8/gsk-reports-eu-regulatory-submission-for-sirukumab-in-rheumatoid-arthritis-20160912-00491,GSK Reports EU Regulatory Submission For Sirukumab In Rheumatoid Arthritis
GSK,GSK:US,BBG000BLB481,GSK sells anaesthetics to Aspen for up to $370 million,2016-09-12 08:24:58 +0000,http://sg.finance.yahoo.com/news/gsk-sells-anaesthetics-aspen-370-082458612.html,GSK sells anaesthetics to Aspen for up to $370 million
GSK,GSK:US,BBG000BLB481,Aspen to Buy Glaxo Drugs for $372 Million as Deal Spree Goes On,2016-09-12 08:19:10 +0000,http://finance.yahoo.com/news/aspen-buy-glaxo-drugs-372-081910607.html,Aspen to Buy Glaxo Drugs for $372 Million as Deal Spree Goes On
GSK,GSK:US,BBG000BLB481,GSK sells anaesthetics to Aspen for up to $370 million,2016-09-12 07:58:01 +0000,http://in.finance.yahoo.com/news/gsk-sells-anaesthetics-aspen-370-075801281.html,GSK sells anaesthetics to Aspen for up to $370 million
GSK,GSK:US,BBG000BLB481,GSK sells anaesthetics to Aspen for up to $370 mln,2016-09-12 07:50:38 +0000,http://uk.finance.yahoo.com/news/gsk-sells-anaesthetics-aspen-370-075038145.html,[Reuters - UK Focus] - GlaxoSmithKline is to sell its portfolio of anaesthetic drugs to South Africa's Aspen Pharmacare for up to 280 million pounds as part of a drive by the British drugmaker to focus on core therapy areas. ...
GSK,GSK:US,BBG000BLB481,GSK divests non-core assets to Aspen,2016-09-12 07:28:07 +0000,http://www.publicnow.com/view/78CCA24EAD8C495A9C5DAA73B4784FE4CC294767,[at noodls] - Issued: London GlaxoSmithKline plc (LSE/NYSE: GSK) today announces a series of agreements with Aspen (JSE: APN) aligned with GSK's strategy of simplification through focusing on core therapeutic areas. ...
GSK,GSK:US,BBG000BLB481,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--Update,2016-09-12 07:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NUhnfLkfUbU/google-parent-and-sanofi-name-diabetes-joint-venture-onduoupdate-20160912-00242,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--Update
GSK,GSK:US,BBG000BLB481,Google Parent and Sanofi Name Diabetes Joint Venture Onduo,2016-09-12 02:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x2kBnDAmZ9U/google-parent-and-sanofi-name-diabetes-joint-venture-onduo-20160912-00040,Google Parent and Sanofi Name Diabetes Joint Venture Onduo
GSK,GSK:US,BBG000BLB481,My 3 Biggest Stock Holdings,2016-09-11 13:30:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9dx7pYsTM0o/my-3-biggest-stock-holdings-cm677442,Over the past two years I bought more shares of higher yielding dividend stocks for two reasons First interest rates seemed likely to stay low for the foreseeable future keeping dividend stocks more attractive than bonds Second I believed that as the market hit record
GSK,GSK:US,BBG000BLB481,My 3 Biggest Stock Holdings,2016-09-11 12:09:14 +0000,http://www.fool.com/investing/2016/09/11/my-3-biggest-stock-holdings.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,My 3 Biggest Stock Holdings
GSK,GSK:US,BBG000BLB481,What Investors Can Glean from GlaxoSmithKline’s Revenue Trend,2016-09-09 22:04:29 +0000,http://marketrealist.com/2016/09/what-investors-can-glean-from-glaxosmithklines-revenue-trend/?utm_source=yahoo&utm_medium=feed,What Investors Can Glean from GlaxoSmithKline’s Revenue Trend
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Fundamentals Show It Has Lots of Room to Run,2016-09-09 20:04:58 +0000,http://marketrealist.com/2016/09/glaxosmithklines-fundamentals-show-it-has-lots-of-room-to-run/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Fundamentals Show It Has Lots of Room to Run
GSK,GSK:US,BBG000BLB481,Merck's Lung Cancer Drug Keytruda Under Priority Review,2016-09-08 18:17:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rXMSGbQNjG0/mercks-lung-cancer-drug-keytruda-under-priority-review-cm676345,Merck amp Co Inc s MRK supplemental Biologics License Application sBLA for its anti PD 1 therapy Keytruda has been accepted for priority review by the FDA The company is looking to expand the label into the first line treatment of patients with advanced non small cell lung
GSK,GSK:US,BBG000BLB481,Merck's Lung Cancer Drug Keytruda Under Priority Review,2016-09-08 15:29:03 +0000,http://finance.yahoo.com/news/mercks-lung-cancer-drug-keytruda-152903026.html,Merck's Lung Cancer Drug Keytruda Under Priority Review
GSK,GSK:US,BBG000BLB481,2 small stocks paying big dividends,2016-09-08 15:21:22 +0000,http://uk.finance.yahoo.com/news/2-small-stocks-paying-big-152122391.html,2 small stocks paying big dividends
GSK,GSK:US,BBG000BLB481,Glaxo Proposes Biopreparedness Unit for Outbreaks Like Zika,2016-09-08 14:53:12 +0000,http://www.bloomberg.com/news/articles/2016-09-08/glaxo-proposes-global-body-to-tackle-outbreaks-like-zika-ebola?cmpid=yhoo.headline,Glaxo Proposes Biopreparedness Unit for Outbreaks Like Zika
GSK,GSK:US,BBG000BLB481,Europe: New safe haven?,2016-09-07 21:44:00 +0000,http://finance.yahoo.com/video/europe-safe-haven-214400696.html,Europe: New safe haven?
GSK,GSK:US,BBG000BLB481,"Gilead Sciences: Wait, You're Not Going to Split the Company in Two?",2016-09-07 19:28:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/09/07/gilead-sciences-open-to-opportunities/?mod=yahoobarrons&ru=yahoo,"Gilead Sciences: Wait, You're Not Going to Split the Company in Two?"
GSK,GSK:US,BBG000BLB481,Dynavax Rebounds on Same PDUFA Date for Heplisav BLA,2016-09-07 17:18:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NeGWF2Ss6tM/dynavax-rebounds-on-same-pdufa-date-for-heplisav-bla-cm675730,Shares of Dynavax Technologies Corporation DVAX bounced back after the company indicated that the FDA will review its Biologics License Application BLA for experimental hepatitis B vaccine Heplisav on the current Prescription Drug User Fee Act PDUFA date of Dec 15 2016 The company
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands",2016-09-07 15:21:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y2zTxiMa-Q8/the-zacks-analyst-blog-highlights-inovio-pharmaceuticals-orasure-technologies-glaxosmithkline-sanofi-and-spectrum-brands-cm675577,For Immediate Release Chicago IL September 07 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands",2016-09-07 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-inovio-133001977.html,"The Zacks Analyst Blog Highlights: Inovio Pharmaceuticals, OraSure Technologies, GlaxoSmithKline, Sanofi and Spectrum Brands"
GSK,GSK:US,BBG000BLB481,Why Vectura group plc and GlaxoSmithKline plc could be the perfect combination,2016-09-07 09:22:28 +0000,http://uk.finance.yahoo.com/news/why-vectura-group-plc-glaxosmithkline-092228088.html,Why Vectura group plc and GlaxoSmithKline plc could be the perfect combination
GSK,GSK:US,BBG000BLB481,6 Drug Stocks in Focus as Zika Virus Fear Spreads,2016-09-06 21:12:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/377OVLemKoY/6-drug-stocks-in-focus-as-zika-virus-fear-spreads-cm674922,The mosquito borne Zika virus remains a hot topic of discussion this year as more cases are coming to light Concerns have increased with the Florida Department of Agriculture and Consumer Services announcing last week that it has detected Zika in three mosquito samples from a small area in
GSK,GSK:US,BBG000BLB481,Glaxo Bexsero Meningitis B Immunization Shows Positive Data,2016-09-06 16:18:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SrcYlgqaznA/glaxo-bexsero-meningitis-b-immunization-shows-positive-data-cm675007,GlaxoSmithKline plc GSK announced positive preliminary data from the world s first meningitis B immunization program on its Bexsero vaccine Data demonstrated 83 effectiveness of Bexsero against any meningitis B strain and 94 effectiveness against vaccine preventable strains in
GSK,GSK:US,BBG000BLB481,Glaxo Bexsero Meningitis B Immunization Shows Positive Data,2016-09-06 14:32:02 +0000,http://finance.yahoo.com/news/glaxo-bexsero-meningitis-b-immunization-143202146.html,Glaxo Bexsero Meningitis B Immunization Shows Positive Data
GSK,GSK:US,BBG000BLB481,GSK's triple drug cuts flare-ups in chronic lung disease,2016-09-06 14:01:46 +0000,http://sg.finance.yahoo.com/news/gsks-triple-drug-cuts-flare-140146916.html,"[Reuters] - An experimental three-in-one inhaled drug from GlaxoSmithKline (GSK.L) significantly cut flare-ups in patients with chronic lung disease in a clinical trial, researchers said on Tuesday. GSK is ahead of rivals AstraZeneca (AZN.L) and Novartis (NOVN.S) in developing a ""closed triple"" inhaler and plans to file the new treatment for chronic obstructive pulmonary disease (COPD) for regulatory approval this year. The study found patients taking the new triple therapy for 24 weeks had 35 percent fewer moderate or severe exacerbations compared to those on AstraZeneca's two-in-one Symbicort."
GSK,GSK:US,BBG000BLB481,Results of Phase III FULFIL Study Presented at ERS,2016-09-06 13:59:04 +0000,http://www.publicnow.com/view/CF12402B1C4D3E17F06CAD841616A1788E6A21C5,"[at noodls] - Issued: Tuesday, 6 September 2016, London UK - LSE Announcement GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort Turbohaler in ..."
GSK,GSK:US,BBG000BLB481,GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress,2016-09-06 13:59:04 +0000,http://www.publicnow.com/view/80A33333220D695BC4E9B90E2A6C63822590A847,"[at noodls] - Issued: London Improvements in lung function and health-related quality of life supported by statistically significant reductions in exacerbations GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. ..."
GSK,GSK:US,BBG000BLB481,6 Drug Stocks in Focus as Zika Virus Fear Spreads,2016-09-06 12:00:12 +0000,http://finance.yahoo.com/news/6-drug-stocks-focus-zika-120012245.html,6 Drug Stocks in Focus as Zika Virus Fear Spreads
GSK,GSK:US,BBG000BLB481,Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after today’s news?,2016-09-05 10:44:27 +0000,http://uk.finance.yahoo.com/news/dechra-pharmaceuticals-plc-better-buy-104427141.html,Is Dechra Pharmaceuticals plc a better buy than GlaxoSmithKline plc after today’s news?
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Announces Positive Results From COPD Salford Lung Study,2016-09-05 02:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0VzcndFg2_g/glaxosmithkline-announces-positive-results-from-copd-salford-lung-study-20160905-00022,GlaxoSmithKline Announces Positive Results From COPD Salford Lung Study
GSK,GSK:US,BBG000BLB481,How Google Plans to Reinvent Healthcare,2016-09-04 18:05:59 +0000,http://www.fool.com/investing/2016/09/03/how-google-plans-to-reinvent-healthcare.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How Google Plans to Reinvent Healthcare
GSK,GSK:US,BBG000BLB481,GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress,2016-09-04 09:18:05 +0000,http://www.publicnow.com/view/4EECDCA4EA17CDB04E3D96AC1115C9DCB454B843,"[at noodls] - Issued: London GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the results from the pioneering Salford Lung Study (SLS) have been published in the New England ..."
GSK,GSK:US,BBG000BLB481,Positive Results From the COPD Salford Lung Study Published in the NEJM and Presented at European Respiratory Congress,2016-09-04 09:00:00 +0000,http://uk.finance.yahoo.com/news/positive-results-copd-salford-lung-090000019.html,Positive Results From the COPD Salford Lung Study Published in the NEJM and Presented at European Respiratory Congress
GSK,GSK:US,BBG000BLB481,How Google Plans to Reinvent Healthcare,2016-09-03 19:17:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/reDaqp32aL0/how-google-plans-to-reinvent-healthcare-cm674467,Image source Flickr Creative Commons Glucose monitoring contact lenses for diabetics wrist computers that read diagnostic nanoparticles injected in the blood stream implantable devices that modify electrical signals that pass along nerves medication robots human augmentation
GSK,GSK:US,BBG000BLB481,LONDON MARKETS: FTSE 100 Logs Best Day In 2 Months As U.S. Jobs Data Seen Delaying Rate Hike,2016-09-02 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Tee07UTSPzA/london-markets-ftse-100-logs-best-day-in-2-months-as-us-jobs-data-seen-delaying-rate-hike-20160902-00461,LONDON MARKETS: FTSE 100 Logs Best Day In 2 Months As U.S. Jobs Data Seen Delaying Rate Hike
GSK,GSK:US,BBG000BLB481,LONDON MARKETS: FTSE 100 Rallies As Weak U.S. Jobs Data Seen Delaying Rate Hike,2016-09-02 09:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q_bRtiMxe-4/london-markets-ftse-100-rallies-as-weak-us-jobs-data-seen-delaying-rate-hike-20160902-00318,LONDON MARKETS: FTSE 100 Rallies As Weak U.S. Jobs Data Seen Delaying Rate Hike
GSK,GSK:US,BBG000BLB481,LONDON MARKETS: FTSE 100 Higher As Investors Wait For U.S. Jobs Report,2016-09-02 06:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mtTynkxT24A/london-markets-ftse-100-higher-as-investors-wait-for-us-jobs-report-20160902-00153,LONDON MARKETS: FTSE 100 Higher As Investors Wait For U.S. Jobs Report
GSK,GSK:US,BBG000BLB481,"AstraZeneca, Glaxo Explore Prevention Potential of Asthma Shots",2016-09-02 06:45:57 +0000,http://www.bloomberg.com/news/articles/2016-09-02/astrazeneca-glaxo-explore-prevention-potential-of-asthma-shots?cmpid=yhoo.headline,"AstraZeneca, Glaxo Explore Prevention Potential of Asthma Shots"
GSK,GSK:US,BBG000BLB481,LONDON MARKETS: FTSE 100 Notches Higher As Investors Wait For U.S. Jobs Report,2016-09-02 04:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qsk2LllWHMM/london-markets-ftse-100-notches-higher-as-investors-wait-for-us-jobs-report-20160902-00083,LONDON MARKETS: FTSE 100 Notches Higher As Investors Wait For U.S. Jobs Report
GSK,GSK:US,BBG000BLB481,Why Pfizer’s Vaccines Business Is Declining,2016-09-01 15:04:13 +0000,http://marketrealist.com/2016/08/why-pfizers-vaccines-business-is-declining/?utm_source=yahoo&utm_medium=feed,Why Pfizer’s Vaccines Business Is Declining
GSK,GSK:US,BBG000BLB481,Total Voting Rights,2016-09-01 13:53:07 +0000,http://www.publicnow.com/view/072B4CDACEA1BBAE8E4249CCCE914BD2D01C1728,"[at noodls] - GlaxoSmithKline plc and Capital Inconformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital ..."
GSK,GSK:US,BBG000BLB481,How Analysts See United Therapeutics’ Continued Performance,2016-09-01 12:04:29 +0000,http://marketrealist.com/2016/08/analyst-recommendations-united-therapeutics-2016/?utm_source=yahoo&utm_medium=feed,How Analysts See United Therapeutics’ Continued Performance
GSK,GSK:US,BBG000BLB481,Is this the best healthcare stock money can buy after today’s update?,2016-09-01 09:59:18 +0000,http://uk.finance.yahoo.com/news/best-healthcare-stock-money-buy-095918100.html,Is this the best healthcare stock money can buy after today’s update?
GSK,GSK:US,BBG000BLB481,4 Off-the-Radar Analyst Picks Yielding More Than 4%,2016-08-31 14:35:02 +0000,http://247wallst.com/investing/2016/08/31/4-off-the-radar-analyst-picks-yielding-more-than-4/,[at 24/7 Wall St.] - It’s getting harder and harder for investors seeking income. Most investors are looking for yields that are at least 4% and have some degree of safety as well.
GSK,GSK:US,BBG000BLB481,7 Healthy Dividend Stocks for Quality and Security,2016-08-31 12:50:01 +0000,http://portal.kiplinger.com/article/investing/T052-C000-S015-7-healthcare-dividend-stocks-for-quality-and-secur.html?rid=SYN-yahoo&rpageid=15410,7 Healthy Dividend Stocks for Quality and Security
GSK,GSK:US,BBG000BLB481,Struggling Vaccines From Novartis Turn Into Sales Boon for Glaxo,2016-08-31 04:00:00 +0000,http://www.bloomberg.com/news/articles/2016-08-31/struggling-vaccines-from-novartis-turn-into-sales-boon-for-glaxo?cmpid=yhoo.headline,Struggling Vaccines From Novartis Turn Into Sales Boon for Glaxo
GSK,GSK:US,BBG000BLB481,$1 Billion Sales Target in Place for Tyvaso,2016-08-30 22:04:06 +0000,http://marketrealist.com/2016/08/united-therapeutics-expects-tyvaso-annual-sales-reach-1-billion/?utm_source=yahoo&utm_medium=feed,$1 Billion Sales Target in Place for Tyvaso
GSK,GSK:US,BBG000BLB481,Generic Competition Not a Threat to UTHR’s Remodulin,2016-08-30 20:04:21 +0000,http://marketrealist.com/2016/08/united-therapeutics-expects-safeguard-remodulin-sales-generic-competition-2016/?utm_source=yahoo&utm_medium=feed,Generic Competition Not a Threat to UTHR’s Remodulin
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-08-30 11:43:09 +0000,http://www.publicnow.com/view/933D4BA3E4E9ABFF5DA3475D88BAA856DE749356,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 30 August ...
GSK,GSK:US,BBG000BLB481,"Why Gilead Sciences, Inc. (GILD), Valeant Pharmaceuticals Intl Inc (VRX) and Core-Mark Holding Company, Inc. (CORE) Are 3 of Today’s Worst Stocks",2016-08-30 07:11:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A9i7FeTusT4/why-gilead-sciences-inc-gild-valeant-pharmaceuticals-intl-inc-vrx-and-core-mark-holding-company-inc-core-are-3-of-todays-worst-stocks-cm671969,"After having a weekend to think about it, investors decided the prospect and potential impact of rising interest rates may not be as great as"
GSK,GSK:US,BBG000BLB481,"Gilead Sciences (GILD) Stock Down, Piper Jaffray 'Doubts' HIV Competitors",2016-08-29 18:16:00 +0000,https://www.thestreet.com/story/13688095/1/gilead-sciences-gild-stock-down-piper-jaffray-doubts-hiv-competitors.html?puc=yahoo&cm_ven=YAHOO,"Gilead Sciences (GILD) Stock Down, Piper Jaffray 'Doubts' HIV Competitors"
GSK,GSK:US,BBG000BLB481,Gilead Sciences: Don't Expect Perfection,2016-08-29 17:34:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/29/gilead-sciences-dont-expect-perfection/?mod=yahoobarrons&ru=yahoo,Gilead Sciences: Don't Expect Perfection
GSK,GSK:US,BBG000BLB481,"Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)",2016-08-29 16:11:22 +0000,http://www.insidermonkey.com/blog/inside-the-fda-ebola-edition-frontrunners-merck-co-inc-mrk-glaxosmithkline-plc-adr-gsk-471188/,"Inside the FDA Ebola Edition: Frontrunners Merck & Co., Inc. (MRK), GlaxoSmithKline PLC (ADR) (GSK)"
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. AbbVie,2016-08-29 15:15:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gRLCjEA8Zdg/better-buy-glaxosmithkline-plc-vs-abbvie-cm671626,"Image source  Getty Images.  Within the ecosystem of large cap drug stocks, AbbVie (NYSE  ABBV) and GlaxoSmithKline (NYSE  GSK) are easily top dogs when it comes to their respective dividend yields."
GSK,GSK:US,BBG000BLB481,Better Buy: GlaxoSmithKline plc vs. AbbVie,2016-08-29 13:49:49 +0000,http://www.fool.com/investing/2016/08/29/better-buy-glaxosmithkline-plc-vs-abbvie.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: GlaxoSmithKline plc vs. AbbVie
GSK,GSK:US,BBG000BLB481,How Will GlaxoSmithKline (GSK) Stock React to New HIV Drug Development?,2016-08-29 13:15:00 +0000,https://www.thestreet.com/story/13687556/1/how-will-glaxosmithkline-gsk-stock-react-to-new-hiv-drug-development.html?puc=yahoo&cm_ven=YAHOO,How Will GlaxoSmithKline (GSK) Stock React to New HIV Drug Development?
GSK,GSK:US,BBG000BLB481,"Zika Virus Vaccine Overturns Pharma Industry Playbook (GSK, SNY, ION)",2016-08-29 05:10:00 +0000,http://www.investopedia.com/news/zika-virus-vaccine-overturns-pharma-industry-playbook-gsk-sny-ion/?partner=YahooSA,"Zika Virus Vaccine Overturns Pharma Industry Playbook (GSK, SNY, ION)"
GSK,GSK:US,BBG000BLB481,Glaxo Bets It Can Shake Up HIV Treatment,2016-08-29 04:09:48 +0000,http://www.wsj.com/articles/glaxo-bets-it-can-shake-up-hiv-treatment-1472409636?ru=yahoo?mod=yahoo_itp,Glaxo Bets It Can Shake Up HIV Treatment
GSK,GSK:US,BBG000BLB481,[$$] Glaxo Bets It Can Shake Up HIV Treatment,2016-08-28 18:40:40 +0000,http://www.wsj.com/articles/glaxo-bets-it-can-shake-up-hiv-treatment-1472409636?mod=yahoo_hs,[$$] Glaxo Bets It Can Shake Up HIV Treatment
GSK,GSK:US,BBG000BLB481,3 High-Yield Dividend Stocks to Buy in September,2016-08-28 13:19:46 +0000,http://www.fool.com/investing/2016/08/27/3-high-yield-dividend-stocks-to-buy-in-september.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 High-Yield Dividend Stocks to Buy in September
GSK,GSK:US,BBG000BLB481,3 High-Yield Dividend Stocks to Buy in September,2016-08-27 14:28:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8tpFtxdVrY8/3-high-yield-dividend-stocks-to-buy-in-september-cm671195,"Image source  Getty Images.  With interest rates at historic lows, yield hungry investors are looking elsewhere for income. Unfortunately, too many get blinded by the allure of high yield stocks, only to learn"
GSK,GSK:US,BBG000BLB481,GSK’s continued commitment to innovative respiratory research demonstrated in European Respiratory Society congress data presentations,2016-08-27 08:08:01 +0000,http://www.publicnow.com/view/62B46140A9445A7D2BA636A035F092A29368607D,"[at noodls] - GlaxoSmithKline plc (GSK) will provide updates on emerging areas of research with data from across its comprehensive respiratory portfolio of approved medicines, investigational programmes and scientific ..."
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemon and Whole Foods",2016-08-26 15:31:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a915SWhBem8/the-zacks-analyst-blog-highlights-glaxosmithkline-blackstone-group-mylan-lululemon-and-whole-foods-cm670742,"For Immediate Release  Chicago, IL   August 26, 2016   Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events"
GSK,GSK:US,BBG000BLB481,"The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemon and Whole Foods",2016-08-26 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-glaxosmithkline-133001672.html,"The Zacks Analyst Blog Highlights: GlaxoSmithKline, Blackstone Group, Mylan, Lululemon and Whole Foods"
GSK,GSK:US,BBG000BLB481,How safe is GlaxoSmithKline plc’s dividend?,2016-08-26 10:09:03 +0000,http://uk.finance.yahoo.com/news/safe-glaxosmithkline-plc-dividend-100903827.html,How safe is GlaxoSmithKline plc’s dividend?
GSK,GSK:US,BBG000BLB481,"Top Research Reports for August 25, 2016",2016-08-25 22:46:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nh3qTH7JZu4/top-research-reports-for-august-25-2016-cm670355,"Thursday, August 25, 2016  Today's must read reports are for GlaxoSmithKline (GSK), Blackstone Group (BX) and Mylan (MYL).  Shares of Glaxo have gained more than 8% year to date. Glaxo's Q2 results were good with"
GSK,GSK:US,BBG000BLB481,"Top Research Reports for August 25, 2016",2016-08-25 18:39:06 +0000,http://finance.yahoo.com/news/top-research-reports-august-25-183906453.html,"Top Research Reports for August 25, 2016"
GSK,GSK:US,BBG000BLB481,Tiffany Q2 16 Earnings Conference Call At 8:30 AM ET,2016-08-25 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IkKHPw18u9k/tiffany-q2-16-earnings-conference-call-at-830-am-et-20160825-00240,Tiffany Q2 16 Earnings Conference Call At 8:30 AM ET
GSK,GSK:US,BBG000BLB481,7 Healthcare Dividend Stocks for Quality and Security,2016-08-24 22:47:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L3UN7Qmj07I/7-healthcare-dividend-stocks-for-quality-and-security-cm669340,"When it comes to finding great dividend stocks , some sectors are just natural winners. Steady and growing demand, big time cash flows and large"
GSK,GSK:US,BBG000BLB481,"Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares",2016-08-24 19:30:36 +0000,http://finance.yahoo.com/news/waiting-growth-better-valuation-argus-193036539.html,"Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares"
GSK,GSK:US,BBG000BLB481,Performance of AstraZeneca’s RI&A Segment in 2Q16,2016-08-24 15:04:05 +0000,http://marketrealist.com/2016/08/performance-astrazenecas-ria-segment-2q16/?utm_source=yahoo&utm_medium=feed,Performance of AstraZeneca’s RI&A Segment in 2Q16
GSK,GSK:US,BBG000BLB481,Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?,2016-08-24 10:40:23 +0000,http://uk.finance.yahoo.com/news/hikma-pharmaceuticals-plc-best-ftse-104023614.html,Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
GSK,GSK:US,BBG000BLB481,Is AstraZeneca’s Valuation Improving Compared to Peers?,2016-08-23 19:13:34 +0000,http://marketrealist.com/2016/08/astrazenecas-valuation-improving-compared-peers/?utm_source=yahoo&utm_medium=feed,Is AstraZeneca’s Valuation Improving Compared to Peers?
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-08-23 14:58:02 +0000,http://www.publicnow.com/view/F6FED7C154AB1114C08D93FFD964ECAD6A6C0196,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 23 August ...
GSK,GSK:US,BBG000BLB481,Which of these Neil Woodford dividend stocks should you buy today?,2016-08-23 14:42:18 +0000,http://uk.finance.yahoo.com/news/neil-woodford-dividend-stocks-buy-144218801.html,Which of these Neil Woodford dividend stocks should you buy today?
GSK,GSK:US,BBG000BLB481,Are these 3 top stocks still mighty income machines?,2016-08-22 13:36:28 +0000,http://uk.finance.yahoo.com/news/3-top-stocks-still-mighty-133628340.html,Are these 3 top stocks still mighty income machines?
GSK,GSK:US,BBG000BLB481,Inside the Performance of Sanofi’s Human Vaccines Segment in 2Q16,2016-08-22 13:04:33 +0000,http://marketrealist.com/2016/08/inside-the-performance-of-sanofis-human-vaccines-segment-in-2q16/?utm_source=yahoo&utm_medium=feed,Inside the Performance of Sanofi’s Human Vaccines Segment in 2Q16
GSK,GSK:US,BBG000BLB481,3 blue chip bargains you can’t afford to miss!,2016-08-22 06:05:25 +0000,http://uk.finance.yahoo.com/news/3-blue-chip-bargains-t-060525897.html,3 blue chip bargains you can’t afford to miss!
GSK,GSK:US,BBG000BLB481,3 High-Yielding Healthcare Stocks I'm Not Buying,2016-08-20 14:45:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SWjiZ9kuSwY/3-high-yielding-healthcare-stocks-im-not-buying-cm668106,"Image source  Getty Images.  Income investors often hunt for stocks in the healthcare sector because demand for healthcare isn't as tightly tied as other sectors to economic whims and whispers. However, not every"
GSK,GSK:US,BBG000BLB481,3 High-Yielding Healthcare Stocks I'm Not Buying,2016-08-20 13:01:00 +0000,http://www.fool.com/investing/2016/08/20/3-high-yielding-healthcare-stocks-im-not-buying.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 High-Yielding Healthcare Stocks I'm Not Buying
GSK,GSK:US,BBG000BLB481,Teva Cinqaero Gets EU Nod for Severe Eosinophilic Asthma,2016-08-19 16:48:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/araLmZHvzi4/teva-cinqaero-gets-eu-nod-for-severe-eosinophilic-asthma-cm667826,Positive news flowed in at Teva Pharmaceutical Industries Ltd.TEVA when the European Commission approved its marketing authorisation application for Cinqaero (reslizumab  interleukin 5 (IL 5) antagonist monoclonal antibody) for use as add on therapy in adult
GSK,GSK:US,BBG000BLB481,What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?,2016-08-19 15:04:35 +0000,http://marketrealist.com/2016/08/what-happened-to-sanofis-consumer-healthcare-and-generics-franchise-in-2q16/?utm_source=yahoo&utm_medium=feed,What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?
GSK,GSK:US,BBG000BLB481,Now is the perfect time to buy these 3 healthcare stocks!,2016-08-19 07:58:04 +0000,http://uk.finance.yahoo.com/news/now-perfect-time-buy-3-075804075.html,Now is the perfect time to buy these 3 healthcare stocks!
GSK,GSK:US,BBG000BLB481,Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study,2016-08-17 22:47:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cth52lAZsdA/glaxopfizer-viiv-healthcare-starts-hiv-drug-combo-study-cm666638,"GlaxoSmithKlineGSK announced that its HIV focused company, ViiV Healthcare has initiated a phase III program to support regulatory filings for a two drug regimen of Tivicay and Epivir for the treatment for HIV 1 infection in adults who have"
GSK,GSK:US,BBG000BLB481,Veeva Helps The Medicine Go Down Faster for Drug Giants,2016-08-17 21:52:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XEXMTIljXb8/veeva-helps-the-medicine-go-down-faster-for-drug-giants-cm657120,"When health care behemoth Johnson & Johnson ( JNJ ) decided last year to use Veeva Systems' ( VEEV ) software for gathering data from clinical trials needed to get a new drug approved, its rivals took notice."
GSK,GSK:US,BBG000BLB481,Inside Sanofi’s Valuation Changes,2016-08-17 21:05:06 +0000,http://marketrealist.com/2016/08/inside-sanofis-valuation-changes/?utm_source=yahoo&utm_medium=feed,Inside Sanofi’s Valuation Changes
GSK,GSK:US,BBG000BLB481,Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study,2016-08-17 13:59:01 +0000,http://finance.yahoo.com/news/glaxo-pfizer-viiv-healthcare-starts-135901136.html,Glaxo/Pfizer ViiV Healthcare Starts HIV Drug Combo Study
GSK,GSK:US,BBG000BLB481,Is Valeant’s Xifaxan Resuming Growth?,2016-08-17 13:04:39 +0000,http://marketrealist.com/2016/08/is-valeants-xifaxan-resuming-growth/?utm_source=yahoo&utm_medium=feed,Is Valeant’s Xifaxan Resuming Growth?
GSK,GSK:US,BBG000BLB481,"FTSE 100 snaps win streak, but miners cap losses",2016-08-16 16:03:11 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=D46ED426-637B-11E6-8BC1-2FDC5DAE47E3&siteid=yhoof2,"[at MarketWatch] - U.K. stocks are pulling back after eight consecutive advances, but gains for BHP Billiton and Antofagasta on earnings reports help limit the decline."
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-08-16 14:21:02 +0000,http://www.publicnow.com/view/A5799FFAC54CEE49ABF81A8EC93A67406EFA3CC9,"[at noodls] - RNS Number : 3430H GlaxoSmithKline PLC 16 August 2016 GlaxoSmithKline plc(the 'Company') Transaction notification 1. ... This is an abstract of the original noodl. To continue reading this document, click ..."
GSK,GSK:US,BBG000BLB481,ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment,2016-08-16 12:55:00 +0000,http://finance.yahoo.com/news/viiv-healthcare-launches-phase-iii-125500352.html,"[PR Newswire] - LONDON, August 16, 2016 /PRNewswire/ -- ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine ..."
GSK,GSK:US,BBG000BLB481,ViiV starts PhIII Programme for dolutegravir & 3TC,2016-08-16 12:11:02 +0000,http://www.publicnow.com/view/5C95FC0A0EA68B84756CCD600BF759FD87C7423E,"[at noodls] - ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment London, UK, 15 August 2016-ViiV Healthcare today announced the start ..."
GSK,GSK:US,BBG000BLB481,Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?,2016-08-16 08:38:29 +0000,http://uk.finance.yahoo.com/news/time-profits-glaxosmithkline-plc-astrazeneca-083829934.html,Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
GSK,GSK:US,BBG000BLB481,ViiV Begins Phase III Programme To Evaluate Two-drug Regimen For HIV-1 Treatment,2016-08-16 08:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xQ-6gGx9PtI/viiv-begins-phase-iii-programme-to-evaluate-twodrug-regimen-for-hiv1-treatment-20160816-00362,ViiV Begins Phase III Programme To Evaluate Two-drug Regimen For HIV-1 Treatment
GSK,GSK:US,BBG000BLB481,ViiV Begins Phase III Programme To Evaluate Two-drug Regimen For HIV-1 Treatment,2016-08-16 08:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SZU9fxNb47o/viiv-begins-phase-iii-programme-to-evaluate-twodrug-regimen-for-hiv1-treatment-20160816-00363,ViiV Begins Phase III Programme To Evaluate Two-drug Regimen For HIV-1 Treatment
GSK,GSK:US,BBG000BLB481,Inovio Expands Enrollment in Ebola Vaccine Phase I Study,2016-08-15 16:35:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t6ham9zIzZ4/inovio-expands-enrollment-in-ebola-vaccine-phase-i-study-cm665383,"Late last week, Inovio Pharmaceuticals, Inc.INO announced that it is expanding the enrollment in a phase I study evaluating its Ebola DNA vaccine, INO 4212. The company is enrolling 125 patients in the second stage of a phase I"
GSK,GSK:US,BBG000BLB481,Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow,2016-08-14 20:33:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DJnuQtNmmkY/bristol-myers-revolutionary-cancer-drug-suffers-a-big-blow-cm665108,"Bristol Myers Squibb 's  (NYSE  BMY) Opdivo is approved to treat some patients who see their lung cancer return following chemotherapy, but a key trial evaluating Opdivo's use in previously untreated patients recently came up"
GSK,GSK:US,BBG000BLB481,Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow,2016-08-14 19:02:00 +0000,http://www.fool.com/investing/2016/08/14/bristol-myers-revolutionary-cancer-drug-suffers-a.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Bristol-Myers' Revolutionary Cancer Drug Suffers A Big Blow
GSK,GSK:US,BBG000BLB481,Apple Files Patent Application For A Heart-Monitoring Wearable Device,2016-08-12 20:54:03 +0000,http://www.investors.com/news/technology/apple-files-patent-application-for-heart-monitoring-wearable-device/,Apple Files Patent Application For A Heart-Monitoring Wearable Device
GSK,GSK:US,BBG000BLB481,Director/PDMR Shareholding,2016-08-12 15:21:05 +0000,http://www.publicnow.com/view/AECC305220D564FAC3D6345526918987B43C2744,[at noodls] - Director/PDMR Shareholding The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 12 August ...
GSK,GSK:US,BBG000BLB481,"Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook",2016-08-10 21:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qQ9rjB5yWNY/ionis-ions-q2-loss-narrower-than-expected-issues-outlook-cm663688,"Ionis Pharmaceuticals, Inc.IONS reported a loss of 47 cents per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 48 cents but wider than the year ago loss of 29 cents."
GSK,GSK:US,BBG000BLB481,"Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook",2016-08-10 19:49:07 +0000,http://finance.yahoo.com/news/ionis-ions-q2-loss-narrower-194907473.html,"Ionis (IONS) Q2 Loss Narrower than Expected, Issues Outlook"
GSK,GSK:US,BBG000BLB481,Is this stock the best buy in its sector following today’s update?,2016-08-10 08:57:28 +0000,http://uk.finance.yahoo.com/news/stock-best-buy-sector-following-085728180.html,Is this stock the best buy in its sector following today’s update?
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline Trades Ex-Dividend Wednesday (GSK),2016-08-10 03:49:00 +0000,http://www.investopedia.com/news/glaxosmithkline-trades-exdividend-wednesday-gsk/?partner=YahooSA,GlaxoSmithKline Trades Ex-Dividend Wednesday (GSK)
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline's Dividend Health,2016-08-09 17:57:25 +0000,http://finance.yahoo.com/news/glaxosmithklines-dividend-health-175725110.html,GlaxoSmithKline's Dividend Health
GSK,GSK:US,BBG000BLB481,"Epizyme (EPZM) Q2 Loss Lower than Expected, Costs to Rise",2016-08-09 15:38:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kJ0sF-HKcpI/epizyme-epzm-q2-loss-lower-than-expected-costs-to-rise-cm662544,"Epizyme, Inc.EPZM reported a loss of 49 cents per share in the second quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 50 cents and the year ago loss of 63 cents. Epizyme Inc."
GSK,GSK:US,BBG000BLB481,What can Google do that GlaxoSmithKline plc cannot?,2016-08-09 08:58:42 +0000,http://uk.finance.yahoo.com/news/google-glaxosmithkline-plc-cannot-085842338.html,What can Google do that GlaxoSmithKline plc cannot?
GSK,GSK:US,BBG000BLB481,9 Stocks for the Bank of England's Corporate-Bond Purchases,2016-08-08 12:00:00 +0000,http://realmoney.thestreet.com/articles/08/08/2016/9-stocks-bank-englands-corporate-bond-purchases?puc=yahoo&cm_ven=YAHOO,9 Stocks for the Bank of England's Corporate-Bond Purchases
GSK,GSK:US,BBG000BLB481,[$$] Week in review: August 6,2016-08-05 22:29:24 +0000,"https://ad.doubleclick.net/ddm/clk/304029932;131365232;t?http://www.ft.com/cms/s/6959f954-5af7-11e6-9f70-badea1b336d4,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev",[at Financial Times] - A round up of some of the week's most significant corporate events and news stories. Coming to a big screen near you China has continued its love affair with Hollywood after a subsidiary of Dalian Wanda ...
GSK,GSK:US,BBG000BLB481,Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick,2016-08-05 14:20:28 +0000,http://247wallst.com/healthcare-business/2016/08/05/jefferies-keeps-red-hot-dividend-pharmaceutical-stock-as-top-sector-pick/,Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick
GSK,GSK:US,BBG000BLB481,"ETF’s with exposure to GlaxoSmithKline Plc : August 4, 2016",2016-08-04 18:57:00 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-glaxosmithkline-plc-august-4-2016/,"ETF’s with exposure to GlaxoSmithKline Plc : August 4, 2016"
GSK,GSK:US,BBG000BLB481,Publication of a Prospectus,2016-08-04 15:02:05 +0000,http://www.publicnow.com/view/5374E3AB1E569ECF5354D010D1B88A696207220E,[at noodls] - Publication of Base Prospectus The following Base Prospectus dated 4 August 2016 has been approved by the UK Listing Authority and is available for viewing: GlaxoSmithKline plc and GlaxoSmithKline Capital ...
GSK,GSK:US,BBG000BLB481,Can This Moonshot Reverse GlaxoSmithKline's Fortunes?,2016-08-04 14:56:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_igWWi7eMgI/can-this-moonshot-reverse-glaxosmithklines-fortunes-cm660304,"Image source  Getty Images.  Since 2012, GlaxoSmithKline (NYSE  GSK) has been quietly pioneering an entirely new scientific field  bioelectronic medicines. The basic idea is to build miniaturized implantable devices that could precisely"
GSK,GSK:US,BBG000BLB481,Ionis Pharmaceuticals (IONS) Q2 Earnings: Stock to Beat?,2016-08-04 13:58:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UyheEFM1iMg/ionis-pharmaceuticals-ions-q2-earnings-stock-to-beat-cm660220,"Ionis Pharmaceuticals, Inc.IONS is scheduled to report second quarter 2016 results on Aug 9. Last quarter, the company recorded a negative earnings surprise of 4.00%. Let's see how things are shaping up for this announcement.Factors to Consider Through partnerships"
GSK,GSK:US,BBG000BLB481,Google’s parent company wants to treat disease by zapping you with electricity,2016-08-03 21:42:00 +0000,http://finance.yahoo.com/news/why-googles-parent-company-betting-175038451.html,Google’s parent company wants to treat disease by zapping you with electricity
GSK,GSK:US,BBG000BLB481,We've Just Found the 'Apple' of Biotechnology,2016-08-03 17:13:00 +0000,https://www.thestreet.com/story/13663130/1/we-ve-just-found-the-apple-of-biotechnology.html?puc=yahoo&cm_ven=YAHOO,"[at TheStreet] - Two companies, one a tech giant and the other a Big Pharma stalwart, have formed a joint venture that's bringing disruptive technology to new drug development."
GSK,GSK:US,BBG000BLB481,Here's Why GlaxoSmithKline's Stock Is Ready to Scale New Heights,2016-08-03 15:33:00 +0000,https://www.thestreet.com/story/13662935/1/here-s-why-glaxosmithkline-s-stock-is-ready-to-scale-new-heights.html?puc=yahoo&cm_ven=YAHOO,Here's Why GlaxoSmithKline's Stock Is Ready to Scale New Heights
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016",2016-08-03 15:21:36 +0000,http://www.capitalcube.com/blog/index.php/glaxosmithkline-plc-gsk-us-earnings-analysis-q2-2016-by-the-numbers-august-3-2016/,"GlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 3, 2016"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline’s Consumer Healthcare Grows in 2Q16,2016-08-03 13:05:32 +0000,http://marketrealist.com/2016/07/glaxosmithklines-consumer-healthcare-grows-2q16/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Consumer Healthcare Grows in 2Q16
GSK,GSK:US,BBG000BLB481,"Is it too late to buy GlaxoSmithKline plc, Glencore plc and Royal Bank of Scotland Group plc?",2016-08-03 11:39:42 +0000,http://uk.finance.yahoo.com/news/too-buy-glaxosmithkline-plc-glencore-113942960.html,"Is it too late to buy GlaxoSmithKline plc, Glencore plc and Royal Bank of Scotland Group plc?"
GSK,GSK:US,BBG000BLB481,64 Actions to Take this Week,2016-08-02 17:52:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/glJaKwzftkc/64-actions-to-take-this-week-cm659009,"        During these busy times, it pays to stay on top of the latest profit opportunities, and today's"
GSK,GSK:US,BBG000BLB481,The C-Suite Speaks: No One Called This an Expansion,2016-08-02 14:46:08 +0000,http://finance.yahoo.com/tumblr/blog-the-c-suite-speaks-no-one-called-this-an-144615298.html,The C-Suite Speaks: No One Called This an Expansion
GSK,GSK:US,BBG000BLB481,Alphabet and Glaxo Team Up to Jumpstart Your Profits,2016-08-02 14:44:00 +0000,https://www.thestreet.com/story/13660096/1/alphabet-and-glaxo-team-up-to-jumpstart-your-profits.html?puc=yahoo&cm_ven=YAHOO,[at TheStreet] - The Google parent and Big Pharma major have announced a joint venture into the developing world of bioelectronics treatments.
GSK,GSK:US,BBG000BLB481,How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16?,2016-08-02 13:07:34 +0000,http://marketrealist.com/2016/07/glaxosmithklines-pharmaceuticals-segment-2q16/?utm_source=yahoo&utm_medium=feed,How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16?
GSK,GSK:US,BBG000BLB481,Alphabet looks to piggyback tiny implants onto body's nerves,2016-08-02 11:10:40 +0000,http://www.mercurynews.com/business/ci_30195079/alphabet-looks-piggyback-tiny-implants-onto-bodys-nerves,Alphabet looks to piggyback tiny implants onto body's nerves
GSK,GSK:US,BBG000BLB481,"Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture",2016-08-02 03:42:23 +0000,http://www.wsj.com/articles/glaxo-alphabet-plan-700-million-bioelectric-treatment-venture-1470035507?ru=yahoo?mod=yahoo_itp,"Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture"
GSK,GSK:US,BBG000BLB481,Pfizer To Acquire Gene-Tech Company -- WSJ,2016-08-02 02:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zhi_9o_ZWUU/pfizer-to-acquire-genetech-company--wsj-20160802-00053,Pfizer To Acquire Gene-Tech Company -- WSJ
GSK,GSK:US,BBG000BLB481,"Alphabet, Glaxo Team Up On 'Bioelectronic' Medicines -- WSJ",2016-08-02 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P8KArQteUKM/alphabet-glaxo-team-up-on-bioelectronic-medicines--wsj-20160802-00052,"Alphabet, Glaxo Team Up On 'Bioelectronic' Medicines -- WSJ"
GSK,GSK:US,BBG000BLB481,ADAP: a Biotech Stock Using T-Cell Immunotherapy to Treat Cancer,2016-08-02 00:56:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I9ZYqNCJu38/adap-a-biotech-stock-using-t-cell-immunotherapy-to-treat-cancer-cm658501,"Within the world of biotech stocks lies the potential to reap massive profits.  At the same time though, this space is full of companies who ultimately fail to live up to their ambitions.  Because of the tendency for many"
GSK,GSK:US,BBG000BLB481,"Shock treatment: Bioelectronic med devices jolted with new venture between GSK, former Google life sciences unit",2016-08-01 23:07:39 +0000,http://www.bizjournals.com/sanfrancisco/blog/biotech/2016/08/verily-gsk-goog-bioelectronics-medical-devices.html?ana=yahoo,"[at American City Business Journals] - The former Google life sciences unit and pharmaceutical giant GlaxoSmithKline will work together in a $715 million partnership to develop tiny devices that manipulate nerves with electrical pulses to change the course of conditions such as diabetes and chronic pain. Galvani Bioelectronics will be based within GlaxoSmithKline's (GSK) global research and development center north of London, but a second research hub will be in the new South San Francisco home of Google's former life sciences division, now called Verily Life Sciences. Verily earlier this year leased the 400,000-square-foot former home of Onyx Pharmaceuticals Inc., where it ultimately could place about 1,000 employees working on a broad range of products, including cancer, neurodegenerative and medical device projects for Mountain View-based parent company Alphabet Inc. (GOOG)."
GSK,GSK:US,BBG000BLB481,"GSK, GOOGL: GlaxoSmithKline plc (ADR), Alphabet Inc Team Up on Bioelectronics",2016-08-01 22:54:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Of_J5PdUtFA/gsk-googl-glaxosmithkline-plc-adr-alphabet-inc-team-up-on-bioelectronics-cm658447,"GlaxoSmithKline plc (ADR) (NYSE GSK ) is teaming up with  Alphabet Inc's (NASDAQ GOOG ,NASDAQ GOOGL ) Verily Life Sciences to form a new company called ""Galvani Bioelectronics."" Source Flickr>The new"
GSK,GSK:US,BBG000BLB481,Portfolio Roundup: Humira Helps Buoy AbbVie Shares,2016-08-01 21:05:00 +0000,http://realmoney.thestreet.com/articles/08/01/2016/portfolio-roundup-humira-helps-buoy-abbvie-shares?puc=yahoo&cm_ven=YAHOO,[at TheStreet] - The drug maker continued to rally Monday.
GSK,GSK:US,BBG000BLB481,Veeva Helps The Medicine Go Down Faster for Drug Giants,2016-08-01 20:58:43 +0000,http://www.investors.com/research/the-new-america/veeva-is-key-partner-in-big-pharmas-race-against-the-clock/,Veeva Helps The Medicine Go Down Faster for Drug Giants
GSK,GSK:US,BBG000BLB481,GSK And Alphabet Team Up For Bioelectronics Medicine,2016-08-01 18:25:00 +0000,http://uk.finance.yahoo.com/news/gsk-alphabet-team-bioelectronics-medicine-111700998.html,GSK And Alphabet Team Up For Bioelectronics Medicine
GSK,GSK:US,BBG000BLB481,GSK and Google parent forge $715 mln bioelectronic medicines firm,2016-08-01 17:40:43 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-alphabet-create-715-mln-071702585.html,GSK and Google parent forge $715 mln bioelectronic medicines firm
GSK,GSK:US,BBG000BLB481,"Google sister company, drug maker to develop nerve implants",2016-08-01 14:23:41 +0000,http://sg.finance.yahoo.com/news/gsk-google-parent-company-bioelectronic-081800331.html,"Google sister company, drug maker to develop nerve implants"
GSK,GSK:US,BBG000BLB481,"Pharma and tech converge in ""fantastic voyage"" to fight disease",2016-08-01 13:59:12 +0000,http://sg.finance.yahoo.com/news/pharma-tech-converge-fantastic-voyage-135912276.html,"Pharma and tech converge in ""fantastic voyage"" to fight disease"
GSK,GSK:US,BBG000BLB481,Pharma and tech converge in 'fantastic voyage' to fight disease,2016-08-01 13:46:38 +0000,http://sg.finance.yahoo.com/news/pharma-tech-converge-fantastic-voyage-134638566.html,Pharma and tech converge in 'fantastic voyage' to fight disease
GSK,GSK:US,BBG000BLB481,Pfizer to Buy Gene Therapy Company Bamboo Therapeutics,2016-08-01 11:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/62uzpzz2WEA/pfizer-to-buy-gene-therapy-company-bamboo-therapeutics-20160801-00724,Pfizer to Buy Gene Therapy Company Bamboo Therapeutics
GSK,GSK:US,BBG000BLB481,5 Dividend Stocks to Buy in August,2016-08-01 11:51:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1qeszxq0Vkw/5-dividend-stocks-to-buy-in-august-cm657862,"Image Source  Getty Images.  Dividend stocks are the heart and soul of any well constructed portfolio. Having said that, there are so many dividend paying stocks populating the landscape these days that it can be"
GSK,GSK:US,BBG000BLB481,3 stocks set to soar after today’s news flow?,2016-08-01 11:32:52 +0000,http://uk.finance.yahoo.com/news/3-stocks-set-soar-today-113252456.html,3 stocks set to soar after today’s news flow?
GSK,GSK:US,BBG000BLB481,Total Voting Rights,2016-08-01 11:21:03 +0000,http://www.publicnow.com/view/41861C4B48F7F472BEDEFAAE37FE88AC53BB3ECB,"[at noodls] - GlaxoSmithKline plc and Capital Inconformity with Disclosure and Transparency Rule 5.6.1R, GlaxoSmithKline plc (the 'Company') hereby notifies the market of the following: The Company's issued share capital ..."
GSK,GSK:US,BBG000BLB481,GSK and Google parent forge 540 million pound bioelectronic medicines firm,2016-08-01 09:32:13 +0000,http://sg.finance.yahoo.com/news/gsk-creates-540-million-pound-061654705.html,"[Reuters] - GlaxoSmithKline (GSK.L) and Google parent Alphabet's (GOOGL.O) life sciences unit are creating a new company focussed on fighting diseases by targeting electrical signals in the body, jump-starting a novel field of medicine called bioelectronics. Verily Life Sciences - known as Google's life sciences unit until last year - and Britain's biggest drugmaker will together contribute 540 million pounds over seven years to Galvani Bioelectronics, they said on Monday. It is GSK's second notable investment in Britain since the country voted to leave the European Union in June."
GSK,GSK:US,BBG000BLB481,GSK forms bioelectronics venture with Alphabet,2016-08-01 09:06:44 +0000,http://sg.finance.yahoo.com/news/gsk-forms-bioelectronics-venture-alphabet-090644938.html,GSK forms bioelectronics venture with Alphabet
GSK,GSK:US,BBG000BLB481,Another Economic Stat Adds to Brexit Jitters,2016-08-01 05:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Sia19i-NoBg/another-economic-stat-adds-to-brexit-jitters-20160801-00873,Another Economic Stat Adds to Brexit Jitters
GSK,GSK:US,BBG000BLB481,U.K. Manufacturing Activity Hurt by Brexit,2016-08-01 05:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8sCN2cVZcWo/uk-manufacturing-activity-hurt-by-brexit-20160801-00463,U.K. Manufacturing Activity Hurt by Brexit
GSK,GSK:US,BBG000BLB481,Another Economic Stat Adds to Brexit Jitters,2016-08-01 05:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/joDbZJwvBJI/another-economic-stat-adds-to-brexit-jitters-20160801-00875,Another Economic Stat Adds to Brexit Jitters
GSK,GSK:US,BBG000BLB481,"Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture -- Update",2016-08-01 04:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JAFbVoX9i-0/glaxo-alphabet-plan-700-million-bioelectric-treatment-venture--update-20160801-00079,"Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture -- Update"
GSK,GSK:US,BBG000BLB481,"Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture",2016-08-01 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_NpN1fGECGg/glaxo-alphabet-plan-700-million-bioelectric-treatment-venture-20160801-00077,"Glaxo, Alphabet Plan $700 Million Bioelectric Treatment Venture"
GSK,GSK:US,BBG000BLB481,PM Holds Talks With 'FTSE Fraud Squad',2016-07-31 13:53:00 +0000,http://uk.finance.yahoo.com/news/pm-holds-talks-ftse-fraud-131200321.html,PM Holds Talks With 'FTSE Fraud Squad'
GSK,GSK:US,BBG000BLB481,PM May Holds Talks With 'FTSE Fraud Squad',2016-07-31 12:59:00 +0000,http://uk.finance.yahoo.com/news/pm-may-holds-talks-ftse-125800538.html,PM May Holds Talks With 'FTSE Fraud Squad'
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y",2016-07-28 17:28:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rL6ULw1hNDA/glaxo-gsk-beats-q2-earnings-estimates-revenues-up-yy-cm656671,"GlaxoSmithKline plcGSK reported second quarter 2016 core earnings of 70 cents per American Depositary Share (ADS), beating the Zacks Consensus Estimate of 55 cents. Core earnings were also up 16% year over year at a constant exchange rate (CER)."
GSK,GSK:US,BBG000BLB481,GSK Plans £275m UK Investment After EU Vote,2016-07-27 16:40:00 +0000,http://uk.finance.yahoo.com/news/gsk-plans-275m-uk-investment-072400327.html,GSK Plans £275m UK Investment After EU Vote
GSK,GSK:US,BBG000BLB481,"Q2 Earnings Checklist Keeps Rolling Out: BA, CMCSA, GSK & Others",2016-07-27 16:31:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gNNleKz7Ha8/q2-earnings-checklist-keeps-rolling-out-ba-cmcsa-gsk-others-cm655749,"Wednesday, July 27, 2016 The Q2 earnings checklist just keeps getting longer. After a busy session after the bell yesterday, we see another long list of reporting companies this morning. Boeing BA is up 1.75% ahead of regular Wednesday"
GSK,GSK:US,BBG000BLB481,GSK invests $A481m in post-Brexit UK,2016-07-27 13:32:03 +0000,http://au.finance.yahoo.com/news/gsk-invests-a481m-post-brexit-083106232.html,"[AAP] - GlaxoSmithKline plans STG275 million ($A481 million) of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. The decision came as Britain's biggest drugmaker reported better-than-expected quarterly earnings on Wednesday, buoyed by new drug sales and currency gains from a falling pound, which it said could pump up full-year results by 19 per cent. The country's so-called patent box boosts profits from patented innovations by halving the rate of corporation tax."
GSK,GSK:US,BBG000BLB481,"Glaxo (GSK) Beats Q2 Earnings, Revenues Rise Y/Y",2016-07-27 13:25:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uDEFCyY0U1I/glaxo-gsk-beats-q2-earnings-revenues-rise-yy-cm655546,"GlaxoSmithKline plcGSK , one of the largest health care companies, reshaped its business following the Mar 2015 completion of the three part, inter conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. This UK based"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline invests 275 million pounds in UK despite Brexit,2016-07-27 13:21:26 +0000,http://sg.finance.yahoo.com/news/glaxosmithkline-invests-275-million-pounds-060531878.html,GlaxoSmithKline invests 275 million pounds in UK despite Brexit
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline invests $360 mln in UK despite Brexit,2016-07-27 13:19:53 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-invests-360-mln-post-062854961.html,"[Reuters - UK Focus] - GlaxoSmithKline (Other OTC: GLAXF - news) plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union. The decision came as Britain's biggest drugmaker reported better-than-expected quarterly earnings on Wednesday, buoyed by new drug sales and currency gains from a falling pound, which it said could pump up full-year results by 19 percent. GSK, which had argued against Brexit before the referendum, said the UK remained an attractive place for making medicines, thanks to a skilled workforce and relatively low tax rates."
GSK,GSK:US,BBG000BLB481,Glaxo reports 2Q loss,2016-07-27 13:14:39 +0000,http://sg.finance.yahoo.com/news/glaxo-reports-2q-loss-131439942.html,Glaxo reports 2Q loss
GSK,GSK:US,BBG000BLB481,"Pre-Market Most Active for Jul 27, 2016 :  SQNM, AAPL, TWTR, DB, X, FB, AZN, GSK, RBS^S, TMUS, LLTC, VNOM",2016-07-27 12:58:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qmfXl_HIUhI/pre-market-most-active-for-jul-27-2016-sqnm-aapl-twtr-db-x-fb-azn-gsk-rbss-tmus-lltc-vnom-cm655454,"The NASDAQ 100 Pre Market Indicator is up 43.96 to 4,716.07. The total Pre Market volume is currently 6,086,122 shares traded. The following are the most active stocks for the pre market session Sequenom, Inc. ( SQNM ) is"
GSK,GSK:US,BBG000BLB481,Should you buy GlaxoSmithKline plc after today’s results?,2016-07-27 12:53:47 +0000,http://uk.finance.yahoo.com/news/buy-glaxosmithkline-plc-today-results-125347207.html,Should you buy GlaxoSmithKline plc after today’s results?
GSK,GSK:US,BBG000BLB481,UK drugs giant GSK invests £275 mn despite Brexit,2016-07-27 12:18:16 +0000,http://uk.finance.yahoo.com/news/uk-drugs-giant-gsk-invests-083329747.html,UK drugs giant GSK invests £275 mn despite Brexit
GSK,GSK:US,BBG000BLB481,GSK outlook brightens as Brexit brings currency windfall,2016-07-27 11:20:50 +0000,http://sg.finance.yahoo.com/news/gsk-outlook-brightens-brexit-brings-112216397.html,GSK outlook brightens as Brexit brings currency windfall
GSK,GSK:US,BBG000BLB481,GSK chases next biotech asthma drug with 175 million pounds J&J deal,2016-07-27 11:20:50 +0000,http://sg.finance.yahoo.com/news/gsk-chases-next-biotech-asthma-110302967.html,GSK chases next biotech asthma drug with 175 million pounds J&J deal
GSK,GSK:US,BBG000BLB481,GSK chases next biotech asthma drug with $230 mln J&J deal,2016-07-27 11:00:01 +0000,http://uk.finance.yahoo.com/news/gsk-chases-next-biotech-asthma-110001478.html,GSK chases next biotech asthma drug with $230 mln J&J deal
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline invests $360 mln in post-Brexit UK manufacturing,2016-07-27 06:03:51 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-invests-360-mln-post-060351262.html,"[Reuters - UK Focus] - GlaxoSmithKline plans 275 million pounds of new investments at three drug manufacturing sites in Britain, signalling its confidence in the country despite last month's vote to leave the European Union...."
GSK,GSK:US,BBG000BLB481,UK drugs giant GSK invests £275 mn despite Brexit,2016-07-27 02:18:16 +0000,http://au.finance.yahoo.com/news/uk-drugs-giant-gsk-invests-223329038.html,"[AFP] - The investment -- worth $361 million or 328 million euros -- will be ploughed into facilities in Barnard Castle in northeastern England, Ware in the southeast, and Montrose in Scotland, GSK said in a statement. GSK, which already employs 6,000 staff across its nine manufacturing plants in Britain, also noted that the investment would provide new job opportunities. ""Today's announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products,"" said chief executive Andrew Witty, who had backed the unsuccessful 'Remain' campaign in Britain's June 23 EU membership vote."
GSK,GSK:US,BBG000BLB481,Your inhaler's watching you: drugmakers race for smart devices,2016-07-20 12:50:49 +0000,http://sg.finance.yahoo.com/news/inhalers-watching-drugmakers-race-smart-125049425.html,"[Reuters] - Makers of inhalers to treat asthma and chronic lung disease are racing to develop a new generation of smart devices with sensors to monitor if patients are using their puffers properly. Drugmakers believe giving patients and doctors the ability to check inhaler use in this way could be a big help in proving the value of their medicines to governments and insurers, though they need to tread carefully on data privacy. GlaxoSmithKline, AstraZeneca and Novartis are all chasing the opportunity via deals with device firms including U.S.-based Propeller Health and Australian-listed Adherium, as well as technology players like Qualcomm."
GSK,GSK:US,BBG000BLB481,Novartis in no rush to sell down stake on GSK consumer venture,2016-07-19 13:25:37 +0000,http://sg.finance.yahoo.com/news/novartis-no-rush-sell-down-132537303.html,Novartis in no rush to sell down stake on GSK consumer venture
GSK,GSK:US,BBG000BLB481,Will GlaxoSmithKline plc and AstraZeneca plc continue to be Brexit winners?,2016-07-19 06:10:45 +0000,http://uk.finance.yahoo.com/news/glaxosmithkline-plc-astrazeneca-plc-continue-061045524.html,Will GlaxoSmithKline plc and AstraZeneca plc continue to be Brexit winners?
GSK,GSK:US,BBG000BLB481,These 5 FTSE 100 stars are looking far too cheap!,2016-07-18 06:00:41 +0000,http://uk.finance.yahoo.com/news/5-ftse-100-stars-looking-060041401.html,These 5 FTSE 100 stars are looking far too cheap!
GSK,GSK:US,BBG000BLB481,Price Monitoring Extension,2016-07-14 11:18:09 +0000,http://www.publicnow.com/view/E71E1E732652F4157898F124D59E882BFEDEE792,[at noodls] - Price Monitoring Extension The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 14 July ...
GSK,GSK:US,BBG000BLB481,Second Price Monitoring Extn,2016-07-14 11:18:08 +0000,http://www.publicnow.com/view/0F7289002A0B50077FF377C69DE884914E6F0121,[at noodls] - Second Price Monitoring Extn The text version of this document is not available at the moment. The original content was posted at original link . GSK - GlaxoSmithKline plc published this content on 14 ...
GSK,GSK:US,BBG000BLB481,Drug industry CEOs lead new task force on Brexit's pharma fallout,2016-07-07 16:27:48 +0000,http://sg.finance.yahoo.com/news/drug-industry-ceos-lead-task-162748812.html,Drug industry CEOs lead new task force on Brexit's pharma fallout
GSK,GSK:US,BBG000BLB481,FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients,2016-06-20 07:49:05 +0000,http://www.publicnow.com/view/8CB5C12CC80EAF183D04F0FC69B139E1C6568BD4,"[at noodls] - Issued London. ... This is an abstract of the original noodl. To continue reading this document, click here for the original version."
GSK,GSK:US,BBG000BLB481,FULFIL Study Results Closed Triple EU,2016-06-20 06:19:04 +0000,http://www.publicnow.com/view/CEAD865EC23DE6D472674FCB9A3C254832E31A43,"[at noodls] - Issued: Monday 20 June 2016, London UK - LSE Announcement FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort Turbohalerin improving lung function and health-related ..."
GSK,GSK:US,BBG000BLB481,Directorate Change,2016-06-14 10:09:05 +0000,http://www.publicnow.com/view/0103F8AE782B6F3FFA5815864D1332F8DDBEE2E0,"[at noodls] - GlaxoSmithKline plc (the 'Company') Executive Director Change GSK today announces that Dr Moncef Slaoui, Chairman, Vaccines, has indicated to the Board his intention to retire from the Company in 2017. ..."
GSK,GSK:US,BBG000BLB481,U.S. top court rejects GSK bid to throw out racketeering lawsuits,2016-06-06 14:11:48 +0000,http://sg.finance.yahoo.com/news/u-top-court-rejects-gsk-141148964.html,U.S. top court rejects GSK bid to throw out racketeering lawsuits
GSK,GSK:US,BBG000BLB481,"In fight for GSK's Advair, generic firms step carefully on price",2016-06-03 11:59:54 +0000,http://in.finance.yahoo.com/news/fight-gsks-advair-generic-firms-115954871.html,"In fight for GSK's Advair, generic firms step carefully on price"
GSK,GSK:US,BBG000BLB481,Anti-graft group says drugmakers failing to tackle corruption,2016-06-01 23:28:02 +0000,http://in.finance.yahoo.com/news/anti-graft-group-says-drugmakers-232802040.html,Anti-graft group says drugmakers failing to tackle corruption
GSK,GSK:US,BBG000BLB481,GSK gets EU approval for first gene therapy for children,2016-05-27 16:16:20 +0000,http://in.finance.yahoo.com/news/gsk-gets-eu-approval-first-161620550.html,GSK gets EU approval for first gene therapy for children
GSK,GSK:US,BBG000BLB481,Ionis shares plummet as GSK scraps heart drug trial plans,2016-05-26 20:08:20 +0000,http://sg.finance.yahoo.com/news/ionis-shares-slump-40-percent-183200177.html,Ionis shares plummet as GSK scraps heart drug trial plans
GSK,GSK:US,BBG000BLB481,"GSK lung drug succeeds in big UK study, after earlier miss",2016-05-24 12:49:05 +0000,http://sg.finance.yahoo.com/news/gsk-lung-drug-succeeds-big-111456135.html,"GSK lung drug succeeds in big UK study, after earlier miss"
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline promises reduced drug patents to help world's poor,2016-03-31 13:25:14 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-promises-reduced-drug-patents-132514518.html,GlaxoSmithKline promises reduced drug patents to help world's poor
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline CEO Witty to bow out in March 2017,2016-03-17 08:55:37 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-ceo-witty-bow-march-085537799.html,GlaxoSmithKline CEO Witty to bow out in March 2017
GSK,GSK:US,BBG000BLB481,GSK dismisses near-term split as new drugs offset falling Advair,2016-02-03 18:01:04 +0000,http://in.finance.yahoo.com/news/gsk-dismisses-near-term-split-180104524.html,GSK dismisses near-term split as new drugs offset falling Advair
GSK,GSK:US,BBG000BLB481,Five charged in U.S. with stealing secrets from GlaxoSmithKline,2016-01-21 18:09:17 +0000,http://in.finance.yahoo.com/news/five-charged-u-stealing-secrets-180917828.html,Five charged in U.S. with stealing secrets from GlaxoSmithKline
GSK,GSK:US,BBG000BLB481,Amgen reacquires rights to three drugs from Glaxo in 48 countries,2015-12-14 21:49:18 +0000,http://in.finance.yahoo.com/news/amgen-reacquires-rights-three-drugs-214918966.html,Amgen reacquires rights to three drugs from Glaxo in 48 countries
GSK,GSK:US,BBG000BLB481,GSK plan to file up to 20 new drugs by 2020 underwhelms market,2015-11-03 18:03:57 +0000,http://in.finance.yahoo.com/news/gsk-aims-file-20-drugs-143332138.html,GSK plan to file up to 20 new drugs by 2020 underwhelms market
GSK,GSK:US,BBG000BLB481,GlaxoSmithKline net dips 26 percent in Q2,2015-10-31 15:24:03 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-net-dips-26-percent-152403482.html,GlaxoSmithKline net dips 26 percent in Q2
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline beats forecasts as HIV drugs, flu vaccines shine",2015-10-28 14:42:13 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-beats-forecasts-hiv-drugs-144213082.html,"GlaxoSmithKline beats forecasts as HIV drugs, flu vaccines shine"
GSK,GSK:US,BBG000BLB481,Analysis of GSK's Seroxat antidepressant finds key data was held back,2015-09-17 00:37:35 +0000,http://in.finance.yahoo.com/news/analysis-gsks-seroxat-antidepressant-finds-003735084.html,Analysis of GSK's Seroxat antidepressant finds key data was held back
GSK,GSK:US,BBG000BLB481,"Exclusive - GSK faces new corruption allegations, this time in Romania",2015-07-29 18:26:08 +0000,http://in.finance.yahoo.com/news/exclusive-gsk-faces-corruption-allegations-182608826.html,"Exclusive - GSK faces new corruption allegations, this time in Romania"
GSK,GSK:US,BBG000BLB481,"GlaxoSmithKline beats profit forecasts despite Advair hit, lower margins",2015-07-29 12:19:35 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-beats-profit-forecasts-despite-121935818.html,"GlaxoSmithKline beats profit forecasts despite Advair hit, lower margins"
GSK,GSK:US,BBG000BLB481,GSK scraps plan to list HIV drugs business and shields dividend,2015-05-06 14:17:09 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-targets-growth-across-units-114609534.html,GSK scraps plan to list HIV drugs business and shields dividend
GSK,GSK:US,BBG000BLB481,Interview - New-look GSK bets on consumer health spending,2015-05-06 11:22:55 +0000,http://in.finance.yahoo.com/news/interview-look-gsk-bets-consumer-112255844.html,Interview - New-look GSK bets on consumer health spending
GSK,GSK:US,BBG000BLB481,Doubts grow over GlaxoSmithKline's $6 bln capital return plan,2015-05-01 11:36:49 +0000,http://in.finance.yahoo.com/news/doubts-grow-over-glaxosmithklines-6-113649231.html,Doubts grow over GlaxoSmithKline's $6 bln capital return plan
GSK,GSK:US,BBG000BLB481,GSK gets a lift as Express Scripts reinstates lung drug Advair,2014-08-04 18:04:09 +0000,http://in.finance.yahoo.com/news/gsk-gets-lift-express-scripts-180409430.html,GSK gets a lift as Express Scripts reinstates lung drug Advair
